

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name Jennifer Kim Examiner #: 77469 Date: 8/21/03
An Unit 1619 Phone Number 308-2232 Serial Number 10/652,691
Mail Box and Bldg. Room Location 2D19 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc. if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Methods of treating neurological disorders
Inventors (please provide full names): Gullans et al.

Earliest Priority Filing Date: 1/19/00

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

- 1) Please search claim 1-12.
2) Please provide the registry #'s + structures of active agents in claims 1-12.

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CMI 1107--700.500.100
jan.delaval@uspso.gov

THX,

Jan

STAFF USE ONLY

Searcher	Type of Search	Vendors and cost where applicable
Searcher Phone # <u>4498</u>	NA Sequence (#) <u>✓</u>	STN <u>✓</u>
Searcher Location	AA Sequence (#)	Dialog
Date Requested <u>8/21/03</u>	Structure (#) <u>✓</u>	Quester/Orbit
Date Filled <u>8/21/03</u>	Bibliographic	Index
Searcher Prep & Review Time	Litigation	Legal Review
Claims Prep Time <u>20</u>	Fulltext	Sequence Systems
Indexing Time <u>25</u>	Patent Family	WWW Internet
	Other	Other vendors



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 102287

TO: Jennifer Kim
Location: 2d17 / 2b19
Wednesday, August 27, 2003
Art Unit: 1617
Phone: 308-2232
Serial Number: 10 / 052691

From: Jan Delaval
Location: Biotech-Chem Library
CM1-1E07
Phone: 308-4498

jan.delaval@uspto.gov

Search Notes

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1-1E07 - 703-308-4498
jan.delaval@uspto.gov

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 68-22-4 REGISTRY
CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 19-Nor-17.alpha.-pregn-4-en-20-yn-3-one, 17-hydroxy- (7CI, 8CI)

OTHER NAMES:

CN (17.alpha.)-17-Hydroxy-19-Norpregn-4-en-20-yn-3-one
CN 17-Hydroxy-19-nor-17.alpha.-pregn-4-en-20 yn-3-one
CN 17.alpha.-Ethynyl-17.beta.-hydroxy-.DELTA.4-estren-3-one
CN 17.alpha.-Ethynyl-19-nortestosterone
CN 17.alpha.-Ethynylestr-4-en-17.beta.-ol-3-one
CN 17.alpha.-Ethynyl-17-hydroxy-4-estrene-3-one
CN 17.alpha.-Ethynyl-17-hydroxyest-4-en-3-one
CN 17.alpha.-Ethynyl-17-hydroxyestr-4-en-3-one
CN 17.alpha.-Ethynyl-17.beta.-hydroxy-19-norandrost-4-en-3-one
CN 17.alpha.-Ethynyl-17.beta.-hydroxyestr-4-en-3-one
CN 17.alpha.-Ethynyl-19-nor-androst-4-en-17.beta.-ol-3-one
CN 17.alpha.-Ethynyl-19-nortestosterone
CN 17.alpha.-Ethynyl-3-oxo-4-estren-17.beta.-ol
CN 17.beta.-Hydroxy-17.alpha.-ethynylestr-4-en-3-one
CN 19-Nor-17.alpha.-ethynyl-17.beta.-hydroxy-4-androsten-3-one
CN 19-Nor-17.alpha.-ethynylandrosten-17.beta.-ol-3-one
CN 19-Nor-17.alpha.-ethynyltestosterone
CN 19-Norandrost-4-en-3-one, 17.alpha.-ethynyl-17.beta.-hydroxy-
CN 19-Nortestosterone, 17-ethynyl-
CN Anovule
CN Conludaf
CN Conludag
CN Estr-4-ene-17.alpha.-ethynyl-17.beta.-ol-3-one
CN Ethynylnortestosterone
CN Ethynylnortestosterone
CN Gestest
CN Menzol
CN Micronett
CN Micronor
CN Micronovum
CN Mini-Pe
CN Mini-pill
CN Nor-QD
CN Noralutin
CN Norcolut
CN **Norethindrone**
CN Norethisteron
CN Norethisterone
CN Norethynodrone
CN Norfor
CN Norgestin
CN Norluten
CN Norlutin
CN Norluton
CN Normapause
CN Norpregneninolone
CN NSC 9564
CN Primolut N
CN Proluteasi

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for
DISPLAY

FS STEREOSEARCH


MF C20 H26 O2

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,

Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2183 REFERENCES IN FILE CA (1937 TO DATE)
63 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2185 REFERENCES IN FILE CAPLUS (1937 TO DATE)
7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

 \Rightarrow

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 3562-63-8 REGISTRY
 CN Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl- (6CI, 7CI, 8CI, 9CI)
 (CA INDEX NAME)
 OTHER NAMES:
 CN 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione
 CN **Megestrol**
 FS STEREOSEARCH
 MF C22 H30 O3
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CBNB, CHEMLIST, CIN,
 DDFU, DRUGPAT, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA,
 MEDLINE, PHARMASEARCH, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

122 REFERENCES IN FILE CA (1937 TO DATE)
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 122 REFERENCES IN FILE CAPLUS (1937 TO DATE)
 6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 3385-03-3 REGISTRY
 CN Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 2H-Naphth[2',1':4,5]indeno[1,2-d][1,3]dioxole, pregna-1,4-diene-3,20-dione deriv.
 CN Pregna-1,4-diene-3,20-dione, 6.alpha.-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (7CI, 8CI)
 OTHER NAMES:
 CN 6.alpha.-Fluoro-11.beta.,21-dihydroxy-16.alpha.,17.alpha.-(isopropylidenedioxy)pregna-1,4-diene-3,20-dione
 CN Aerobid
 CN Aerobid M
 CN Bronalide
 CN **Flunisolid**
 CN Lunis
 CN Nasalide
 CN Nasarel
 CN Nisolid
 CN Rhinalar
 CN RS 3999
 CN Soluzione
 CN Synaclyn
 CN Syntaris
 FS STEREOSEARCH
 MF C24 H31 F O6
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSChem, DDFU, DIOGENES, DRUGPAT, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDb, MEDLINE, MRCK*, MSDS-OHS, PHAR, PHARMASEARCH, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

340 REFERENCES IN FILE CA (1937 TO DATE)
 8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 344 REFERENCES IN FILE CAPLUS (1937 TO DATE)
 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 595-33-5 REGISTRY
 CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-, acetate (6CI, 8CI)
 OTHER NAMES:
 CN 17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
 CN 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
 CN 17.alpha.-Acetoxy-6-dehydro-6-methylprogesterone
 CN 17.alpha.-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
 CN 17.alpha.-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
 CN 5071
 CN 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone
 CN 6-Methyl-.DELTA.4,6-pregnadien-17.alpha.-ol-3,20-dione acetate
 CN 6-Methyl-17.alpha.-acetoxy-4,6-pregnadiene-3,20-dione
 CN 6-Methyl-17.alpha.-hydroxy-.DELTA.6-progesterone acetate
 CN 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone
 CN BDH 1298
 CN DMAP
 CN Magestin
 CN Maygace
 CN Megace
 CN Megeron
 CN Megestat
 CN Megestil
 CN Megestin
 CN Megestrol acetate
 CN Megestryl acetate
 CN MGA
 CN Nia
 CN Niagestin
 CN NSC 71423
 CN Ovaban
 CN Ovarid
 CN SC 10363
 FS STEREOSEARCH
 MF C24 H32 O4
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM, DDFU, DIOGENES, DRUGPAT, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, NIOSHTIC, PHARMASEARCH, PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 110012-47-0 REGISTRY
CN Estra-1,3,5,7,9-pentaene-3,17-diol (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Estra-1,3,5(10),6,8-pentaene-3,17-diol (6CI)
OTHER NAMES:
CN Dihydroequilenin
FS STEREOSEARCH
MF C18 H20 O2
SR CAOLD
LC STN Files: BEILSTEIN*, BIOBUSINESS, CA, CAOLD, CAPLUS, CASREACT
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1937 TO DATE)
8 REFERENCES IN FILE CAPLUS (1937 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
RN 68-22-4 REGISTRY
CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 19-Nor-17.alpha.-pregn-4-en-20-yn-3-one, 17-hydroxy- (7CI, 8CI)

OTHER NAMES:

CN (17.alpha.)-17-Hydroxy-19-Norpregn-4-en-20-yn-3-one
CN 17-Hydroxy-19-nor-17.alpha.-pregn-4-en-20 yn-3-one
CN 17.alpha.-Ethynyl-17.beta.-hydroxy-.DELTA.4-estren-3-one
CN 17.alpha.-Ethynyl-19-nortestosterone
CN 17.alpha.-Ethynylestr-4-en-17.beta.-ol-3-one
CN 17.alpha.-Ethynyl-17-hydroxy-4-estrene-3-one
CN 17.alpha.-Ethynyl-17-hydroxyest-4-en-3-one
CN 17.alpha.-Ethynyl-17-hydroxyestr-4-en-3-one
CN 17.alpha.-Ethynyl-17.beta.-hydroxy-19-norandrost-4-en-3-one
CN 17.alpha.-Ethynyl-17.beta.-hydroxyestr-4-en-3-one
CN 17.alpha.-Ethynyl-19-nor-androst-4-en-17.beta.-ol-3-one
CN 17.alpha.-Ethynyl-19-nortestosterone
CN 17.alpha.-Ethynyl-3-oxo-4-estren-17.beta.-ol
CN 17.beta.-Hydroxy-17.alpha.-ethynylestr-4-en-3-one
CN 19-Nor-17.alpha.-ethynyl-17.beta.-hydroxy-4-androsten-3-one
CN 19-Nor-17.alpha.-ethynylandrosten-17.beta.-ol-3-one
CN 19-Nor-17.alpha.-ethynyltestosterone
CN 19-Norandrost-4-en-3-one, 17.alpha.-ethynyl-17.beta.-hydroxy-
CN 19-Nortestosterone, 17-ethynyl-
CN Anovule
CN Conludaf
CN Conludag
CN Estr-4-ene-17.alpha.-ethynyl-17.beta.-ol-3-one
CN Ethynylnortestosterone
CN Ethynylnortestosterone
CN Gestest
CN Menzol
CN Micronett
CN Micronor
CN Micronovum
CN Mini-Pe
CN Mini-pill
CN Nor-QD
CN Noralutin
CN Norcolut
CN **Norethindrone**
CN Norethisteron
CN Norethisterone
CN Norethynodrone
CN Norfor
CN Norgestin
CN Norluten
CN Norlutin
CN Norluton
CN Normapause
CN Norpregneninolone
CN NSC 9564
CN Primolut N
CN Proluteasi.

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY

FS STEREOSEARCH


MF C20 H26 O2

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,

CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM,
 CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA,
 MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PHARMASEARCH, PIRA, PROMT,
 RTECS*, SPECINFO, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2185 REFERENCES IN FILE CA (1937 TO DATE)
 64 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2185 REFERENCES IN FILE CAPLUS (1937 TO DATE)
 7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=>

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 595-33-5 REGISTRY
 CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-, acetate (6CI, 8CI)
 OTHER NAMES:
 CN 17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
 CN 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
 CN 17.alpha.-Acetoxy-6-dehydro-6-methylprogesterone
 CN 17.alpha.-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
 CN 17.alpha.-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
 CN 5071
 CN 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone
 CN 6-Methyl-.DELTA.4,6-pregnadien-17.alpha.-ol-3,20-dione acetate
 CN 6-Methyl-17.alpha.-acetoxy-4,6-pregnadiene-3,20-dione
 CN 6-Methyl-17.alpha.-hydroxy-.DELTA.6-progesterone acetate
 CN 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone
 CN BDH 1298
 CN DMAP
 CN Magestin
 CN Maygace
 CN Megace
 CN Megeron
 CN Megestat
 CN Megestil
 CN Megestin
 CN Megestrol acetate
 CN Megestryl acetate
 CN MGA
 CN Nia
 CN Niagestin
 CN NSC 71423
 CN Ovaban
 CN Ovarid
 CN SC 10363
 FS STEREOSEARCH
 MF C24 H32 O4
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM, DDFU, DIOGENES, DRUGPAT, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, NIOSHTIC, PHARMASEARCH, PIRA, PROMT, RTECS*, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

837 REFERENCES IN FILE CA (1937 TO DATE)
8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
837 REFERENCES IN FILE CAPLUS (1937 TO DATE)
35 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=>

L9 ANSWER 62 OF 62 USPATFULL on STN
 AN 2000:50737 USPATFULL
 TI Methods and compositions for modulating responsiveness to
 corticosteroids
 IN Sekut, Les, Westborough, MA, United States
 Carter, Adam, Newburyport, MA, United States
 Ghayur, Tariq, Grafton, MA, United States
 Banerjee, Subhashis, Shrewsbury, MA, United States
 Tracey, Daniel E., Harvard, MA, United States
 PA BASF Aktiengesellschaft, Rheinland Pfalz, Germany, Federal Republic of
 (non-U.S. corporation)
 PI US 6054487 20000425 <--
 AI US 1997-820692 19970318 (8)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Jarvis, William R. A.
 LREP Lahive & Cockfield, LLP
 CLMN Number of Claims: 46
 ECL Exemplary Claim: 1
 DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
 LN.CNT 2404
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 PI US 6054487 20000425 <--
 DETD As used herein, the term "**corticosteroid**" refers to a class of
 therapeutic agents useful in treatment of inflammatory conditions,
 including those resulting from infection, transplant rejection. . .
 presence of a steroid nucleus of four fused rings, for example, as found
 in cholesterol, dihydroxycholesterol, stigmasterol, and lanosterol
 structures. **Corticosteroid** drugs include cortisone, cortisol,
 hydrocortisone (11.beta.17-dihydroxy-21-(phosphonoxy)-pregn-4-ene-3,20-
 dione disodium), dihydroxycortisone, dexamethasone (21-(acetyloxy)-9-
 fluoro-11.beta., 17-dihydroxy-16.alpha.-methylpregna-1,4-diene-3,20-
 dione), and highly derivatized steroid drugs such as beconase
 (beclomethasone dipropionate, which is 9-chloro-11.beta.,17,21,
 trihydroxy-16.beta.-methylpregna-1,4 diene-3,20-dione
 17,21-dipropionate). Other examples of corticosteroids include
flunisolide, prednisone, prednisolone, methylprednisolone,
 triamcinolone, deflazacort and betamethasone.
 DETD . . . interferon-.gamma. (IFN-.gamma.) is administered to a subject
 in combination with one or more corticosteroids. The term "in
 combination with" a **corticosteroid** is intended to include
 simultaneous administration of the agent and the **corticosteroid**
 , administration of the agent first, followed by the
corticosteroid and administration of the **corticosteroid**
 first, followed by the agent. Any of the therapeutically useful
 corticosteroids known in the art can be used in the. . . methods of
 the invention. Corticosteroids are typically classified by the duration
 of their tissue effects: short acting compounds (e.g., beclomethasone,
flunisolide, hydrocortisone, cortisone), intermediate acting
 compounds (e.g., prednisone, prednisolone, methylprednisolone,
 triamcinolone, deflazacort) and long-acting compounds (e.g.,
 dexamethasone, beta methasone). One or. . . administration,
 administration by inhalation (e.g., bronchial administration), and local
 injection (e.g., intra-joint). The exact dosage and regimen for
 administering a **corticosteroid** to the subject will necessarily
 depend upon the needs of the subject being treated, the type of
 treatment, the efficacy. . . example of a dosage range for
 corticosteroids is from about 0.05 mg/day to about 1 gm/day, depending
 upon the particular **corticosteroid** used. Certain preferred
 dosage regimens utilize alternate day administration (e.g., high dose
 intravenous pulse therapy).
 CLM What is claimed is:
 3. The method of claim 1, wherein the **corticosteroid** is

selected from the group consisting of cortisone, hydrocortisone, beclomethasone, **flunisolide**, prednisone, prednisolone, methylprednisolone, triamcinolone, deflazacort, betamethasone and dexamethasone.

16. The method of claim 15, wherein the **corticosteroid** is selected from the group consisting of cortisone, hydrocortisone, beclomethasone, **flunisolide**, prednisone, prednisolone, methylprednisolone, triamcinolone, deflazacort, betamethasone and dexamethasone.

=>

(FILE 'HOME' ENTERED AT 10:03:23 ON 06 SEP 2003)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS, CEN, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, DRUGNL, DRUGU, EMBAL, EMBASE, ESBIODBASE, IFIPAT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, NLDB, NUTRACEUT, ...' ENTERED AT 10:03:31 ON 06 SEP 2003

L1	1119 S FLUNISOLIDE (P) CORTICOSTEROID
L2	381 S L1 AND PD<2000
L3	217 S (FLUNISOLIDE OR CORTICOSTEROID)/TI AND L2
L4	156 DUP REM L3 (61 DUPLICATES REMOVED)
L5	20 S (FLUNISOLIDE AND CORTICOSTEROID)/TI AND L3
L6	4 S L3 AND (ANTI-INFLAMMATORY AND STEROID)
L7	738 S L1 NOT L2
L8	62 S L7 AND PD<2001
L9	62 S L8 AND PD>1999

=>

L3 ANSWER 63 OF 72 USPATFULL on STN
 AN 1998:17301 USPATFULL
 TI Method of preventing neurodegeneration and cognitive dysfunction using
 17.alpha.-**dihydroequilenin**
 IN Washburn, Scott A., Winston-Salem, NC, United States
 Shively, Carol Ann, Winston-Salem, NC, United States
 PA Wake Forest University, Winston-Salem, NC, United States (U.S.
 corporation)
 PI US 5719137 19980217
 AI US 1996-753988 19961203 (8)
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Criares, Theodore J.
 LREP Rhodes, Coats & Bennett, L.L.P.
 CLMN Number of Claims: 24
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
 LN.CNT 624
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB A method of using a steroidal compound, 17.alpha.-
dihydroequilenin, to prevent and treat neurodegeneration and
 cognitive dysfunction in estrogen deficient females and to reduce the
 risk of Alzheimer's related dementia and other senile dementia related
 conditions in both males and females. The method comprises administering
 17.alpha.-**dihydroequilenin** in a therapeutically effective
 amount to a mammal in need of increased cognitive function or to a
 mammal susceptible to estrogen deficiency-related neurodegeneration or
 to senile dementia of the Alzheimer's type.
 TI Method of preventing neurodegeneration and cognitive dysfunction using
 17.alpha.-**dihydroequilenin**
 AB A method of using a steroidal compound, 17.alpha.-
dihydroequilenin, to prevent and treat neurodegeneration and
 cognitive dysfunction in estrogen deficient females and to reduce the
 risk of Alzheimer's related dementia and other senile dementia related
 conditions in both males and females. The method comprises administering
 17.alpha.-**dihydroequilenin** in a therapeutically effective
 amount to a mammal in need of increased cognitive function or to a
 mammal susceptible to. . .
 SUMM . . . with cognitive functions like memory and attention in mammals.
 More particularly, the present invention relates to a method of using
 17.alpha.-**dihydroequilenin** to prevent neurodegeneration and
 cognitive dysfunction in estrogen deficient females and to reduce the
 risk of Alzheimer's related dementia in. . .
 SUMM . . . may positively effect cognitive function in this neural region.
 Neither the Phillips nor the Gould references suggested the use of
 17.alpha.-**dihydroequilenin** as a hormonal therapeutic agent for
 effecting positive changes in cognitive function.
 SUMM . . . sulfates blended to represent the average composition of
 material derived from the pregnant mares' urine. Premarin.RTM. contains
 estrone, equilin and 17.alpha.-**dihydroequilenin**, together with
 trace amounts of 17.alpha.-estradiol, equilenin, and 17.alpha.-
dihydroequilenin as salts of sulfate esters. 17.alpha.-
dihydroequilenin sulfate comprises approximately 1-2% of the
 total steroidal content of Premarin.RTM., and is actually classified as
 an impurity in Premarin.RTM.. . .
 SUMM The present invention is directed to the use of 17.alpha.-
dihydroequilenin, a steroidal compound, to prevent
 neurodegeneration associated with cognitive dysfunction in female
 mammals exhibiting estrogen deficiency conditions and/or diseases
 including menopause. The present invention additionally provides a
 method of using 17.alpha.-**dihydroequilenin** to reduce the risk
 of Alzheimer's disease and other dementia related conditions in both
 males and females. The present invention further provides a method of

using 17.alpha.-**dihydroequilenin** for the treatment of the above conditions and/or diseases by administering a therapeutically effective amount of 17.alpha.-**dihydroequilenin** or a mammalian metabolic conjugate thereof and an appropriate pharmaceutical carrier.

SUMM The use of 17.alpha.-**dihydroequilenin** to prevent and/or treat neurodegeneration associated with cognitive dysfunction in estrogen deficient mammals and to reduce the risk of senile dementia of the Alzheimer's type provides distinct advantages over traditional estrogen replacement therapies. 17.alpha.-**dihydroequilenin** has demonstrated beneficial effects on the central nervous system function without uterotrophic effects of the type associated with estradiol. In. . . estradiol which are known to cause a thickening of the uterine lining and increase uterine weight, studies have shown that 17.alpha.-**dihydroequilenin** has minimal to no estrogenic activity in the uterus or the hypothalamic pituitary portions of the gonadal axis as determined. . .

SUMM Additionally, one of the co-inventors of the present invention has demonstrated that 17.alpha.-**dihydroequilenin** reduces plasma cholesterol in rats and improves coronary artery vasomotor function in macaques at doses that have no apparent uterotrophic. . . require concomitant administration with a sufficient dose of progestin to avoid vaginal bleeding and reduce the risk of endometrial carcinoma, 17.alpha.-**dihydroequilenin** may be administered by itself as a single hormonal therapeutic agent without the risk of endometrial cancer.

SUMM In the present invention, 17.alpha.-**dihydroequilenin** prevents atrophy of hippocampal CA-1 pyramidal cell apical dendritic spines, a brain region critical for memory and attention. While estradiol. . .

SUMM The mammalian metabolic conjugates used in the present invention are sulfates and glucuronides of 17.alpha.-dihydro-equilenin. 17.alpha.-**dihydroequilenin** can be used either in the form of a mono- or di-conjugate. It is further contemplated that any derivative of 17.alpha.-**dihydroequilenin** that forms 17.alpha.-**dihydroequilenin** or conjugate thereof in vivo may be used in treating or preventing the conditions and/or diseases described hereinabove.

SUMM . . . dysfunction in a mammal, comprising administering to a mammal susceptible to estrogen deficiency related neurodegeneration a therapeutically effective amount of 17.alpha.-**dihydroequilenin** or mammalian metabolic conjugate thereof.

SUMM In another aspect of the present invention, the route of administration for 17.alpha.-**dihydroequilenin** is selected from the group consisting of oral, intravenous, parental, transdermal, rectal, intravaginal, intranasal, and intrabronchial administration.

SUMM In yet another aspect of the present invention, 17.alpha.-**dihydroequilenin** or mammalian metabolic conjugate thereof is used to treat an estrogen deficient mammal in need of increased cognitive function.

SUMM . . . dementia related disorders, comprising administering to a mammal susceptible to neurodegeneration associated with dementia disorders a therapeutically effective amount of 17.alpha.-**dihydroequilenin** or mammalian metabolic conjugate thereof.

DRWD . . . the hippocampus expressed as the number of spines per 10 .mu.m of dendrite in ovariectomized rats (n=4 brains/group). EST=estradiol; SQ=subcutaneous; .alpha.DHEN=17.alpha.-**dihydroequilenin**.

DETD . . . present invention using ovariectomized rats, the effects of short-term (2 to 3 days) oral 17.beta.-estradiol, subcutaneous estradiol benzoate, and oral 17.alpha.-**dihydroequilenin** treatment were compared versus untreated controls on the apical dendrite spine density of pyramidal cells of the CA1 region of. . . increased spine densities relative to untreated controls, and there were no apparent differences between the treatments. These results suggest that 17.alpha.-**dihydroequilenin** is a prime candidate for a single-agent hormone replacement therapy to treat mammals with an

estrogen deficiency condition such as.

DETD 17.alpha.-**dihydroequilenin** is commercially available and the conjugates are either commercially available or can be prepared using standard chemical methodology.

DETD . . . estradiol group (n=12), given 0.05 mg/day/rat of 171.beta.-estradiol in the diet (see details below) for 3 days; and 4) the 17.alpha.-**dihydroequilenin** sulfate group (n=13), given 0.15 mg/day/rat of 17.alpha.-**dihydroequilenin** sulfate in the diet (see details below) for 3 days.

DETD Micronized 171.beta.-estradiol and 17.varies.-**dihydroequilenin** sulfate were added to a semi-synthetic diet containing approximately 40% of calories as fat and 0.08 mg/Cal cholesterol. A diet.

DETD The results obtained from these studies demonstrate that 17.varies.-**dihydroequilenin** has protective effects on hippocampal CA1 region dendritic spines, an area of the brain known to be involved with cognitive. . . to be altered in senile dementia of the Alzheimer type [see Woolley, Catherine et al., J. Comp. Neurol. 336:293 (1993)], 17.alpha.-**dihydroequilenin** may indeed exert beneficial effects on the cognitive functions of the central nervous system.

DETD Additionally, other physiological effects of 17.alpha.-**dihydroequilenin** make this potential pharmaceutical agent far superior for use in the prevention and treatment of estrogen deficiency related neurodegeneration and cognitive dysfunction than other ERTs and hormone replacement therapies. In this regard, 17.alpha.-**dihydroequilenin** does not cause hyperplasia in uteri or mammary glands of ovariectomized rats and nonhuman primates as demonstrated by one of.

DETD 17.alpha.-**dihydroequilenin** also appears to have beneficial effects on the cardiovascular system, including improvement in cholesterol concentrations in ovariectomized rats [see Washburn. . . in both female and male nonhuman primates [see Washburn et al., supra, (1996)]. In addition, male nonhuman primates responded to 17.alpha.-**dihydroequilenin** with reduced levels of arterial low density lipoprotein accumulation and no effect on prostatic or testicular weight [see Washburn et al., supra, (1996)]. 17.varies.-**dihydroequilenin** may also have beneficial effects on bone (see U.S. Pat. No. 5,545,635).

DETD When 17.alpha.-**dihydroequilenin** is used in accordance with the present invention, it can be formulated into normal dosage forms such as capsules, tablets, powders, suspensions, emulsions, solutions, syrups, aerosols, soft and hard gelatin capsules, suppositories, injectable solutions and the like. 17.alpha.-**dihydroequilenin** can be administered by itself or in combination with pharmaceutically acceptable carriers, diluents, stabilizers, solubilizers, lubricants, binders and the like or excipients thereof. Regardless of the pharmaceutical formulation, 17.alpha.-**dihydroequilenin** will be found in a proportion that will impart the desired activity to the mammal.

DETD 17.alpha.-**dihydroequilenin** may also be injected parenterally, in which case it is administered in the form of a sterile solution containing other components such as glucose or saline. It is further contemplated that 17.alpha.-**dihydroequilenin** may be administered transdermally with the use of a transdermal patch containing the active ingredient, 17.alpha.-**dihydroequilenin**, and a pharmaceutical carrier. The transdermal patch allows the delivery of 17.alpha.-**dihydroequilenin** to the skin for systemic absorption into the blood stream.

DETD The dosage requirements for 17.alpha.-**dihydroequilenin** for administration to patients will be based upon dosage requirements to achieve benefits for central nervous system, cardiovascular and bone.

DETD . . . to the patient will be determined by the administering physician based on their experience with the patient being treated. Generally, 17.alpha.-**dihydroequilenin** should be administered

at a concentration that will achieve the desired result without causing any harmful or deleterious side effects. While it is contemplated that 17.alpha.-**dihydroequilenin** has demonstrated potential as a single agent therapeutic regimen, it is contemplated that this compound may be combined with another hormonal compound to enhance the overall beneficial effects of 17.alpha.-**dihydroequilenin**.

DETD In view of the foregoing, 17.alpha.-**dihydroequilenin** appears to prevent the deleterious effects of hypoestrogenism on the central nervous, cardiovascular and skeletal systems without trophic effects on the uterus, endometrium or breast. Its target-tissue specificity suggests that 17.alpha.-**dihydroequilenin** has a great deal of potential as a single-agent therapeutic regimen for hormone replacement therapy in women suffering from estrogen. . . . Additionally, those individuals, both males and females, at risk for cognitive dysfunction would likely benefit from a prophylactic administration of 17.alpha.-**dihydroequilenin** in accordance with the methods of the present invention.

DETD . . . described herein will be apparent to those skilled in the art. By way of example, central nervous system protection by 17.alpha.-**dihydroequilenin** may enhance balance in elderly individuals, thereby reducing falls and preventing hip and other fractures.

CLM What is claimed is:

. . . dysfunction in a mammal, comprising administering to a mammal susceptible to estrogen deficiency related neurodegeneration a therapeutically effective amount of 17.alpha.-**dihydroequilenin** or a mammalian metabolic conjugate thereof.

2. The method according to claim 1, wherein the route of administration for 17.alpha.-**dihydroequilenin** is selected from the group consisting of oral, intravenous, parental, transdermal, rectal, intravaginal, intranasal, and intrabronchial administration.

3. The method according to claim 1, wherein the administered compound is 17.alpha.-**dihydroequilenin** sulfate.

. . . a mammal, comprising administering to an estrogen deficient mammal in need of increased cognitive function a therapeutically effective amount of 17.alpha.-**dihydroequilenin** or a mammalian metabolic conjugate thereof.

8. The method according to claim 7, wherein the route of administration for 17.alpha.-**dihydroequilenin** is selected from the group consisting of oral, intravenous, parental, transdermal, rectal, intravaginal, intranasal, and intrabronchial administration.

9. The method according to claim 7, wherein the administered compound is 17.alpha.-**dihydroequilenin** sulfate.

. . . to a mammal susceptible to neurodegeneration associated with Alzheimer's disease or other dementia related disorders a therapeutically effective amount of 17.alpha.-**dihydroequilenin** or a mammalian metabolic conjugate thereof.

12. The method according to claim 11, wherein the route of administration for 17.alpha.-**dihydroequilenin** is selected from the group consisting of oral, intravenous, parental, transdermal, rectal, intravaginal, intranasal, and intrabronchial administration.

13. The method according to claim 11, wherein the administered compound is 17.alpha.-**dihydroequilenin** sulfate.

. . . diseases and/or conditions, comprising administering to a mammal susceptible to estrogen deficiency diseases and/or conditions a therapeutically effective amount of 17.alpha.-**dihydroequilenin**

or a mammalian metabolic conjugate thereof.

17. The method according to claim 16, wherein the route of administration for 17.alpha.-**dihydroequilenin** is selected from the group consisting of oral, intravenous, parental, transdermal, rectal, intravaginal, intranasal, and intrabronchial administration.

18. The method according to claim 16, wherein the administered compound is 17.alpha.-**dihydroequilenin** sulfate.

. . . to a mammal susceptible to neurodegeneration associated with Alzheimer's disease or other dementia related disorders a therapeutically effective amount of 17.alpha.-**dihydroequilenin** or a mammalian metabolic conjugate thereof.

22. The method according to claim 21, wherein the route of administration for 17.alpha.-**dihydroequilenin** is selected from the group consisting of oral, intravenous, parental, transdermal, rectal, intravaginal, intranasal, and intrabronchial administration.

=>

=> fil reg

FILE 'REGISTRY' ENTERED AT 13:14:41 ON 27 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 - 703-308-4498
jan.delaval@uspto.gov

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 AUG 2003 HIGHEST RN 573649-48-6
DICTIONARY FILE UPDATES: 25 AUG 2003 HIGHEST RN 573649-48-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STN Note 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide can tot l12

L12 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2003 ACS on STN

RN 3385-03-3 REGISTRY

CN Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-
methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA
INDEX NAME)

OTHER CA INDEX NAMES:

CN 2H-Naphth[2',1':4,5]indeno[1,2-d][1,3]dioxole, pregna-1,4-diene-3,20-dione
deriv.

CN Pregna-1,4-diene-3,20-dione, 6.alpha.-fluoro-11.beta.,16.alpha.,17,21-
tetrahydroxy-, cyclic 16,17-acetal with acetone (7CI, 8CI)

OTHER NAMES:

CN 6.alpha.-Fluoro-11.beta.,21-dihydroxy-16.alpha.,17.alpha.-
(isopropylidenedioxy)pregna-1,4-diene-3,20-dione

CN Aerobid

CN Aerobid M

CN Bronalide

CN Flunisolide

CN Lunis

CN Nasalide

CN Nasarel

CN Nisolid

CN Rhinalar

CN RS 3999

CN Soluzione

CN Synaclyn

CN Syntaris

FS STEREOSEARCH

MF C24 H31 F O6


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS,
BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CBNB, CEN, CHEMCATS,
CHEMLIST, CIN, CSCHM, DDFU, DIOGENES, DRUGPAT, DRUGU, EMBASE, IFICDB,
IFIPAT, IFIUDB, MEDLINE, MRCK*, MSDS-OHS, PHAR, PHARMASEARCH, PROMT,
RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

336 REFERENCES IN FILE CA (1937 TO DATE)
 8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 340 REFERENCES IN FILE CAPLUS (1937 TO DATE)
 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 139:138763
 REFERENCE 2: 139:122742
 REFERENCE 3: 139:79535
 REFERENCE 4: 139:79252
 REFERENCE 5: 139:79178
 REFERENCE 6: 139:47304
 REFERENCE 7: 139:41843
 REFERENCE 8: 139:26449
 REFERENCE 9: 139:17578
 REFERENCE 10: 139:12244

L12 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2003 ACS on STN

RN 595-33-5 REGISTRY

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-, acetate (6CI, 8CI)

OTHER NAMES:

CN 17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione

CN 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate

CN 17.alpha.-Acetoxy-6-dehydro-6-methylprogesterone

CN 17.alpha.-Acetoxy-6-methylpregna-4,6-diene-3,20-dione

CN 17.alpha.-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate

CN 5071

CN 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone

CN 6-Methyl-.DELTA.4,6-pregnadien-17.alpha.-ol-3,20-dione acetate

CN 6-Methyl-17.alpha.-acetoxy-4,6-pregnadiene-3,20-dione

CN 6-Methyl-17.alpha.-hydroxy-.DELTA.6-progesterone acetate
 CN 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone
 CN BDH 1298
 CN DMAP
 CN Magestin
 CN Maygace
 CN Megace
 CN Megeron
 CN Megestat
 CN Megestil
 CN Megestin
 CN Megestrol acetate
 CN Megestryl acetate
 CN MGA
 CN Nia
 CN Niagestin
 CN NSC 71423
 CN Ovaban
 CN Ovarid
 CN SC 10363
 FS STEREOSEARCH
 MF C24 H32 O4
 CI COM


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
 BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST,
 CIN, CSCHM, DDFU, DIOGENES, DRUGPAT, DRUGU, EMBASE, IFICDB, IFIPAT,
 IFIUDB, IPA, MRCK*, NIOSHTIC, PHARMASEARCH, PIRA, PROMT, RTECS*,
 TOXCENTER, USAN, USPAT2, USPATFULL, VETU

(*File contains numerically searchable property data)

Other Sources: EINECS**

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

834 REFERENCES IN FILE CA (1937 TO DATE)

8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

837 REFERENCES IN FILE CAPLUS (1937 TO DATE)

35 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 139:128155

REFERENCE 2: 139:112171

REFERENCE 3: 139:111857

REFERENCE 4: 139:111641

REFERENCE 5: 139:101145

REFERENCE 6: 139:101144

REFERENCE 7: 139:101141

REFERENCE 8: 139:79130

REFERENCE 9: 139:78281

REFERENCE 10: 139:69281

L12 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2003 ACS on STN

RN 68-22-4 REGISTRY

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 19-Nor-17.alpha.-pregn-4-en-20-yn-3-one, 17-hydroxy- (7CI, 8CI)

OTHER NAMES:

CN (17.alpha.)-17-Hydroxy-19-Norpregn-4-en-20-yn-3-one

CN 17-Hydroxy-19-nor-17.alpha.-pregn-4-en-20 yn-3-one

CN 17.alpha.-Ethynyl-17.beta.-hydroxy-.DELTA.4-estren-3-one

CN 17.alpha.-Ethynyl-19-nortestosterone

CN 17.alpha.-Ethynylestr-4-en-17.beta.-ol-3-one

CN 17.alpha.-Ethynyl-17-hydroxy-4-estrene-3-one

CN 17.alpha.-Ethynyl-17-hydroxyest-4-en-3-one

CN 17.alpha.-Ethynyl-17-hydroxyestr-4-en-3-one

CN 17.alpha.-Ethynyl-17.beta.-hydroxy-19-norandrost-4-en-3-one

CN 17.alpha.-Ethynyl-17.beta.-hydroxyestr-4-en-3-one

CN 17.alpha.-Ethynyl-19-nor-androst-4-en-17.beta.-ol-3-one

CN 17.alpha.-Ethynyl-19-nortestosterone

CN 17.alpha.-Ethynyl-3-oxo-4-estren-17.beta.-ol

CN 17.beta.-Hydroxy-17.alpha.-ethynylestr-4-en-3-one

CN 19-Nor-17.alpha.-ethynyl-17.beta.-hydroxy-4-androsten-3-one

CN 19-Nor-17.alpha.-ethynylandrosten-17.beta.-ol-3-one

CN 19-Nor-17.alpha.-ethynyltestosterone

CN 19-Norandrost-4-en-3-one, 17.alpha.-ethynyl-17.beta.-hydroxy-

CN 19-Nortestosterone, 17-ethynyl-

CN Anovule

CN Conludaf

CN Conludag

CN Estr-4-ene-17.alpha.-ethynyl-17.beta.-ol-3-one

CN Ethynylnortestosterone

CN Ethynylnortestosterone

CN Gestest

CN Menzol

CN Micronett

CN Micronor

CN Micronovum

CN Mini-Pe

CN Mini-pill

CN Nor-QD

CN Noralutin

CN Norcolut

CN Norethindrone

CN Norethisteron

CN Norethisterone

CN Norethynodrone

CN Norfor

CN Norgestin

CN Norluten

CN Norlutin

CN Norluton
 CN Normapause
 CN Norpregneninolone
 CN NSC 9564
 CN Primolut N
 CN Proluteasi

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY

FS STEREOSEARCH

MF C20 H26 O2


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PHARMASEARCH, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)

Other Sources: EINECS**, WHO

(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2181 REFERENCES IN FILE CA (1937 TO DATE)
 63 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2184 REFERENCES IN FILE CAPLUS (1937 TO DATE)
 7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 139:128188
 REFERENCE 2: 139:128155
 REFERENCE 3: 139:111845
 REFERENCE 4: 139:78376
 REFERENCE 5: 139:57959
 REFERENCE 6: 139:57947
 REFERENCE 7: 139:47580
 REFERENCE 8: 139:30975
 REFERENCE 9: 139:30151
 REFERENCE 10: 139:7052

=> d his

(FILE 'HOME' ENTERED AT 12:27:28 ON 27 AUG 2003)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 12:27:40 ON 27 AUG 2003

FILE 'HCAPLUS' ENTERED AT 12:27:52 ON 27 AUG 2003

L1 7 S US20030013692/PN OR (WO2002-US1700# OR US2001-262720#)/AP, PRN
L2 1 S L1 AND (GULLANS S? OR SARANG S?)/AU
L3 23 S 17() (OH OR HYDROXY#) ()19 NORPREGN?
L4 3 S 17() (OH OR HYDROXY#) ()19 NORPREGN?(S)4 EN 20 YN 3 ONE
L5 0 S 17 ALPHA ACETYLOXY 6 METHYLPREGN? (L) 4 6 DIENE 3 20 DIONE
L6 0 S 17(L) ACETYLOXY 6 METHYLPREGN? (L) 4 6 DIENE 3 20 DIONE
L7 67 S 6 METHYLPREGN? (L) 4 6 DIENE 3 20 DIONE
L8 3 S L7 (L) 17 ALPHA (L) ACYLOXY

FILE 'REGISTRY' ENTERED AT 12:34:01 ON 27 AUG 2003

L9 1 S 3385-03-3
L10 1 S 68-22-4
L11 1 S 595-33-5
L12 3 S L9-L11
SEL RN
L13 40 S E1-E3/CRN
L14 5 S L13 NOT MXS/CI

FILE 'HCAPLUS' ENTERED AT 12:35:39 ON 27 AUG 2003

L15 3194 S L12
L16 348 S FLUNISOLID# OR AEROBID OR BRONALIDE OR NASALIDE OR NASAREL OR
L17 773 S MAGESTIN# OR MAYGACE OR MEGACE OR MEGERON OR MEGESTAT OR MEGE
L18 1454 S DMAP
L19 1288 S ANOVULE OR CONLUDAF OR CONLUDAG OR ETH!NYLNORTESTOSTERONE OR
L20 1539 S NORETHISTERONE
L21 5918 S L4, L8, L15-L20
E GULLANS S/AU
L22 98 S E3-E9
E SARANG S/AU
L23 11 S E3-E6
L24 1 S L21 AND L22, L23
L25 1 S L2, L24
E CELL DEATH/CT
L26 3881 S E4
E E3+ALL
L27 59825 S E4, E3+NT
E OXIDATIVE STRESS/CT
E E5+ALL
L28 21459 S E1
E APOPTOSIS/CT
E E3+ALL
L29 52921 S E5, E4
E PARKINSON/CT
E E6+ALL
L30 10331 S E4, E3+NT
E E10+ALL
L31 961 S E3+NT
E E6+ALL
E E9+ALL
L32 2690 S E4
E HUNTINGTON/CT
E E6+ALL
L33 0 S E2
E ALZHEIMER/CT

L34 12282 S E9-E20
 E E9+ALL
 L35 12296 S E6,E5+NT
 L36 7454 S E23+NT OR E24+NT OR E27+NT OR E28+NT OR E29+NT
 E E25+ALL
 L37 3442 S E4
 E E9+ALL
 L38 11090 S E4,E3
 E E9+ALL
 L39 2196 S E6,E5+NT
 E E15+ALL
 L40 29693 S E2+NT
 E E15+ALL
 L41 2171 S E3
 E E8+ALL
 L42 20364 S E15,E14+NT
 E E28+ALL
 L43 151105 S E5,E4+NT
 L44 6659 S E25+NT
 E E27+ALL
 L45 30136 S E4,E5,E3+NT
 E AMYOTROPHIC/CT
 E E4+ALL
 L46 2784 S E2
 E DIABETIC NEUROPATH/CT
 E E4+ALL
 L47 1337 S E2
 E HYPOXIA/CT
 L48 16248 S E3,E5-E8
 E E3+ALL
 E E2+ALL
 E BRAIN, DISEASE/CT
 L49 915 S E3 (L) HYPOX?
 L50 6166 S E3 (L) STROKE
 E MENINGIT/CT
 E MENINGIT/CT
 L51 2730 S E5-E10
 E E5+ALL
 L52 2730 S E3
 E ENCEPHALIT/CT
 L53 2313 S E4-E10
 E E4+ALL
 L54 6505 S E7,E6+NT
 E HUNTINGTON/CT
 E E7+ALL
 E NERVOUS SYSTEM, DISEASE/CT
 L55 5974 S E3-E6
 E NERVOUS SYSTEM DISEASE/CT
 E E4+ALL
 L56 3239 S NERVOUS SYSTEM?/CT (L) (HUNTINGTON? OR CHOREA?)
 L57 125 S L21 AND L26-L56
 L58 89 S L57 AND (PD<=20010117 OR PRD<=20010117 OR AD<=20010117)
 L59 44 S L58 AND L15
 L60 2 S L59 AND RELEASE PROFILE
 L61 9 S L59 AND CORTICOSTEROID
 L62 1 S L59 AND SOLUBILITY NOT L61
 L63 2 S L59 AND CLAY
 L64 3 S L59 AND TOPICAL?/TI
 L65 1 S L59 AND ALZHEIM?/TI
 L66 1 S L59 AND CYCLODEXTRIN?/TI
 L67 8 S L59 AND MATRIX
 L68 38 S L12(L)THU/RL AND L59
 L69 30 S L59 AND (1 OR 63)/SC

L70 14 S L68,L59 NOT L69
 L71 7 S L70 AND (?ALZHEIM? OR NERVOUS SYSTEM OR STROKE OR NERV? DISEA
 L72 7 S L70 NOT L71
 L73 1 S L72 AND NEUROCOGN?
 L74 38 S L69,L71,L73
 L75 45 S L58 NOT L59
 L76 39 S L25,L74 AND L1-L8,L15-L75

FILE 'REGISTRY' ENTERED AT 13:14:41 ON 27 AUG 2003

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 13:14:54 ON 27 AUG 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Aug 2003 VOL 139 ISS 9

FILE LAST UPDATED: 25 Aug 2003 (20030825/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d 176 all hitstr tot

L76 ANSWER 1 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN
 AN 2003:319266 HCAPLUS
 DN 138:343857
 TI Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
 IN Chen, Feng-Jing; Venkateshwaran, Srinivasan; Krill, Steven L.; Patel, Mahesh V.
 PA USA
 SO U.S. Pat. Appl. Publ., 55 pp., Cont.-in-part of U.S. Ser. No. 898,553.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K009-00
 NCL 424400000
 CC 63-6 (Pharmaceuticals)
 FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2003077297	A1	20030424	US 2002-74687	20020211	<--
	US 6294192	B1	20010925	US 1999-258654	19990226	<--
	US 6267985	B1	20010731	US 1999-345615	19990630	<--
	US 6248363	B1	20010619	US 1999-447690	19991123	<--
	US 2003064097	A1	20030403	US 2001-800593	20010306	<--
	US 6569463	B2	20030527			
	US 2002032171	A1	20020314	US 2001-877541	20010608	<--
	US 2002012680	A1	20020131	US 2001-898553	20010702	<--
	US 6451339	B2	20020917			

WO 2003068186 A1 20030821 WO 2003-US4195 20030211

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG

PRAI US 1999-258654 A1 19990226 <--
US 1999-345615 A2 19990630 <--
US 1999-447690 A3 19991123 <--
US 2001-800593 A2 20010306
US 2001-877541 A2 20010608
US 2001-898553 A2 20010702
US 1999-375636 A2 19990817 <--
US 2000-751968 A2 20001229 <--
US 2002-74687 A 20020211

AB The present invention pertains to pharmaceutical formulations and systems for delivery of active agents, wherein a first fraction of an active agent is suspended in a vehicle and a second fraction of active agent is solubilized in the vehicle, with the suspended fraction representing about 5 wt. % to about 80 wt. % of the active agent and the second fraction representing about 20 wt. % to about 95 wt. % of the active agent. One or more addnl. active agents, which may be fully solubilized, partially solubilized, or suspended, may also be present. The first and second fractions of the active agent may or may not have different **release profiles**. Generally, a significant fraction of the solubilized drug will release rapidly, providing for rapid onset, while the suspended drug may be formulated for delayed and/or sustained release. A pharmaceutical suspension contained isotretinoin 40, soybean oil 200, Maisine 35-1 100, and Lutrol F68 100 mg.

ST pharmaceutical formulation absorption isotretinoin

IT Taste

(-masking agent; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Lactams

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(N-vinyl, polymers; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Precipitation (chemical)

(antisolvent; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Thyroid gland

(antithyroid agents; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Mental disorder

(attention deficit disorder; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Drug delivery systems

(beads; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Ion channel blockers

(calcium; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Drug delivery systems

(capsules; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Vinyl compounds, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(carboxy-contg., polymers; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Drug delivery systems
(controlled-release; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Pelletization
(cryo-; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Drug delivery systems
(delayed release; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Tackifiers
(detackifiers; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Supercritical fluids
(expanded; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Drug delivery systems
(granules; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Fats and Glyceridic oils, biological studies
Soybean oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogenated; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrophilic; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Bladder, disease
(incontinence, inhibitors; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Gout
Osteoporosis
Pruritus
(inhibitors; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Enzymes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Extrusion, nonbiological
(melt; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Encapsulation
(microencapsulation; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Pulverization
(micronization; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Viscosity
(modulators; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Drug delivery systems
(oral, sustained release; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Drug delivery systems
(pellets; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Absorption
Acacia
Adrenoceptor agonists
Anesthetics

Anthelmintics
Anti-inflammatory agents
Antianginal agents
Antiarrhythmics
Antiarthritics
Antiasthmatics
Antibacterial agents
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetic agents
Antidiarrheals
Antiemetics
Antifoaming agents
Antihistamines
Antihypertensives
Antimalarials
Antimigraine agents
Antiobesity agents
Antioxidants

Antiparkinsonian agents

Antipsychotics
Antipyretics
Antitumor agents
Antiulcer agents
Antiviral agents
Anxiolytics
Appetite depressants
Beeswax
Binders
Buffers
Chelating agents
Cholinergic antagonists
Coacervation

Cognition enhancers

Crystallization
Decongestants
Dissolution
Diuretics
Fillers
Flavoring materials
Freeze drying
Fungicides
Hypnotics and Sedatives
Immunosuppressants
Inotropics
Leukotriene antagonists
Lubricants
Milling (size reduction)
Muscarinic antagonists
Muscle relaxants
Nervous system stimulants
Odor and Odorous substances
Opacifiers
Opioid antagonists
Plasticizers
Preservatives
Protozoacides
Size reduction
Solubilizers
Spheronization
Surfactants
Tranquilizers

Tuberculostatics
 Vasodilators
 (pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Bentonite, biological studies
Corticosteroids, biological studies
 Estrogens
 Fats and Glyceridic oils, biological studies
 Gelatins, biological studies
 Glycerides, biological studies
 Lipids, biological studies
 Macrolides
 Paraffin oils
 Polyoxyalkylenes, biological studies
 Polysaccharides, biological studies
 Sex hormones
 Silica gel, biological studies
 Vitamins
 Waxes
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Drug delivery systems
 (powders; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Polyoxyalkylenes, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (saccharide derivs.; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Muscle relaxants
 (spasmolytics; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Coating process
 Drying
 (spray; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Fats and Glyceridic oils, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (vegetable, hydrogenated; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT Adrenoceptor antagonists.
 (.beta.-; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT 7631-86-9, Silicon dioxide, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (fumed; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)


IT 329900-75-6, COX 2
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT 9004-34-6, Cellulose, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (microcryst.; pharmaceutical formulations and systems for improved absorption and multistage release of active agents)

IT 50-27-1, Estriol 50-28-2, 17.beta.-Estradiol, biological studies
 50-35-1, Thalidomide 50-50-0, 17.beta.-Estradiol benzoate 51-98-9, **Norethindrone** acetate 52-76-6, Lynestrenol 53-16-7, Estrone, biological studies 54-11-5, Nicotine 57-63-6, Ethynylestradiol 57-83-0, Progesterone, biological studies **68-22-4**, **Norethindrone** 68-23-5, Norethynodrel 68-96-2, Hydroxyprogesterone 71-58-9, Medroxyprogesterone acetate 72-33-3, Mestranol 79-10-7D, Acrylic acid, polymers 79-41-4D, Methacrylic acid,


polymers 79-64-1, Dimethisterone 128-13-2, Ursodeoxycholic Acid 152-43-2, Quinestrol 297-76-7, Ethynodiol diacetate 302-22-7, Chlormadinone acetate 302-23-8, Hydroxyprogesterone acetate 313-06-4, 17.beta.-Estradiol cypionate 427-51-0, Cyproterone acetate 432-60-0, Allylestrenol 434-03-7, Ethisterone 481-97-0, Estrone sulfate 514-61-4, Normethisterone 514-68-1, Estriol succinate 566-65-4
595-33-5, Megestrol acetate 630-56-8, Hydroxyprogesterone caproate 637-07-0, Clofibrate 797-63-7, Levonorgestrel 848-21-5, Norgestrienone 882-09-7, Clofibric acid 901-93-9, Estrone acetate 977-79-7, Medrogestone 979-32-8, 17.beta.-Estradiol valerate 1318-93-0, Montmorillonite, biological studies 1323-54-2, Acetoxypregnenolone 1327-43-1, Magnesium aluminum silicate 1335-30-4, Aluminum silicate 1343-88-0, Magnesium silicate 1405-86-3, Glycyrrhizin 1743-60-8 1951-25-3, Amiodarone 2098-66-0, Cyproterone 2529-45-5, Flurogestone acetate 2919-66-6, Melengestrol acetate 3137-73-3, Anagestone acetate 3434-88-6, 17.beta.-Estradiol diacetate 3562-63-8, Megestrol 4759-48-2, Isotretinoin 4956-37-0 5779-47-5, Ethynylestradiol 3-acetate 5934-04-3, Ethynylestradiol 3-benzoate 6533-00-2, Norgestrel 7280-37-7, Piperazine estrone sulfate 9000-07-1, Carrageenan 9000-30-0, Guar gum 9000-40-2, Locust bean gum 9000-65-1, Tragacanth 9000-69-5, Pectin 9002-18-0, Agar 9003-39-8, Polyvinyl pyrrolidone 9004-32-4, Sodium carboxymethylcellulose 9004-57-3, Ethylcellulose 9004-58-4, Ethyl hydroxyethylcellulose 9004-59-5, Ethyl methylcellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methylcellulose 9004-67-5, Methylcellulose 9005-25-8, Starch, biological studies 9005-37-2, Propylene glycol alginate 9005-38-3, Sodium alginate 9063-38-1, Sodium starch glycolate 11138-66-2, Xanthan gum 12173-47-6, Hectorite 12174-11-7, Attapulgate 14291-86-2 14929-11-4, Simfibrate 21829-25-4, Nifedipine 23288-49-5, Probucol 25189-83-7, Poly(N-vinyl caprolactam) 25322-68-3, Polyethylene glycol 25812-30-0, Gemfibrozil 30299-08-2, Clinofibrate 31637-97-5, Etofibrate 31694-55-0 31980-29-7, Nicofibrate 35189-28-7, Norgestimate 39386-78-2, Tamarind gum 41859-67-0, Bezafibrate 42017-89-0, Fenofibric acid 42408-82-2, Butorphanol 42597-57-9, Ronifibrate 49562-28-9, Fenofibrate 52214-84-3, Ciprofibrate 53694-15-8, Polyoxyethylene sorbitol 54024-22-5, Desogestrel 54048-10-1, 3-Ketodesogestrel 55285-45-5, Pirifibrate 55937-99-0, Beclobrate 60282-87-3, Gestodene 61748-93-4 61931-73-5, Ethoxylated glucose 68693-11-8, Modafinil 69047-39-8, Binifibrate 73963-72-1, Cilostazol 76547-98-3, Lisinopril 82626-48-0, Zolpidem 91161-71-6, Terbinafine 95233-18-4, Atovaquone 99614-02-5, Ondansetron 103062-96-0 107753-78-6, Zafirlukast 144034-80-0, Rizatriptan 151319-34-5, Zaleplon 159989-64-7, Nelfinavir 161814-49-9, Amprenavir 162011-90-7, Rofecoxib 163222-33-1, Ezetimibe 169590-42-5, Celecoxib
 RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
 (pharmaceutical formulations and systems for improved absorption and multistage release of active agents)
 IT **68-22-4, Norethindrone 595-33-5, Megestrol acetate**
 RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
 (pharmaceutical formulations and systems for improved absorption and multistage release of active agents)
 RN 68-22-4 HCAPLUS
 CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 595-33-5 HCAPLUS
 CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 2 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:591707 HCAPLUS
 DN 137:140509
 TI Preparation of nicotinamides and mimetics as inhibitors of
 phosphodiesterase IV isozymes
 IN Chambers, Robert J.; Magee, Thomas V.; Marfat, Anthony
 PA Pfizer Products Inc., USA
 SO Eur. Pat. Appl., 180 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 IC ICM C07D401-12
 ICS C07D405-12; C07D405-14; C07D413-12; C07D213-64; A61K031-44;
 A61K031-455; A61P029-00; A61P037-08; A61P011-06
 CC 28-5 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 27
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1229034	A1	20020807	EP 2002-250202	20020111
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002111495	A1	20020815	US 2002-62811	20020131 <--
	BR 2002000250	A	20021008	BR 2002-250	20020131
PRAI	US 2001-265240P	P	20010131		
	US 1997-43403P	P	19970404	<--	
	US 1998-105120P	P	19981021	<--	
OS	MARPAT 137:140509				
GI					



I

- AB Title compds. [I; p, q = 0, 1; m = 0-2; n = 1, 2; A = CO₂R₇, CONR₉CO₂R₇, CONR₇R₉, OP(O)(OH)₂, SO₃H, acylsulfonamido, etc.; W = O, S, SO, SO₂, NR₃; Y = N, NO, CR₁₁; R₁, R₂ = H, F, Cl, cyano, NO₂, alkyl, alkynyl, fluoroalkyl, etc.; R₃ = H, alkyl, Ph, PhCH₂, etc.; R₄-R₆ = H, F, Cl, alkynyl, cyano, NO₂, etc.; R₇ = H, (substituted) alkyl, alkenyl, alkynyl; R₉ = H, alkyl, cycloalkyl, Ph, PhCH₂, pyridyl, etc.; R₁₁ = H, F, Cl, cyano, NO₂, alkyl, alkynyl, fluoroalkyl, fluoroalkoxy, etc.; R_a, R_b = H, F, CF₃, alkyl, (substituted) cycloalkyl, Ph, PhCH₂; B₁, B₂ = 3-7 membered (hetero)cyclyl, 7-12 membered poly(hetero)cyclyl; pairs of variables may form rings; with provisos], were prepd. (no data). Thus, Me 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionate was suspended in Me₃COH. Aq. NaOH was added to the suspension, and the reaction mixt. was refluxed 1 h to give 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionic acid.
- ST nicotinamide prepn phosphodiesterase inhibitor;
benzodioxolyloxy pyridine carbonylaminomethylphenylmethylpropionate prepn
PDE4 inhibitor; drug nicotinamide deriv prepn
- IT Bradykinin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(B₁, inhibitors, combination therapy; prepn. of nicotinamides and
mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Bradykinin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(B₂, inhibitors, combination therapy; prepn. of nicotinamides and
mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Intestine, disease
(Crohn's, treatment; prepn. of nicotinamides and mimetics as inhibitors
of phosphodiesterase IV isoenzymes)
- IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(FLAP (arachidonate lipoygenase-activating protein), antagonists,
combination therapy; prepn. of nicotinamides and mimetics as inhibitors
of phosphodiesterase IV isoenzymes)
- IT **Nervous system, disease**
(Huntington's chorea, treatment; prepn. of
nicotinamides and mimetics as inhibitors of phosphodiesterase IV
isoenzymes)
- IT Antihistamines
(H₂, combination therapy; prepn. of nicotinamides and mimetics as
inhibitors of phosphodiesterase IV isoenzymes)
- IT Muscarinic antagonists
(M₁, combination therapy; prepn. of nicotinamides and mimetics as
inhibitors of phosphodiesterase IV isoenzymes)
- IT Muscarinic antagonists
(M₂, combination therapy; prepn. of nicotinamides and mimetics as
inhibitors of phosphodiesterase IV isoenzymes)
- IT Muscarinic antagonists
(M₃, combination therapy; prepn. of nicotinamides and mimetics as
inhibitors of phosphodiesterase IV isoenzymes)
- IT Eosinophil
(activation and degranulation regulators; prepn. of nicotinamides and

mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Immune system
(agents; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Nose, disease
(allergic rhinitis, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Dermatitis
(allergic, contact, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Dermatitis
(allergic, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Lung, disease
(alveolitis, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Pneumoconiosis
(anthracosis, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Anemia (disease)
(aplastic, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Aspergillus
(aspergillosis from, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Dermatitis
(atopic, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Bronchi, disease
(bronchiectasis, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Bronchi, disease
(bronchitis, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Bronchi
(bronchoconstriction, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT **Nervous system, disease**
(central, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Lung, disease
(chronic obstructive, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Immunosuppressants
(combination therapy; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Platelet-derived growth factors
Transforming growth factors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Eye, disease
(conjunctivitis, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Dermatitis
(contact, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Mental disorder
(dementia, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Bone, disease
(demineralization, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

- IT Mental disorder
(depression, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Eye, disease
(dry eye syndrome, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Breathing (animal)
(dyspnea, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Kidney, disease
(failure, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Lung, disease
(fibrosis, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Kidney, disease
(glomerulonephritis, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Anemia (disease)
(hemolytic, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Skin, disease
(hyperproliferation, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT **Learning**
 - Memory, biological**
(impairment treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Cytomegalovirus
- Fungi
- Human adenovirus
- Human herpesvirus
- Human immunodeficiency virus 1
- Human immunodeficiency virus 2
- Human immunodeficiency virus 3
- Influenza
- Yeast
(infection treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Respiratory tract, disease
(inflammation, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Intestine, disease
(inflammatory, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Liver, disease
- Reperfusion
(injury, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Lung, disease
(interstitial fibrosis, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Leukemia
(lymphocytic, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Erythema
(multiforme, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Kidney, disease
(nephrotic syndrome, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Anti-inflammatory agents
(nonsteroidal, combination therapy; prepn. of nicotinamides and

mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Respiratory tract, disease
(obstructive, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Skin, disease
(pemphigus foliaceus, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Skin, disease
(pemphigus vulgaris, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Skin, disease
(pemphigus, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Allergy inhibitors
Analgesics
Anti-AIDS agents
Anti-inflammatory agents
Antiasthmatics
Antidepressants
Antihypertensives
Antiparkinsonian agents
Antipyretics
Bronchodilators
Cognition enhancers
Fungicides
Human
Nervous system agents
(prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Arthritis
(psoriatic arthritis, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Hypertension
(pulmonary, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Connective tissue, disease
(scleroderma, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Shock (circulatory collapse)
(septic, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Disease, animal
(siderosis, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Respiratory tract, disease
(sinusitis, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Digestive tract, disease
(sprue, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT **Nervous system, disease**
(tardive dyskinesia, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT Osteoporosis
(therapeutic agents; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT AIDS (disease)
Addison's disease
Antiviral agents
Asbestosis
Asthma
Autoimmune disease
Cachexia

Cirrhosis
 Cystic fibrosis
 Dermatitis
 Dermatomyositis
 Diabetes mellitus
 Digestive tract, disease
 Drug dependence
 Emphysema
 Eosinophilia
 Fever and Hyperthermia
 Gout
 Graves' disease
 Hepatitis
 Infection
 Kidney, disease
 Lupus erythematosus
 Multiple sclerosis
 Myasthenia gravis
 Osteoporosis
 Pain

Parkinson's disease

Pneumoconiosis
 Prostate gland, disease
 Psoriasis
 Rheumatoid arthritis
 Sarcoidosis
 Silicosis
 Transplant rejection
 Urticaria
 Wilson's disease

(treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

- IT Intestine, disease
 (ulcerative colitis, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Eye, disease
 (uveitis, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Blood vessel, disease
 (vasculitis, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Infection
 (viral, treatment; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT Integrins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (.alpha.4.beta.1, inhibitors, combination therapy; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT 9036-21-9
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IV, inhibitors; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT 65154-06-5, Platelet activating factor 71160-24-2, Ltb4 72025-60-6, Ltc4 73836-78-9, Ltd4 75715-89-8, Lte4
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (antagonists, combination therapy; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)
- IT 444807-05-0P 444807-06-1P 444807-07-2P 444807-08-3P 444807-10-7P
 444807-11-8P 444807-12-9P 444807-13-0P 444807-14-1P 444807-15-2P
 444807-16-3P 444807-17-4P 444807-18-5P 444807-19-6P 444807-20-9P
 444807-21-0P 444807-22-1P 444807-23-2P 444807-24-3P 444807-25-4P
 444807-26-5P 444807-27-6P 444807-28-7P 444807-29-8P 444807-30-1P

444807-31-2P 444807-32-3P 444807-33-4P 444807-34-5P 444807-35-6P
 444807-36-7P 444807-37-8P 444807-38-9P 444807-39-0P 444807-40-3P
 444807-41-4P 444807-42-5P 444807-43-6P 444807-44-7P 444807-45-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(claimed compd.; prepn. of nicotinamides and mimetics as inhibitors of
 phosphodiesterase IV isoenzymes)

IT 59-05-2, Methotrexate 446-86-6, Azathioprine

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(combination therapy; prepn. of nicotinamides and mimetics as
 inhibitors of phosphodiesterase IV isoenzymes)

IT 50-24-8, Prednisolone 57-22-7, Vincristin 57-66-9, Probenecid
 57-96-5, Sulfinpyrazone 58-55-9, Theophylline, biological studies
 59-42-7, Phenylephrine 64-86-8, Colchicine 76-25-5, Triamcinolone
 acetone 84-22-0, Tetrahydrozoline 90-82-4, Pseudoephedrine
 101-40-6, Propylhexedrine 113-92-8, Chlorpheniramine 315-30-0,
 Allopurinol 317-34-0, Aminophyllin 404-86-4, Capsaicin 586-06-1,
 Orciprenaline 835-31-4, Naphazoline 865-21-4, Vinblastine 1218-35-5,
 Xylometazoline hydrochloride 1397-89-3, Amphotericin b 1404-26-8,
 Polymyxin B 1491-59-4, Oxymetazoline 3198-07-0 **3385-03-3**,
Flunisolide 3562-84-3, Benzbromarone 5534-09-8, Beclomethasone
 dipropionate 7440-57-5D, Gold, aurothio compds. 7683-59-2,
 Isoproterenol 14838-15-4, Phenylpropanolamine 15826-37-6, Sodium
 cromoglycate 18559-94-9, Albuterol 22916-47-8, Miconazole
 23031-25-6, Terbutaline 23593-75-1, Clotrimazole 27220-47-9, Econazole
 28797-61-7, Pirenzepine 30286-75-0, Oxitropium bromide 30392-40-6,
 Bitolterol 38677-81-5, Pirbuterol 51333-22-3, Budesonide 58581-89-8,
 Azelastine 59865-13-3, Cyclosporine 60205-81-4, Ipratropium
 65277-42-1, Ketoconazole 68844-77-9, Astemizole 73573-87-2, Formoterol
 75706-12-6, Leflunomide 79794-75-5, Loratidine 80880-90-6, Telenzepine
 83799-24-0, Fexofenadine 83869-56-1, Granulocyte macrophage colony
 stimulating factor 83881-51-0, Cetirizine 83919-23-7, Mometasone
 furoate 86386-73-4, Fluconazole 89365-50-4, Salmeterol 90566-53-3,
 Fluticasone 93211-49-5, L-651392 100643-71-8, Desloratadine
 103177-37-3, Pranlukast 103475-41-8, Tepoxalin 106096-93-9, Basic
 fibroblast growth factor 107753-78-6, Zafirlukast 111406-87-2,
 Zileuton 118414-82-7, Mk-886 120128-20-3, RG-12525 120443-16-5,
 Verlukast 126544-47-6, Ciclesonide 128253-31-6, BAY x 1005
 136310-93-5, Tiotropium bromide 140841-32-3, ZD-2138 141579-54-6,
 Fenleuton 141579-87-5, A 79175 143538-27-6, BAY x 7195 147030-01-1,
 Mk-591 147398-01-4, CGS-25019c 147432-77-7, Ontazolast 151581-24-7,
 Iralkast 154355-76-7, ABT-761 158930-07-5, L-739010 158966-92-8,
 Montelukast 162011-90-7, Rofecoxib 162750-10-9, SB-210661
 168154-07-2, L-746530 170277-31-3, Infliximab 171964-73-1, ZD-0892
 174636-32-9, Talnetant 185243-69-0, Etanercept 204974-93-6, BIIL 260
 257892-34-5, D 4418 331731-18-1, D 2E7 346735-24-8, BIIL 284
 350610-64-9, Nkp-608c 411267-65-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination therapy; prepn. of nicotinamides and mimetics as
 inhibitors of phosphodiesterase IV isoenzymes)

IT 9001-40-5, Glucose-6-phosphate dehydrogenase 9002-17-9, Xanthine oxidase
 9004-06-2, Elastase 9004-08-4, Cathepsin 9040-48-6, Gelatinase
 79955-99-0, Stromelysin 80619-02-9, 5-Lipoxygenase 97501-93-4,
 Trypsin 122191-40-6, Interleukin converting enzyme 140610-48-6,
 Stromelysin-2 142243-02-5, Map kinase 145267-01-2, Stromelysin-3
 147172-61-0, AggreCANase 175449-82-8, Collagenase-3

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors, combination therapy; prepn. of nicotinamides and mimetics
 as inhibitors of phosphodiesterase IV isoenzymes)

IT 67763-96-6, Insulin-like growth factor-1

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(mimetics, combination therapy; prepn. of nicotinamides and mimetics as

inhibitors of phosphodiesterase IV isoenzymes)

IT 106-93-4, 1,2-Dibromoethane 109-64-8, 1,3-Dibromopropane 371-41-5,
 4-Fluorophenol 458-09-3 533-31-3, Sesamol 768-09-2,
 2,1,3-Benzoxadiazol-5-ol 1452-94-4, Ethyl 2-chloronicotinate
 1878-68-8, 4-Bromophenylacetic acid 2516-47-4, Aminomethylcyclopropane
 17201-43-3, 4-Cyanobenzyl bromide 38076-80-1, 5-Chloro-2-
 hydroxynicotinic acid 82380-18-5, 2-Fluoro-4-hydroxybenzonitrile
 139911-30-1 214758-90-4

RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of nicotinamides and mimetics as inhibitors of
 phosphodiesterase IV isoenzymes)

IT 1528-41-2P 10406-25-4P 17138-28-2P 41841-16-1P 52798-01-3P
 54629-13-9P 79280-92-5P 83164-83-4P 148065-10-5P 154825-97-5P
 214758-41-5P 223513-83-5P 259543-80-1P 353282-56-1P 353282-60-7P
 444807-46-9P 444807-47-0P 444807-48-1P 444807-49-2P 444807-50-5P
 444807-51-6P 444807-52-7P 444807-53-8P 444807-54-9P 444807-55-0P
 444807-56-1P 444807-57-2P 444807-58-3P 444807-59-4P 444807-60-7P
 444807-61-8P 444807-62-9P 444807-63-0P 444807-64-1P 444807-65-2P
 444807-66-3P 444807-67-4P 444807-68-5P 444807-69-6P 444807-70-9P
 444807-71-0P 444807-72-1P 444807-73-2P 444807-74-3P 444807-75-4P
 444807-76-5P 444807-77-6P 444807-78-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of nicotinamides and mimetics as inhibitors of
 phosphodiesterase IV isoenzymes)

IT 9002-72-6, Growth hormone

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (secretagogues, combination therapy; prepn. of nicotinamides and
 mimetics as inhibitors of phosphodiesterase IV isoenzymes)

IT 9002-72-6, Growth hormone

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (secretagogues, combination therapy; prepn. of nicotinamides and
 mimetics as inhibitors of phosphodiesterase IV isoenzymes)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Geisen, K; US 4157395 A 1979 HCAPLUS
 (2) Geisen, K; US 4181658 A 1980 HCAPLUS
 (3) James, C; WO 9845268 A 1998 HCAPLUS
 (4) James, C; WO 0157025 A 2001 HCAPLUS
 (5) Tanabe Seiyaku Co; EP 0661274 A 1995 HCAPLUS
 (6) Thomae GmbH Dr K; EP 0023569 A 1981 HCAPLUS


IT 3385-03-3, Flunisolide

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination therapy; prepn. of nicotinamides and mimetics as
 inhibitors of phosphodiesterase IV isoenzymes)

RN 3385-03-3 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-
 methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)-. (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 3 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:555357 HCAPLUS
 DN 137:119684
 TI Methods of treating neurological disorders using a cytoprotective compn.
 IN **Gullans, Steven R.; Sarang, Satinder**
 PA The Brigham and Women's Hospital, Inc., USA
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 IC ICM A61K031-569

ICS A61K031-57; A61K031-573; A61K031-58; A61K045-08; A61K031-495;
 A61K031-46; A61K031-7048; A61K031-65; A61K031-4422; A61K033-14;
 A61K031-496; A61K031-137; A61K031-138; A61K031-63; A61K031-5383;
 A61K033-30; A61K031-475; A61K031-07; A61K031-192

CC 1-11 (Pharmacology)
 Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002056892	A2	20020725	WO 2002-US1700	20020122 <--
	WO 2002056892	A3	20021031		
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	US 2003013692	A1	20030116	US 2002-52691	20020118 <--
PRAI	US 2001-262720P	P	20010119 <--		
	US 2002-52691	A	20020118		
AB	The invention features a method for inhibiting neuronal cell death in a mammal by administering to the mammal a cytoprotective compn.				
ST	neuroil disorder treatment cytoprotective compn				
IT	Nervous system, disease (Huntington's chorea; methods of treating neurol. disorders using a cytoprotective compn.)				
IT	Antihistamines (H1; methods of treating neurol. disorders using a cytoprotective compn.)				
IT	Motion sickness (agents for; methods of treating neurol. disorders using a cytoprotective compn.)				
IT	Nervous system, disease (amyotrophic lateral sclerosis; methods of treating neurol. disorders using a cytoprotective compn.)				
IT	Macrolides RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL				

- (Biological study); USES (Uses)
(antibiotics; methods of treating neurol. disorders using a cytoprotective compn.)
- IT Alkaloids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(belladonna; methods of treating neurol. disorders using a cytoprotective compn.)
- IT Ion channel blockers
(calcium; methods of treating neurol. disorders using a cytoprotective compn.)
- IT **Hypoxia, animal**
(cerebral; methods of treating neurol. disorders using a cytoprotective compn.)
- IT **Nerve, disease**
Nerve, disease
(death, inhibition; methods of treating neurol. disorders using a cytoprotective compn.)
- IT **Nervous system, disease**
(degeneration; methods of treating neurol. disorders using a cytoprotective compn.)
- IT **Nerve, disease**
(diabetic neuropathy; methods of treating neurol. disorders using a cytoprotective compn.)
- IT **Brain, disease**
(hypoxia; methods of treating neurol. disorders using a cytoprotective compn.)
- IT Antibiotics
(macrolide; methods of treating neurol. disorders using a cytoprotective compn.)
- IT **Alzheimer's disease**
Anti-Alzheimer's agents
Antiarrhythmics
Antibiotics
Antidepressants
Antiparkinsonian agents
Apoptosis
Dopamine agonists
Encephalitis
Meningitis
Muscle relaxants
Nervous system, disease
Opioid antagonists
Parkinson's disease
(methods of treating neurol. disorders using a cytoprotective compn.)
- IT Alkali metals, biological studies
Corticosteroids, biological studies
Progestogens
Steroids, biological studies
Tetracyclines
Thiols (organic), biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(methods of treating neurol. disorders using a cytoprotective compn.)
- IT **Cell death**
Cell death
(neuron, inhibition; methods of treating neurol. disorders using a cytoprotective compn.)
- IT **Oxidative stress, biological**
(neuronal death from; methods of treating neurol. disorders using a cytoprotective compn.)
- IT **Cytoprotective agents**
(neuroprotectants; methods of treating neurol. disorders using a

cytoprotective compn.)

IT Anti-inflammatory agents
(nonsteroidal; methods of treating neurol. disorders using a cytoprotective compn.)

IT Ion channel blockers
(sodium; methods of treating neurol. disorders using a cytoprotective compn.)

IT **Brain, disease**
(stroke; methods of treating neurol. disorders using a cytoprotective compn.)

IT Diet
(supplements; methods of treating neurol. disorders using a cytoprotective compn.)

IT Adrenoceptor antagonists
(.alpha.-; methods of treating neurol. disorders using a cytoprotective compn.)

IT Adrenoceptor antagonists
(.beta.-; methods of treating neurol. disorders using a cytoprotective compn.)

IT 9002-62-4, Prolactin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(dopaminergic agonist as inhibitor of; methods of treating neurol. disorders using a cytoprotective compn.)

IT 9001-03-0, Carbonic anhydrase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; methods of treating neurol. disorders using a cytoprotective compn.)

IT 50-23-7, Hydrocortisone 51-34-3 52-53-9 53-03-2, Prednisone 53-06-5, Cortisone 57-62-5 59-66-5, Acetazolamide 75-08-1, Ethylmercaptan 79-57-2, Oxytetracycline 103-90-2, Acetaminophen 107-03-9, Propylmercaptan 109-79-5, Butylmercaptan 114-07-8, Erythromycin 127-33-3, Demeclocycline 127-47-9, Retinol acetate 137-58-6, Lidocaine 140-65-8, Pramoxine 144-80-9D, Sulfacetamide, analogs 146-48-5, Yohimbine 359-83-1, Pentazocine 378-44-9, Betamethasone 469-62-5, Propoxyphene 499-81-0, 3,5-Pyridinedicarboxylic acid 536-43-6, Dyclonine hydrochloride 554-13-2, Lithium carbonate 554-57-4, Methazolamide 564-25-0, Doxycycline 569-65-3 **595-33-5** 721-50-6, Prilocaine 914-00-1, Methacycline 959-24-0 1143-38-0 2751-09-9, Troleandomycin 3375-50-6, 2-Mercaptoethanesulfonic acid **3385-03-3**, **Flunisolide** 7235-40-7, .beta.-Carotene 7439-93-2, Lithium, biological studies 7440-17-7, Rubidium, biological studies 7440-46-2, Cesium, biological studies 7440-66-6; Zinc, biological studies 7440-73-5, Francium, biological studies 10118-90-8, Minocycline 15687-27-1, Ibuprofen 16590-41-3, Naltrexone 19794-93-5, Trazodone 21829-25-4 22204-53-1, Naproxen 25614-03-3, Bromocriptine 26921-17-5 31677-93-7, Bupropion hydrochloride 31828-71-4, Mexiletine 32839-18-2, Docosahexaenoic acid 32986-56-4D, Tobramycin, analogs 38194-50-2, Sulindac 38673-36-8 42924-53-8, Nabumetone 49627-27-2 51333-22-3, Budesonide 56296-78-7, Fluoxetine hydrochloride 66085-59-4 79559-97-0, Sertraline hydrochloride 81103-11-9, Clarithromycin 83905-01-5, Azithromycin 86347-15-1, Medetomidine hydrochloride 104054-27-5, Atipamezole 120279-96-1, Dorzolamide 138890-62-7, Brinzolamide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of treating neurol. disorders using a cytoprotective compn.)


IT **595-33-5 3385-03-3, Flunisolide**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of treating neurol. disorders using a cytoprotective compn.)

RN 595-33-5 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX

NAME)


Absolute stereochemistry.



RN 3385-03-3 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 4 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:521462 HCAPLUS

DN 137:88442

TI Incensole and furanogermacrene and compounds in treatment for inhibiting neoplastic lesions and microorganisms

IN Shanahan-Pendergast, Elisabeth

PA Ire.

SO PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DT Patent

LA English

IC A61K031-00

CC 1-6 (Pharmacology)

Section cross-reference(s): 10, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002053138	A2	20020711	WO 2002-IE1	20020102 <--
	WO 2002053138	A3	20020919		
	W: AE, AG, AT, AU, BB, BG, CA, CH, CN, CO, CU, CZ, LU, LV, MA, MD, UA, UG, US, VN, YU, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, ES, FI,
ML, MR, NE, SN, TD, TG

PRAI IE 2001-2 A 20010102 <--

OS MARPAT 137:88442

AB The invention discloses the use of incensole and/or furanogermacrene, derivs. metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immunodysregulatory disorders. These compds. can be administered alone or in combination with conventional chemotherapeutic, antiviral, antiparasite agents, radiation and/or surgery. Incensole and furanogermacrene and their mixt. showed antitumor activity against various human carcinomas and melanomas and antimicrobial activity against Staphylococcus aureus and Enterococcus faecalis.

ST neoplastic lesion treatment incensole furanogermacrene compd; antitumor incensole furanogermacrene; antimicrobial incensole furanogermacrene

IT Proteins

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(A, immunomodulator based on, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Leukemia

Lymphoma

(B-cell; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Fusion proteins (chimeric proteins)

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(BCR-ABL, antagonists, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Intestine, disease

(Crohn's, treatment of; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Canarypox virus

(IL-2 of, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT GTPase-activating protein

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(Ras-GAP, inhibitors, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Proteins

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Sdi 1, mimetics, pharmaceutical formulation further including; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Skin, neoplasm

(Sezary syndrome; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Leukemia

Lymphoma

(T-cell; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Transcription factors

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(WT1 (Wilms' tumor suppressor 1), therapy based on; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Keratosis

(actinic; incensole and furanogermacrene and compds. as antitumor and antimicrobial agents)

IT Leukemia

(acute; incensole and furanogermacrene and compds. as antitumor and

antimicrobial agents)

IT Lung, neoplasm
(adenocarcinoma; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Melanoma
(amelanotic; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Urokinase-type plasminogen activator receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-dorsalizing morphogenetic protein-1, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Androgens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiandrogens, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Estrogens
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiestrogens, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Antitumor agents
(antineoplastons, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Nutrients
(antinutrients, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Drug resistance
(antitumor; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Lung, disease
(aspergillosis, treatment of immunodysregulation condition caused by; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Infection
(bacterial, intracellular or extracellular, treatment of immunodysregulation condition caused by; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-Raf, antagonists, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Candida
(candidiasis from, treatment of immunodysregulation condition caused by; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Prostate gland, neoplasm
(carcinoma, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Ovary, neoplasm
Stomach, neoplasm
(carcinoma; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Mycobacterium
(cell wall sk and monophosphoryl lipid A, pharmaceutical formulation

- further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Diterpenes
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cembranoid, alcs.; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Diterpenes
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cembranoid; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT **Nervous system, disease**
(central, precancerous lesion in; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Nervous system, neoplasm
(central; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Uterus, disease
(cervix, dysplasia; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Uterus, neoplasm
(cervix; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Porphyrins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chlorins, benzo-, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Porphyrins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chlorins, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Leukemia
(chronic; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-, enteric coating of; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Intestine, neoplasm
(colon, carcinoma; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Intestine, neoplasm
(colon, polyp; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Intestine
(colon, precancerous lesion in; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Intestine, neoplasm
(colon; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Polyoxyalkylenes, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates with pyridoxylated Hb; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Quinones
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclopentantraquinones, pharmaceutical formulation further including;

- incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Immunity
(disorder, treatment of; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Stem cell
(division inhibitors, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Carbohydrates, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug delivery systems contg.; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug targeting to HIV infected cells using; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Bronchi, disease
Prostate gland, disease
(dysplasia; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Skin, neoplasm
(dysplastic nevus syndrome; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Dendritic cell
(enhancement of endogenous precursor; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Heat-shock proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(enhancement of endogenous; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enteric coating of; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Drug delivery systems
(enteric-coated; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Drug delivery systems
(enteric; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Escherichia coli
(enterohemorrhagic, treatment of immunodysregulation condition caused by infection with; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Escherichia coli
(enteroinvasive, treatment of immunodysregulation condition caused by infection with; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Escherichia coli
(enteropathogenic, treatment of immunodysregulation condition caused by infection with; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Escherichia coli
(enterotoxigenic, treatment of immunodysregulation condition caused by infection with; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Lung, neoplasm
(epidermoid; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT Gene therapy
(erythrocyte, vector system, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and

antimicrobial agents)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(for apoptosis, modulators of, pharmaceutical formulation further
including; incensole and furanogermacrems and compds. as antitumor and
antimicrobial agents)

IT Multidrug resistance
(gene inhibitor, pharmaceutical formulation further including;
incensole and furanogermacrems and compds. as antitumor and
antimicrobial agents)

IT **Apoptosis**
(gene modulators or regulators, pharmaceutical formulation further
including; incensole and furanogermacrems and compds. as antitumor and
antimicrobial agents)

IT Erythrocyte
(gene therapy vector system, pharmaceutical formulation further
including; incensole and furanogermacrems and compds. as antitumor and
antimicrobial agents)

IT Envelope proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gp120env, drug targeting to HIV infected cells using antibodies to;
incensole and furanogermacrems and compds. as antitumor and
antimicrobial agents)

IT Envelope proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(gp160env, drug targeting to HIV infected cells using antibodies to;
incensole and furanogermacrems and compds. as antitumor and
antimicrobial agents)

IT Leukemia
(hairy-cell; incensole and furanogermacrems and compds. as antitumor
and antimicrobial agents)

IT Peptides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(immunostimulant, pharmaceutical formulation further including;
incensole and furanogermacrems and compds. as antitumor and
antimicrobial agents)

IT Chemotherapy
Parasiticides
Radiotherapy
Surgery
(in combination with; incensole and furanogermacrems and compds. as
antitumor and antimicrobial agents)

IT Adrenal gland, neoplasm
Anti-AIDS agents
Anti-infective agents
Antiarthritics
Antiasthmatics
Antidiabetic agents
Antidiarrheals
Antitumor agents
Bladder, neoplasm
Brain, neoplasm
Burn
Drug delivery systems
Enterococcus faecalis
Hodgkin's disease
Human
Lymphoma
Mammary gland, neoplasm
Melanoma
Mouth, neoplasm
Multiple myeloma

Neoplasm
Newborn
Ovary, neoplasm
Pancreas, neoplasm
Prostate gland, neoplasm
Sarcoma
Staphylococcus aureus
Stomach, neoplasm
Testis, neoplasm
 (incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Yeast
 (infection with, treatment of immunodysregulation condition caused by; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Intestine, disease
 (inflammatory, treatment of; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Cartilage
 (inhibitor derived from, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Stem cell
 (inhibitor, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Insulin-like growth factor I receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitor, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Translation, genetic
 (inhibitors of, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Signal transduction, biological
 (inhibitors or modulators, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Macrophage migration inhibitory factor
 Ras proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Insulin-like growth factor-binding proteins
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (insulin-like growth factor I-binding, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Parasite
 (intracellular or extracellular infection with, treatment of immunodysregulation condition caused by; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Gamma ray
 (irradn., treatment of immunodysregulation condition caused by treatment with; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Intestine, disease
 (irritable bowel syndrome, treatment of; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Digestive tract
 (irritation, treatment of immunodysregulation condition caused by; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Paracoccidioides

- (juvenile paracoccidiomyosis, treatment of immunodysregulation condition caused by; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT Lung, neoplasm
(large-cell carcinoma; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT Bladder, disease
Skin, disease
(lesions; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT Virus
(lipid envelope, treatment of immunodysregulation condition caused by infection with; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT Peptides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipophilic disaccharide, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT Drug delivery systems
(liposomes; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT Peptides, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lytic, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT Pulverization
(micronization; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT Double stranded RNA
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mismatched, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT Antibodies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, conjugates, with liposome or carbohydrate vehicles, to tumor-assocd. antigen; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT Antibodies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, to human chorionic gonadotropin, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT Leukemia
(monocytic; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT Lipid A
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monophosphates, and mycobacterium cell wall sk, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT Nerve, disease
(motor, treatment of; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT Gram-positive bacteria (Firmicutes)
(multi-drug resistant; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Gene
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(multidrug resistance, inhibitor, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Leukemia
(myelogenous; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Leukemia
(myelomonocytic; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
(nasal; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Hematopoietic precursor cell
(neoplasm; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT **Nerve, neoplasm**
(**neuroblastoma**; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Antioxidants
(nitroxide, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Lymphocyte
(null cell, leukemia; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Interleukin 2
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(of canarypox virus, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Cytokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(oral inducer, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
(oral; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
(parenterals; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Antiviral agents
(pharmaceutical formulation further contg.; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulation further contg.; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Angiogenesis inhibitors

Antivenoms

Cytotoxic agents

Immunostimulants

Mycobacterium bovis

Venoms
(pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Antisense oligonucleotides

Estrogens

Heregulins

Hormones, animal, biological studies

Interleukins

Leukemia inhibitory factor
Oligonucleotides
Polyamines
Ribozymes
Steroids, biological studies
Taxanes
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(pharmaceutical formulation further including; incensole and
furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Disease, animal
(polyposis syndrome; incensole and furanogermacrens and compds. as
antitumor and antimicrobial agents)

IT Fatty acids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(poppy seed-oil, Et esters, labeled with iodine-131, pharmaceutical
formulation further including; incensole and furanogermacrens and
compds. as antitumor and antimicrobial agents)

IT Kidney, disease
Lung, disease
Mammary gland, disease
Stomach, disease
(precancerous lesion in; incensole and furanogermacrens and compds. as
antitumor and antimicrobial agents)

IT Drug delivery systems
(prodrugs; incensole and furanogermacrens and compds. as antitumor and
antimicrobial agents)

IT Hemoglobins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(reaction products, with pyridoxal phosphate, conjugates with
polyoxyethylene, pharmaceutical formulation further including;
incensole and furanogermacrens and compds. as antitumor and
antimicrobial agents)

IT Drug delivery systems
(rectal; incensole and furanogermacrens and compds. as antitumor and
antimicrobial agents)

IT Kidney, neoplasm
(renal cell carcinoma; incensole and furanogermacrens and compds. as
antitumor and antimicrobial agents)

IT Antitumor agents
(resistance to; incensole and furanogermacrens and compds. as antitumor
and antimicrobial agents)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(saporins, fibroblast growth factor conjugates; incensole and
furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(senescence-derived inhibitor 1, pharmaceutical formulation further
including; incensole and furanogermacrens and compds. as antitumor and
antimicrobial agents)

IT Oligonucleotides
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(sense, pharmaceutical formulation further including; incensole and
furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Shock (circulatory collapse)
(septic, treatment of; incensole and furanogermacrens and compds. as
antitumor and antimicrobial agents)

IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(single chain antigen binding protein, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Cell wall
(sk of mycobacteria and monophosphoryl lipid A, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Leukemia
(small cell; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Lung, neoplasm
(small-cell carcinoma; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Neoplasm
(solid; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Carcinoma
(squamous cell; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
(sublingual; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Glycosaminoglycans, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthetic, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Lupus erythematosus
(systemic, treatment of; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Human immunodeficiency virus
(targeting to cells infected with; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(thymopoietin, agonists, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
(topical; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Stem cell factor
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(totipotent, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT Adeno-associated virus
Balantidium
Balantidium coli
Borrelia
Campylobacter
Candida
Coronavirus
Cryptococcus (fungus)
Cryptosporidium
DNA viruses
Entamoeba
Entamoeba histolytica
Filovirus
Flavivirus

Haemophilus
Hantavirus
Human papillomavirus
Human parainfluenza virus
Human poliovirus
Influenza virus
Legionella
Leishmania
Leishmania braziliensis
Leishmania donovani
Leishmania mexicana
Leishmania tropica
Listeria
Measles virus
Mycoplasma
Papillomavirus
Pestivirus
Picornaviridae
Plasmodium berghei
Plasmodium falciparum
Plasmodium malariae
Plasmodium ovale
Plasmodium vivax
Pneumocystis
Pneumocystis carinii
Poxviridae
Pseudomonas
RNA viruses
Respiratory syncytial virus
Retroviridae
Rhinovirus
Rubivirus
Salmonella
Shigella
Staphylococcus
Streptococcus
Togaviridae
Toxoplasma
Toxoplasma gondii
Trichomonas
Trichomonas vaginalis
Trypanosoma
Trypanosoma brucei
Trypanosoma cruzi
Trypanosoma gambiense
Trypanosoma rhodesiense
Vibrio
Yersinia

(treatment of immunodysregulation condition caused by infection with;
incensole and furanogermacrens and compds. as antitumor and
antimicrobial agents)

IT **Corticosteroids**, biological studies

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(treatment of immunodysregulation condition caused by treatment with;
incensole and furanogermacrens and compds. as antitumor and
antimicrobial agents)

IT **Nucleoside analogs**

RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(treatment of immunodysregulation condition caused by treatment with;
incensole and furanogermacrens and compds. as antitumor and
antimicrobial agents)

IT **Immunosuppressants**

Mycosis
Protozoa
Wound
 (treatment of immunodysregulation condition caused by; incensole and
 furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Arthritis
Asthma
Autoimmune disease
Cachexia
Cirrhosis
Diabetes mellitus
Diarrhea
Multiple sclerosis
Respiratory distress syndrome
 (treatment of; incensole and furanogermacrems and compds. as antitumor
 and antimicrobial agents)

IT Antigens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (tumor-assocd., drug targeting with monoclonal antibody to; incensole
 and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Cytotoxic agents
 (tyrophostins, pharmaceutical formulation further including; incensole
 and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Drug delivery systems
 (vaginal; incensole and furanogermacrems and compds. as antitumor and
 antimicrobial agents)

IT Infection
 (viral, treatment of immunodysregulation condition caused by; incensole
 and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Disease, animal
 (wasting, treatment of; incensole and furanogermacrems and compds. as
 antitumor and antimicrobial agents)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (.alpha., n1, pharmaceutical formulation further including; incensole
 and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (.alpha., n3, pharmaceutical formulation further including; incensole
 and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (.alpha., pharmaceutical formulation further including; incensole and
 furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (.alpha.-2a, pharmaceutical formulation further including; incensole
 and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (.alpha.-2b, pharmaceutical formulation further including; incensole
 and furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Lactams
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (.beta.-, pharmaceutical formulation further including; incensole and
 furanogermacrems and compds. as antitumor and antimicrobial agents)

IT Interferons

- RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta.1, a, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT Interferons
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.gamma., 1b, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT 37221-79-7, Vasoactive intestinal peptide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonist, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT 9002-06-6, Thymidine kinase
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonists, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT 505-60-2, Mustard
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anticancer, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT 7585-39-9, .beta.-Cyclodextrin 7585-39-9D, .beta.-Cyclodextrin, hydroxypropyl derivs. 10016-20-3, .alpha.-Cyclodextrin 12619-70-4, Cyclodextrin 17465-86-0, .gamma.-Cyclodextrin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as pharmaceutical carrier; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT 80-62-6, Methyl methacrylate 2867-47-2, (2-Dimethylaminoethyl) methacrylate 9004-38-0, Cellulose acetate phthalate 34346-01-5, Poly(lactic acid-glycolic acid) 441015-98-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enteric coating of; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT 121749-39-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epharmaeputical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)
- IT 54-47-7D, Pyridoxal phosphate, reaction products with Hb conjugates
76-49-3, Bornyl acetate 80-57-9, Verbenone 87-44-5, .beta.-Caryophyllene 88-84-6, .beta.-Guaiene 99-49-0, Carvone 99-83-2, .alpha.-Phellandrene 99-87-6, p-Cymene 112-14-1, Octyl acetate 123-35-3, Myrcene 473-11-0, Eudesmane 489-80-5, Guaiane 495-61-4, .beta.-Bisabolene 502-61-4, Farnesene 507-70-0, Borneol 511-59-1, .beta.-Santalene 512-61-8, .alpha.-Santalene 515-12-8, Elemene 523-47-7, .beta.-Cadinene 555-10-2, .beta.-Phellandrene 562-74-3, Terpinen-4-ol 1335-14-4 1674-08-4, trans-Pinocarveol 1820-09-3, trans-Verbenol 2867-05-2, .alpha.-Thujene 3856-25-5, .alpha.-Copaene 4602-84-0, Farnesol 5208-59-3, .beta.-Bourbonene 6753-98-6, Humulene 6895-56-3, .beta.-Bergamotene 7663-66-3, Bergamotane 8007-35-0, Terpinyl acetate 8013-00-1, Terpinene 10178-38-8, Echinodol 14998-63-1D, Rhenium-186, etidronate complexes, biological studies 17627-44-0, .alpha.-Bisabolene 18794-84-8, .beta.-Farnesene 19912-61-9, Furanodiene 20479-06-5, .beta.-Ylangene 21698-66-8, Incensole oxide 21698-67-9, Incensole oxide acetate 22419-74-5, Incensole 25269-16-3, Isocembrene 25322-68-3D, conjugates with pyridoxylated Hb 28028-64-0, Germacrene 29063-28-3, Octanol 29350-73-0, Cadinene 31570-39-5, Cembrene-A 34701-53-6 35731-88-5, Isoincensole oxide 67921-02-2, Cembrenol 94325-73-2 94325-73-2D, compds. 122537-31-9, Oplopane 441771-56-8, Isoincensole 441771-57-9,

- Isoincensole acetate 441771-74-0, SKB 4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT 141436-78-4, Protein kinase C
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitor, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT 52660-18-1, Casein kinase 1 366806-33-9, Casein kinase 2
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors (ICOS), pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT 144114-21-6, HIV-1 Protease
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors, pharmaceutical formulation further contg.; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT 70-18-8, Glutathione, biological studies 9030-21-1, Purine nucleoside phosphorylase 9040-48-6, Gelatinase 79747-53-8, Protein tyrosine phosphatase 79955-99-0, Stromelysin 80449-02-1, Tyrosine kinase 106096-93-9, Basic fibroblast growth factor 120178-12-3, Telomerase 131384-38-8, Ras farnesyltransferase 140879-24-9, Proteasome 141256-52-2, Matrilysin 141907-41-7, **Matrix** metalloproteinase 375798-61-1, Phosphatase, phosphoprotein
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT 10102-43-9, Nitric oxide, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (modulators, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT 9002-61-3, Chorionic gonadotrophin
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (monoclonal antibody to human, pharmaceutical formulation further including; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT 9068-38-6, Reverse transcriptase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (nonnucleoside inhibitors of, pharmaceutical formulation further contg.; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT 1406-18-4, Vitamin E
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oil, as pharmaceutical carrier; incensole and furanogermacrems and compds. as antitumor and antimicrobial agents)
- IT 54-05-7, Chloroquine 54-42-2, Idoxuridine 60-54-8, Tetracycline 69-74-9, Cytarabine Hydrochloride 70-00-8, Trifluridine 80-08-0, Dapsone 90-34-6, Primaquine 100-33-4, Pentamidine 130-95-0, Quinine 443-48-1, Metronidazole 494-79-1, Melarsoprol 665-66-7, Amantadine Hydrochloride 1501-84-4, Rimantadine Hydrochloride 1910-68-5, Methisazone 3056-17-5, d4T 3736-81-0, Diloxanide furoate 5536-17-4, Vidarabine 7481-89-2, DdC 8064-90-2 9004-70-0, HE-2000 10500-82-0, Famotidine Hydrochloride 10540-97-3, Memotidine Hydrochloride 11006-77-2, Statolon 15176-29-1, Edoxudine 15185-43-0, DOTC 19387-91-8, Tinidazole 19885-51-9, Aranotin 22994-85-0, Benznidazole 23256-30-6, Nifurtimox 25526-93-6, Alovudine 27591-69-1, Tilorone Hydrochloride 27762-78-3, Kethoxal 29984-33-6, Vidarabine Phosphate 30516-87-1, AZT 35607-20-6, Avridine 36791-04-5, Ribavirin 36983-81-0, Fosfonet Sodium 37338-39-9 39809-25-1, Penciclovir 51867-87-9 53230-10-7, Mefloquine 56219-57-9, Arildone 59277-89-3, Acyclovir 63198-97-0, Viroxime 63585-09-1, Foscarnet Sodium 63968-64-9D, Artemisinin, derivs. 68693-30-1, Somantadine Hydrochloride 69123-90-6, Fiacitabine

69123-98-4, Fialuridine 69655-05-6, DdI 69657-51-8, Acyclovir Sodium
 69756-53-2, Halofantrine 72301-78-1, Ziniviroxime 72301-79-2,
 Enviroxime 73514-87-1, Fosarilate 77181-69-2, Sorivudine 80883-55-2,
 Enviradene 82410-32-0, Ganciclovir 84408-37-7, Desciclovir
 85087-20-3, Doxycycline 87495-31-6, Disoxaril 95233-18-4, Atovaquone
 100817-46-7, Stibogluconic acid 104227-87-4, Famciclovir 106362-32-7,
 Peptide T 106941-25-7, PMEA 107910-75-8, Ganciclovir Sodium
 110042-95-0, Acemannan 110143-10-7, Lodenosine 113852-37-2, Cidofovir
 124436-59-5, Pirodavis 124832-27-5, Valacyclovir Hydrochloride
 127759-89-1, Lobucavir 127779-20-8, Saquinavir 129618-40-2, Nevirapine
 132210-43-6, Cipamfylline 134678-17-4, 3TC 136470-78-5, Abacavir
 136817-59-9, Delavirdine 137487-62-8, Alvircept Sudotox 138540-32-6,
 Ateviridine Mesylate 141204-94-6, Co-artemether 142340-99-6
 142632-32-4, Calanolide A 143491-57-0, Coviracil 145514-04-1, DAPD
 147127-20-6, Tenofovir 147221-93-0, Delavirdine Mesylate 147318-81-8,
 KNI-272 147362-57-0, Loviride 149845-06-7, Saquinavir Mesylate
 149950-60-7, Emivirine 150378-17-9, Indinavir 153127-49-2, ALX40-4C
 154598-52-4, DMP 266 155148-31-5, AMD 3100 155213-67-5, Ritonavir
 156879-70-8 159519-65-0, Pentafuside 159989-64-7, Nelfinavir
 163451-80-7 170020-61-8, FP-21399 174484-41-4, Tipranavir
 177932-89-7, DMP-450 178979-85-6, AG 1549 185220-03-5, PNU142721
 192725-17-0, ABT-378 214287-88-4, DPC961 216863-66-0, L-756423
 251562-00-2, T-1249 383198-56-9, BW 141 383198-57-0, BMS-232630
 383198-58-1, PRO 542.

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(pharmaceutical formulation further contg.; incensole and
 furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 50-07-7, Mutamycin 50-18-0, Cyclophosphamide 50-28-2, Estradiol,
 biological studies 50-35-1, Thalidomide 50-76-0, Dactinomycin
 50-91-9, Floxuridine 51-21-8, Fluorouracil 51-75-2, Mechlorethamine
 52-24-4, Thiotepe 53-19-0, Mitotane 53-43-0, DHEA 53-79-2, Puromycin
 54-71-7, Pilocarpine hydrochloride 54-91-1, Pipobroman 55-21-0D,
 Benzamide, N-substituted compds. 55-86-7, Mechlorethamine Hydrochloride
 55-86-7D, Nitrogen mustard, derivs. 55-98-1, Busulfan 56-53-1,
 Diethylstilbestrol 57-22-7, Vincristine 57-63-6, Ethinyl oestradiol
 57-83-0, Progesterone, biological studies 58-05-9, Leucovorin 58-58-2,
 Puromycin Hydrochloride 59-05-2, Methotrexate 66-75-1, Uracil Mustard
 83-89-6, Acriquine 101-60-0, Porphyrin 106-60-5, Aminolevulinic acid
 114-70-5, Sodium phenylacetate 122-79-2, Phenylacetate 125-45-1,
 Azetepa 125-84-8, Aminogluthethimide 127-07-1, Hydroxyurea 143-67-9,
 Vinblastine Sulfate 145-63-1, Suramin 147-94-4, Cytarabine 148-82-3,
 Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine 302-49-8,
 Uredopa 302-79-4, Tretinoin 305-03-3, Chlorambucil 320-67-2,
 Azacitidine 359-83-1, Pentazocine 364-62-5, Metoclopramide 366-70-1,
 Procarbazine Hydrochloride 378-44-9, Betamethasone 423-55-2,
 Perflubron 459-86-9, Mitoguazone 465-65-6, Naloxone 472-15-1,
 Betulinic acid 481-29-8, Epiandrosterone 518-28-5, Podophyllotoxin
 520-85-4, Medroxyprogesterone 521-12-0, Dromostanolone Propionate
 536-59-4, Perillyl alcohol 548-04-9, Hypericin 566-48-3, Formestane
 569-57-3, Chlorotrianisene 578-95-0D, Acridone, imidazo derivs..
 578-95-0D, Acridone, propylbis derivs. 595-33-5,
Megestrol Acetate 645-05-6, Altretamine 646-08-2,
 .beta.-Alethine 671-16-9, Procarbazine 801-52-5, Porfiromycin
 865-21-4, Vinblastine 911-45-5, Clomifene 968-93-4, Testolactone
 1271-19-8, Titanocene dichloride 1402-81-9, Ambomycin 1403-99-2,
 Mitogillin 1404-00-8, Mitomycin 1404-15-5, Nogalamycin 1404-20-2,
 Peliomycin 1404-64-4, Sparsomycin 1661-29-6, Meturedopa 1972-08-3,
 Dronabinol 1980-45-6, Benzodopa 2068-78-2, Vincristine Sulfate
 2353-33-5, Decitabine 2508-89-6 2608-24-4, Puposulfan 2809-21-4D,
 Etidronic acid, rhenium-186 complexes 2919-66-6, Melengestrol acetate
 2998-57-4, Estramustine 2998-57-4D, Estramustine, analogs 3073-59-4,
 Hexamethylene bisacetamide 3094-09-5, Doxifluridine 3562-63-8,

Megestrol 3778-73-2, Ifosfamide 3930-19-6, Streptonigrin 4105-38-8
 4291-63-8, Cladribine 4342-03-4, Dacarbazine 4342-07-8 4803-27-4,
 Anthramycin 5072-26-4, Buthionine sulfoximine 5373-42-2, Thaliblastine
 5508-58-7, Andrographolide 5579-27-1, Simtrazene 5581-52-2,
 Thiamiprine 5696-17-3, Epipropidine 6157-87-5, Trestolone Acetate
 7281-31-4, Vinglycinat Sulfate 7440-06-4D, Platinum, lipophilic compds.
 or complexes 7440-06-4D, Platinum, triamine complexes 7644-67-9,
 Azotomycin 7689-03-4D, Camptothecin, derivs. 7724-76-7, Riboprine
 7761-45-7, Metoprine 8052-16-2, Cactinomycin 9002-71-5,
 Thyroid-stimulating hormone 9014-02-2, Zinostatin 9014-42-0,
 Thrombopoietin 9014-42-0D, Thrombopoietin, mimetics 9015-68-3,
 Asparaginase 9027-98-9 9041-93-4, Bleomycin Sulfate 9050-67-3,
 Sizofiran 10043-49-9, Gold-198, biological studies 10087-89-5,
 Enpromate 10318-26-0, Mitolactol 10403-51-7, Mitindomide 10540-29-1,
 Tamoxifen 11002-22-5, Apurinic acid 11029-06-4, Elemene 11043-98-4,
 Mitocromin 11043-99-5, Mitomalcin 11056-06-7, Bleomycin 11056-12-5,
 Cirolemycin 11056-14-7, Mitocarcin 11056-15-8, Mitosper 12713-07-4D,
 Verdin, compds. 13010-47-4, Lomustine 13311-84-7, Flutamide
 13494-90-1, Gallium nitrate 13665-88-8, Mopidamol 13909-09-6,
 Semustine 14769-73-4, Levamisole 15475-56-6, Methotrexate Sodium
 15639-50-6, Safingol 15663-27-1, Cisplatin 17021-26-0, Calusterone
 17902-23-7, Tegafur 18378-89-7, Plicamycin 18416-85-8, Lombricine
 18556-44-0, Vinrosidine Sulfate 18588-57-3, Etoprine 18883-66-4,
 Streptozocin 19916-73-5, O6-Benzylguanine 20098-14-0, Idramantone
 20537-88-6, Amifostine 20638-84-0, Retinamide 20830-81-3, Daunorubicin
 21059-48-3, Veramine 21679-14-1, Fludarabine 22668-01-5, Etanidazole
 23214-92-8, Doxorubicin 23541-50-6, Daunorubicin Hydrochloride
 23593-75-1, Clotrimazole 24280-93-1, Mycophenolic Acid 24584-09-6,
 Dexrazoxane 25316-40-9, Adriamycin 27302-90-5, Oxisuran 27314-97-2,
 Tirapazamine 27548-93-2D, Baccatin III, derivs. 27686-84-6, Masoprocol
 29069-24-7, Prednimustine 29767-20-2, Teniposide 30303-65-2, Docosanol
 30387-51-0, Asperlin 30868-30-5, Pyrazofurin 31430-18-9, Nocodazole
 31441-78-8, Mercaptopurine 32954-58-8, Ipomeanol 33069-62-4,
 Paclitaxel 33069-62-4D, Paclitaxel, analogs and derivs. 33419-42-0,
 Etoposide 35301-24-7, Cedefingol 35846-53-8, Maytansine 35943-35-2,
 Triciribine 36508-71-1, Zorubicin Hydrochloride 37717-21-8,
 Flurocitabine 38270-90-5, Strontium Chloride Sr 89 38321-02-7,
 Dexverapamil 39325-01-4, Picibanil 40391-99-9, Pamidronic acid
 41575-94-4, Carboplatin 41729-52-6, Dezaguanine 41992-22-7,
 Spirogermanium Hydrochloride 42228-92-2, Acivicin 42616-25-1,
 Methioninase 50264-69-2, Lonidamine 51264-14-3, Amsacrine
 51321-79-0, Sparfosic acid 52128-35-5, Trimetrexate 52205-73-9,
 Estramustine Phosphate Sodium 52794-97-5, Carubicin Hydrochloride
 53643-48-4, Vindesine 53714-56-0, Leuprolide 53910-25-1, Pentostatin
 54081-68-4, Vinleurosine Sulfate 54824-17-8, Mitonafide 55435-65-9,
 Acodazole Hydrochloride 56390-09-1, Epirubicin Hydrochloride
 56420-45-2, Epirubicin 56605-16-4, Spiromustine 56741-95-8,
 Bropirimine 57381-26-7, Irsogladine 57576-44-0, Aclarubicin
 57773-63-4, Triptorelin 57773-65-6, Deslorelin 57852-57-0, Idamycin
 57998-68-2, Diaziquone 58066-85-6, Miltefosine 58525-82-9, Azatyrosine
 58957-92-9, Idarubicin 58970-76-6, Ubenimex 59653-73-5, Teroxirone
 59917-39-4, Vindesine Sulfate 59989-18-3, 5-Ethynyluracil 60084-10-8,
 Tiazofurin 60203-57-8, Prostaglandin J2 60940-34-3, Ebselen
 61825-94-3, Oxaliplatin 61966-08-3, Triciribine Phosphate 62304-98-7,
 Thymalfasin 62435-42-1, Perfosfamide 62488-57-7 62816-98-2,
 Ormaplatin 62928-11-4, Iproplatin 63590-19-2, Balanol 63612-50-0,
 Nilutamide 63950-06-1, Esorubicin Hydrochloride 65057-90-1,
 Talisomycin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(pharmaceutical formulation further including; incensole and
 furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 65093-40-5, Cytarabine ocfosfate 65222-35-7, Pazelliptine 65271-80-9,

Mitoxantrone 65646-68-6, Fenretinide 65807-02-5, Goserelin
 65886-71-7, Fazarabine 66569-27-5, Sparfosate Sodium 66849-34-1,
 Dexifosfamide 67699-41-6, Vinzolidine Sulfate 68278-23-9, Eflornithine
 Hydrochloride 68475-42-3, Anagrelide 69839-83-4, Didox 70052-12-9,
 Eflornithine 70384-29-1, Peplomycin Sulfate 70476-82-3, Mitoxantrone
 Hydrochloride 70641-51-9, Edelfosine 70711-40-9, Ametantrone Acetate
 71294-60-5, Rohitukine 71439-68-4, Bisantrene Hydrochloride
 71486-22-1, Vinorelbine 71522-58-2, Forfenimex 71628-96-1, Menogaril
 72238-02-9D, Retelliptine, demethyl derivs. 72496-41-4, Pirarubicin
 72629-69-7, Sarcophytol A 72732-56-0, Piritrexim 72741-87-8,
 Swainsonine 73105-03-0, Pentamustine 74149-70-5, Parabactin
 74381-53-6, Leuprolide Acetate 74790-08-2, Spiroplatin 75219-46-4,
 Atrimustine 75330-75-5, Lovastatin 75607-67-9, Fludarabine Phosphate
 75775-33-6D, Purpurin, compds. 75957-60-7, Splenopentin 76932-56-4,
 Nafarelin 77016-85-4, Plomestane 77327-05-0, Didemnin B 77599-17-8,
 Panomifene 77858-21-0, Velaresol 78113-36-7, Romurtide 78186-34-2,
 Bisantrene 79778-41-9, Neridronic acid 79831-76-8, Castanospermine
 80451-05-4, Cecropin B 80576-83-6, Edatrexate 80663-95-2 80841-47-0,
 Asulacrine 81424-67-1, Caracemide 81965-43-7, SarcNU 82230-03-3,
 Carbetimer 82413-20-5, Droloxifene 82707-54-8, Neutral endopeptidase
 82855-09-2D, Combretastatin, analogs 82952-64-5, Trimetrexate
 Glucuronate 83086-73-1, Tubulozole Hydrochloride 83150-76-9,
 Octreotide 83200-11-7, Vinepidine Sulfate 83519-04-4, Ilmofofosine
 83997-75-5, Iododoxorubicin 84030-84-2, Telluropyrylium 84088-42-6,
 Roquinimex 84371-65-3, Mifepristone 84412-94-2, Ruboxyl 85465-82-3,
 Thymotrinan 85622-93-1, Temozolomide 85754-59-2, Ambamustine
 85969-07-9, Budotitane 85977-49-7, Tauromustine 86976-56-9,
 Betaclamycins 87005-03-6, Panaxytriol 87434-82-0, Dezaguanine Mesylate
 87806-31-3, Porfimer Sodium 87810-56-8, Fostriecin 87860-39-7,
 Fostriecin Sodium 88303-60-0, Losoxantrone 88303-61-1, Losoxantrone
 Hydrochloride 89565-68-4, Tropisetron 89778-26-7, Toremifene
 89778-27-8, Toremifene Citrate 90357-06-5, Bicalutamide 90996-54-6,
 Rhizoxin 92047-76-2, Tetrachlorodecaoxide 92118-27-9, Fotemustine
 92788-10-8, Rogletimide 92803-82-2, Aphidicolin glycinate 94079-80-8,
 Cicaprost 95058-81-4, Gemcitabine 95734-82-0, Nedaplatin 95933-72-5,
 Amidox 96201-88-6, Brequinar Sodium 96301-34-7, Atamestane
 96346-61-1, Onapristone 96389-68-3, Crisnatol 96389-69-4, Crisnatol
 Mesylate 96392-96-0, Dexormaplatin 96892-57-8, Hepsulfam 97068-30-9,
 Elsamitrucin 97534-21-9, Merbarone 97682-44-5, Irinotecan
 97752-20-0, Droloxifene Citrate 97919-22-7 98319-26-7, Finasteride
 98383-18-7, Ecomustine 98631-95-9, Sobuzoxane 99009-20-8,
 Pyrazoloacridine 99011-02-6, Imiquimod 99283-10-0, Molgramostim
 99614-02-5, Ondansetron 100286-90-6, Irinotecan Hydrochloride
 100324-81-0, Lisofylline 102396-24-7, Jasplakinolide 102676-31-3,
 Fadrozole Hydrochloride 102676-47-1, Fadrozole 102822-56-0,
 Mannostat A 103222-11-3, Vapreotide 103612-80-2 104493-13-2,
 Adécypenol 105118-12-5, Piroxantrone Hydrochloride 105149-04-0,
 Osaterone 105615-58-5, Oxaunomycin 105844-41-5, Plasminogen activator
 inhibitor 106096-93-9D, Basic Fibroblast growth factor, saporin
 conjugates 106400-81-1, Lometrexol 107000-34-0, Zanoterone
 107256-99-5, Tamoxifen methiodide 107868-30-4, Exemestane 108736-35-2,
 Lanreotide 108852-90-0, Nemorubicin 109837-67-4, Cycloplatan
 110267-81-7, Amrubicin 110311-27-8, Sulofenur 110314-48-2, Adozelesin
 110690-43-2, Emitetur 110942-02-4, Aldesleukin 110942-08-0, Luprolide
 111490-36-9, Zaniplatin 111523-41-2, Enloplatin 112515-43-2, Topsentin
 112522-64-2, Acetyldinaline 112809-51-5, Letrozole 112859-71-9,
 Fluasterone 112887-68-0, Raltitrexed 112965-21-6, Calcipotriol
 114084-78-5, Ibandronic acid 114285-68-6, Lentinan sulfate
 114517-02-1, Fosquidone 114977-28-5, Taxotere 115150-59-9, Antagonist
 G 115308-98-0, Tallimustine 115566-02-4, Bistratene A 115575-11-6,
 Liarozole 115956-12-2, Dolasetron 116057-75-1, Idoxifene
 117048-59-6, Combretastatin A4 117091-64-2, Etoposide Phosphate
 118292-40-3, Tazarotene 119169-78-7, Epristeride 119413-54-6,

Topotecan Hydrochloride 119813-10-4, Carzelesin 120287-85-6, Cetorelix 120408-07-3, Lometrexol Sodium 120500-15-4, Leinamycin 120511-73-1, Anastrozole 120685-11-2, Benzoylstauosporine 121181-53-1, Filgrastim 121263-19-2, Calphostin C 121288-39-9, Loxoribine 121547-04-4, Mirimostim 122111-03-9, Gemcitabine Hydrochloride 122341-38-2, Temoporfin 122431-96-3 122898-63-9, Phenazinomycin 123040-69-7, Azasetron 123258-84-4, Itasetron 123760-07-6, Zinostatin stimalamer 123774-72-1, Sargramostim 123830-79-5, Teloxantrone Hydrochloride 123948-87-8, Topotecan 124012-42-6, Galocitabine 124689-65-2D, Cryptophycin A, derivs. 124784-31-2, Erbulozole 124904-93-4, Ganirelix 125317-39-7, Vinorelbine Tartrate 125392-76-9, Acylfulvene 125533-88-2, Mofarotene 126297-39-0, Lissoclinamide 7 126443-96-7, Napavin 127984-74-1, Lanreotide Acetate 128505-88-4, Naphterpin 128768-09-2, Placetin A 128768-11-6, Placetin B 129497-78-5, Verteporfin 129564-92-7, Azatoxin 129655-21-6, Bizelesin 129731-10-8, Vorozole 130167-69-0, Pegaspargase 130288-24-3, Duocarmycin SA 130364-39-5, Rubiginone B1 130370-60-4, Batimastat 131190-63-1, Saintopin 132036-88-5, Ramosetron 132073-72-4, Tetrazomine 133432-71-0, Peldesine 134088-74-7, Nartograstim 134381-30-9, Conagenin 134523-84-5 134633-29-7, Tecogalan Sodium 134861-62-4, Dioxamycin 135257-45-3, Crambescidin 816 135381-77-0, Flezelastine 135383-02-7, Stipiamide 135558-11-1, Lobaplatin 135819-69-1 135968-09-1, Lenograstim 137018-54-3, Okicenone 137099-09-3, Turosteride 137219-37-5, Dehydrodidemnin B 137647-92-8, Axinastatin 1 137964-32-0 139755-79-6, Safingol Hydrochloride 140207-93-8, Pentosan polysulfate sodium 140703-49-7, Meterelin 142880-36-2, Ilomastat 144885-51-8, Sodium borocaptate 144916-42-7, Sonermin 145124-30-7, Bisnafide dimesylate 145858-50-0, Liarozole Hydrochloride 146426-40-6, Flavopiridol 148317-76-4, Oracin 148584-53-6 148717-58-2, Palauamine 148717-90-2, Squalamine 149204-42-2, Kahalalide F 149260-80-0, Mycaperoxide B 149355-77-1, Lamellarin-N triacetate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 149633-91-0, Leptolstatin 149715-96-8, Spongistatin 1 149882-10-0, Lurtotecan 150829-93-9, Nisamycin 151272-78-5, Antarelix 152923-56-3, Dacliximab 153723-34-3, Axinastatin 2 153723-35-4, Axinastatin 3 154039-60-8, Marimastat 154229-19-3, Abiraterone 154248-96-1, Iroplact 154277-21-1, Cypemycin 154361-50-9, Capecitabine 155233-30-0, Curacin A 156586-89-9, Edrecolomab 156790-85-1, Variolin B 156856-30-3, Cytostatin 157078-48-3, Isohomohalichondrin B 157857-21-1, Maspin 158792-24-6, Collismycin A 158792-25-7, Collismycin B 168482-36-8, Cryptophycin 8 172793-30-5 173046-02-1, Thiocoraline 174305-65-8, Breflate 181887-82-1, Nitrullin 188364-40-1, CARN 700 200139-38-4, Suradista 212894-59-2, Pentrozole 246252-04-0, Lutetium texaphyrin 246252-06-2, Gadolinium texaphyrin 284041-10-7 324740-00-3, Vitaxin 441070-87-7, 1,2,3-Triazolecarboxamide 441070-88-8 441070-92-4 441772-39-0, Isobengazole 441772-43-6, Nagrestip 441772-66-3, Vinxaltine 441772-81-2, Sulfmosine 441774-07-8, Spicamycin D 441774-77-2, Solverol

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 60529-76-2, Thymopoietin

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(receptor agonists, pharmaceutical formulation further including; incensole and furanogermacrens and compds. as antitumor and antimicrobial agents)

IT 79217-60-0, Cyclosporin


RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (treatment of immunodysregulation condition caused by treatment with;
 incensole and furanogermacrene and compds. as antitumor and
 antimicrobial agents)

IT 50-07-7, Mitomycin C 1397-89-3, Amphotericin B
 RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (treatment of immunodysregulation condition caused by treatment with;
 incensole and furanogermacrene and compds. as antitumor and
 antimicrobial agents)

IT 595-33-5, Megestrol Acetate
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (pharmaceutical formulation further including; incensole and
 furanogermacrene and compds. as antitumor and antimicrobial agents)

RN 595-33-5 HCAPLUS
 CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




L76 ANSWER 5 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:449673 HCAPLUS
 DN 137:20389
 TI Preparation of indenopyrazolone semicarbazides as cyclin dependent kinase
 inhibitors.
 IN Carini, David J.
 PA Bristol-Myers Squibb Company, USA
 SO PCT Int. Appl., 107 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07D401-12
 ICS A61K031-496; A61P035-00; C07D403-12; C07D417-12; C07D407-12;
 C07D231-54; C07D407-14
 CC 28-17 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046182	A1	20020613	WO 2001-US46904	20011207 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002028849 A5 20020618 AU 2002-28849 20011207 <--
 US 2002091127 A1 20020711 US 2001-10979 20011207 <--
 PRAI US 2000-254116P P 20001208 <--
 WO 2001-US46904 W 20011207
 OS MARPAT 137:20389
 GI



- AB Title compds. [I; X = O, S; R1 = (substituted) carbocyclyl, heterocyclyl; R2 = H, (substituted) alkyl, alkenyl alkynyl, carbocyclyl, heterocyclyl; R3 = H, alkyl, cycloalkyl, cycloalkylalkyl; with provisos], were prepd. as cdk inhibitors (no data). Thus, 3-(4-piperazinophenyl)-5-[[N-methyl-N-(2-pyridinyl)amino]carbamoylamino]indeno[1,2-c]pyrazol-4-1 was prepd. in several steps starting from 4-piperazinoacetophenone.
- ST indenopyrazolone semicarbazide prepn cyclin dependent kinase inhibitor; cdk1 inhibitor indenopyrazolone semicarbazide prepn; stenosis treatment indenopyrazolone semicarbazide prepn; anticancer antiviral indenopyrazolone semicarbazide prepn; neurodegeneration treatment indenopyrazolone semicarbazide prepn
- IT Sarcoma
 (Kaposi's, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)
- IT Antiarteriosclerotics
 (antiatherosclerotics; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)
- IT Uterus, neoplasm
 (cervix, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)
- IT Intestine, neoplasm
 (colon, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)
- IT Artery, disease
 (coronary, restenosis, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)
- IT Nerve, disease
 (degeneration, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)
- IT Sarcoma
 (fibrosarcoma, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)
- IT Lung, disease
 (fibrosis; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)
- IT Kidney, disease
 (glomerulonephritis, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)
- IT Neoplasm
 (metastasis, inhibitors; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT DNA formation
RNA formation
(modulators; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT Astrocyte
(neoplasm, astrocytoma, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT Schwann cell
(neoplasm, schwannoma, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT **Nerve, neoplasm**
(**neuroblastoma**, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT Bone, neoplasm
(osteosarcoma, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT **Alzheimer's disease**
Angiogenesis inhibitors
Anti-Alzheimer's agents
Antiarthritics
Antitumor agents
Antiviral agents
Cytotoxic agents
Fungicides
(prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT Leukemia
(promyelocytic, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT Myoma
(rhabdomyosarcoma, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT Testis, neoplasm
(seminoma, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT Carcinoma
(squamous cell, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT Carcinoma
(teratocarcinoma, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT Arthritis
Atherosclerosis
Autoimmune disease
Bladder, neoplasm
Esophagus, neoplasm
Gallbladder, neoplasm
Hodgkin's disease
Kidney, neoplasm
Leukemia
Liver, neoplasm
Lung, neoplasm
Lymphoma
Mammary gland, neoplasm
Melanoma
Mycosis
Myelodysplastic syndromes
Neoplasm
Neuroglia, neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Prostate gland, neoplasm
Psoriasis

Skin, neoplasm

Stomach, neoplasm

Thyroid gland, neoplasm

(treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT Infection

(viral, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT Skin, disease

(xeroderma pigmentosum, treatment; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT 50-02-2, Dexamethasone 50-07-7, Mitomycin-c 50-18-0, Cyclophosphamide
50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 50-91-9, Floxuridine
51-21-8, 5-Fluorouracil 51-75-2, Mechlorethamine 52-24-4, Thiotepa
53-03-2, Prednisone 55-98-1, Busulfan 56-53-1 57-22-7, Vincristine
59-05-2, Methotrexate 125-84-8, Aminoglutethimide 127-07-1,
Hydroxyurea 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7,
Thioguanine 154-93-8, Carmustine 305-03-3, Chlorambucil 427-51-0,
Cyproterone acetate 595-33-5, Megestrol

acetate 645-05-6, Altretamine 671-16-9, Procarbazine

865-21-4, Vinblastine 2998-57-4, Estramustine 3778-73-2, Ifosfamide

4291-63-8, Cladribine 9015-68-3, Asparaginase 10540-29-1, Tamoxifen

11056-06-7, Bleomycin 13010-47-4, Lomustine 13311-84-7, Flutamide

15663-27-1, Cisplatin 18378-89-7, Plicamycin 18883-66-4,

Streptozotocin 20830-81-3, Daunorubicin 21679-14-1, Fludarabine

23214-92-8, Doxorubicin 29767-20-2, Teniposide 33069-62-4, Paclitaxel

33419-42-0, Etoposide 41575-94-4, Carboplatin 53714-56-0, Leuprolide

53910-25-1, Pentostatin 58957-92-9, Idarubicin 61825-94-3, Oxaliplatin

62816-98-2, Tetraplatin 62928-11-4, Iproplatin 65271-80-9,

Mitoxantrone 65807-02-5, Goserelin 71486-22-1, Vinorelbine

83150-76-9, Octreotide 88303-60-0, Losoxantrone 90357-06-5,

Bicalutamide 91421-42-0, 9-Nitrocamptothecin 91421-43-1,

9-Aminocamptothecin 95058-81-4, Gemcitabine 97682-44-5, Irinotecan

100286-90-6, Cpt-11 114977-28-5, Docetaxel 120511-73-1, Anastrozole

123948-87-8, Topotecan 129580-63-8, JM216 130167-69-0, Pegaspargase

135558-11-1, Lobaplatin 146924-11-0, JM335 264601-43-6, GS-211

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(coadministration; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT 141349-86-2, Cyclin-dependent kinase-2 143375-65-9, Cyclin-dependent

kinase-1 147014-96-8, Cyclin-dependent kinase-5 147014-97-9,

Cyclin-dependent kinase-4 153190-71-7, Cyclin-dependent kinase-3

182938-13-2, Cyclin-dependent kinase-9 303014-92-8, Cyclin-dependent

kinase-6 330197-29-0, Cyclin-dependent kinase-7 403652-37-9

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT 435337-10-3P 435337-11-4P 435337-13-6P 435337-14-7P 435337-16-9P

435337-18-1P 435337-20-5P 435337-22-7P 435337-24-9P 435337-26-1P

435337-28-3P 435337-30-7P 435337-32-9P 435337-34-1P 435337-36-3P

435337-37-4P 435337-39-6P 435337-41-0P 435337-43-2P 435337-45-4P

435337-47-6P 435337-49-8P 435337-51-2P 435337-53-4P 435337-55-6P

435337-57-8P 435337-59-0P 435337-61-4P 435337-62-5P 435337-64-7P

435337-66-9P 435337-68-1P 435339-57-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT 67-64-1, Acetone, reactions 75-07-0, Acetaldehyde, reactions 123-75-1,

Pyrrolidine, reactions 641-70-3, 3-Nitrophthalic anhydride 870-46-2,

tert-Butyl carbazate 4231-74-7 29943-42-8, Tetrahydropyran-4-one

38205-60-6, 5-Acetyl-2,4-dimethylthiazole 51639-48-6 76319-95-4

76890-04-5 79421-41-3 99979-60-9 364734-99-6 435337-82-9
 435337-84-1 435337-87-4 435337-89-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

IT 189763-86-8P 247150-02-3P 360793-01-7P 360793-02-8P 360793-04-0P
 435337-70-5P 435337-72-7P 435337-74-9P 435337-76-1P 435337-78-3P
 435337-80-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Basf Ag; WO 9917769 A 1999 HCAPLUS

(2) Basf Ag; WO 0027822 A 2000 HCAPLUS

(3) Du Pont Pharm Co; WO 9954308 A 1999 HCAPLUS

IT 595-33-5, **Megestrol acetate**


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(coadministration; prepn. of indenopyrazolone semicarbazides as cyclin dependent kinase inhibitors)

RN 595-33-5 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 6 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:332184 HCAPLUS

DN 136:345766

TI A novel crystalline form of arzoxifene

IN Luke, Wayne Douglas

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D333-64

ICS A61K031-445; A61P035-00

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1, 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002034741	A2	20020502	WO 2001-US27773	20011018 <--
	WO 2002034741	A3	20030103		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,			

FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002014534 A5 20020506 AU 2002-14534 20011018 <--
 EP 1328521 A2 20030723 EP 2001-983079 20011018 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

NO 2003001753 A 20030415 NO 2003-1753 20030415 <--
 PRAI US 2000-242252P P 20001020 <--
 WO 2001-US27773 W 20011018

AB The present invention is directed to a novel, non-solvated, anhyd. crystal form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]-phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride (arxoxifene-HCl), its formulations and therapeutic uses, including inhibition of disease states assocd. with estrogen deprivation such as cardiovascular disease, hyperlipidemia, and osteoporosis; and inhibition of other pathol. conditions such as endometriosis, uterine fibrosis, estrogen-dependent cancer (including breast and uterine cancer), prostate cancer, benign prostatic hyperplasia, CNS disorders including Alzheimer's disease, prevention of breast cancer, and up-regulating ChAT. For example, tablets contained arxoxifene-HCl 11.3 mg (10 mg base), L-cysteine HCl 0.10 mg, Povidone 12.50 mg, Polysorbate 80 1.25 mg, lactose 148.67 mg, Crosspovidone 12.50 mg, microcryst. cellulose 25.00 mg, and magnesium stearate 1.50 mg.

ST arxoxifene crystal form delivery system estrogen progestin; antitumor nervous system agent arxoxifene crystal form

IT Artery
 (aorta, smooth muscle cell proliferation, inhibitors; prepn., formulation and therapeutic uses of cryst. form of arxoxifene-HCl)

IT Prostate gland, disease
 (benign hyperplasia; prepn., formulation and therapeutic uses of cryst. form of arxoxifene-HCl)

IT Estrogens
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (conjugated; prepn., formulation and therapeutic uses of cryst. form of arxoxifene-HCl)

IT Bone, disease
 (demineralization; prepn., formulation and therapeutic uses of cryst. form of arxoxifene-HCl)

IT Uterus, disease
 (endometriosis; prepn., formulation and therapeutic uses of cryst. form of arxoxifene-HCl)

IT Uterus, neoplasm
 (endometrium, inhibitors; prepn., formulation and therapeutic uses of cryst. form of arxoxifene-HCl)

IT Antitumor agents
 (endometrium; prepn., formulation and therapeutic uses of cryst. form of arxoxifene-HCl)

IT Ovary, neoplasm
 Uterus, neoplasm
 (inhibitors; prepn., formulation and therapeutic uses of cryst. form of arxoxifene-HCl)

IT Uterus, neoplasm
 (leiomyoma; prepn., formulation and therapeutic uses of cryst. form of arxoxifene-HCl)

IT Antitumor agents
 (mammary gland; prepn., formulation and therapeutic uses of cryst. form of arxoxifene-HCl)

- IT Mammary gland
Prostate gland
(neoplasm, inhibitors; prepn., formulation and therapeutic uses of
cryst. form of arzoxifene-HCl)
- IT Antitumor agents
(ovary; prepn., formulation and therapeutic uses of cryst. form of
arzoxifene-HCl)
- IT **Anti-Alzheimer's agents**
Cardiovascular agents
Crystal morphology
Crystallization
Cytotoxic agents
Drug delivery systems
Hypolipemic agents
Nervous system agents
Stabilizing agents
(prepn., formulation and therapeutic uses of cryst. form of
arzoxifene-HCl)
- IT Estrogens
Progestogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn., formulation and therapeutic uses of cryst. form of
arzoxifene-HCl)
- IT Antitumor agents
(prostate gland; prepn., formulation and therapeutic uses of cryst.
form of arzoxifene-HCl)
- IT Artery, disease
(restenosis; prepn., formulation and therapeutic uses of cryst. form of
arzoxifene-HCl)
- IT Drug delivery systems
(solns., i.v.; prepn., formulation and therapeutic uses of cryst. form
of arzoxifene-HCl)
- IT Drug delivery systems
(suspensions; prepn., formulation and therapeutic uses of cryst. form
of arzoxifene-HCl)
- IT Drug delivery systems
(tablets; prepn., formulation and therapeutic uses of cryst. form of
arzoxifene-HCl)
- IT Osteoporosis
(therapeutic agents; prepn., formulation and therapeutic uses of cryst.
form of arzoxifene-HCl)
- IT Antitumor agents
(uterus; prepn., formulation and therapeutic uses of cryst. form of
arzoxifene-HCl)
- IT 64-17-5, Ethanol, uses 67-56-1, Methanol, uses 67-63-0, Isopropanol,
uses
RL: NUU (Other use, unclassified); USES (Uses)
(crystn. form; prepn., formulation and therapeutic uses of cryst. form
of arzoxifene-HCl)
- IT 9000-81-1, Acetylcholine esterase 9039-48-9, Aromatase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; prepn., formulation and therapeutic uses of cryst. form of
arzoxifene-HCl)
- IT 182133-27-3, Arzoxifene hydrochloride
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)
(prepn., formulation and therapeutic uses of cryst. form of
arzoxifene-HCl)
- IT 52-89-1, Cysteine hydrochloride 52-90-4, Cysteine, biological studies
57-63-6, Ethynyl estradiol 57-64-7, Physostigmine salicylate 63-68-3,
Methionine, biological studies **68-22-4, Norethindrone**
68-23-5, Norethynodrel 72-33-3, Mestranol 125-84-8, Aminoglutethimide
520-85-4, Medroxyprogesterone 566-48-3, Formestane 616-91-1,

Acetylcysteine 1684-40-8, Tacrine hydrochloride 9034-40-6D, LHRH, analogs 53714-56-0, Leuprolide 65807-02-5, Goserelin 107868-30-4, Exemestane 112809-51-5, Letrozole 120011-70-3, Donepezil hydrochloride 120511-73-1, Anastrozole

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses) (prepn., formulation and therapeutic uses of cryst. form of arzoxifene-HCl)


IT **68-22-4, Norethindrone**

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses) (prepn., formulation and therapeutic uses of cryst. form of arzoxifene-HCl)

RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 7 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:293387 HCAPLUS

DN 136:314998

TI Compositions for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase

IN Kragie, Laura

PA USA

SO PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K

CC **63-6** (Pharmaceuticals)

Section cross-reference(s): 1, 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002030355	A2	20020418	WO 2001-US32066	20011010 <--
	WO 2002030355	A3	20030206		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002013198	A5	20020422	AU 2002-13198	20011010 <--
PRAI	US 2000-239457P	P	20001011 <--		
	WO 2001-US32066	W	20011010		

AB This disclosure describes compns. and methods of use of compns., that can replace the role of estrogens in the functions of humans and other animals, when these humans or animals are under the influence of compns.,

devices and biologicals that can inhibit the activity of aromatase enzyme (estrogen synthetase). The estrogen function replacement agent is chosen from the group consisting of (i) prodrugs that are metabolized into an active agent in vivo by such enzymes reactions as hydrolysis, dehydroxylation, etc., (ii) a caged-precursor, a chem. structure that undergoes transformation when triggered by a stimulus such as light or bioelec. activity; a compd. produced de novo in a protected compartment implanted within the human or animal; and a full estrogen receptor agonist such as estradiol.

ST aromatase inhibitor estrogen function

IT Drug delivery systems

(aerosols, inhalants; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Skin, disease

(aging; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Estrogen receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(agonists; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Estrogens

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiestrogens; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Polycyclic compounds

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(arom. hydrocarbons; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems

(beads, latex; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Transplant and Transplantation

(bone marrow; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems

(buccal; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Candida

(candidiasis from, esophageal; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems

(caplets; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems

(capsules, soft; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems

(capsules; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Tobacco products

(cigarettes; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Acne

Alopecia

Bacteria (Eubacteria)

Bark

Biosensors

Candy

Cardiovascular system, disease

Cereal (grain)

Chewing gum

Contraceptives

DNA sequences

Embryophyta
 Flower
 Food
 Fruit
 Fungicides
 Headache
 Hirsutism
 Human
 Hydrolysis
 Hyperplasia
 Hypertension
 Immunodeficiency
 Leaf
 Mammary gland, neoplasm
 Organelle
 Osteoporosis
 Perfumes
 Plasmids
 Pregnancy
 Prostate gland, neoplasm
 Psychotropics
 Soups
 Spices
 Stem cell
 Thrombosis
 Tobacco smoke
 Vaccines
 Vegetable
 Virus

(compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Antibodies
 Flavonoids
 Gelatins, biological studies
 Glycoproteins
 Hormones, animal, biological studies
 Lipids, biological studies
 Nucleic acids
 Nucleoproteins
 Oligonucleotides
 Peptides, biological studies
 Pheromones, animal
 Polymers, biological studies
 Proteins
 Soaps

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT **Nervous system, disease**

(degeneration; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems

(depot; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Parturition

(dysfunctional; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems

(elixirs; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems

(emulsions; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Gene
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(expression, recombinant; compns. for alleviating adverse side effects
and/or enhancing efficacy of agents inhibiting aromatase)

IT Smoke
(exts.; compns. for alleviating adverse side effects and/or enhancing
efficacy of agents inhibiting aromatase)

IT Heart, disease
(failure; compns. for alleviating adverse side effects and/or enhancing
efficacy of agents inhibiting aromatase)

IT Estrogens
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(function replacement; compns. for alleviating adverse side effects
and/or enhancing efficacy of agents inhibiting aromatase)

IT **Meningitis**
(fungal; compns. for alleviating adverse side effects and/or enhancing
efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(gels; compns. for alleviating adverse side effects and/or enhancing
efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(granules; compns. for alleviating adverse side effects and/or
enhancing efficacy of agents inhibiting aromatase)

IT Candy
(hard; compns. for alleviating adverse side effects and/or enhancing
efficacy of agents inhibiting aromatase)

IT Reproductive tract, disease
(hypogonadism; compns. for alleviating adverse side effects and/or
enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(immediate-release; compns. for alleviating adverse side effects and/or
enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(implants; compns. for alleviating adverse side effects and/or
enhancing efficacy of agents inhibiting aromatase)

IT Vagina, disease
(infection; compns. for alleviating adverse side effects and/or
enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(infusion pumps; compns. for alleviating adverse side effects and/or
enhancing efficacy of agents inhibiting aromatase)

IT Medical goods
(inhalers; compns. for alleviating adverse side effects and/or
enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(injections, i.m.; compns. for alleviating adverse side effects and/or
enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(injections, i.v.; compns. for alleviating adverse side effects and/or
enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(injections, s.c.; compns. for alleviating adverse side effects and/or
enhancing efficacy of agents inhibiting aromatase)

IT Tobacco
(leaves; compns. for alleviating adverse side effects and/or enhancing
efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(liposomes; compns. for alleviating adverse side effects and/or
enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(lotions; compns. for alleviating adverse side effects and/or enhancing
efficacy of agents inhibiting aromatase)

IT Drug delivery systems

(lozenges; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Fertility
(male, disorder; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(microparticles; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(microspheres; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Headache
(migraine; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(mucosal; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(ointments, creams; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(ointments; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(ophthalmic; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(oral; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(osmotic pumps; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(parenterals; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Blood vessel, disease
(peripheral; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Estrogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phytoestrogens; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Aromatic hydrocarbons, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polycyclic; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(powders, inhalants; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(powders; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(prodrugs; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(rectal; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(solns.; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(sublingual; compns. for alleviating adverse side effects and/or

enhancing efficacy of agents inhibiting aromatase)

IT Diet
(supplements; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(supplements; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(suppositories; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(suspensions; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(sustained-release; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(tablets, chewable; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(tablets, effervescent; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(tablets; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Beverages
Tea (Camellia sinensis)
(tobacco-derived; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(topical; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Drug delivery systems
(transdermal; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT Bone marrow
(transplant; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT 50-28-2, Estradiol, biological studies 50-29-3, DDT, biological studies 53-16-7, Estrone, biological studies **68-22-4, Norethisterone** 80-05-7, Bisphenol A, biological studies 92-52-4D, 1,1'-Biphenyl, chloro derivs. 112-80-1, Oleic acid, biological studies 125-84-8, Aminoglutethimide 446-72-0, Genistein 480-40-0, Chrysin 486-66-8, Daidzein 491-80-5, Genistein 4'-methyl ether 566-48-3, 4-Hydroxyandrostenedione 604-59-1, .alpha.-Naphthoflavone 4416-57-3, Testololactone 10540-29-1, Tamoxifen 22916-47-8, Miconazole 23593-75-1, Clotrimazole 25265-71-8, Dipropylene glycol 27220-47-9, Econazole 27523-40-6, Isoconazole 35212-22-7, Ipriflavone 42959-18-2, Teas 59467-70-8, Midazolam 60628-96-8, Bifonazole 65277-42-1, Ketoconazole 65899-73-2, Tioconazole 78473-71-9, Enterolactone 84449-90-1, Raloxifene 92788-10-8, Rogletimide 96301-34-7, Atamestane 97322-87-7, Troglitazone 102676-47-1, Fadrozole 107868-30-4, Exemestane 112809-51-5, Letrozole 120051-39-0, NKS 01 120511-73-1, Arimidex 129731-10-8, Vorozole 137234-62-9, Voriconazole 148869-05-0, YM-511

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)

IT 9039-48-9, Aromatase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; compns. for alleviating adverse side effects and/or enhancing efficacy of agents inhibiting aromatase)


IT 9039-48-9, Aromatase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitors; compns. for alleviating adverse side effects and/or
 enhancing efficacy of agents inhibiting aromatase)

IT 68-22-4, Norethisterone
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. for alleviating adverse side effects and/or enhancing efficacy
 of agents inhibiting aromatase)

RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



L76 ANSWER 8 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:275781 HCAPLUS
 DN 136:289052
 TI Methods of inducing cancer cell death and tumor regression
 IN Daley, George Q.
 PA USA
 SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-00
 CC 1-6 (Pharmacology)

Section cross-reference(s): 63

FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002028381	A2	20020411	WO 2001-US42509	20011005 <--
	WO 2002028381	A3	20030327		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002011862	A5	20020415	AU 2002-11862	20011005 <--
	US 2002128280	A1	20020912	US 2001-971545	20011005 <--
	EP 1322334	A2	20030702	EP 2001-979952	20011005 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	NO 2003001531	A	20030605	NO 2003-1531	20030404 <--
PRAI	US 2000-238240P	P	20001005 <--		
	WO 2001-US42509	W	20011005		
AB	Methods are provided for treating cancer, comprising administering, a				

farnesyl protein transferase (FPT) inhibitor in conjunction with an addnl. Ras signaling pathway inhibitor to induce a synergistic level of cancer cell death and tumor regression, thus permitting low dose treatment regimens. Treatment compds. included were FPT inhibitor, fused-ring tricyclic benzocycloheptapyrinine and tyrosine kinase inhibitor, 2-phenylaminopyrimidine deriv.

- ST farnesyl protein transferase inhibitor antitumor apoptosis ras signaling pathway
- IT Antitumor agents
 - (bladder carcinoma; methods of inducing cancer cell death and tumor regression)
- IT Drug delivery systems
 - (capsules; methods of inducing cancer cell death and tumor regression)
- IT Bladder
 - (carcinoma, inhibitors; methods of inducing cancer cell death and tumor regression)
- IT Intestine, neoplasm
 - (colon, inhibitors; methods of inducing cancer cell death and tumor regression)
- IT Antitumor agents
 - (colon; methods of inducing cancer cell death and tumor regression)
- IT Thyroid gland, neoplasm
 - (follicular cell carcinoma, metastasis, inhibitors; methods of inducing cancer cell death and tumor regression)
- IT Neuroglia
 - (glioma, inhibitors; methods of inducing cancer cell death and tumor regression)
- IT Antitumor agents
 - (glioma; methods of inducing cancer cell death and tumor regression)
- IT Liver, neoplasm
 - (hepatoma, inhibitors; methods of inducing cancer cell death and tumor regression)
- IT Antitumor agents
 - (hepatoma; methods of inducing cancer cell death and tumor regression)
- IT Lung, neoplasm
- Ovary, neoplasm
- Pancreas, neoplasm
 - (inhibitors; methods of inducing cancer cell death and tumor regression)
- IT Antitumor agents
 - (lung; methods of inducing cancer cell death and tumor regression)
- IT Antitumor agents
 - (mammary gland; methods of inducing cancer cell death and tumor regression)
- IT Antitumor agents
 - (melanoma; methods of inducing cancer cell death and tumor regression)
- IT Antitumor agents
 - Apoptosis**
 - Cell death**
 - Myelodysplastic syndromes
 - Radiotherapy
 - Signal transduction, biological
 - (methods of inducing cancer cell death and tumor regression)
- IT Interferons
 - RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (methods of inducing cancer cell death and tumor regression)
- IT Antitumor agents
 - (myelogenous leukemia; methods of inducing cancer cell death and tumor regression)
- IT Mammary gland
- Prostate gland
 - (neoplasm, inhibitors; methods of inducing cancer cell death and tumor regression)

- regression)
- IT Antitumor agents
(ovary; methods of inducing cancer cell death and tumor regression)
- IT Antitumor agents
(pancreas; methods of inducing cancer cell death and tumor regression)
- IT Antitumor agents
(prostate gland; methods of inducing cancer cell death and tumor regression)
- IT Drug delivery systems
(solns.; methods of inducing cancer cell death and tumor regression)
- IT Drug interactions
(synergistic; methods of inducing cancer cell death and tumor regression)
- IT Antitumor agents
(thyroid gland follicular cell carcinoma, metastasis; methods of inducing cancer cell death and tumor regression)
- IT 50-07-7, Mitomycin-C 50-18-0, Cyclophosphamide 50-24-8, Prednisolone 50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-18-3, Triethylenemelamine 51-21-8, 5-Fluorouracil 51-75-2, Chlormethine 52-24-4 53-03-2, Prednisone 53-19-0, Mitotane 54-91-1, Pipobroman 55-98-1, Busulfan 56-53-1, Diethylstilbestrol 57-22-7, Vincristine 57-63-6, 17.alpha.-Ethinylestradiol 58-18-4, Methyltestosterone 58-22-0, Testosterone 66-75-1, Uracil mustard 68-96-2, Hydroxyprogesterone 71-58-9, Medroxyprogesteroneacetate 76-43-7, Fluoxymesterone 83-43-2, Methylprednisolone 124-94-7, Triamcinolone 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, 6-Thioguanine 154-93-8, Carmustine 305-03-3, Chlorambucil 521-12-0, Dromostanolone propionate 569-57-3, Chlorotrianisene 595-33-5, Megestrolacetate 645-05-6, Hexamethylmelamine 671-16-9, Procarbazine 865-21-4, Vinblastine 968-93-4, Testolactone 2998-57-4, Estramustine 3778-73-2, Ifosfamide 9015-68-3, L-Asparaginase 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 13010-47-4, Lomustine 13311-84-7, Flutamide 14769-73-4, Levamisole 15663-27-1, Cisplatin 18378-89-7, Mithramycin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 29767-20-2, Teniposide 33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4, Carboplatin 51264-14-3, Amsacrine 53643-48-4, Vindesine 53714-56-0, Leuprolide 53910-25-1, Pentostatin 56420-45-2, Epirubicin 58957-92-9, Idarubicin 65271-80-9, Mitoxantrone 65807-02-5, Goserelin 75607-67-9, Fludarabine phosphate 82413-20-5, Droloxifene 84449-90-1, Raloxifene 85622-93-1, Temozolomide 89778-26-7, Toremifene 95058-81-4, Gemcitabine 100286-90-6, CPT-11 112809-51-5, Letrozole 120511-73-1, Anastrozole 125317-39-7, Navelbine 154361-50-9, Capecitabine
- RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of inducing cancer cell death and tumor regression)
- IT 595-33-5, Megestrolacetate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of inducing cancer cell death and tumor regression)
- RN 595-33-5 HCAPLUS
- CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 9 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:868447 HCAPLUS
 DN 136:5917
 TI Preparation of (hetero)arylacyl-piperidinyl-benzylamines for use as
 tryptase inhibitors
 IN Astles, Peter C.; Eastwood, Paul R.; Houille, Olivier; Levell, Julian;
 Pauls, Heinz; Czekaj, Mark; Liang, Guyan; Gong, Yong; Pribish, James;
 Neuenschwander, Kent
 PA Aventis Pharmaceuticals Products Inc., USA
 SO PCT Int. Appl., 267 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07D401-06
 ICS C07D211-16; C07D401-10; C07D409-06; C07D413-10; C07D405-06;
 C07D513-04; C07D413-14; C07D495-04; C07D409-14; C07D401-12;
 C07D487-04; C07D417-06; C07D471-04; C07D405-14
 CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
 Section cross-reference(s): 1, 28, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001090101	A1	20011129	WO 2001-US13811	20010427 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP	1296972	A1	20030402	EP 2001-930925	20010427 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR	2001011206	A	20030415	BR 2001-11206	20010427 <--
NO	2002005601	A	20030106	NO 2002-5601	20021121 <--
PRAI	GB 2000-12362	A	20000522	<--	
	US 2001-843126	A	20010426		
	WO 2001-US13811	W	20010427		
OS	MARPAT 136:5917				
GI					

- AB Title compds. I [Ar = (hetero)aryl, where the two groups on the Ar ring are .beta. to each other; R1-2 = H, alkyl; R3 = (un)substituted(hetero)aryl, arylalkenyl, cycloalkenyl, cycloalkyl, etc.; R4 = H, acyl, alkoxy, alkyloxycarbonyl, carboxy, CN, halo, etc.; n = 0 - 4] were prepd. Over 300 synthetic examples were disclosed. For instance, 3-bromobenzylbromide was converted in two steps to boronate II. II was coupled to the triflate ester deriv. of the enol of 4-oxo-N-benzyloxycarbonylpiperidine (DMF, K2CO3, PdCl2(dppf).bul.CH2Cl2, 80.degree.C, 18 h) to give the corresponding bicyclic intermediate. This intermediate was deprotected and reduced to the piperidine (EtOH, 10% Pd-C/H2, room temp., 5 h) and coupled to 5-phenethylthiophene-2-carboxylic acid (DMF, HAPyU, iPr2NEt, room temp., 18 h) to give III. III had Ki = 50 nM for tryptase. I are useful in the treatment of e.g., asthma and inflammatory diseases.
- ST piperidinylbenzylamine tryptase inhibitors prepn; pyridine quinoline thiophene furan indole piperidine tryptase inhibitor prepn
- IT Eye, disease
(allergic conjunctivitis; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)
- IT Nose, disease
(allergic rhinitis; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)
- IT Dermatitis
(atopic; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)
- IT Eye, disease
(conjunctivitis; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)
- IT Cartilage, disease
(degeneration; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)
- IT Eye, disease
(diabetic retinopathy; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)
- IT Joint, anatomical
(disease, inflammation; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)
- IT Heart, disease
Lung, disease
(fibrosis; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)
- IT Skin, disease
(hypertrophic scar; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)
- IT Heart, disease
(infarction; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors).
- IT Intestine, disease
(inflammatory; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)
- IT Lung, disease
(interstitial; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)
- IT Schwann cell
(neoplasm, neurofibroma; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)
- IT Ulcer
(peptic; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)
- IT Cholinergic antagonists
(pharmaceutical combination; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)

IT **Corticosteroids**, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical combination; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)

IT Atherosclerosis
 (plaque; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)

IT Anaphylaxis
 Anti-inflammatory agents
 Antianginal agents
 Antiarthritics
 Antiasthmatics
 Antirheumatic agents
 Antitumor agents
 Cirrhosis
 Dermatitis
 Fibrosis
 Gout
 Human respiratory syncytial virus
 Osteoarthritis
 Periodontium, disease
 Psoriasis
 (prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)

IT Arthritis
 (psoriatic arthritis; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)

IT Connective tissue, disease
 (scleroderma; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)

IT Spinal column, disease
 (spondylitis, rheumatoid; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)

IT **Brain, disease**
 (stroke; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)

IT Multiple sclerosis
 (therapeutic agents; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)

IT Adrenoceptor agonists
 (.beta.-, pharmaceutical combination; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)

IT 375847-91-9P 375847-93-1P
 RL: BSU (Biological study, unclassified); BYP (Byproduct); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)

IT 823-78-9P, 3-Bromobenzyl bromide 51779-32-9P, Di-tert-butyl iminodicarboxylate 375846-93-8P 375846-94-9P 375846-95-0P
 375846-96-1P 375846-97-2P 375846-98-3P 375846-99-4P 375847-00-0P
 375847-01-1P 375847-02-2P 375847-03-3P 375847-04-4P 375847-05-5P
 375847-06-6P 375847-07-7P 375847-08-8P 375847-09-9P 375847-10-2P
 375847-11-3P 375847-12-4P 375847-13-5P 375847-15-7P 375847-17-9P
 375847-19-1P 375847-21-5P 375847-23-7P 375847-25-9P 375847-27-1P
 375847-29-3P 375847-31-7P 375847-33-9P 375847-34-0P 375847-35-1P
 375847-36-2P 375847-38-4P 375847-41-9P 375847-43-1P 375847-44-2P
 375847-46-4P 375847-48-6P 375847-50-0P 375847-52-2P 375847-55-5P
 375847-58-8P 375847-60-2P 375847-62-4P 375847-64-6P 375847-65-7P
 375847-68-0P 375847-71-5P 375847-74-8P 375847-77-1P 375847-80-6P
 375847-83-9P 375847-86-2P 375847-89-5P 375847-95-3P 375847-97-5P
 375847-99-7P 375848-01-4P 375848-03-6P 375848-05-8P 375848-07-0P
 375848-09-2P 375848-11-6P 375848-13-8P 375848-15-0P 375848-17-2P

375848-19-4P	375848-21-8P	375848-23-0P	375848-25-2P	375848-27-4P
375848-29-6P	375848-31-0P	375848-33-2P	375848-35-4P	375848-37-6P
375848-39-8P	375848-41-2P	375848-43-4P	375848-45-6P	375848-47-8P
375848-49-0P	375848-51-4P	375848-53-6P	375848-54-7P	375848-55-8P
375848-57-0P	375848-59-2P	375848-61-6P	375848-63-8P	375848-65-0P
375848-66-1P	375848-67-2P	375848-68-3P	375848-69-4P	375848-70-7P
375848-71-8P	375848-72-9P	375848-73-0P	375848-75-2P	375848-76-3P
375848-77-4P	375848-78-5P	375848-79-6P	375848-80-9P	375848-81-0P
375848-82-1P	375848-83-2P	375848-84-3P	375848-85-4P	375848-86-5P
375848-87-6P	375848-88-7P	375848-89-8P	375848-90-1P	375848-91-2P
375848-92-3P	375848-93-4P	375848-95-6P	375848-97-8P	375848-99-0P
375849-01-7P	375849-03-9P	375849-05-1P	375849-07-3P	375849-09-5P
375849-11-9P	375849-13-1P	375849-15-3P	375849-17-5P	375849-19-7P
375849-21-1P	375849-23-3P	375849-25-5P	375849-27-7P	375849-29-9P
375849-31-3P	375849-33-5P	375849-35-7P	375849-37-9P	375849-39-1P
375849-41-5P	375849-43-7P	375849-45-9P	375849-47-1P	375849-48-2P
375849-49-3P	375849-51-7P	375849-53-9P	375849-55-1P	375849-57-3P
375849-59-5P	375849-61-9P	375849-63-1P	375849-65-3P	375849-67-5P
375849-69-7P	375849-71-1P	375849-73-3P	375849-75-5P	375849-77-7P
375849-78-8P	375849-79-9P	375849-81-3P	375849-82-4P	375849-83-5P
375849-85-7P	375849-87-9P	375849-89-1P	375849-91-5P	375849-93-7P
375849-95-9P	375849-97-1P	375849-99-3P	375850-01-4P	375850-03-6P
375850-05-8P	375850-07-0P	375850-09-2P	375850-11-6P	375850-13-8P
375850-15-0P	375850-17-2P	375850-19-4P	375850-21-8P	375850-23-0P
375850-25-2P	375850-27-4P	375850-29-6P	375850-31-0P	375850-33-2P
375850-35-4P	375850-37-6P	375850-40-1P	375850-43-4P	375850-45-6P
375850-47-8P	375850-49-0P	375850-51-4P	375850-53-6P	375850-55-8P
375850-57-0P	375850-59-2P	375850-61-6P	375850-63-8P	375850-65-0P
375850-67-2P	375850-69-4P	375850-71-8P	375850-73-0P	375850-75-2P
375850-77-4P	375850-79-6P	375850-81-0P	375850-83-2P	375850-85-4P
375850-87-6P	375850-89-8P	375850-91-2P	375850-93-4P	375850-95-6P
375850-97-8P	375850-99-0P	375851-01-7P	375851-03-9P	375851-05-1P
375851-07-3P	375851-08-4P	375851-09-5P	375851-11-9P	

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as tryptase inhibitors)

IT	375851-13-1P	375851-15-3P	375851-17-5P	375851-19-7P	375851-21-1P
	375851-23-3P	375851-25-5P	375851-27-7P	375851-29-9P	375851-31-3P
	375851-33-5P	375851-35-7P	375851-37-9P	375851-39-1P	375851-41-5P
	375851-43-7P	375851-45-9P	375851-47-1P	375851-49-3P	375851-51-7P
	375851-53-9P	375851-55-1P	375851-57-3P	375851-59-5P	375851-61-9P
	375851-63-1P	375851-65-3P	375851-67-5P	375851-69-7P	375851-71-1P
	375851-73-3P	375851-75-5P	375851-77-7P	375851-79-9P	375851-81-3P
	375851-83-5P	375851-85-7P	375851-87-9P	375851-89-1P	375851-91-5P
	375851-93-7P	375851-95-9P	375851-97-1P	375851-99-3P	375852-01-0P
	375852-03-2P	375852-05-4P	375852-07-6P	375852-09-8P	375852-11-2P
	375852-13-4P	375852-15-6P	375852-17-8P	375852-19-0P	375852-21-4P
	375852-23-6P	375852-25-8P	375852-27-0P	375852-29-2P	375852-31-6P
	375852-33-8P	375852-35-0P	375852-37-2P	375852-39-4P	375852-41-8P
	375852-43-0P	375852-45-2P	375852-47-4P	375852-49-6P	375852-51-0P
	375852-53-2P	375852-55-4P	375852-57-6P	375852-59-8P	375852-61-2P
	375852-63-4P	375852-65-6P	375852-67-8P	375852-69-0P	375852-71-4P
	375852-73-6P	375852-75-8P	375852-77-0P	375852-79-2P	375852-81-6P
	375852-83-8P	375852-85-0P	375852-87-2P	375852-89-4P	375852-91-8P
	375852-93-0P	375852-95-2P	375852-97-4P	375852-99-6P	375853-01-3P
	375853-03-5P	375853-05-7P	375853-07-9P	375853-09-1P	375853-11-5P
	375853-13-7P	375853-15-9P	375853-17-1P	375853-18-2P	375853-19-3P
	375853-21-7P	375853-23-9P	375853-25-1P	375853-27-3P	375853-29-5P
	375853-31-9P	375853-33-1P	375853-35-3P	375853-37-5P	375853-39-7P
	375853-41-1P	375853-43-3P	375853-45-5P	375853-47-7P	375853-49-9P
	375853-50-2P	375853-51-3P	375853-52-4P	375853-53-5P	375853-54-6P

375853-56-8P 375853-57-9P 375853-58-0P 375853-60-4P 376353-42-3P
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)

(drug; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as
 tryptase inhibitors)

IT 785-79-5P 3601-62-5P 5027-65-6P, Pyridine-3,5-dicarboxylic acid
 monomethyl ester 16532-78-8P, 3-Cyanobenzyl cyanide 118753-70-1P
 118791-14-3P 132797-91-2P 138647-49-1P, tert-Butyl
 1,2,3,6-tetrahydro-4-(trifluoromethylsulfonyloxy)pyridine-1-carboxylate
 181701-30-4P 209899-59-2P 226252-30-8P 250355-46-5P 286961-24-8P,
 Benzyl 1,2,3,6-tetrahydro-4-(trifluoromethylsulfonyloxy)pyridine-1-
 carboxylate 317358-76-2P, 4-Benzylloxy-3-bromobenzonitrile 317358-77-3P
 337904-92-4P 370864-58-7P 375853-63-7P 375853-65-9P 375853-67-1P
 375853-69-3P 375853-71-7P 375853-73-9P 375853-75-1P 375853-77-3P
 375853-79-5P 375853-80-8P 375853-83-1P 375853-84-2P 375853-85-3P
 375853-86-4P 375853-87-5P 375853-88-6P 375853-89-7P 375853-90-0P
 375853-91-1P 375853-92-2P 375853-93-3P 375853-94-4P 375853-95-5P
 375853-96-6P 375853-97-7P 375853-98-8P 375853-99-9P 375854-00-5P
 375854-01-6P 375854-02-7P 375854-03-8P 375854-04-9P 375854-05-0P
 375854-06-1P 375854-08-3P 375854-12-9P 375854-14-1P 375854-16-3P
 375854-18-5P 375854-19-6P 375854-21-0P 375854-23-2P 375854-25-4P
 375854-27-6P 375854-28-7P 375854-29-8P 375854-31-2P 375854-33-4P
 375854-35-6P 375854-37-8P 375854-38-9P 375854-40-3P 375854-42-5P
 375854-44-7P 375854-46-9P 375854-48-1P 375854-49-2P 375854-50-5P
 375854-51-6P 375854-52-7P 375854-53-8P 375854-54-9DP, resin bound
 375854-55-0P 375854-56-1P 375854-57-2P 375854-58-3P 375854-59-4P
 375854-60-7P 375854-62-9P 375854-65-2P 375854-66-3P,
 3-[5-(2-Chlorophenyl)[1,3,4]oxadiazol-2-yl]benzoic acid 375854-69-6P,
 [3-[4-Hydroxy-1-[-1-(5-phenethylpyridin-3-yl)methanoyl]piperidin-4-
 yl]benzyl]carbamic acid benzyl ester 375854-71-0P 375854-76-5P,
 5-tert-Butoxycarbonylaminonicotinic acid ethyl ester 375854-77-6P,
 2-(Trimethylsilyl)ethyl 1,2,3,6-tetrahydro-4-(trifluoromethylsulfonyloxy)p
 yridine-1-carboxylate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for
 use as tryptase inhibitors)

IT 50-02-2, Dexamethasone 76-25-5, Triamcinolone acetonide
 3385-03-3, Flunisolide 5534-09-8, Beclomethasone
 dipropionate 13392-18-2, Fenoterol 15826-37-6, Sodium cromoglycate
 18559-94-9, Albuterol 22254-24-6, Ipratropium bromide 23031-25-6,
 Terbutaline 69049-74-7; Nedocromil sodium 73573-87-2, Formoterol
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical combination; prepn. of (hetero)arylacyl-piperidinyl-
 benzylamines for use as tryptase inhibitors)

IT 97501-93-4, Tryptase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as
 tryptase inhibitors)

IT 65-85-0, Benzoic acid, reactions 100-39-0, Benzyl bromide 1822-51-1,
 4-Picolyl chloride hydrochloride
 RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use as
 tryptase inhibitors)

IT 74-11-3, 4-Chlorobenzoic acid 93-09-4, 2-Naphthoic acid 102-36-3,
 3,4-Dichlorophenyl isocyanate 133-32-4, 4-(Indol-3-yl)butanoic acid
 348-52-7, 1-Fluoro-2-iodobenzene 352-34-1, 1-Fluoro-4-iodobenzene
 444-29-1, 2-Iodobenzotrifluoride 501-53-1, Benzylchloroformate
 531-81-7, Coumarin-3-carboxylic acid 533-58-4, 2-Iodophenol 535-80-8,
 3-Chlorobenzoic acid 540-38-5, 4-Iodophenol 585-76-2, 3-Bromobenzoic
 acid 589-15-1, 4-Bromobenzyl bromide 591-50-4, Iodobenzene 609-65-4,
 2-Chlorobenzoyl chloride 613-94-5, Benzoic hydrazide 615-37-2,

2-Iodotoluene 615-41-8, 1-Chloro-2-iodobenzene 619-84-1 624-28-2,
2,5-Dibromopyridine 637-87-6, 1-Chloro-4-iodobenzene 771-50-6,
Indole-3-carboxylic acid 821-48-7, Bis(2-chloroethyl)amine hydrochloride
939-26-4, 2-(Bromomethyl)naphthalene 942-24-5, 1H-Indole-3-carboxylic
acid methyl ester 1121-86-4, 1-Fluoro-3-iodobenzene 1141-45-3,
3-(2-Naphthylthio)propionic acid 1670-82-2, Indole-6-carboxylic acid
2243-42-7, 2-Phenoxybenzoic acid 4393-09-3, 2,3-Dimethoxybenzylamine
4591-56-4, Diethyl 3,5-pyridinedicarboxylate 4644-61-5, Ethyl
4-piperidone-3-carboxylate hydrochloride 5122-94-1, 4-Biphenylboronic
acid 5807-30-7, 3,4-Dichlorophenylacetic acid 6314-28-9,
Benzo[b]thiophene-2-carboxylic acid 6435-75-2 6480-68-8,
Quinoline-3-carboxylic acid 6952-59-6, 3-Bromobenzonitrile 6959-47-3,
2-(Chloromethyl)pyridine hydrochloride 6959-48-4, 3-
(Chloromethyl)pyridine hydrochloride 10517-21-2, 5-Chloro-1H-indole-2-
carboxylic acid 10601-99-7, 3-Ethynylbenzoic acid 13139-17-8,
N-(Benzyloxycarbonyloxy)succinimide 13771-75-0 17570-26-2
18282-51-4, 4-Iodobenzyl alcohol 18791-75-8, 4-Bromothiophene-2-
carboxaldehyde 19099-93-5, Benzyl 4-oxo-1-piperidinecarboxylate
19900-52-8, 2-Bromo-4-(bromomethyl)benzyl bromide 20000-56-0
20260-53-1, Nicotinoyl chloride hydrochloride 20511-12-0,
6-Amino-3-iodopyridine 20826-04-4, 5-Bromonicotinic acid 21168-41-2,
Ethyl 4,6-Dichloroquinoline-3-carboxylate 22106-33-8,
4-(1H-Pyrrol-1-yl)benzoic acid 22494-42-4, Diflunisal 24280-05-5
26018-73-5, 6-Chlorobenzo[b]thiophene-2-carboxylic acid 28188-41-2,
.alpha.-Bromo-m-tolunitrile 31719-75-2, 3-Phenoxyethylbenzoic acid
32084-55-2, 5-Oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylic
acid 32387-21-6, 1-Methyl-1H-indole-3-carboxylic acid 34785-11-0,
4-Hydroxyquinoline-3-carboxylic acid 36330-85-5 37669-64-0,
3-Bromo-5-hydroxymethylpyridine 37868-26-1, 2-Indanylacetic acid
41979-39-9, 4-Piperidone hydrochloride 45767-66-6, 2-Chloro-4-
fluorobenzyl bromide 50824-05-0, 4-(Trifluoromethoxy)benzyl bromide
57341-98-7, 4-(2-Phenylethynyl)benzaldehyde 63503-60-6,
3-Chlorophenylboronic acid 69026-14-8, 3-Benzyloxybenzoic acid
69193-39-1 70060-15-0, 5-Chlorothiopheno[3,2-b]thiophene-2-carboxylic acid
70060-18-3, 5-Fluorothiopheno[3,2-b]thiophene-2-carboxylic acid 70060-21-8,
5-Methylthieno[3,2-b]thiophene-2-carboxylic acid 70060-24-1,
6-Chlorothiopheno[3,2-b]thiophene-2-carboxylic acid 73183-34-3
74877-08-0, 1-(3-Bromophenyl)ethylamine 76283-09-5, 4-Bromo-2-
fluorobenzyl bromide 78348-01-3, 4-(2-Phenylethyl)thiophene-2-carboxylic
acid 79099-07-3, tert-Butyl 4-oxo-1-piperidinecarboxylate 79630-23-2,
3-Bromo-4-fluorobenzonitrile 79757-98-5, 4-Bromo-2-bromomethylthiophene
80149-80-0 83451-61-0, 1-Acetyl-1H-indole-3-carboxylic acid
89639-97-4, (6-Chloropyridin-2-yl)oxy)acetic acid 111331-82-9
130423-83-5, 5-(2-Phenylethynyl)furan-2-carboxylic acid 133659-14-0,
2-Chloro-3-methoxythiophene-4-carboxylic acid 135008-92-3 136386-75-9
139926-23-1, 3-Ethoxythiophene-2-carboxylic acid 148345-63-5,
3-(2H-Tetrazol-5-yl)benzoic acid methyl ester 150255-96-2,
3-Cyanophenylboronic acid 168279-58-1, 3-Methylsulfanyl-4-oxo-4,5,6,7-
tetrahydrobenzo[c]thiophene-1-carboxylic acid 172516-30-2,
4-Oxo-3-propylsulfanyl-4,5,6,7-tetrahydrobenzo[c]thiophene-1-carboxylic
acid ethyl ester 172516-31-3, 3-Isopropylsulfanyl-4-oxo-4,5,6,7-
tetrahydrobenzo[c]thiophene-1-carboxylic acid ethyl ester 172516-41-5,
6,6-Dimethyl-3-methylsulfanyl-4-oxo-4,5,6,7-tetrahydrobenzo[c]thiophene-1-
carboxylic acid 172516-42-6, 3-Ethylsulfanyl-6,6-dimethyl-4-oxo-4,5,6,7-
tetrahydrobenzo[c]thiophene-1-carboxylic acid methyl ester 172596-63-3,
5-Methoxy-1-methyl-1H-indole-3-carboxylic acid 175202-54-7,
3-Methylsulfanyl-6,7-dihydrobenzo[c]thiophene-1-carboxylic acid
175203-69-7, 5-Phenylethynylpyridine-3-carboxylic acid 190656-34-9,
3-Bromo-6-fluorobenzylamine 202865-68-7, 3-Bromo-4-fluorobenzylamine
hydrochloride 234098-52-3 255395-56-3 259231-26-0,
4-Methyl-3-bromobenzyl bromide 375846-30-3, 3-Cyano-6,6-dimethyl-4-oxo-
4,5,6,7-tetrahydrobenzo[c]thiophene-1-carboxylic acid ethyl ester
375854-54-9, 4-(3-Aminomethylphenyl)piperidine 375854-61-8,

5-(2-Phenylethyl)thiophene-2-carboxylic acid 375854-63-0,
 4-(2-Phenylethynyl)thiophene-2-carboxylic acid 375854-64-1,
 6-Phenylquinoline-3-carboxylic acid 375854-67-4, 3-Methoxy-6,6-dimethyl-
 4-oxo-4,5,6,7-tetrahydrobenzo[c]thiophene-1-carboxylic acid 375854-68-5,
 (5-Chloropyridin-3-yloxy)acetic acid 375854-70-9 375854-72-1,
 N,N-Bis(tert-butoxycarbonyl)-3-[1-[3-(2-hydroxyphenyl)ethynylbenzoyl]piper-
 idin-4-yl]benzylamine 375854-74-3 375854-75-4, [4-[5-(N,N-Bis-tert-
 butoxycarbonyl)aminomethylpyridin-3-yl]-piperidin-1-yl]-1-(5-
 phenylethylpyridin-3-yl)methanone

RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; prepn. of (hetero)arylacyl-piperidinyl-benzylamines for use
 as tryptase inhibitors)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Burgess, L; DRUG NEWS AND PERSPECTIVES 2000, V13(3), P147 HCAPLUS

(2) Thomae GmbH Dr K; DE 4407139 A 1995 HCAPLUS


IT 3385-03-3, Flunisolid

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical combination; prepn. of (hetero)arylacyl-piperidinyl-
 benzylamines for use as tryptase inhibitors)

RN 3385-03-3 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-
 methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 10 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:817200 HCAPLUS

DN 135:352775

TI Nitric oxide and analogues thereof effectuate sensitization of neoplasm
 and immunologically undesired tissues to cytotoxicity

IN Bonavida, Benjamin; Garban, Hermes

PA USA

SO U.S. Pat. Appl. Publ., 13 pp.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K038-19

ICS A61K038-21; A61K033-00

NCL 424085500

CC 1-6 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001038832	A1	20011108	US 2001-833539	20010411 <--

PRAI US 2000-196210P P 20000411 <--

AB This invention discloses a method for treatment of cancers, infectious diseases, and unwanted tissues by interferon-gamma (IFN-.gamma.), Nitric Oxide (NO), NO donors, or inducible nitric oxide synthase (iNOS), applied either individually or in combination. This method for treating resistant cancer, infectious diseases, and immunol. unwanted tissues in an individual involves administering a therapeutically effective amt. of NO, NO donors, or iNOS thereby inducing the cancer cells to undergo Fas and TNF receptor family-mediated cytotoxicity. This treatment regimen may also be combined with the administration of immunotherapeutic and/or cytotoxic agents.

ST nitric oxide analog tumor sensitization infectious disease interferon; Fas antigen cytokine cytotoxicity nitric oxide analog cancer; TNF cytotoxicity Fas antigen nitric oxide analog cancer; synthase nitric oxide tumor sensitization infectious disease interferon

IT Tumor necrosis factors

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(TNF-.alpha.; nitric oxide and analogs in sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

IT Drug resistance

(antitumor; nitric oxide and analogs in sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

IT Ovary, neoplasm

(inhibitors; nitric oxide and analogs in sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

IT Antibodies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(monoclonal, anti-Fas; nitric oxide and analogs in sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

IT Prostate gland

(neoplasm, inhibitors; nitric oxide and analogs in sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

IT Antitumor agents

Apoptosis

Drug interactions

(nitric oxide and analogs in sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

IT Cytokines

Fas ligand

Interleukin 10

Interleukin 1.beta.

Interleukin 2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nitric oxide and analogs in sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

IT Fas antigen

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(nitric oxide and analogs in sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

IT Antitumor agents

(ovary; nitric oxide and analogs in sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

IT Antitumor agents

(prostate gland; nitric oxide and analogs in sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

IT Antitumor agents

Chemotherapy

Immunotherapy

Radiotherapy

(resistance to; nitric oxide and analogs in sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

IT Interferons

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(.gamma.; nitric oxide and analogs in sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

IT 10102-43-9, Nitric oxide, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(NO donors and mimics; nitric oxide and analogs in sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

IT 125978-95-2, Nitric oxide synthase

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(inducible; nitric oxide and analogs in sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

IT 50-07-7, Mitomycin-C 50-18-0, Cyclophosphamide 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-21-8, 5-FU 52-24-4, Thio-TEPA 53-03-2, Prednisone 55-86-7, Mechlorethamine hydrochloride 57-22-7, Vincristine 59-05-2, Amethopterin 127-07-1, Hydrea 147-94-4, Ara-C 148-82-3, Melphalan 154-93-8, BCNU 302-79-4, Retinoic acid 520-85-4, Medroxyprogesterone 595-33-5, Megestrol

Acetate 865-21-4, Vinblastine 3778-73-2, Ifosfamide

4291-63-8, Cladribine 4342-03-4, DTIC 10540-29-1, Tamoxifen

11056-06-7, Bleomycin 14769-73-4, Levamisole 18883-66-4, Streptozocin

19767-45-4, Mesna 23214-92-8, Doxorubicin 33069-62-4, Taxol

33419-42-0, Etoposide 41575-94-4, Paraplatin 57852-57-0, Idamycin

67776-06-1, SNAP 79517-01-4, Octreotide acetate

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(nitric oxide and analogs in sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

IT 297279-42-6 372992-65-9 372992-66-0 372992-67-1 372992-68-2 372992-69-3

RL: PRP (Properties)

(unclaimed nucleotide sequence; nitric oxide and analogs thereof effectuate sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

IT 595-33-5, Megestrol Acetate


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(nitric oxide and analogs in sensitization of neoplasm and immunol. undesired tissues to cytotoxicity)

RN 595-33-5 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 11 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:798040 HCAPLUS

DN 135:339222

TI Inhibition of abnormal cell proliferation with camptothecin or a derivative, analog, metabolite, or prodrug thereof, and combinations including camptothecin

IN Rubinfeld, Joseph

PA Supergen, Inc., USA

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-00

CC 1-6 (Pharmacology)

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2001080843	A2	20011101	WO 2001-US12848	20010419 <--	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	US 6420378	B1	20020716	US 2000-553710	20000420 <--	
	EP 1276479	A2	20030122	EP 2001-930607	20010419 <--	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
PRAI	US 2000-553710	A1	20000420 <--			
	US 1999-418862	A2	19991015 <--			
	WO 2001-US12848	W	20010419			
AB	A method for treating diseases assocd. with abnormal cell proliferation comprises delivering to a patient in need of treatment a compd. selected from 20(S)-camptothecin, an analog of 20(S)-camptothecin, a deriv. of 20(S)-camptothecin, a prodrug of 20(S)-camptothecin, and pharmaceutically active metabolite of 20(S)-camptothecin, in combination with an effective amt. of one or more agents selected from the group consisting of alkylating agent, antibiotic agent, antimetabolic agent, hormonal agent, plant-derived agent, anti-angiogenesis agent and biol. agent. The method can be used to treat benign tumors, malignant or metastatic tumors, leukemia and diseases assocd. with abnormal angiogenesis.					
ST	camptothecin cell proliferation inhibition tumor; metastasis tumor camptothecin cell proliferation inhibition; angiogenesis disease camptothecin cell proliferation inhibition; leukemia camptothecin cell					

- proliferation inhibition; prodrug camptothecin cell proliferation inhibition
- IT Macroglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(2 macroglobulin-serum; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Angiogenic factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Ang-1, monoclonal antibodies to; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Angiogenic factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Ang-2, monoclonal antibodies to; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Gene, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BRCA2; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Gene, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BRCA; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Gene, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(DPC-4; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Papillomavirus
(E6 or E7 fragment; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Proteins, specific or class
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E6, papillomavirus, fragment; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Transcription factors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E7, papillomavirus, fragment; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(Ewing's sarcoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Hemocyanins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(KLH; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Antitumor agents

(Kaposi's sarcoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Gene, animal

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(NF-1; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Gene, animal

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(NF-2; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Disease, animal

(Oster Webber syndrome; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Gene, animal

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(RB1; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Gene, animal

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(TP53; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Gene, animal

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(WT1; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Antitumor agents

(Wilms' tumor; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Kidney, neoplasm

(Wilms', inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Nerve, neoplasm

(acoustic neuroma, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Antitumor agents

(acoustic neuroma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

- IT Antitumor agents
(adenocarcinoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Liver, neoplasm
(adenoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Immunostimulants
(adjuvants; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Sulfonates
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkyl alkane; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Steroids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(angiostatic; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Nutrients
(anti-; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antiarteriosclerotics
(antiatherosclerotics; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Skin, neoplasm
(basal cell carcinoma, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(basal cell carcinoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Biliary tract
(bile duct, neoplasm, adenoma and cystanoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(bone; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(brain; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(bronchi; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Adenoma
Adrenal gland, neoplasm
Alkylating agents, biological
Angiogenesis inhibitors
Anti-ischemic agents

Antibiotics
Antiglaucoma agents
Antirheumatic agents
Antiserums
Antitumor agents
Calculi, biliary
Carcinoid
Cell
Drug delivery systems
Hyperplasia
Immunomodulators
Mycobacterium BCG
Pheochromocytoma
Polycythemia vera
Psoriasis
 (camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
IT Carcinoembryonic antigen
Gangliosides
Interferons
Interleukin 12
Interleukin 2
Interleukin 4
Natural products
Prostate-specific antigen
 .alpha.-Fetoproteins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
IT Antitumor agents
 (carcinoma, epidermoid; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
IT Antitumor agents
 (carcinoma, medullary carcinoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
IT Neoplasm
 (cell; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
IT Antitumor agents
 (cervix carcinoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
IT Uterus, neoplasm
 (cervix, carcinoma, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
IT Uterus, disease
 (cervix, dysplasia; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
IT Intestine, neoplasm
 (colon, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
IT Antitumor agents
 (colon; camptothecin or deriv., analog, metabolite, or prodrug thereof

- for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Eye
(cornea, hyperplastic corneal nerve tumor; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Eye
(cornea, transplant; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Transplant and Transplantation
(cornea; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Transplant rejection
(corneal; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Brain
(cortex, cortical ischemia; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Eye, disease
(diabetic retinopathy; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Brain, disease
(edema, ischemic-reperfusion-related; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Uterus, disease
(endometriosis; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Lipopolysaccharides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endotoxin; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Toxins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(endotoxins, lipopolysaccharides; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Neoplasm
(fibroma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Mycosis
(fungoides, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(gallbladder tumor inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Nerve, neoplasm
(ganglioneuroma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and

- combinations including camptothecin)
- IT Antitumor agents
(giant cell tumor; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Neuroglia
(glioblastoma multiforme, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(glioblastoma multiforme; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Glycoproteins, specific or class
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gp100; camptothecin or deriv., analog; metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(hairy cell leukemia; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(head; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Blood vessel, neoplasm
(hemangioma, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(hemangioma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Liver, neoplasm
(hepatoma, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(hepatoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Hormones, animal, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hormonal agents; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Neoplasm
(humoral hypercalcemia of malignancy; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Ovary, disease
(hyperplasia and hypervascularity; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Proteins, specific or class
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immunomodulating; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and

- combinations including camptothecin)
- IT Bone, neoplasm
- Brain, neoplasm
- Kidney, neoplasm
- Lung, neoplasm
- Nerve, neoplasm**
- Ovary, neoplasm
- Pancreas, neoplasm
- Skin, neoplasm
- Stomach, neoplasm
- Thyroid gland, neoplasm
- (inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Brain, disease
- (injury, ischemic-reperfusion-related; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Ischemia
- Reperfusion
- (ischemic-reperfusion-related brain edema and injury; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
- (kidney; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
- (larynx tumor inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
- (leiomyoma inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Myoma
- (leiomyoma, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Myoma
- (leiomyoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
- (leukemia; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Adipose tissue, neoplasm
- (lipoma, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
- (lipoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
- (lung small-cell carcinoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
- (lung; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

- IT Antitumor agents
(lymphocytic leukemia; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(lymphoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Eye, disease
(macula, degeneration; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(mammary gland; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(marfanoid habitus tumor; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antigens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(melanoma-assocd., MART-1; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(melanoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Mesothelium
(mesothelioma, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(mesothelioma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(metastasis, skin carcinoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Angiogenic factors
Hepatocyte growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(monoclonal antibodies to; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Skin, neoplasm
(mycosis fungoides, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin).
- IT Antitumor agents
(mycosis fungoides; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and

- combinations including camptothecin)
- IT Antitumor agents
(myelogenous leukemia; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(myeloma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(myxoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(neck; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Bronchi
Head
Mammary gland
Neck, anatomical
Pancreatic islet of Langerhans
Prostate gland
(neoplasm, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Parathyroid gland
(neoplasm; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(nerve; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT **Nerve, neoplasm**
(**neuroblastoma**, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(neuroblastoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Schwann cell
(neurofibroma, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(neurofibroma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(neuroma inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT **Nerve, neoplasm**
(neuroma, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Bone, neoplasm
(osteosarcoma, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents

- Bone, neoplasm
(osteosarcoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(ovary; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(pancreas; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(pancreatic islet; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Ovary, disease
(polycystic; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Proliferation inhibition
(proliferation inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(prostate gland; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Granuloma
(pyogenic; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Intestine, neoplasm
(rectum, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(rectum; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Artery, disease
(restenosis; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Eye, neoplasm
(retinoblastoma, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(retinoblastoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Eye, disease
(retrolental fibroplasia; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(rhabdomyosarcoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)
- IT Antitumor agents
(sarcoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

including camptothecin)

IT Testis, neoplasm
(seminoma, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Antitumor agents
(seminoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Antitumor agents
(skin; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Lung, neoplasm
(small-cell carcinoma, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Antitumor agents
(soft tissue sarcoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Animal tissue
(soft, sarcoma, inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Antitumor agents
(squamous cell carcinoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Antitumor agents
(stomach; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Peptidoglycans
Polysaccharides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sulfated polysaccharide peptidoglycan complex; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Protamines
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sulfates; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Neoplasm
(teratoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Antitumor agents
(thyroid; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Eye, disease
(trachoma; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Gallbladder
Larynx
(tumor inhibitors; camptothecin or deriv., analog, metabolite, or

prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Gene, animal

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(tumor suppressor; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Antigens

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(tumor-assocd., monoclonal antibodies to; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Vaccines

(tumor; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Antitumor agents

(vaccines; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Interferons

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(.alpha.; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Interferons

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(.beta.; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT Interferons

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(.gamma.; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT

50-18-0, Cytosin 50-35-1, Thalidomide 50-44-2, Mercaptopurine
50-76-0, Dactinomycin 50-91-9, Floxuridine 51-21-8, Fluorouracil
52-67-5, D-Penicillamine 56-53-1, Diethylstilbestrol 57-22-7,
Vincristine 58-05-9, Leucovorin 59-05-2, Methotrexate 76-43-7,
Fluoxymesterone 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea
145-63-1, Suramin 147-94-4, Cytarabine 151-56-4D, Aziridine, derivs.,
biological studies 154-42-7, Thioguanine 302-79-4, Retinoic acid
334-22-5D, derivs. 362-07-2, 2-Methoxyestradiol 366-18-7,
2,2'-Bipyridine 444-27-9, Thiaproline 595-33-5,
Megestrol acetate 618-27-9, cis-Hydroxyproline
865-21-4, Vinblastine 1119-28-4, .beta.-Aminopropionitrile fumarate
1398-61-4D, Chitin, sulfated derivs. 1404-00-8, Mitomycin 2133-34-8,
L-Azetidine-2-carboxylic acid 3395-35-5, D,L-3,4-Dehydroproline
4291-63-8, Cladribine 7440-06-4D, Platinum, compds., biological studies
7689-03-4, 20(S)-Camptothecin 7689-03-4D, 20(S)-Camptothecin, analogs,
derivs., metabolites, and prodrugs 9005-49-6, Heparin, biological
studies 9015-68-3, Asparaginase 9076-44-2, Chymostatin 10540-29-1,
Tamoxifen 11056-06-7, Bleomycin 11096-26-7, Erythropoietin
12244-57-4 13010-20-3D, Nitrosourea, derivs. 13311-84-7, Flutamide
14769-73-4, Levamisole 18378-89-7, Plicamycin 20830-81-3, Daunorubicin

23110-15-8, Fumagillin 23214-92-8, Doxorubicin 27988-97-2, Tetrazole
 29767-20-2, Teniposide 33069-62-4, Paclitaxel 33419-42-0, Etoposide
 34913-17-2 37270-94-3, Platelet factor 4 53643-48-4, Vindesine
 53714-56-0, Leuprolide 53910-25-1, Pentostatin 56420-45-2, Epirubicin
 58957-92-9, Idarubicin 62996-74-1, Staurosporine 63612-50-0,
 Nilutamide 64808-48-6, Lobenzarit disodium 65271-80-9, Mitoxantrone
 65277-42-1, Ketoconazole 67699-40-5, Vinzolidine 71486-22-1,
 Vinorelbine 75607-67-9, Fludarabine phosphate 78186-34-2, Bisantrene
 83150-76-9, Octreotide 83869-56-1, GM-CSF 84371-65-3, Mifepristone
 84449-90-1, Raloxifene 86090-08-6, Angiostatin 89778-26-7, Toremifene
 90357-06-5, Bicalutamide 91421-42-0, 9-Nitro-20(S)-camptothecin
 91421-43-1, 9-Amino-20(S)-camptothecin 95058-81-4, Gemcitabine
 108121-76-2, Anthracenedione 110124-55-5 114977-28-5, Docetaxel
 121369-51-5, .beta.-Cyclodextrin tetradecasulfate 124861-55-8, TIMP-2
 126509-46-4, Eponemycin 138757-15-0, .alpha.2-Antiplasmin 140208-23-7,
 PAI-1 140208-24-8, TIMP-1 142243-03-6, Proteinase inhibitor PAI-2
 143011-72-7, G-CSF 145781-92-6, Goserelin acetate 148717-90-2,
 Squalamine 174722-31-7, Rituxan 180288-69-1, Herceptin 187888-07-9,
 Endostatin 371171-68-5, Chimp 3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT 81669-70-7, Metalloproteinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT 106096-92-8, Acidic fibroblast growth factor 106096-93-9, Basic fibroblast growth factor 129653-64-1, Fibroblast growth factor 5 188417-84-7, Vascular endothelial growth factor C

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(monoclonal antibodies to; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT 106096-92-8, Acidic fibroblast growth factor 106096-93-9, Basic fibroblast growth factor 129653-64-1, Fibroblast growth factor 5 188417-84-7, Vascular endothelial growth factor C

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(monoclonal antibodies to; camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

IT 595-33-5, **Megestrol acetate**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(camptothecin or deriv., analog, metabolite, or prodrug thereof for inhibition of abnormal cell proliferation, and combinations including camptothecin)

RN 595-33-5 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 12 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN.

AN 2001:792223 HCAPLUS

DN 135:348878

TI Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric **matrix**

IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; Mcqueen, Charles E.; Jarboe, Daniel L.; Cassels, Frederick; Brown, William; Thies, Curt; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil

PA United States of America as Represented by the Secretary of the Army, USA

SO U.S., 141 pp., Cont.-in-part of U.S. Ser. No. 590,973, abandoned.

CODEN: USXXAM

DT Patent

LA English

IC A61K009-52; A61K047-30

NCL 424486000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6309669	B1	20011030	US 1997-789734	19970127 <--
	US 5417986	A	19950523	US 1992-867301	19920410 <--
	US 6410056	B1	20020625	US 1995-446148	19950522 <--
	NZ 335409	A	20001222	NZ 1996-335409	19961118 <--
	US 6447796	B1	20020910	US 1997-920326	19970821 <--
	US 2003082193	A1	20030501	US 1998-13077	19980126 <--
	WO 9832427	A1	19980730	WO 1998-US1556	19980127 <--
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9863175	A1	19980818	AU 1998-63175	19980127 <--
	US 2003129233	A1	20030710	US 2002-165975	20020610 <--
PRAI	US 1984-590308	B1	19840316 <--		
	US 1992-867301	A2	19920410 <--		
	US 1995-446148	A2	19950522 <--		
	US 1995-446149	B2	19950522 <--		
	US 1996-590973	B2	19960124 <--		
	US 1990-493597	B2	19900315 <--		
	US 1990-521945	B2	19900511 <--		
	US 1991-690485	B2	19910424 <--		

US 1991-805721	B2	19911121	<--
US 1993-64559	B2	19930521	<--
US 1994-209350	B2	19940107	<--
US 1994-242960	A2	19940516	<--
US 1994-247884	B2	19940523	<--
US 1996-675895	A2	19960705	<--
US 1996-698896	A2	19960816	<--
NZ 1996-325561	A1	19961118	<--
US 1997-789734	A2	19970127	<--
US 1997-920326	A1	19970821	<--
WO 1998-US1556	W	19980127	<--

- AB Novel burst-free, sustained-release biocompatible and biodegradable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aq. physiol. environment are disclosed. The microcapsules are comprised of a core of polypeptide or other biol. active agent encapsulated in a **matrix** of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of uncapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99. Ampicillin microcapsules effectively prevented infection in 73% of rats whose wound were inoculated with ampicillin-resistant strains of Staphilococcus aureus, while systemic ampicillin failed in 100% of animals.
- ST bioactive microcapsule biodegradable biocompatible polymer; ampicillin microcapsule polylactide polyglycolide
- IT Antitumor agents
(Kaposi's sarcoma; therapeutic treatment and prevention of infections with bioactive materials encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Immunostimulants
(adjuvants; therapeutic treatment and prevention of infections with bioactive materials encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Rauvolfia
(alkaloid; therapeutic treatment and prevention of infections with bioactive materials encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Glycosides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino; therapeutic treatment and prevention of infections with bioactive materials encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Drugs
(appetite stimulants; therapeutic treatment and prevention of infections with bioactive materials encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Natural products, pharmaceutical
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(belladonna; therapeutic treatment and prevention of infections with bioactive materials encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biodegradable; therapeutic treatment and prevention of infections with bioactive materials encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Drug delivery systems
(capsules; therapeutic treatment and prevention of infections with bioactive materials encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Vasodilators
(coronary; therapeutic treatment and prevention of infections with bioactive materials encapsulated within biodegradable-biocompatible

- polymeric **matrix**)
- IT Alkaloids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ergot; therapeutic treatment and prevention of infections with
bioactive materials encapsulated within biodegradable-biocompatible
polymeric **matrix**)
- IT Amino acids, biological studies
Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(essential; therapeutic treatment and prevention of infections with
bioactive materials encapsulated within biodegradable-biocompatible
polymeric **matrix**)
- IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(esters; therapeutic treatment and prevention of infections with
bioactive materials encapsulated within biodegradable-biocompatible
polymeric **matrix**)
- IT Embryo, animal
(fetus; therapeutic treatment and prevention of infections with
bioactive materials encapsulated within biodegradable-biocompatible
polymeric **matrix**)
- IT Calymmatobacterium granulomatis
(granuloma inguinale from; therapeutic treatment and prevention of
infections with bioactive materials encapsulated within
biodegradable-biocompatible polymeric **matrix**)
- IT Human herpesvirus 3
(herpes zoster from; therapeutic treatment and prevention of infections
with bioactive materials encapsulated within biodegradable-
biocompatible polymeric **matrix**)
- IT Fertility
(inhibitors, non-steroidal; therapeutic treatment and prevention of
infections with bioactive materials encapsulated within
biodegradable-biocompatible polymeric **matrix**)
- IT Disease, animal
(lymphopathia venerum; therapeutic treatment and prevention of
infections with bioactive materials encapsulated within
biodegradable-biocompatible polymeric **matrix**)
- IT Antibiotics
(macrolide; therapeutic treatment and prevention of infections with
bioactive materials encapsulated within biodegradable-biocompatible
polymeric **matrix**)
- IT Drug delivery systems
(microcapsules; therapeutic treatment and prevention of infections with
bioactive materials encapsulated within biodegradable-biocompatible
polymeric **matrix**)
- IT Surfactants
(nonionic; therapeutic treatment and prevention of infections with
bioactive materials encapsulated within biodegradable-biocompatible
polymeric **matrix**)
- IT Anti-inflammatory agents
(nonsteroidal; therapeutic treatment and prevention of infections with
bioactive materials encapsulated within biodegradable-biocompatible
polymeric **matrix**)
- IT Nitrites
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(org.; therapeutic treatment and prevention of infections with
bioactive materials encapsulated within biodegradable-biocompatible
polymeric **matrix**)
- IT Drug delivery systems
(prodrugs; therapeutic treatment and prevention of infections with
bioactive materials encapsulated within biodegradable-biocompatible
polymeric **matrix**)
- IT Alkaloids, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (quinolone, fluoro-; therapeutic treatment and prevention of infections
 with bioactive materials encapsulated within biodegradable-
 biocompatible polymeric **matrix**)

- IT Antitumor agents
 (sarcoma; therapeutic treatment and prevention of infections with
 bioactive materials encapsulated within biodegradable-biocompatible
 polymeric **matrix**)
- IT Drug delivery systems
 (solns.; therapeutic treatment and prevention of infections with
 bioactive materials encapsulated within biodegradable-biocompatible
 polymeric **matrix**)
- IT Muscle relaxants
 (spasmolytics; therapeutic treatment and prevention of infections with
 bioactive materials encapsulated within biodegradable-biocompatible
 polymeric **matrix**)
- IT Contraceptives
 (spermicidal; therapeutic treatment and prevention of infections with
 bioactive materials encapsulated within biodegradable-biocompatible
 polymeric **matrix**)
- IT Appetite
 (stimulants; therapeutic treatment and prevention of infections with
 bioactive materials encapsulated within biodegradable-biocompatible
 polymeric **matrix**)
- IT Absidia ramosa
 Actinobacillus equuli
 Actinobacillus seminis
 Adrenoceptor agonists
 Allergy inhibitors
 Analgesics
 Anesthetics
 Anti-inflammatory agents
 Antiarrhythmics
 Antibacterial agents
 Antibiotics
 Anticoagulants
 Anticonvulsants
 Antidepressants
 Antiemetics
 Antihistamines
 Antihypertensives
 Antimalarials
 Antimigraine agents
Antiparkinsonian agents
 Antipyretics
 Antitumor agents
 Antitussives
 Antiviral agents
 Appetite depressants
 Arcanobacterium pyogenes
 Aspergillus fumigatus
 Babesia caballi
 Bile
 Blood plasma
 Bovine herpesvirus 1
 Bronchodilators
 Brucella melitensis
 Campylobacter fetus
 Campylobacter fetus intestinalis
 Candida albicans
 Candida tropicalis
 Cardiotonics
 Cardiovascular agents

Cardiovascular system
Chlamydia psittaci
Cholinergic agonists
Clostridium tetani
Contraceptives
Cytotoxic agents
Decongestants
Digesters
Diuretics
Electrolytes
Encapsulation
Equid herpesvirus 1
Equine arteritis virus
Escherichia coli
Expectorants
Fungicides
Gardnerella vaginalis
Haemophilus ducreyi
Human herpesvirus 1
Human herpesvirus 2
Hypnotics and Sedatives
Immunomodulators
Leptospira interrogans pomona
Listeria monocytogenes
Microorganism
Muscle relaxants
Mycobacterium tuberculosis
Mycoplasma bovis
Mycoplasma hominis
Narcotics
Neisseria gonorrhoeae
Nutrients
Opioid antagonists
Parasiticides
Pseudomonas aeruginosa
Psychotropics
Rhodococcus equi
Salmonella abortus
Salmonella abortusovis
Stabilizing agents
Streptococcus
Surfactants
Toxoplasma gondii
Tranquilizers
Treponema pallidum
Trichomonas vaginalis
Tritrichomonas foetus
Trypanosoma equiperdum
Vaccines
Vasodilators
Wound healing
 (therapeutic treatment and prevention of infections with bioactive
 materials encapsulated within biodegradable-biocompatible polymeric
 matrix)
IT Alkaloids, biological studies
Amino acids, biological studies
Antibodies
Antigens
Carbohydrates, biological studies
Enzymes, biological studies
Estrogens
Fatty acids, biological studies
Glycolipids

Glycols, biological studies
 Glycopeptides
 Glycoproteins, general, biological studies
 Growth factors, animal
 Hormones, animal, biological studies
 Lipids, biological studies
 Lipopolysaccharides
 Peptides, biological studies
 Pheromones, animal
 Polysaccharides, biological studies
 Progestogens
 Prostaglandins
 Proteins, general, biological studies
 RNA
 Steroids, biological studies
 Sulfonamides
 Tetracyclines
 Vitamins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (therapeutic treatment and prevention of infections with bioactive materials encapsulated within biodegradable-biocompatible polymeric **matrix**)

IT Lactams

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (.beta.-; therapeutic treatment and prevention of infections with bioactive materials encapsulated within biodegradable-biocompatible polymeric **matrix**)

IT 9001-92-7, Protease

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibitors; therapeutic treatment and prevention of infections with bioactive materials encapsulated within biodegradable-biocompatible polymeric **matrix**)

IT 9001-54-1, Hyaluronidase 9001-60-9, Lactic dehydrogenase

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (sperm; therapeutic treatment and prevention of infections with bioactive materials encapsulated within biodegradable-biocompatible polymeric **matrix**)

IT 50-06-6, Phenobarbital, biological studies 50-12-4, Mephentoin
 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8,
 Prednisolone 50-28-2, .beta.-Estradiol, biological studies 50-33-9,
 Phenylbutazone, biological studies 50-52-2, Thioridazine 50-55-5,
 Reserpine 50-78-2, Aspirin 51-55-8, Atropine, biological studies
 52-24-4, Thiotepe 52-76-6, Lynestrenol 53-03-2, Prednisone 53-16-7,
 Estrone, biological studies 53-86-1, Indomethacin 54-11-5, Nicotine;
 55-48-1, Atropine sulfate 55-63-0, Nitroglycerin 55-86-7, Nitrogen
 mustard 56-53-1, Diethyl stilbestrol 56-75-7, Chloramphenicol
 57-27-2, Morphine, biological studies 57-33-0, Sodium pentobarbital
 57-42-1, Meperidine 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol
 57-85-2, Testosterone propionate 57-92-1, Streptomycin A, biological
 studies 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine
 58-22-0, Testosterone 58-25-3, Chlordiazepoxide 58-39-9, Perphenazine
 58-73-1, Diphenhydramine 59-01-8, Kanamycin A 59-05-2, Methotrexate
 59-92-7, L-Dopa, biological studies 61-33-6, Penicillin G, biological
 studies 67-20-9, Nitro-furantoin **68-22-4**,
Norethindrone 68-23-5, Norethynodrel 69-53-4, Ampicillin
 69-72-7D, Salicylic acid, derivs. 71-58-9, Medroxyprogesterone acetate
 72-33-3, Mestranol 76-57-3, Codeine 78-11-5, Pentaerythritol
 tetranitrate 79-57-2, Oxytetracycline 79-64-1, Dimethisterone
 91-81-6, Tripeleminamine 103-90-2, Acetaminophen 113-15-5, Ergotamine
 114-07-8, Erythromycin 114-49-8, Hyoscine hydrobromide 121-54-0,
 Benzethonium chloride 122-09-8, Phentermine 125-29-1, Dihydrocodeinone
 125-71-3, Dextromethorphan 127-48-0, Trimethadione 128-62-1, Noscipine
 145-94-8, Chlorindanol 155-41-9, Methscopolamine bromide 288-32-4D,

Imidazole, derivs. 297-76-7, Ethynodiol diacetate 302-22-7, Chlormadinone acetate 305-03-3, Chlorambucil 309-43-3, Sodium secobarbital 315-30-0, Allopurinol 434-03-7, Ethisterone 439-14-5, Diazepam 443-48-1, Metronidazole 469-62-5 471-34-1, Calcium carbonate, biological studies 497-19-8, Sodium carbonate, biological studies 523-87-5, Dimenhydrinate 546-93-0, Magnesium carbonate 578-66-5D, 8 Aminoquinoline, derivs. 578-68-7D, 4-Aminoquinoline, derivs. **595-33-5, Megestrol acetate**
 738-70-5, Trimethoprim 846-50-4, Temazepam 1397-89-3, Amphotericin-B 1397-94-0, Antimycin A 1403-66-3, Gentamicin 1404-26-8, Polymyxin-B; 1404-90-6, Vancomycin 1406-05-9, Penicillin 4696-76-8, Kanamycin B 5588-33-0, Mesoridazine 5633-18-1, Melengestrol 5786-21-0, Clozapine 5800-19-1, Metiapine 6533-00-2, Norgestrel 7447-40-7, Potassium chloride, biological studies 8063-07-8, Kanamycin 9000-83-3, Adenosine triphosphatase 9000-92-4, Amylase 9001-46-1, Glutamic acid dehydrogenase 9001-67-6, Neuraminidase 9001-78-9 9001-99-4, RNase 9002-07-7, Trypsin 9004-07-3, Chymotrypsin 9004-10-8, Insulin, biological studies 9005-63-4D, Polyoxyethylene sorbitan, fatty acid esters 9016-45-9, Polyethylene glycol nonylphenyl ether 9035-74-9, Glycogen phosphorylase 10118-90-8, Minocycline 11111-12-9, Cephalosporins 13292-46-1, Rifampin 14271-04-6 14271-05-7 21645-51-2, Aluminum hydroxide, biological studies 22232-71-9, Mazindol 24730-10-7, Dihydroergocristine methanesulfonate 25953-19-9, Cefazoline 26780-50-7, Poly(lactide-co-glycolide) 30516-87-1 32986-56-4, Tobramycin 35189-28-7, Norgestimate 37517-28-5, Amikacin 53678-77-6, Muramyl dipeptide 53994-73-3, Cefaclor 55268-75-2, Cefuroxime 61036-62-2, Teicoplanin 64221-86-9, Imipenem 78110-38-0, Aztreonam 80738-43-8, Lincosamide 81103-11-9, Clarithromycin 82009-34-5, Cilastatin 82419-36-1, Ofloxacin 85721-33-1, Ciprofloxacin 123781-17-9, Histatin 189200-69-9, Polygen

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
 (therapeutic treatment and prevention of infections with bioactive materials encapsulated within biodegradable-biocompatible polymeric matrix)

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE

- (1) Anon; EP 052510 B2 1994 HCAPLUS
- (2) Anon; Materials 1996, P351
- (3) Bodmer; US 5538739 1996 HCAPLUS
- (4) Bodmer; US 5639480 1997 HCAPLUS
- (5) Bodmer; US 5688530 1997 HCAPLUS
- (6) Cleland; US 5643605 1997 HCAPLUS
- (7) Damani; US 5198220 1993 HCAPLUS
- (8) Dunn; US 5707647 1998
- (9) Dunn; US 5990194 1999 HCAPLUS
- (10) Gardner; US 4637905 1987 HCAPLUS
- (11) Gombotz; US 5942253 1999 HCAPLUS
- (12) Hunter; US 5716981 1998 HCAPLUS
- (13) Hunter; US 5886026 1999 HCAPLUS
- (14) Hunter; US 5994341 1999 HCAPLUS
- (15) Jeyanthi; Proceedings International Symposium on Controlled Release of Bioactive
- (16) Kent; US 4675189 1987 HCAPLUS
- (17) Wang; J of Controlled Release 1991, V17, P23 HCAPLUS
- (18) Yan; J of Con Rel 1994, V32(3), P231 HCAPLUS
- (19) Yeh; A Novel Emulsification-Solvent extraction Technique for Production of Protein Loaded Biodegradable Microparticles for vaccine and Drug Delivery 1995, V33(3), P437 HCAPLUS

IT **68-22-4, Norethindrone 595-33-5, Megestrol acetate**


RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
 (therapeutic treatment and prevention of infections with bioactive materials encapsulated within biodegradable-biocompatible polymeric

matrix)

RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 595-33-5 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 13 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:730928 HCAPLUS

DN 135:267221

TI Bladder cancer-specific peptides for diagnosis and therapy

IN Frangioni, John V.; Cantley, Lewis C.; O'Donnell, Michael A.

PA Beth Israel Deaconess Medical Center, USA

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C12N

CC 1-6 (Pharmacology)

Section cross-reference(s): 8, 9, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072958	A2	20011004	WO 2001-US10116	20010328 <--
	WO 2001072958	A3	20020321		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,

VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001049608 A5 20011008 AU 2001-49608 20010328 <--

PRAI US 2000-192505P P 20000328 <--

WO 2001-US10116 W 20010328

AB Peptides are disclosed which selectively bind to bladder tumor cells relative to normal (untransformed) bladder cells, also referred to herein as Bladder Tumor Cell-Specific (BTCS) peptides or BTCS binding sequence. The peptides may be conjugated to e.g. cytotoxic agents or imaging agents.

ST bladder tumor specific peptide therapy diagnosis; imaging agent peptide conjugate bladder tumor diagnosis; cytotoxic agent peptide conjugate bladder tumor therapy

IT Glycoproteins, specific or class

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CVF (cobra venom factor), peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Toxins

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ML-I (mistletoe lectin I), peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Imaging agents

(NMR contrast, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Proteins, specific or class

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(PAP (pokeweed antiviral protein), peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Imaging agents

(acoustic, microbubble, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Adeno-associated virus

(adeno-assocd. viral particle; bladder cancer-specific peptides for diagnosis and therapy)

IT Adenoviridae

(adenoviral particle; bladder cancer-specific peptides for diagnosis and therapy)

IT Adrenal cortex

(adrenocortical suppressants, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Intercalation

(agents, DNA, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Light scattering

(agents, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Sulfonates

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(alkanesulfonates, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Abrins

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

- (and abrin A chain, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)
- IT Fluorescent substances
 - (and near IR fluorophores, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)
- IT Polyelectrolytes
 - (anionic, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)
- IT Hormones, animal, biological studies
 - RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (antagonists, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)
- IT Estrogens
 - RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (antiestrogens, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)
- IT Drug delivery systems
 - Imaging agents
 - Peptidomimetics
 - (bladder cancer-specific peptides for diagnosis and therapy)
- IT Fusion proteins (chimeric proteins)
 - Peptides, biological studies
 - RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (bladder cancer-specific peptides for diagnosis and therapy)
- IT Antitumor agents
 - (bladder carcinoma; bladder cancer-specific peptides for diagnosis and therapy)
- IT Pancreas
 - (bovine pancreatic RNase, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)
- IT Bladder
 - (carcinoma, inhibitors; bladder cancer-specific peptides for diagnosis and therapy)
- IT Polyelectrolytes
 - (cationic, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)
- IT Paramagnetic materials
 - (chelates, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)
- IT Proteins, specific or class
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (coat, chimeric; bladder cancer-specific peptides for diagnosis and therapy)
- IT Colloids
 - (colloidal particles, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)
- IT Enzymes, biological studies
 - RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (conjugates, with peptides; bladder cancer-specific peptides for diagnosis and therapy)
- IT Peptides, biological studies
 - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 - (conjugates; bladder cancer-specific peptides for diagnosis and therapy)
- IT Toxins

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(diphtheria, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Pseudomonas

(exotoxin, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Toxins

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(exotoxins, Pseudomonas, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Proteins, specific or class

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(fiber knob protein; bladder cancer-specific peptides for diagnosis and therapy)

IT **Apoptosis**

(inducers, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT DNA formation

Ribosome

(inhibitors, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Enzymes, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT DNA

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(intercalators, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Optical reflection

(light reflecting agents, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Optical absorption

(light-absorbing agents, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Cytolysis

(lytic agents, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Metabolism

(metabolites, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Bubbles

(microbubbles, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Spheres

(nanospheres, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT IR radiation

(near-IR, fluorophores, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Bladder

(neoplasm; bladder cancer-specific peptides for diagnosis and therapy)

IT Toxins

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(neurotoxins, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Chloramines

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nitrogen mustards, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Alkylating agents, biological

Antibiotics

Chelating agents

Cytotoxic agents

Liposomes

Mycobacterium BCG

(peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Androgens

Chelates

Corticosteroids, biological studies

Estrogens

Hormones, animal, biological studies

Metals, biological studies

Polymers, biological studies

Progestogens

Rare earth metals, biological studies

Ricins

Taxanes

Toxins

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Nucleic acids

RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(peptide-encoding; bladder cancer-specific peptides for diagnosis and therapy)

IT Membrane, biological

(permeability modifiers, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Biological transport

(permeation, membrane permeability modifiers, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Clostridium perfringens

(phospholipase C, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Proliferation inhibition

(proliferation inhibitors, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Proteins, general, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(protein prodn. inhibitors, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Radionuclides, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(radiometals, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT Proteins, specific or class

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(saporins, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

- IT RNA
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis inhibitors, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)
- IT Alkaloids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vinca, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)
- IT Virus
(viral particle; bladder cancer-specific peptides for diagnosis and therapy)
- IT 9001-86-9, Phospholipase C
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Clostridium perfringens, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)
- IT 364038-48-2 364038-49-3 364038-50-6 364038-51-7 364038-52-8
364038-53-9 364038-54-0 364038-55-1 364038-56-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bladder cancer-specific peptides for diagnosis and therapy)
- IT 50-18-0D, Cyclophosphamide, peptide conjugates 50-44-2D, Mercaptopurine, peptide conjugates 50-76-0D, Dactinomycin, peptide conjugates 51-21-8D, Fluorouracil, peptide conjugates 51-75-2D, Mechlorethamine, peptide conjugates 52-24-4D, Thiotepa, peptide conjugates 53-03-2D, Prednisone, peptide conjugates 53-19-0D, Mitotane, peptide conjugates 53-79-2D, Puromycin, peptide conjugates 55-98-1D, Busulfan, peptide conjugates 56-53-1D, Diethylstilbestrol, peptide conjugates 57-13-6D, Urea, derivs., peptide conjugates, biological studies 57-22-7D, Vincristine, peptide conjugates 57-63-6D, Ethinyl estradiol, peptide conjugates 57-85-2D, Testosterone propionate, peptide conjugates 59-05-2D, Methotrexate, peptide conjugates 59-30-3D, Folic acid, analogs, peptide conjugates 60-34-4D, Methylhydrazine, derivs., peptide conjugates 66-75-1D, Uracil mustard, peptide conjugates 66-81-9D, Cycloheximide, peptide conjugates 71-58-9D, Medroprogesterone acetate, peptide conjugates 76-43-7D, Fluoxymesterone, peptide conjugates 120-73-0D, Purine, analogs, peptide conjugates 127-07-1D, Hydroxyurea, peptide conjugates 147-94-4D, Cytarabine, peptide conjugates 148-82-3D, Melphalan, peptide conjugates 151-56-4D, Ethylenimine, derivs., peptide conjugates 154-42-7D, Thioguanine, peptide conjugates 154-93-8D, Carmustine, peptide conjugates 289-95-2D, Pyrimidine, analogs, peptide conjugates 305-03-3D, Chlorambucil, peptide conjugates **595-33-5D, Megestrol acetate**, peptide conjugates 630-56-8D, Hydroxyprogesterone caproate, peptide conjugates 671-16-9D, Procarbazine, peptide conjugates 865-21-4D, Vinblastine, peptide conjugates 1404-00-8D, Mitomycin, peptide conjugates 2169-64-4D, Azaribine, peptide conjugates 4342-03-4D, Dacarbazine, peptide conjugates 7440-06-4D, Platinum, coordination complexes, peptide conjugates, biological studies 9001-99-4D, Ribonuclease, peptide conjugates 9015-68-3D, L-Asparaginase, peptide conjugates 10043-49-9D, gold-198, chelates, peptide conjugates, biological studies 10043-66-0D, iodine-131, chelates, peptide conjugates, biological studies 10098-91-6D, yttrium-90, chelates, peptide conjugates, biological studies 10540-29-1D, Tamoxifen, peptide conjugates 11056-06-7D, Bleomycin, peptide conjugates 13010-20-3D, Nitrosourea, derivs., peptide conjugates 13010-47-4D, Lomustine, peptide conjugates 13909-09-6D, Semustine, peptide conjugates 13967-65-2D, holmium-166, chelates, peptide conjugates, biological studies 13981-25-4D, copper-64, chelates; peptide conjugates, biological studies 13981-50-5D, cobalt-57, chelates, peptide

conjugates, biological studies 13981-51-6D, mercury-197, chelates, peptide conjugates, biological studies 14093-04-0D, iron-52, chelates, peptide conjugates, biological studies 14119-09-6D, gallium-67, chelates, peptide conjugates, biological studies 14119-24-5D, osmium-191, chelates, peptide conjugates, biological studies 14133-76-7D, technetium-99, chelates, peptide conjugates, biological studies 14158-31-7D, iodine-125, chelates, peptide conjugates, biological studies 14158-35-1D, iridium-194, chelates, peptide conjugates, biological studies 14265-75-9D, lutetium-177, chelates, peptide conjugates, biological studies 14374-81-3D, germanium-71, chelates, peptide conjugates, biological studies 14378-26-8D, rhenium-188, chelates, peptide conjugates, biological studies 14378-53-1D, rhodium-101, chelates, peptide conjugates, biological studies 14391-11-8D, gold-199, chelates, peptide conjugates, biological studies 14391-19-6D, terbium-161, chelates, peptide conjugates, biological studies 14391-96-9D, scandium-47, chelates, peptide conjugates, biological studies 14596-37-3D, phosphorus-32, chelates, peptide conjugates, biological studies 14683-06-8D, tin-121, chelates, peptide conjugates, biological studies 14687-25-3D, lead-203, chelates, peptide conjugates, biological studies 14687-61-7D, arsenic-77, chelates, peptide conjugates, biological studies 14809-47-3D, bromine-75, chelates, peptide conjugates, biological studies 14885-78-0D, indium-113, chelates, peptide conjugates, biological studies 14903-02-7D, potassium-43, chelates, peptide conjugates, biological studies 14913-49-6D, bismuth-212, chelates, peptide conjugates, biological studies 14913-89-4D, chelates, peptide conjugates, biological studies 14914-68-2D, antimony-119, chelates, peptide conjugates, biological studies 14914-76-2D, cesium-131, chelates, peptide conjugates, biological studies 14967-68-1D, palladium-103, chelates, peptide conjugates, biological studies 14981-64-7D, palladium-109, chelates, peptide conjugates, biological studies 14981-79-4D, praseodymium-143, chelates, peptide conjugates, biological studies 14998-63-1D, rhenium-186, chelates, peptide conjugates, biological studies 15047-05-9D, cesium-129, chelates, peptide conjugates, biological studies 15056-34-5D, Triazene, derivs., peptide conjugates 15092-94-1D, lead-212, chelates, peptide conjugates, biological studies 15663-27-1D, Cisplatin, peptide conjugates 15690-69-4D, palladium-100, chelates, peptide conjugates, biological studies 15715-08-9D, iodine-123, chelates, peptide conjugates, biological studies 15720-35-1D, cesium-127, chelates, peptide conjugates, biological studies 15735-70-3D, platinum-193, chelates, peptide conjugates, biological studies 15741-25-0D, barium-128, chelates, peptide conjugates, biological studies 15749-66-3D, phosphorus-33, chelates, peptide conjugates, biological studies 15750-15-9D, indium-111, chelates, peptide conjugates, biological studies 15755-39-2D, astatine-211, chelates, peptide conjugates, biological studies 15757-14-9D, gallium-68, chelates, peptide conjugates, biological studies 15757-86-5D, copper-67, chelates, peptide conjugates, biological studies 15758-35-7D, ruthenium-97, chelates, peptide conjugates, biological studies 15760-04-0D, silver-111, chelates, peptide conjugates, biological studies 15765-38-5D, bromine-76, chelates, peptide conjugates, biological studies 15765-39-6D, bromine-77, chelates, peptide conjugates, biological studies 15765-78-3D, rhenium-189, chelates, peptide conjugates, biological studies 15766-00-4D, samarium-153, chelates, peptide conjugates, biological studies 15776-20-2D, bismuth-213, chelates, peptide conjugates, biological studies 18268-34-3D, rubidium-81, chelates, peptide conjugates, biological studies 18378-89-7D, Mithramycin, peptide conjugates 18883-66-4D, Streptozocin, peptide conjugates 20830-81-3D, Daunorubicin, peptide conjugates 23214-92-8D, Doxorubicin, peptide conjugates 33069-62-4D, Paclitaxel, peptide conjugates 51632-96-3D, europium-169, chelates, peptide conjugates, biological studies 65988-88-7D, Modeccin, peptide conjugates 75037-46-6D, Gelonin, peptide conjugates 91933-11-8D, Volkensin, peptide

conjugates 114977-28-5D, Docetaxel; peptide conjugates

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(bladder cancer-specific peptides for diagnosis and therapy)

IT 13982-64-4, strontium-87, biological studies 15678-91-8, krypton-81, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(metastable, chelates, peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT 1332-37-2, Iron oxide, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(monocryst. nanocompds., peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT 1332-37-2, Iron oxide, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(monocryst. nanocompds., peptide conjugates; bladder cancer-specific peptides for diagnosis and therapy)

IT 595-33-5D, **Megestrol acetate**, peptide conjugates


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(bladder cancer-specific peptides for diagnosis and therapy)

RN 595-33-5 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 14 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:545462 HCAPLUS

DN 135:127206

TI Compositions and methods to effect the **release profile** in the transdermal administration of active agents

IN Kanios, David

PA Noven Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-70


CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001052823	A2	20010726	WO 2001-US1999	20010119 <--
	WO 2001052823	A3	20020502		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002004065	A1	20020110	US 2001-765932	20010119 <--
PRAI	US 2000-177103P	P	20000120	<--	
AB	Comps. and methods for the transdermal delivery of active agents up to a period of seven days or more at substantially a zero-order release rate comprise a pharmaceutically acceptable adhesive matrix and a polymeric plastic material that provides a release rate regulating effect on the active agents. A compn. was prepd. contg. estradiol/ norethindrone acetate, Et cellulose, EtOAc, toluene, isopropanol, polyacrylate adhesive and polysiloxane adhesive. Dipropylene glycol and oleyl alc. were added to the mixt.				
ST	transdermal pharmaceutical controlled release				
IT	Alzheimer's disease Analgesics Anesthetics Anti-inflammatory agents Antidepressants Antimicrobial agents Antipsychotics Antitumor agents Anxiolytics Cardiotonics Hypnotics and Sedatives Nervous system agents Nervous system stimulants Parkinson's disease Permeation enhancers (comps. and methods to effect the release profile in transdermal delivery systems)				
IT	Polycarbonates, biological studies Polysiloxanes, biological studies Polyurethanes, biological studies RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (comps. and methods to effect the release profile in transdermal delivery systems)				
IT	Corticosteroids , biological studies Hormones, animal, biological studies Steroids, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (comps. and methods to effect the release profile in transdermal delivery systems)				
IT	Crystallization (inhibitors; comps. and methods to effect the release profile in transdermal delivery systems)				
IT	Alcohols, biological studies RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (polyhydric; comps. and methods to effect the release				

- profile** in transdermal delivery systems)
- IT Drug delivery systems
(transdermal; compns. and methods to effect the **release profile** in transdermal delivery systems)
- IT 9003-39-8, Pvp 9004-34-6, Cellulose, biological studies 9004-35-7, Cellulose acetate 9004-36-8, Cellulose acetate butyrate 9004-38-0, Cellulose acetate phthalate 9004-39-1, Cellulose acetate propionate
RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(compns. and methods to effect the **release profile** in transdermal delivery systems)
- IT 143-28-2, Oleyl alcohol 9004-57-3, Ethyl cellulose 25265-71-8, Dipropylene glycol
RL: MOA (Modifier or additive use); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(compns. and methods to effect the **release profile** in transdermal delivery systems)
- IT 9002-86-2, Pvc 9003-53-6, Polystyrene 25014-41-9, Polyacrylonitrile
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods to effect the **release profile** in transdermal delivery systems)
- IT 51-98-9, **Norethindrone** acetate 57-63-6, Ethinylestradiol 57-83-0, Progesterone, biological studies **68-22-4**, **Norethindrone**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(compns. and methods to effect the **release profile** in transdermal delivery systems)
- IT 50-28-2, 17.beta.-Estradiol, biological studies 58-18-4, Methyltestosterone 58-22-0, Testosterone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods to effect the **release profile** in transdermal delivery systems)
- IT **68-22-4, Norethindrone**
RL: PEP (Physical, engineering or chemical process); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(compns. and methods to effect the **release profile** in transdermal delivery systems)
- RN 68-22-4 HCAPLUS
- CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AN 2001:338762 HCAPLUS
 DN 134:362292
 TI Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile
 IN Farr, Spencer
 PA Phase-1 Molecular Toxicology, USA
 SO PCT Int. Appl., 222 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C12Q001-68
 ICS G01N033-50
 CC 3-4 (Biochemical Genetics)
 Section cross-reference(s): 1, 6, 7, 13, 15

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001032928	A2	20010510	WO 2000-US30474	20001103 <--
	WO 2001032928	A3	20020725		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1999-165398P	P	19991105	<--	
	US 2000-196571P	P	20000411	<--	

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to det. the hypersensitivity of individuals to a given agent, such as drug or other chem., in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes assocd. with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes assocd. with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes assocd. with hypersensitivity. The expression of the genes predetd. to be assocd. with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and app. useful for identifying hypersensitivity in a subject are also disclosed.

ST drug hypersensitivity gene expression DNA microarray app

IT Uncoupling protein

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(1, 2 and 3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(11 beta-hydroxysteroid dehydrogenase type II; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

- (Biological study); PROC (Process)
(12-lipoxygenase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Metallothioneins
Presenilins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cyclin dependent kinase inhibitors
(1A; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Metallothioneins
Synaptobrevins
Thrombospondins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Connexins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(30; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Connexins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(32; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Syntaxins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Connexins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(40; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Bone morphogenetic proteins
Keratins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(4; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(5-Aminolevulinate synthase 2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(6-C-kine; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(60S ribosomal protein L6; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Keratins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

- (Biological study); PROC (Process)
(6; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Apolipoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(A-I; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Apolipoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(A-II; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cyclins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(A1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ACP (acyl-carrier); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transport proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ADP/ATP carrier; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ALDH1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ALDH2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ATF (activating transcription factor), ATF3 and ATF4; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ATF-2 (activating transcription factor 2); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ATF4; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ATP dep. helicase II (70kDa); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

- (Biological study); PROC (Process)
(ATP dep. helicase II (Ku80); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ATPase subunit 6; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(B-myb; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Platelet-derived growth factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(BAG-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(BCRP; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(BRCA1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Sialoglycoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(BSP II (bone sialoglycoprotein II); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Bak; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Bax (alpha); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Bax; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Bcl-xL; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

- IT Chemokines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(C-C, C10; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Chemokines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(C-C, I-309; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Apolipoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(C-III; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(C-reactive; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(C/EBP (CCAAT box/enhancer element-binding protein), .epsilon.; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(C/EBP-.alpha. (CCAAT box/enhancer element-binding protein .alpha.); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Glycoproteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(C4bp (complement C4b-binding protein); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(C5a anaphylatoxin receptor; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Complement receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(C5a; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CAP (adenylate cyclase-assocd. protein); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT CD antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CD82; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

- (CHD2 and CIG49; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CIDEB; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CLP; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CTCF; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Chemokine receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CXCR4; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CYP1A1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(CYP4A; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Chk1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Clusterin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Csa-19; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cyclins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(D1, A1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cyclins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(D3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DCC (deleted in colorectal cancer); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DEAD-box protein p72; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DNA binding protein inhibitor ID-2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DNA dependent helicase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DNA dependent protein kinase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Enzymes, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DNA helicase II, ERCC3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Enzymes, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DNA helicase II; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Enzymes, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DNA helicases; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DNA ligase IV; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DNA polymerase alpha; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DNA repair protein XRCC1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DNA topoisomerase I; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DNA-binding, APRF; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DNA-binding, p48; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DNA-binding, zinc finger-contg.; ZNF134; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DNA-binding, zinc finger-contg.; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DOC-2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(DRA; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Dopamine receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(D2(short); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Calbindins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(D28k; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Calbindins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(D9k; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Cadherins
Selectins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(E-; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(E-cadherin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(E2F1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Apolipoproteins
Cyclins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(E; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ELAV-like neuronal protein-2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ERA-B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ERCC-5; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ERCC1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ERCC3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ERp72; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Egr-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(FEN-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(FIC1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(FYN proto-oncogene; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Fra-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(G/T mismatch binding protein; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

- IT Cyclins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(G1, cyclin G1 interacting protein; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(G6PD; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cyclins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(G; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(GAS-7, GCLR, and GCLS; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(GOS24; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(GRP (glucose-regulated protein), glucose-regulated protein 170; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(GRP (glucose-regulated protein), glucose-regulated protein 58; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(GRP78 (glucose-regulated protein, 78,000-mol-wt.); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(GRP94; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(GT mismatch binding protein; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Gadd153; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Proteins, specific or class

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Gadd45; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Garg-16; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Ferritins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(H chain; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Glycoproteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(H-CAM (homing cell adhesion mol.); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(H-cadherins; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Histones
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(H2A; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Histones
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(H2B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(HDLCL1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(HIF-1 (hypoxia-inducible factor 1), .alpha.; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(HMG CoA reductase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT High-mobility group proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(HMG1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(HNF-4 (hepatocyte nuclear factor 4); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal

- RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(HNF4; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Heat-shock proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(HSP 27; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Heat-shock proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(HSP 47; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Heat-shock proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(HSP 70; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Heat-shock proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(HSP 90; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Heat-shock proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(HSP12; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(HSP70; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Hsp90; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(I, II and III subunits for cytochrome oxidase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Synaptotagmin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(I; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ICAM-1 (intercellular adhesion mol. 1); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ICAM-2 (intercellular adhesion mol. 2); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cell adhesion molecules

- RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ICAM-3 (intercellular adhesion mol. 3); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ICE RelII; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ID-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Metallothioneins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(IG; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Insulin-like growth factor-binding proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(IGF-BP-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Insulin-like growth factor-binding proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(IGF-BP-2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Insulin-like growth factor-binding proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(IGF-BP-3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Insulin-like growth factor-binding proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(IGF-BP-5; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Synaptophysin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(II; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(IL1B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(IRF-7; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ISG-15; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)
(ISGF-3 (interferon-stimulated gene factor 3); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Id2 (inhibitor of differentiation 2); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Immunoglobulin receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(IgG type I; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(IkB-a; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Il-13; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Il-8; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Phosphoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(I.kappa.B-.alpha. (inhibitor of RNA formation factor NF-.kappa.B, .alpha.); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(JNK1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Jagged 1 and Jagged 2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(JunD; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(K-cadherin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Keratins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(K17; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

- (Biological study); PROC (Process)
(Ki67; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Animal cell
(Kupffer, bile duct epithelial cells; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(L-FABP (liver fatty acid-binding protein); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(L09604; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Ribosomal proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(L13; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Ribosomal proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(L13A, L37a, and S9; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Ribosomal proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(L34; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Ribosomal proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(L6; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Lipoprotein receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(LDL, low d. Lipoprotein; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Liposin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MAD related protein 2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MAP kinase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cytokines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MBP (major basic protein); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

- profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MCL-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Multidrug resistance proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MDR1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Multidrug resistance proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MDR2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Multidrug resistance proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MDR3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MEF-2 (myocyte-specific enhancer element-binding factor 2); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Histocompatibility antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MHC (major histocompatibility complex), MHC class II transactivator; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Histocompatibility antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MHC (major histocompatibility complex), class I; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Histocompatibility antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MHC (major histocompatibility complex), class II; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Proteins, specific or class
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MLH1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MRTF1 (metal regulatory 1); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MSH2; methods of detg. individual hypersensitivity to a pharmaceutical

agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MSH2M; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MSH3 gene; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MSH3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Mcl-1 (myeloid cell leukemia sequence-1); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Mim; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(MnSOD; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Mr 110,000; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(N-; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(N-CAM; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NADH oxidoreductase subunit MWFE; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NF-A2 (nuclear factor A2); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

- (NF-E2 (nuclear factor erythroid 2), NF-E2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NF-III (nuclear factor III); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NF-IV (nuclear factor IV); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NF-.kappa.B (nuclear factor .kappa.B); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NMB; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NY-LU-12; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Steroid receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Ner-1S; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Notch (receptor)
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Notch1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Nucleosome assembly protein; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(OB-cadherin 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(OTK27; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(OX40 ligand; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(P-; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Glycoproteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(P170; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(P311; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PABP (poly(A)-binding protein); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PAPS synthetase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PARP; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PBX2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PCDH7; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PCNA; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PDGF assocd. protein; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PECAM-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PEG3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)
(PIC1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PMS2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PTEN/MMAC1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT **Nerve**
(Purkinje cell; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RAD 51; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RAD23; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RAD50; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RAD51 homolog; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RAD52; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RAD; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RAG-1 (recombination-activating gene, 1); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RANTES; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RAP1A; methods of detg. individual hypersensitivity to a

- pharmaceutical agent from gene expression profile)
- IT Retinoic acid receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RAR-.beta.; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Retinoic acid receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RAR-.gamma.; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT DNA formation factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RF-A (replication factor A); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT DNA formation factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RF-C (replication factor C); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Ribonucleoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RNA U1-contg., C; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Enzymes, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RNA-unwinding, helicases; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RPS21, RPS24, RPS4X and S7; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Retinoid X receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RXR.alpha.; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Retinoid X receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RXR.beta.; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Retinoid X receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(RXR.gamma.; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Rad50; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Rb, p107; methods of detg. individual hypersensitivity to a

- pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Rb; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Ref-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Rel-B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Retinoid X receptor alpha; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Ribosomal proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(S12; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Ribosomal proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(S21, S7 and RPS24; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Ribosomal proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(S4, X-linked; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Ribosomal proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(S4; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(SAA1 (serum amyloid A1); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(SAA2 (serum amyloid A2); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(SAA3 (serum amyloid A3); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Glycophosphoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(SCP2 (hydroxy steroid-carrier protein 2); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression

- profile)
- IT Sialoglycoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(SGP-2 (sulfoglycoprotein 2); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(SII; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(SMT3A and SMT3B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(SOCS-1 (suppressor of cytokine signaling-1); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(SOCS-3 (suppressor of cytokine signaling-3); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(SQM1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(SRE-BP (steroid-responsive element-binding protein), 2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(SRF (serum response factor); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(STAT1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(STAT2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(STAT3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Sec23B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Sod; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(SoxS; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(T cell activation gene 3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(T-cell cyclphilin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(TCF-1 (T-cell factor 1); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(TFIID (transcription factor IID); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(TP53; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(TRADD; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(TRAF2 (tumor necrosis factor receptor-assocd. factor 2); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(UCP2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(UDP-glucuronosyltransferase 2B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

- IT Annexins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(V; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transport proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(VACHT (vesicular acetylcholine transporter); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cell adhesion molecules
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(VCAM-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(VCAM1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transport proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(VMAT; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Wnt-13; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(XP-C; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(XRCC1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ZO-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(acute-phase, Major acute phase protein alpha-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(acyl CoA dehydrogenase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(adenine nucleotide translocator 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(alc. dehydrogenase 2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(alc. dehydrogenase 4; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(alpha-1 acid glycoprotein; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(alpha-2 macroglobulin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(alpha-catenin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(alpha-tubulin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Macrophage inflammatory protein 2
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(alpha; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Macrophage
(alveolar; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(amyloid homolog; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(annexin V; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(antiquitin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(apolipoprotein AII; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(apolipoprotein CIII; methods of detg. individual hypersensitivity to a

- pharmaceutical agent from gene expression profile)
- IT Cell cycle
(arrest, genes assocd. with; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Heart, disease
(arrhythmia; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal.
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(aspartate aminotransferase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ataxia telangeictasia; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Phagocytosis
(autophagocytosis, genes assocd. with; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(bcl-2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(bcl-3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Natural products, pharmaceutical
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(belladonna; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(beta actin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Potassium channel
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(beta subunit; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transport proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(bile acid-sodium-cotransporting; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transport proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(bile acid-transporting, bile salt export pump; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal

- RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(bilirubin UDP-glucuronosyltransferase isoenzyme 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(biliverdin reductase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Spreading
(biol., genes assocd. with; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Macromolecular compounds
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(biol., prevention or repair of toxic damage of; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Neurotrophic factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(brain-derived; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(branched chain acyl-CoA oxidase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(c-Ha-ras; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(c-abl; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(c-erbB2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(c-fms; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(c-fos; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(c-jun; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(c-myb; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(c-myc binding protein; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(c-myc; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(calbindin D; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(calnexin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(calprotectins; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(calreticulin-B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(calreticulin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(carnitine palmitoyl CoAtransferase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(caspase 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(caspase 3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(caspase 7; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)
(caspase 8; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(catalase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(catechol-O-Me transferase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(cathepsin L; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Phosphoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(caveolins, Caveolin-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(cdk4; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Connective tissue
(cell; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Heart
Lung
(cells of; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Toxicity
(cellular, genes assocd. with; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ceruloplasmin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Biliary tract
(cholestasis; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Rhythm, biological
(circadian, genes assocd. with; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(clone 22 mRNA, alpha-1 splice variant; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(clone RP-11-468G5; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Collagens, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(collagen-alginate; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(collagenase type I interstitial; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Intestine
(colon; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(colony stimulating factor 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Estrogens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(conjugated; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(connexin 32; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(connexin 40; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(creatine kinase B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(cyclin D3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(cyclin G; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(cyclin dependent kinase inhibitor p27kip1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(cytochrome c oxidase subunit IV; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Mitochondria

- (damage, genes assocd. with; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT DNA
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(damage, prevention; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cell differentiation
(de-differentiation, genes assocd. with; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cytokine receptors
Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(death receptor 5; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(defender against cell death 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(defender against cell death-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(delta like; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Mental disorder
(dementia; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Hematopoiesis
(disorder, myelosuppression; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Elongation factors (protein formation)
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(eEF-1.alpha., PTI-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Glycophosphoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(endoplasmic; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Blood vessel
(endothelium; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(enolase alpha; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Animal cell
(ependyma, meningotheial and leptomenigeal cells; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene

- expression profile)
- IT Lung
(epithelium, columnar ciliated; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(exchange factor; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(excision repair ERCC3 and ERCC5 and ERCC6; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Kidney, disease
(failure; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Carcinoembryonic antigen
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(family member 2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(farnesol receptor; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(fas antigen; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Liver, disease
(fatty; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ferritin H-chain; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Muscle
(fiber; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(flavin-contg. monooxygenase 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(for .gamma.-interferon inducible early response gene F; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(fosB; methods of detg. individual hypersensitivity to a pharmaceutical

- agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(gamma-glutamyl transpeptidase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(gap junction-specific; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(gene ERCC1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Phosphoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(gene L-myc; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(gene RAD52; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(gene cdc25; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT DNA formation factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(gene dnaC; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Vascular endothelial growth factor receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(gene flt 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Phosphoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(gene fyn; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(gene gadd153; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Lipoproteins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(gene ospA; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(gene pim-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Agranulocytosis

Apoptosis

Cell adhesion
Cell aging
Cell migration

Mutation

Neoplasm

Recombination, genetic

Signal transduction, biological

Teratogenesis

Transformation, genetic

(genes assocd. with; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Kidney, disease

(glomerulitis; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(glucosylceramide synthase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(glutaredoxins; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(glutathione S transferase theta-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(glutathione peroxidase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(glutathione reductase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(glutathione synthetase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Cell membrane

(glycoprotein; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Intestine

(goblet cell; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(growth arrest specific protein 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(growth arrest specific protein 3; methods of detg. individual

- hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(growth arrest-specific protein 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(growth arrest-specific protein 3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(hSNF2b; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(hamartin, hamartin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(helicase like; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(heme-binding, 23; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(hepatic lipase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Liver
(hepatocyte; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Immunophilins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(homolog ARA9; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Allergy
(hypersensitivity; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(hypoxanthine-guanine phosphoribosyltransferase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(hypoxia inducible factor 1 alpha; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Vaccines

- (inactivated hepatitis; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibitor of apoptosis protein 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(inhibitor of apoptosis protein 2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Kidney, disease
(injury; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(insulin-like growth factor 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(insulin-like growth factor binding protein 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(integrin beta-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(intercellular adhesion mol.-3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(interferon inducible protein 15; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cytokines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(interferon-inducible IP-10; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(involucrins; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Natural products, pharmaceutical
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(ippecac; methods of detg. individual hypersensitivity to a

- pharmaceutical agent from gene expression profile)
- IT Transport proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(iron permease FTR1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Disease, animal
(irritation; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(junB; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(junD; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Animal cell
(juxtaglomerular, lacis and macula densa; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Immunoglobulins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(lambda heavy chain; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(leukemia inhibitory factor; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Dyneins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(light chain 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(lipopolysaccharide binding protein; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(lysyl oxidase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Chemokines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(macrophage inflammatory protein 1, alpha and beta; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Macrophage migration inhibitory factor
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(macrophage inflammatory protein 3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(macrophage-stimulating; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Lung
(macrophage; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(mannose receptor; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(mdm-2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(membrane; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Kidney
(mesangium; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Brain
(mesenchymal, capillary endothelial and fibroblasts cells; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Lipids, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metab.; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metallothionein-IG; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Aging, animal
Allergy
Apparatus
Astrocyte
Bone
Brain
Bronchodilators
Computer program
DNA microarray technology
Digestive tract
Dione
Drugs
Eye
Fibroblast
Gallbladder
Hepatitis
Hyperplasia
Hypertension
Hypotension
Immunosuppression
Inflammation
Intestine
Jaundice
Kidney

Leukemia
Leukocyte
Liver
Macrophage
Mast cell
Muscle
Mutagenesis
Necrosis
Nucleic acid hybridization
Oligodendrocyte
Ovary
Pancreas
Plantago psyllium
Podophyllum (plant)
Sex
Skin
Spleen
Statistical analysis
Stomach
Testis
Thyroid gland

- (methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
cDNA
mRNA
RL: ANT (Analyte); BPR (Biological process); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Androgens
Polyoxyalkylenes, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT APC protein
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Androgen receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Aromatic hydrocarbon receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Biliproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT CD14 (antigen)
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT CD44 (antigen)

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT CFTR (cystic fibrosis transmembrane conductance regulator)
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Cadherins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Caldesmon
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Calnexin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Calreticulin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Carcinoembryonic antigen
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Clusterin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Cyclophilins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Dynamin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Eotaxin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Erythropoietin receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Estrogen receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

from gene expression profile)

IT Fas antigen
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Fas antigen
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Fas ligand
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Fibronectin receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Filaggrin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Filamin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Gelsolin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Glucocorticoid receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Gonadotropins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Hemopexins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Hepatocyte growth factor
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Hepatocyte growth factor receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Interleukin 10
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Interleukin 12
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Interleukin 13
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Interleukin 18
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Interleukin 1.alpha.
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Interleukin 1.beta.
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Interleukin 2
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Interleukin 3
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Interleukin 4
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Interleukin 5
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Interleukin 6
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Interleukin 8
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

IT Lactoferrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent
from gene expression profile)

- IT Leukemia inhibitory factor
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Lymphotoxin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Macrophage colony-stimulating factor receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Mannose receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Mdm2 protein
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Monocyte chemoattractant protein-1
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Multidrug resistance proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Myelin basic protein
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Neurofibromin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Osteocalcins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Osteonectin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Osteopontin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Oxytocin receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Potassium channel
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Prion proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Probes (nucleic acid)
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Progesterone receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proliferating cell nuclear antigen
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Prostate-specific antigen
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT RANTES (chemokine)
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Stem cell factor
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT TCR (T cell receptors)
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT **Tau factor**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Tenascins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Thioredoxins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Thrombin receptors

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Thrombomodulin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Transcortins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Transferrin receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Transferrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Transforming growth factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Transthyretin
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Tropoelastins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Tumor necrosis factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Urokinase-type plasminogen activator receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Vimentins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Vitellogenins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT neu (receptor)
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

- from gene expression profile)
- IT p53 (protein)
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Neuroglia
(microglia cells; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(mig-2Or; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(monocyte chemotactic protein-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(mss4; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(mtal; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(myelin basic protein; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(myeloid cell differentiation protein-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(natural killer cell-enhancing factor B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(natural killer enhancing factor A; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(neomycin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Kidney, disease
(nephritis; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Toxicity
(nephrotoxicity; methods of detg. individual hypersensitivity to a

- pharmaceutical agent from gene expression profile)
- IT Endocrine system
(neuroendocrine system, cell; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Nerve
(neuron; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Toxins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(neurotoxins; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Agranulocytosis
(neutropenia; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(non-specific cross reacting; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(nucleic acid binding protein; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Animal cell
Blood
Blood serum
Urine
(nucleic acid or protein expression profile from; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(nucleic acid-binding; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(nucleoside diphosphate kinase beta isoform; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(octamer binding protein 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(oncosis assocd.; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(org. anion transporter 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transport proteins

- RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(org. anion-transporting, MOAT-B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transport proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(org. anion-transporting; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ornithine decarboxylase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(osteopontin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(oxygen regulated protein 150; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(oxysterol binding protein; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cyclin dependent kinase inhibitors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(p16INK4; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(p190-B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Ras proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(p21c-Ha-ras; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cyclin dependent kinase inhibitors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(p21CIP1/WAF1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cyclin dependent kinase inhibitors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(p27KIP1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Tumor necrosis factor receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(p55; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(p55CDC; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Tumor necrosis factor receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(p75; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Pancreas, disease
(pancreatitis, genes assocd. with; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(pancreatitis-assocd. protein; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Insecticides
(pediculicides; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(penicillin band 109-A-2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(penicillin band 117-B-2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(penicillin band 134-A-2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(penicillin band 134-A-4; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(penicillin band 149-B-3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(penicillin band 239-A-2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(penicillin band 240-A-4; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(penicillin band 244-A-2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(penicillin band 69-B-3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(penicillin band 77-C-2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT **Nerve, disease**
(**peripheral neuropathy**; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteoglycans, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(perlecans; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(peroxisomal 3-oxoacyl-CoA thiolase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(peroxisomal acyl-CoA oxidase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(peroxisomal enoyl-CoA hydratase: 3-hydroxyacyl-CoA dehydrogenase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(peroxisome assembly factor 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(peroxisome assembly factor 2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(peroxisome assembly factor-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(peroxisome biogenesis disorder protein 11; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile).
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

- (Biological study); PROC (Process)
(peroxisome biogenesis disorder protein 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(peroxisome biogenesis disorder protein 4; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(phenol sulfotransferase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(phenylalanine hydroxylase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(phosphoenolpyruvate carboxykinase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(phosphoglycerate kinase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(phospholipase A2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Glycoproteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(plasma cell membrane; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(plasminogen activator inhibitor 2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(platelet/endothelial cell adhesion mol.-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Animal tissue
Organ, animal
Organelle
(prevention or repair of toxic damage of; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Nucleotides, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

- (prevention or repair of toxic damage of; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Collagens, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(procollagens, type I, alpha 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(prohibitin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(prohibitins; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Peroxisome
(proliferation, genes assocd. with; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(proline-rich; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(prostaglandin H synthase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(protein tyrosine phosphatase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, general, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(proteinuria; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(prothymosin, alpha; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(psoriasin, 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Antibiotics
(quinolone, fluoroquinolones; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Intestine
(rectum; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Cytokines
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

- (Biological study); PROC (Process)
(release' genes assocd. with; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(retinoic acid receptor gamma 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(retinol binding protein, CRBP-I (cellular retinol binding protein I); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(retinol binding protein, CRBP-II (cellular retinol binding protein II); methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Eye, disease
(retinopathy; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(senescence marker protein-30; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Animal cell
(serous, brush, and clara; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(silencer of death domain; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Vein
(sinusoidal, hepatic venule endothelial cells; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Ribonucleoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(small nuclear RNA-contg., B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Muscle
(smooth, cells; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Transport proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(sodium taurocholate-cotransporting; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Hedgehog protein
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(sonic; methods of detg. individual hypersensitivity to a

pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(spermidine/spermine N1-acetyltransferase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Disease, animal
(steatosis; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Liver
(stellate cell; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(stromelysin-1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(survivin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Phosphoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(synapsins, I; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Heart, disease
(tachycardia; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(thiol-specific antioxidant protein; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(thioredoxin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(thymidine kinase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(thymidylate synthase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Heart
Kidney
Liver
Nerve
(toxicity; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(transferrin receptor; methods of detg. individual hypersensitivity to

- a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(transferrin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(transthyretin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(tryptophanyl-tRNA synthetase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Proteins, specific or class
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(tsll gene encoding G1 progression protein; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Lung
(type I cell; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Activin receptors
Collagens, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(type II; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ubiquitin conjugating enzyme; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Enzymes, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ubiquitin-conjugating, G2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Sterols
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(unsatd., Stanol, esters; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(urokinase plasminogen activator receptor; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(vascular endothelial growth factor receptor 1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)
 (very-long-chain acyl-CoA-dehydrogenase; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (vimentin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Epithelium
 (visceral, parietal and tubular; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (visinin-like peptide; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Proteins, specific or class
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (xl3694; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Gene, animal
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (zinc finger protein 37; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Crystallins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (.zeta.-crystallins; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Interferons
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (.alpha.-2b; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Tubulins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (.alpha.-; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Thyroid hormone receptors
 .alpha.1-Acid glycoprotein
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (.alpha.1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Catenins
 Integrins
 Interferons
 Peroxisome proliferator-activated receptors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (.alpha.; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Integrins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (.alpha.L; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Macroglobulins

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.alpha.2-; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Microglobulins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.alpha.2-microglobulins, .alpha.-2 microglobulin; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Chemokine receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta. chemokine receptor CCR2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Chemokine receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta. chemokine receptor CCR5; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Actins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta.-; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Interferons
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(.beta.1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta.1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta.2; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta.4; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Fibrinogens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.gamma. chain; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Actins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.gamma.-actins; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT Interferons
Peroxisome proliferator-activated receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.gamma.; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

- IT 9038-14-6, Flavin containing monooxygenase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(1 and 3; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 9059-22-7 9076-57-7, Histone deacetylase 52660-18-1 61969-98-0, Bilirubin-UDP-glucuronosyltransferase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(1; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 9030-08-4, UDP-glucuronosyltransferase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(2 and 2B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 22916-47-8, Miconazole
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(2% cream; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 9037-14-3, 5-Aminolevulinate synthase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(2, gene for; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 134678-17-4, Lamivudine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(3TC; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 99011-02-6, Imiquimod
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(5% cream; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 9001-66-5
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(A and B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 9001-60-9, Lactate dehydrogenase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 8064-90-2, Trimeth/sulfa
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(Co-trimoxazole; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 9015-85-4
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(I and III and IV; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 9001-16-5, Cytochrome C oxidase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(I, II and III, gene for; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 9001-03-0
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

- (Biological study); PROC (Process)
(III; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 79871-54-8, Norgestimate-ethinyl estradiol mixt.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(Norgestimate/ethinyl estradiol; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 50812-37-8, Glutathione S-transferase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(Ya, theta-1, and alpha subunit; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 9014-08-8, Enolase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(alpha; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 58-82-2, Bradykinin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antagonist; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 9001-15-4
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(b; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 76901-00-3, Acetyl, hydrolase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(beta subunit; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 66722-44-9, Bisoprolol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bisoprolol/HCTZ; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 9005-32-7, Alginic acid
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(collagen-alginate; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 7440-57-5, Gold, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(compds.; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 9054-89-1, Superoxide dismutase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(copper-zinc-contg. and manganese-contg.; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 154248-97-2, Imiglucerase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(injection; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)
- IT 56-81-5, Glycerol, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); BIOL (Biological study)

(iodinated; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT 50-02-2, Dexamethasone 50-06-6, Phenobarbital, biological studies
 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8,
 Prednisolone 50-28-2, Estradiol, biological studies 50-44-2,
 6-Thiopurine 50-48-6, Amitriptyline 50-55-5, Reserpine 50-76-0,
 Actinomycin D 50-78-2, Aspirin 51-06-9, Procainamide 51-21-8,
 Fluorouracil 51-34-3, Scopolamine 51-48-9, Levothyroxine, biological
 studies 51-49-0, Dextrothyroxine 51-55-8, Atropine, biological studies
 51-75-2, Mechlorethamine 52-01-7, Spironolactone 52-53-9, Verapamil
 52-67-5, Penicillamine 52-86-8, Haloperidol 53-03-2, Prednisone
 53-06-5, Cortisone 53-19-0, Mitotane 53-33-8, Paramethasone 53-86-1,
 Indomethacin 54-05-7, Chloroquine 54-11-5, Nicotine 54-31-9,
 Furosemide 54-36-4, Metyrapone 54-85-3, Isoniazid 55-63-0,
 Nitroglycerin 55-65-2, Guanethidine 55-98-1, Busulfan 56-54-2,
 Quinidine 56-75-7, Chloramphenicol 57-22-7, Vincristine 57-41-0,
 Phenytoin 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol 57-66-9,
 Probenecid 57-83-0, Progestin, biological studies 57-96-5,
 Sulfapyrazole 58-05-9, Leucovorin 58-14-0, Pyrimethamine 58-32-2,
 Dipyrindamole 58-39-9, Perphenazine 58-54-8, Ethacrynic acid 58-55-9,
 Theophylline, biological studies 58-61-7, Adenosine, biological studies
 58-74-2, Papaverine 58-93-5, Hydrochlorothiazide 58-94-6, Thiazide
 59-05-2, Methotrexate 59-42-7, Phenylephrine 59-43-8, Thiamine,
 biological studies 59-92-7, Levodopa, biological studies 59-99-4,
 Neostigmine 60-40-2, Mecamylamine 60-54-8, Tetracycline 60-79-7,
 Ergonovine 60-87-7, Promethazine 61-32-5, Methicillin 61-72-3,
 Cloxacillin 64-75-5, Tetracycline hydrochloride 64-77-7, Tolbutamide
 64-86-8, Colchicine 65-23-6, Pyridoxine 66-79-5, Oxacillin 66-97-7,
 Psoralen 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-68-5,
 Dimethyl sulfoxide, biological studies 68-22-4D,
Norethindrone, mixt. with ethinyl estradiol 68-41-7, Cycloserine
 68-88-2, Hydroxyzine 69-53-4, Ampicillin 69-72-7, biological studies
 69-89-6, Xanthine 73-24-5, 6-Aminopurine, biological studies 73-31-4,
 Melatonin 76-42-6, Oxycodone 76-57-3, Codeine 77-09-8,
 Phenolphthalein 77-19-0, Dicyclomine 77-36-1, Chlorthalidone
 78-44-4, Carisoprodol 80-08-0, Dapsone 81-23-2, Dehydrocholic acid
 81-81-2, Warfarin 82-92-8, Cyclizine 82-95-1, Buclizine 83-43-2,
 Methylprednisolone 83-73-8, Iodoquinol 83-89-6, Quinacrine 83-98-7,
 Orphenadrine 86-54-4, Hydralazine 89-57-6, Mesalamine 90-34-6,
 Primaquine 90-82-4, Pseudoephedrine 91-64-5, Coumarin 92-13-7,
 Pilocarpine 92-84-2, Phenothiazine 93-14-1, Guaifenesin 94-20-2,
 Chlorpropamide 94-36-0, Benzoyl peroxide, biological studies 94-78-0,
 Phenazopyridine 95-25-0, Chlorzoxazone 96-64-0, Soman 97-77-8,
 Disulfiram 99-66-1, Valproic acid 100-33-4, Pentamidine 100-97-0,
 Methenamine, biological studies 101-31-5, Hyoscyamine 103-90-2,
 Acetaminophen 113-18-8, Ethchlorvynol 113-42-8, Methylephedrine
 113-45-1, Methylphenidate 114-07-8, Erythromycin 114-86-3, Phenformin
 118-42-3, Hydroxychloroquine 122-09-8, Phentermine 123-56-8,
 Succinimide 123-63-7, Paraldehyde 124-94-7, Triamcinolone 125-29-1,
 Hydrocodone 125-33-7, Primidone 125-64-4, Methypylon 125-71-3,
 Dextromethorphan 125-84-8, Aminoglutethimide 126-07-8, Griseofulvin
 126-52-3, Ethinamate 127-07-1, Hydroxyurea 127-69-5, Sulfisoxazole
 128-13-2, Ursodiol 130-95-0, Quinine 132-17-2, Benztropine 133-10-8,
 Sodium p-aminosalicylate 137-58-6, Lidocaine 138-56-7,
 Trimethobenzamide 144-11-6, Trihexyphenidyl 147-52-4, Nafcillin
 147-94-4, AraC 148-82-3, Melphalan 154-21-2, Lincomycin 154-42-7,
 Thioguanine 154-93-8, Carmustine 155-97-5, Pyridostigmine 298-46-4,
 5H-Dibenz[b,f]azepine-5-carboxamide 298-50-0, Propantheline 299-42-3,
 Ephedrine 300-62-9D, Amphetamine, mixed 300-62-9D, Amphetamine, mixed
 salts 302-17-0, Chloral hydrate 302-79-4, Tretinoin 303-53-7,
 Cyclobenzaprine 305-03-3, Chlorambucil 315-30-0, Allopurinol
 321-64-2, Tacrine 346-18-9, Polythiazide 361-37-5, Methysergide

363-24-6, Dinoprostone 364-62-5, Metoclopramide 378-44-9, Betamethasone 389-08-2, Nalidixic acid 395-28-8, Isoxsuprine 439-14-5, Diazepam 443-48-1, Metronidazole 446-86-6, Azathioprine 456-59-7, Cyclandelate 461-72-3, Hydantoin 463-04-7, Amyl nitrite 469-62-5, Propoxyphene 474-25-9, Chenodiol 480-30-8, Dichloralphenazone 484-23-1, Dihydralazine 503-01-5, Isometheptene 512-15-2, Cyclopentolate 520-85-4, Medroxyprogesterone 525-66-6, Propranolol 526-36-3, Xylometazoline 536-33-4, Ethionamide 541-15-1, Levocarnitine 546-88-3, Acetohydroxamic acid 555-30-6, Methyl dopa 564-25-0, Doxycycline 569-65-3, Meclizine 577-11-7, Docusate sodium 596-51-0, Glycopyrrolate 599-79-1, Sulfasalazine 603-50-9, Bisacodyl 634-03-7, Phendimetrazine 637-07-0, Clofibrate 657-24-9, Metformin 671-16-9, Procarbazine 672-87-7, Metyrosine 674-38-4, Bethanechol 723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 745-65-3, Alprostadil 791-35-5, Chlophedianol 797-63-7, Levonorgestrel 797-64-8D, L-Norgestrel, ethinyl estradiol mixt. 846-49-1, Lorazepam 846-50-4, Temazepam 911-45-5, Clomiphene 915-30-0, Diphenoxylate 962-58-3, Diazoxon 968-93-4, Testolactone 972-02-1, Diphenidol 990-73-8, Fentanyl citrate 1134-47-0, Baclofen 1143-38-0, Anthralin 1321-13-7, Potassium aminobenzoate 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1404-04-2, Neomycin 1404-04-2D, Neomycin, mixt. with polymx/HC 1404-90-6, Vancomycin 1406-05-9, Penicillin 1491-59-4, Oxymetazoline 1622-61-3, Clonazepam 1953-02-2, Tiopronin 1977-10-2, Loxapine 2152-34-3, Pemoline 2152-44-5, Betamethasone valerate 2447-57-6, Sulfadoxine 2451-01-6, Terpin hydrate 2609-46-3, Amiloride 2809-21-4 2998-57-4, Estramustine 3116-76-5, Dicloxacillin 3313-26-6, Thiothixene **3385-03-3, Flunisolid** 3485-14-1, Cyclacillin 3737-09-5, Disopyramide 3778-73-2, Iphosphamide

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT 3930-20-9, Sotalol 4205-90-7, Clonidine 4419-39-0, Beclomethasone 4499-40-5, Oxtriphyllyne, biological studies 4618-18-2, Lactulose 4697-36-3, Carbenicillin 4759-48-2, Isotretinoin 5051-62-7, Guanabenz 5543-57-7, (s)-Warfarin 5633-20-5, Oxybutynin 5786-21-0, Clozapine 6190-39-2, Dihydroergotamine mesylate 6493-05-6, Pentoxifylline 6621-47-2, Perhexiline 7020-55-5, Clidinium 7235-40-7, Beta carotene 7261-97-4, Dantrolene 7416-34-4, Molindone 7439-93-2, Lithium, biological studies 7447-40-7, Potassium chloride, biological studies 7481-89-2, Zalcitabine 7487-88-9, Magnesium sulfate, biological studies 7648-98-8, Ambenonium 7681-11-0, Potassium iodide, biological studies 7681-93-8, Natamycin 7683-59-2, Isoproterenol 8029-99-0, Paregoric 8049-47-6, Pancreatin 8050-81-5, Simethicone 8063-07-8, Kanamycin 8067-24-1, Ergoloid mesylates 9001-27-8, BLOOD-coagulation factor VIII 9001-75-6, Pepsin 9004-10-8, Insulin, biological studies 9004-67-5, Methyl cellulose 9005-49-6, Enoxaparin, biological studies 9007-92-5, Glucagon, biological studies 9039-53-6, Urokinase 9046-56-4, Ancrod 10118-90-8, Minocycline 10238-21-8, Glyburide 10262-69-8, Maprotiline 10540-29-1, Tamoxifen 11041-12-6, Cholestyramine 11056-06-7, Bleomycin 11111-12-9, Cephalosporin 12174-11-7, Attapulgit 12244-57-4, Gold sodium thiomalate 12650-69-0, Mupirocin 12794-10-4D, Benzodiazepine, derivs. 13010-47-4, Lomustine 13292-46-1, Rifampin 13311-84-7, Flutamide 13392-28-4, Rimantadine 13647-35-3, Trilostane 14028-44-5, Amoxapine 14124-50-6 14611-51-9, Selegiline 14769-73-4, Levamisole 14838-15-4, Phenylpropanolamine 14882-18-9, Bismuth subsalicylate 15301-69-6, Flavoxate 15307-86-5, Diclofenac 15663-27-1, Cisplatin 15686-71-2, Cephalixin 15687-27-1, Ibuprofen 15722-48-2, Olsalazine 16051-77-7, Isosorbide mononitrate 16068-46-5, Potassium phosphate 16110-51-3, Cromolyn 16590-41-3, Naltrexone 16679-58-6, Desmopressin 17230-88-5, Danazol 17784-12-2, Sulfacytine 18323-44-9, Clindamycin 18559-94-9, Albuterol 18883-66-4, Streptozocin 19216-56-9, Prazosin 19794-93-5, Trazodone 20537-88-6, Amifostine 20830-75-5, Digoxin

20830-81-3, Daunomycin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine
 22204-53-1, Naproxen 22232-71-9, Mazindol 23031-32-5, Terbutaline
 sulfate 23214-92-8, Doxorubicin 23288-49-5, Probuco 25322-68-3,
 Polyethylene glycol 25451-15-4, Felbamate 25614-03-3, Bromocriptine
 25812-30-0, Gemfibrozil 26652-09-5, Ritodrine 26787-78-0, Amoxicillin
 26807-65-8, Indapamide 26839-75-8, Timolol 27203-92-5, Tramadol
 27262-47-1, Levobupivacaine 27686-84-6, Masoprocol 28395-03-1,
 Bumetanide 28657-80-9, Cinoxacin 28782-42-5, Difenoxin 28860-95-9,
 Carbidopa 28911-01-5, Triazolam 28981-97-7, Alprazolam 29094-61-9,
 Glipizide 29110-47-2, Guanfacine 29122-68-7, Atenolol 30516-87-1,
 Zidovudine 31441-78-8, Mercaptopurine 31677-93-7, Bupropion
 hydrochloride 31828-71-4, Mexiletine 31883-05-3, Moricizine
 32986-56-4, Tobramycin 33069-62-4, Paclitaxel 33419-42-0, Etoposide
 34089-81-1, Sodium ferric gluconate 35189-28-7, Norgestimate
 36322-90-4, Piroxicam 36505-84-7, Buspirone 36791-04-5, Ribavirin
 38304-91-5, Minoxidil 40180-04-9, Tienilic acid 40580-59-4, Guanadrel
 41575-94-4, Carboplatin 41708-72-9, Tocainide 42399-41-7, Diltiazem
 42924-53-8, Nabumetone 49562-28-9, Fenofibrate 50679-08-8, Terfenadine
 50925-79-6, Colestipol 50972-17-3, Bacampicillin 51022-71-0, Nabilone
 51110-01-1, Somatostatin 51333-22-3, Budesonide 51384-51-1, Metoprolol
 51481-61-9, Cimetidine 53179-11-6, Loperamide 53230-10-7, Mefloquine
 53608-75-6, Pancrelipase 53714-56-0, Leuprolide 53994-73-3, Cefaclor
 54024-22-5, Desogestrel 54063-53-5, Propafenone 54143-56-5, Flecainide
 acetate 54182-58-0, Sucralfate 54350-48-0, Etretinate 54573-75-0,
 Doxercalciferol 54910-89-3, Fluoxetine 55142-85-3, Ticlopidine
 55268-75-2, Cefuroxime 55985-32-5, Nicardipine 56420-45-2, Epirubicin
 58001-44-8, 58581-89-8, Azelastine 59122-46-2, Misoprostol
 59277-89-3, Acyclovir 59729-33-8, Citalopram 59865-13-3, Cyclosporine
 A 60142-96-3, Gabapentin 60205-81-4, Ipratropium 61489-71-2,
 Menotropin 61718-82-9, Fluvoxamine maleate 61869-08-7, Paroxetine
 62571-86-2, Captopril 63585-09-1, Foscarnet sodium 63590-64-7,
 Terazosin 64952-97-2, Latamoxef 65141-46-0, Nicorandil 65277-42-1,
 Ketoconazole 66085-59-4, Nimodipine 66104-22-1, Pergolide
 66357-35-5, Ranitidine 66376-36-1, Alendronate 67227-57-0, Fenoldopam
 mesylate 68475-42-3, Anagrelide 68844-77-9, Astemizole 69049-73-6,
 Nedocromil 69123-98-4, Fialuridine 69655-05-6, Didanosine
 70359-46-5, Brominide tartrate 70989-04-7, S-Mephenytoin 71320-77-9,
 Moclobemide 72432-03-2, Miglitol 72509-76-3, Felodipine 72956-09-3,
 Carvedilol 73590-58-6, Omeprazole 74103-06-3, Ketorolac 74191-85-8,
 Doxazosin 75330-75-5, Lovastatin 75695-93-1, Isradipine 75706-12-6,
 Leflunomide 75847-73-3, Enalapril 76470-66-1, Loracarbef 76547-98-3,
 Lisinopril 76568-02-0, Flosequin 76584-70-8, 76824-35-6, Famotidine
 76932-56-4, Nafarelin 76963-41-2, Nizatidine 78110-38-0, Aztreonam
 78628-80-5, Terbinafine hydrochloride 79516-68-0, Levocabastine
 79617-96-2, Sertraline 79794-75-5, Loratadine 79902-63-9, Simvastatin
 80125-14-0, Remoxipride 80474-14-2, Fluticasone propionate 81093-37-0,
 Pravastatin 81098-60-4, Cisapride 81103-11-9, Clarithromycin
 81669-57-0, Anistreplase 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin
 82626-48-0, Zolpidem 82834-16-0, Perindopril 83366-66-9, Nefazodone
 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 83905-01-5,
 Azithromycin 84057-84-1, Lamotrigine 84449-90-1, Raloxifene
 84625-61-6, Itraconazole 85441-61-8, Quinapril 85721-33-1,
 Ciprofloxacin 86386-73-4, Fluconazole 86541-75-5, Benazepril
 87333-19-5, Ramipril 87679-37-6, Trandolapril 88040-23-7, Cefepime
 88150-42-9, Amlodipine 89365-50-4, Salmeterol 89778-26-7, Toremfene
 90566-53-3, Fluticasone 91714-94-2, Bromfenac 92665-29-7, Cefprozil
 93390-81-9, Fosphenytoin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT 93413-69-5, Venlafaxine 93479-97-1, Glimepiride 93957-54-1,
 Fluvastatin 95058-81-4, Gemcitabine 95233-18-4, Atovaquone

96036-03-2, Meropenem 97322-87-7, Troglitazone 97519-39-6, Ceftibuten
 97534-21-9, Merbarone 97682-44-5, Irinotecan 98048-97-6, Fosinopril
 98319-26-7, Finasteride 100986-85-4, Levofloxacin 102767-28-2,
 Levetiracetam 103577-45-3, Lansoprazole 103628-46-2, Sumatriptan
 104227-87-4, Famciclovir 104632-26-0, Pramipexole 105102-22-5,
 Mometasone 105462-24-6 105857-23-6, Alteplase 106133-20-4,
 Tamsulosin 106266-06-2, Risperidone 106392-12-5, Poloxamer 188
 106650-56-0, Sibutramine 107753-78-6, Zafirlukast 107868-30-4,
 Exemestane 109889-09-0, Granisetron 111025-46-8, Pioglitazone
 112809-51-5, Letrozole 112965-21-6, Calcipotriene 114798-26-4,
 Losartan 115103-54-3, Tiagabine 115956-13-3, Dolasetron mesylate
 116644-53-2, Mibefradil 117976-89-3, Rabeprazole 119383-00-5
 119914-60-2, Grepafloxacin 120014-06-4, Donepezil 121679-13-8,
 Naratriptan 122320-73-4, Rosiglitazone 122647-32-9, Ibutilide fumarate
 122852-42-0, Alosetron 123948-87-8, Topotecan 124937-51-5, Tolterodine
 126040-58-2, Calcium polycarbophil 127779-20-8, Saquinavir
 129311-55-3, Ganirelix acetate 129318-43-0, Alendronate sodium
 130209-82-4, Latanoprost 130929-57-6, Entacapone 134308-13-7,
 Tolcapone 134523-00-5, Atorvastatin 137862-53-4, Valsartan
 138402-11-6, Irbesartan 143003-46-7, Alglucerase 144494-65-5,
 Tirofiban 144701-48-4, Telmisartan 145599-86-6, Cerivastatin
 147059-72-1, Trovafloxacin 147245-92-9, Copolymer 1 150378-17-9,
 Indinavir 151096-09-2, Moxifloxacin 161814-49-9, Amprenavir
 169590-42-5, Celecoxib 171599-83-0, Sildenafil citrate 172820-23-4,
 Pexiganan acetate 180288-69-1, Trastuzumab 185243-69-0, Etanercept
 188627-80-7, Eptifibatide 339524-26-4, Amiodorone 339524-30-0,
 Cyclopegic 339524-35-5, Cytoxin 339524-50-4, Hyperozia 339524-51-5,
 Navirapine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT 107-97-1, Sarcosin 447-41-6, Nyliidrin 8056-51-7 9000-86-6, Alanine
 aminotransferase 9000-97-9 9001-05-2, Catalase 9001-40-5,
 Glucose-6-phosphate dehydrogenase 9001-48-3, Glutathione reductase
 9001-50-7, Glyceraldehyde 3-phosphate dehydrogenase 9001-62-1, Hepatic
 lipase 9001-84-7, Phospholipase A2 9002-03-3, Dihydrofolate reductase
 9002-06-6, Thymidine kinase 9002-12-4, Urate oxidase 9002-67-9,
 Luteinizing hormone 9003-99-0, Myeloperoxidase 9012-25-3,
 Catechol-O-methyltransferase 9012-38-8, PAPS synthetase 9012-39-9
 9012-52-6, S-Adenosylmethionine synthetase 9013-08-5,
 Phosphoenolpyruvate carboxykinase 9013-18-7, Fatty acyl-CoA synthetase
 9013-38-1, Dopamine .beta.-hydroxylase 9013-66-5, Glutathione peroxidase
 9013-79-0, Neuropathy target esterase 9014-55-5, Tyrosine
 aminotransferase 9015-71-8, Corticotropin releasing hormone 9015-81-0,
 17-.beta. Hydroxysteroid dehydrogenase 9016-12-0, Hypoxanthine-guanine
 phosphoribosyltransferase 9023-44-3, Tryptophanyl-tRNA synthetase
 9023-62-5, Glutathione synthetase 9023-64-7, .gamma.-Glutamylcysteinyl
 synthetase 9023-70-5, Glutamine synthetase 9024-60-6, Ornithine
 decarboxylase 9024-61-7, Histidine decarboxylase 9025-32-5, Prolidase
 9026-00-0, Cholesterol esterase 9026-09-9, Phenol sulfotransferase
 9026-43-1, Serine kinase 9026-51-1, Nucleoside diphosphate kinase
 9027-13-8, Enoyl-CoA hydratase 9027-65-0, Acyl-CoA dehydrogenase
 9028-06-2 9028-31-3, Aldose reductase 9028-35-7, HMG CoA reductase
 9028-41-5, Hydroxyacyl-Coenzyme A dehydrogenase 9028-86-8, Aldehyde
 dehydrogenase 9029-73-6, Phenyl alanine hydroxylase 9029-80-5,
 Histamine N-methyltransferase 9029-97-4, 3-Ketoacyl-CoA thiolase
 9031-37-2, Ceruloplasmin 9031-54-3, Sphingomyelinase 9031-61-2,
 Thymidylate synthase 9031-72-5, Alcohol dehydrogenase 9032-20-6,
 DT-Diaphorase 9035-58-9, Blood-coagulation factor III 9036-22-0,
 Tyrosine hydroxylase 9037-21-2, Tryptophan hydroxylase 9037-62-1,
 Glycyl tRNA synthetase 9039-06-9, NADPH cytochrome P450 reductase
 9040-57-7, Ribonucleotide reductase 9041-92-3 9045-77-6, Fatty acid

synthase 9046-27-9, .gamma.-Glutamyl transpeptidase 9048-63-9, Epoxide
 hydrolase 9055-67-8, Poly(ADP-ribose)polymerase 9059-25-0, Lysyl
 oxidase 9068-41-1, Carnitine palmitoyltransferase 9074-02-6, Malic
 enzyme 9074-10-6, Biliverdin reductase 9074-19-5, Hydratase
 9074-87-7, .gamma.-Glutamyl hydrolase 9081-36-1, 25-Hydroxyvitamin D3
 1-hydroxylase 11096-26-7, Erythropoietin 37205-63-3, ATP synthase
 37237-44-8, Glucosylceramide synthase 37289-06-8, Acid ceramidase
 37292-81-2, Cytochrome p 450 11A1 37318-49-3, Protein disulfide
 isomerase 39391-18-9, Prostaglandin H synthase 52228-01-0
 56093-23-3, .alpha.-1,2-Fucosyl transferase 56645-49-9, Cathepsin G
 59536-73-1, Phosphomannomutase 59536-74-2, Very long-chain acyl-CoA
 dehydrogenase 60267-61-0, Ubiquitin 60616-82-2, Cathepsin L
 61116-22-1, Fatty acyl-CoA oxidase 62229-50-9, Epidermal growth factor
 67339-09-7, Thiopurine methyltransferase 67763-96-6, Insulin-like growth
 factor 1 67763-97-7, Insulin-like growth factor II 77271-19-3,
 6-O-Methylguanine-DNA methyltransferase 77271-19-3, O-6-Alkylguanine-DNA-
 alkyltransferase 77847-96-2, Prostacyclin-stimulating factor
 79747-53-8, Protein tyrosine phosphatase 79955-99-0, Stromelysin-1
 80146-85-6, Tissue Transglutaminase 80295-41-6, Complement component C3
 81627-83-0, Colony stimulating factor -1 82391-43-3, 12-Lipoxygenase
 83268-44-4 83869-56-1, Granulocyte-macrophage colony-stimulating factor
 85637-73-6, Atrial natriuretic factor 87397-91-9, Thymosin .beta.10
 88943-21-9, Proteinase .alpha.1-inhibitor III 89964-14-7, Prothymosin,
 alpha 90698-26-3, Ribosomal protein S6 kinase 96024-44-1, Granulin
 105238-46-8, Macropain 106096-92-8, Fibroblast growth factor, acidic
 106956-32-5, Oncostatin M 112130-98-0, Procathepsin L 114949-22-3,
 Activin (protein) 117698-12-1, Paraoxonase 119418-04-1, Galanin
 122191-40-6, Caspase-1 123626-67-5, Endothelin-1 125978-95-2, Nitric
 oxide synthase 127464-60-2, Vascular endothelial growth factor
 137632-07-6, Extracellular-signal-regulated kinase 1 138238-81-0,
 Endothelin converting enzyme-1 140208-24-8, Tissue inhibitor of
 metalloproteinase-1 141176-92-3 141349-86-2, Cyclin dependent kinase 2
 141436-78-4, Protein kinase C 142243-03-6, Plasminogen activator
 inhibitor 2 142805-56-9, DNA topoisomerase II 142805-58-1, MAP kinase
 kinase 143180-75-0, DNA topoisomerase I 143375-65-9, Cyclin dependent
 kinase 1 145809-21-8, Tissue inhibitor of metalloproteinase-3
 146480-35-5, **Matrix** metalloproteinase-2 147014-97-9, Cyclin
 dependent kinase 4 148348-15-6, Fibroblast growth factor 7
 149316-81-4, Branched chain acyl-CoA oxidase 149371-05-1, Kinase
 (phosphorylating), gene c-abl protein 149885-78-9, Hepatocyte growth
 factor activator 154907-65-0, Checkpoint kinase 155807-64-0, FEN-1
 Endonuclease 165245-96-5, p38 Mitogen-activated protein kinase
 169592-56-7, CPP32 proteinase 179241-70-4, Protein kinase ZPK
 179241-78-2, Caspase 8 182372-14-1, Caspase 2 182372-15-2, Caspase 6
 182762-08-9, Caspase 4 189258-14-8, Caspase 7 192465-11-5, Caspase 5
 193363-12-1, Vascular endothelial growth factor D 194554-71-7, Tissue
 factor pathway inhibitor 205944-50-9, Osteoprotegerin 220983-94-8,
 Sorbitol dehydrogenase 289898-51-7, JNK1 protein kinase 303752-61-6,
 DNA dependent protein kinase 329736-03-0, Cytochrome p450 3A4
 329764-85-4, Cytochrome p450 1A1 329900-75-6, Cyclooxygenase 2
 329978-01-0, Cytochrome p450 2C9 330196-64-0, Cytochrome p450 1A2
 330196-93-5, Cytochrome p450 2E1 330207-10-8, Cytochrome p450 2B1
 330589-90-7, Cytochrome p450 2C19 330596-22-0, Cytochrome p450 1B1
 330597-62-1, Cytochrome p450 2D6 330975-22-9, Macrostatin 331462-97-6,
 Cytochrome p450 2B2 331462-98-7, Cytochrome p450 3A1 331823-00-8,
 Cytochrome p450 2C11 331823-12-2, Cytochrome p450 2C12 331823-27-9,
 Cytochrome p450 2A1 331827-06-6, Cytochrome p450 2A6 332847-52-6,
 Cytochrome p450 4A 336884-26-5, Cytochrome p450 2B10 338964-08-2, P
 450 17A 338969-62-3, P 450 2A3 338969-69-0, P 450 2F2 338969-71-4, P
 450 4A1

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)

(methods of detg. individual hypersensitivity to a pharmaceutical agent

from gene expression profile)

IT 9004-02-8, Lipoprotein lipase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(precursor; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT 80449-02-1, Tyrosine protein kinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(receptor; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT 9000-83-3, ATPase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(subunit 6; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT 9025-75-6
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(subunit B; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT 9079-67-8, NADH oxidoreductase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(subunit MWFE, gene for; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT 9041-46-7
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(type II; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT 9001-12-1, Collagenase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(type-1 interstitial; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT 60382-71-0, Diacylglycerol kinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(zeta; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)


IT 60382-71-0, Diacylglycerol kinase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(zeta; methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT **68-22-4D, Norethindrone**, mixt. with ethinyl estradiol
3385-03-3, Flunisolide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(methods of detg. individual hypersensitivity to a pharmaceutical agent from gene expression profile)

RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 3385-03-3 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 16 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:319681 HCAPLUS

DN 134:331629

TI Oral transmucosal drug dosage using solid solution

IN Zhang, Hao; Croft, Jed

PA Anesta Corp., USA

SO PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61F013-02

ICS A61K009-20; A61K009-68

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001030288	A1	20010503	WO 2000-US28113	20001012 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

US 6264981 B1 20010724 US 1999-428071 19991027 <--
 EP 1242013 A1 20020925 EP 2000-972083 20001012 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL
 JP 2003512402 T2 20030402 JP 2001-532709 20001012 <--
 PRAI US 1999-428071 A 19991027 <--
 WO 2000-US28113 W 20001012 <--

AB The present invention is directed toward formulation and method for oral transmucosal delivery of a pharmaceutical. The invention provides a drug formulation comprising a solid pharmaceutical agent in solid soln. with a dissoln. agent. The formulation is administered into a patient's oral cavity, delivering the pharmaceutical agent by absorption through a patient's oral mucosal tissue. The formulation and method provide for improved oral mucosal delivery of the pharmaceutical agent. Oral transmucosal formulation contg. piroxicam 2, mannitol 10, Emdex 86.7, sodium hydroxide 0.24, and magnesium stearate 1% was prepd. Th Cmax and AUC of the drug was two fold of the wet granulation formulation and it was absorbed into the blood stream faster.

ST oral transmucosal drug solid soln piroxicam

IT Tobacco smoke
 (agents for cessation of; oral transmucosal drug dosage using solid soln.)

IT Polyoxyalkylenes, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (alkyl ethers; oral transmucosal drug dosage using solid soln.)

IT Heart, disease
 (angina pectoris; oral transmucosal drug dosage using solid soln.)

IT Solvents
 (cosolvents; oral transmucosal drug dosage using solid soln.)

IT Anesthetics
 (local; oral transmucosal drug dosage using solid soln.)

IT Drug delivery systems
 (mucosal, trans-; oral transmucosal drug dosage using solid soln.)

IT Anti-inflammatory agents
 (nonsteroidal; oral transmucosal drug dosage using solid soln.)

IT Absorbents
 Acacia
 Allergy inhibitors
 Analgesics
 Anti-infective agents
 Anti-inflammatory agents
 Antiarrhythmics
 Antibiotics
 Antidepressants
 Antidiabetic agents
 Antidiuretics
 Antiemetics
 Antihypertensives
 Antimicrobial agents
 Antimigraine agents
 Antiobesity agents
 Antioxidants
Antiparkinsonian agents
 Antitumor agents
 Binders
 Bronchodilators
 Buffers
 Contraceptives
 Dissolution rate
 Diuretics
 Drug bioavailability
 Dyes
 Emulsifying agents

Flavoring materials

Fungicides

Lubricants

Plasticizers

Solvents

Surfactants

Sweetening agents

Viscosity

(oral transmucosal drug dosage using solid soln.)

IT Acrylic polymers, biological studies

Androgens

Antibodies

Antigens

Borates

Carbonates, biological studies

Enkephalins

Enzymes, biological studies

Estrogens

Gelatins, biological studies

Gonadotropins

Lecithins

Opioids

Peptides, biological studies

Phosphates, biological studies

Polyoxyalkylenes, biological studies

Polysaccharides, biological studies

Steroids, biological studies

Zeins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral transmucosal drug dosage using solid soln.)

IT Acids, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(org.; oral transmucosal drug dosage using solid soln.)

IT Phenols, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(substituted; oral transmucosal drug dosage using solid soln.)

IT Essential oils

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(wintergreen; oral transmucosal drug dosage using solid soln.)

IT 9015-82-1 329900-75-6, Cyclooxygenase 2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(inhibitors; oral transmucosal drug dosage using solid soln.)

IT 9004-34-6, Cellulose, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(microcryst.; oral transmucosal drug dosage using solid soln.)

IT 50-02-2, Dexamethasone 50-28-2, Estradiol, biological studies 50-56-6,

Oxytocin, biological studies 50-57-7, Lypressin 50-70-4, Sorbitol,

biological studies 50-81-7, Vitamin C, biological studies 50-99-7,

Dextrose, biological studies 51-30-9, Isoproterenol hydrochloride

51-43-4, Epinephrine 51-61-6, Dopamine, biological studies 54-11-5,

Nicotine 54-31-9, Furosemide 55-63-0, Nitroglycerin 57-48-7,

Fructose, biological studies 57-50-1, Sucrose, biological studies

57-83-0, Progesterone, biological studies 58-22-0, Testosterone 58-38-8,

Prochlorperazine 58-55-9, Theophylline, biological studies 58-82-2,

Bradykinin 59-41-6, Bretylium 59-92-7, Levodopa, biological studies

60-79-7, Ergonovine 63-12-7, Benzquinamide 63-42-3, Lactose 67-52-7,

2,4,6(1H,3H,5H)-Pyrimidinetrione 69-65-8, Mannitol 71-50-1, Acetate,

biological studies 76-74-4, Pentobarbital 76-75-5, Thiopental

77-10-1, Phencyclidine 77-27-0, Thiamylal 77-86-1, Tris 87-99-0,

Xylitol 94-24-6, Tetracaine 97-53-0, Eugenol 107-43-7,

Trimethylglycine 110-16-7, Maleic acid, biological studies 113-15-5,

Ergotamine 129-51-1, Oxytocic 134-03-2, Sodium ascorbate 137-58-6,

Lidocaine 138-56-7, Trimethobenzamide 151-83-7, Methohexital

317-34-0, Aminophylline 361-37-5, Methysergide 364-62-5, Metoclopramide 437-38-7, Fentanyl 465-65-6, Naloxone 479-18-5, Dyphylline 495-40-9, Butyrophenone 511-12-6, Dihydroergotamine 525-66-6, Propranolol 530-08-5, Isoetharine 548-73-2, Droperidol 569-65-3, Meclizine 585-86-4, Lactitol 586-06-1, Metaproterenol 604-75-1, Oxazepam 652-67-5, Isosorbide 721-50-6, Prilocaine 846-49-1, Lorazepam 1400-61-9, Nystatin 1406-18-4, Vitamin E 1421-14-3, Propanidid 2078-54-8, Propofol **3385-03-3**, **Flunisolide** 3715-17-1, Tartrate, biological studies 4205-90-7, Clonidine 4419-39-0, Beclomethasone 4499-40-5, Oxtriphylline, biological studies 6740-88-1, Ketamine 7440-70-2, Calcium, biological studies 9000-30-0, Guar gum 9000-65-1, Tragacanth 9002-60-2, Adrenocorticotrophic hormone, biological studies 9002-64-6, Parathyroid hormone 9002-72-6, Growth hormone 9002-89-5, Polyvinyl alcohol 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethylcellulose 9004-53-9, Dextrin 9004-57-3, Ethylcellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methylcellulose 9004-67-5, Methylcellulose 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-37-2, Propylene glycolalginat 9005-38-3, Sodium alginate 9005-49-6, Heparin), biological studies 9007-12-9, Calcitonin 9041-90-1, Angiotensin I 9050-36-6, Maltodextrin 9063-38-1, Sodium starch glycolate 11000-17-2, Vasopressin 11103-57-4, Vitamin A 11138-66-2, Xanthan gum 12794-10-4, Benzodiazepine 15078-28-1, Nitroprusside 16679-58-6, Desmopressin 17560-51-9, Metolazone 18559-94-9, Albuterol 21829-25-4, Nifedipine 23031-25-6, Terbutaline 23593-75-1, Clotrimazole 25322-68-3, Polyethylene glycol 25322-68-3D, alkyl ethers 28860-95-9, Carbidopa 28911-01-5, Triazolam 33125-97-2, Etomidate 36322-90-4, Piroxicam 36894-69-6, Labetalol 38396-39-3, Bupivacaine 39404-33-6, Dextrates 42200-33-9, Nadolol 51384-51-1, Metoprolol 54182-58-0, Sucralfate 54767-75-8, Suloctidil 56030-54-7, Sufentanil 59467-70-8, Midazolam 59708-52-0, Carfentanil 60617-12-1, .beta.-Endorphin 61380-40-3, Lofentanil 62571-86-2, Captopril 71195-58-9, Alfentanil 75847-73-3, Enalapril 81147-92-4, Esmolol 103628-46-2, Sumatriptan 106392-12-5, Poloxamer

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(oral transmucosal drug dosage using solid soln.)

IT 50-02-2, Dexamethasone 50-28-2, Estradiol, biological studies 50-56-6, Oxytocin, biological studies 50-57-7, Lypressin 50-70-4, Sorbitol, biological studies 50-81-7, Vitamin C, biological studies 50-99-7, Dextrose, biological studies 51-30-9, Isoproterenol hydrochloride 51-43-4, Epinephrine 51-61-6, Dopamine, biological studies 54-11-5, Nicotine 54-31-9, Furosemide 55-63-0, Nitroglycerin 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 57-83-0, Progesteron, biological studies 58-22-0, Testosterone 58-38-8, Prochlorperazine 58-55-9, Theophylline, biological studies 58-82-2, Bradykinin 59-41-6, Bretylium 59-92-7, Levodopa, biological studies 60-79-7, Ergonovine 63-12-7, Benzquinamide 63-42-3, Lactose 67-52-7, 2,4,6(1H,3H,5H)-Pyrimidinetrione 69-65-8, Mannitol 71-50-1, Acetate, biological studies 76-74-4, Pentobarbital 76-75-5, Thiopental 77-10-1, Phencyclidine 77-27-0, Thiamylal 77-86-1, Tris 87-99-0, Xylitol 94-24-6, Tetracaine 97-53-0, Eugenol 107-43-7, Trimethylglycine 110-16-7, Maleic acid, biological studies 113-15-5, Ergotamine 129-51-1, Oxytocic 134-03-2, Sodium ascorbate 137-58-6, Lidocaine 138-56-7, Trimethobenzamide 151-83-7, Methohexital 317-34-0, Aminophylline 361-37-5, Methysergide 364-62-5, Metoclopramide 437-38-7, Fentanyl 465-65-6, Naloxone 479-18-5, Dyphylline 495-40-9, Butyrophenone 511-12-6, Dihydroergotamine 525-66-6, Propranolol 530-08-5, Isoetharine 548-73-2, Droperidol 569-65-3, Meclizine 585-86-4, Lactitol 586-06-1, Metaproterenol 604-75-1, Oxazepam 652-67-5, Isosorbide 721-50-6, Prilocaine 846-49-1, Lorazepam 1400-61-9, Nystatin 1406-18-4, Vitamin E 1421-14-3, Propanidid 2078-54-8, Propofol **3385-03-3**,

Flunisolide 3715-17-1, Tartrate, biological studies 4205-90-7, Clonidine 4419-39-0, Beclomethasone 4499-40-5, Oxtriphylline, biological studies 6740-88-1, Ketamine 7440-70-2, Calcium, biological studies 9000-30-0, Guar gum 9000-65-1, Tragacanth 9002-60-2, Adrenocorticotrophic hormone, biological studies 9002-64-6, Parathyroid hormone 9002-72-6, Growth hormone 9002-89-5, Polyvinyl alcohol 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethylcellulose 9004-53-9, Dextrin 9004-57-3, Ethylcellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methylcellulose 9004-67-5, Methylcellulose 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-37-2, Propylene glycolalginat 9005-38-3, Sodium alginate 9005-49-6, Heparin), biological studies 9007-12-9, Calcitonin 9041-90-1, Angiotensin I 9050-36-6, Maltodextrin 9063-38-1, Sodium starch glycolate 11000-17-2, Vasopressin 11103-57-4, Vitamin A 11138-66-2, Xanthan gum 12794-10-4, Benzodiazepine 15078-28-1, Nitroprusside 16679-58-6, Desmopressin 17560-51-9, Metolazone 18559-94-9, Albuterol 21829-25-4, Nifedipine 23031-25-6, Terbutaline 23593-75-1, Clotrimazole 25322-68-3, Polyethylene glycol 25322-68-3D, alkyl ethers 28860-95-9, Carbidopa 28911-01-5, Triazolam 33125-97-2, Etomidate 36322-90-4, Piroxicam 36894-69-6, Labetalol 38396-39-3, Bupivacaine 39404-33-6, Dextrates 42200-33-9, Nadolol 51384-51-1, Metoprolol 54182-58-0, Sucralfate 54767-75-8, Suloctidil 56030-54-7, Sufentanil 59467-70-8, Midazolam 59708-52-0, Carfentanil 60617-12-1, .beta.-Endorphin 61380-40-3, Lofentanil 62571-86-2, Captopril 71195-58-9, Alfentanil 75847-73-3, Enalapril 81147-92-4, Esmolol 103628-46-2, Sumatriptan 106392-12-5, Poloxamer

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(oral transmucosal drug dosage using solid soln.)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Lovrecich; US 5449521 A 1995 HCAPLUS


IT **3385-03-3, Flunisolide**

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(oral transmucosal drug dosage using solid soln.)

RN 3385-03-3 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 17 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:208111 HCAPLUS

DN 134:247241

TI Methods and compositions for modulating responsiveness to

corticosteroids

IN Sekut, Les; Carter, Adam; Ghayur, Tariq; Banerjee, Subhashis; Tracey, Daniel E.

PA BASF A.-G., Germany

SO PCT Int. Appl., 151 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-57

CC 1-7 (Pharmacology)

Section cross-reference(s): 25, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019373	A2	20010322	WO 2000-US24725	20000908 <--
	WO 2001019373	A3	20011004		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 1999-398555 A1 19990917 <--

AB Methods for modulating responsiveness to **corticosteroids** in a subject are provided. An agent which antagonizes a target that regulates prodn. of IFN-.gamma. in the subject is administered to the subject in combination with a **corticosteroid** such that responsiveness of the subject to the **corticosteroid** is modulated as compared to when a **corticosteroid** alone is administered to the subject. In one embodiment, the agent is an IL-18 antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In yet another embodiment, the agent is an NK cell antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. In yet another preferred embodiment, the agent is an anti-asialo-GM1 antibody or an NK1.1 antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunol. diseases and disorders. Pharmaceutical compns. comprising an agent which antagonizes a target that regulates prodn. of IFN-.gamma. in a subject, a **corticosteroid** and a pharmaceutically acceptable carrier are also provided. A preferred compn. comprises an ICE inhibitor, a **corticosteroid** and a pharmaceutically acceptable carrier.

ST **corticosteroid** responsiveness modulator inflammation immune disease; interferon prodn **corticosteroid** responsiveness modulator; interleukin antagonist **corticosteroid** responsiveness modulator; NK cell antagonist **corticosteroid** responsiveness modulator; caspase inhibitor **corticosteroid** responsiveness modulator; ICE inhibitor **corticosteroid** responsiveness modulator; phosphodiesterase inhibitor **corticosteroid** responsiveness modulator; beta2 adrenergic agonist **corticosteroid** responsiveness modulator; monoclonal antibody **corticosteroid** responsiveness modulator

IT Intestine, disease
(Crohn's; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Eye, disease
Graves' disease
(Graves' ophthalmopathy; methods and compns. for modulating

- responsiveness to **corticosteroids**)
- IT Interleukin receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(IL-18; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Transcription factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(STAT4, inhibitors; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Cell activation
(T cell, marker; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Granulomatous disease
(Wegener's granulomatosis; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT T cell (lymphocyte)
(activation, marker; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Respiratory distress syndrome
(adult; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT T cell (lymphocyte)
(antagonist; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Interleukin 1.alpha.
Interleukin 1.beta.
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antibody to; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Mouth
(aphthous ulcer, inhibitors; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Antiulcer agents
(aphthous ulcer; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Anemia (disease)
(aplastic; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Alopecia
(areata; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Dermatitis
(atopic; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Antiarthritics
(autoimmune arthritis; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Thyroid gland, disease
(autoimmune thyroiditis; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Eye, disease
(autoimmune uveitis; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Encephalomyelitis
Meningitis
(autoimmune; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Arthropod (Arthropoda)
(bite reaction; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Musculoskeletal diseases

- (cartilage, polychondritis; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chimeric; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Stress, animal
Surgery
(complications assocd. with post-surgical stress; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Eye, disease
(conjunctivitis; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Lupus erythematosus
(cutaneous; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Cartilage
(disease, polychondritis; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Drugs
(drug eruptions; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Eye, disease
(dry eye syndrome, secondary to Sjogren's syndrome; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Erythema
(erythema nodosum leprosum; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Transplant and Transplantation
(graft-vs.-host reaction; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(humanized; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Purpura (disease)
(idiopathic thrombocytopenic; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Lung, disease
(inflammatory pulmonary syndrome; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Intestine, disease
(inflammatory; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Drug delivery systems
(inhalants; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Drug delivery systems
(injections, i.m.; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Drug delivery systems
(injections, i.v.; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Drug delivery systems
(injections, s.c.; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Lung, disease
(interstitial fibrosis; methods and compns. for modulating responsiveness to **corticosteroids**)

- IT Eye, disease
(iritis; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Rheumatoid arthritis
(juvenile; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Eye, disease
(keratoconjunctivitis; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Leprosy
(leprosy reversal reactions; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Antitumor agents
(leukemia; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Proteins, specific or class
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ligand-binding, IL-18; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Allergy inhibitors
Anti-inflammatory agents
Antiasthmatics
Antidiabetic agents
Antirheumatic agents
Autoimmune disease
Dermatitis
Drug delivery systems
Drug interactions
Eczema
Myasthenia gravis
Psoriasis
Sepsis
Sjogren's syndrome
Transplant rejection
(methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Interleukin 18
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods and compns. for modulating responsiveness to **corticosteroids**)
- IT **Corticosteroids**, biological studies
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Interleukin 12
Interleukin 6
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Antibodies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(monoclonal; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Erythema

(multiforme; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Lymphocyte

(natural killer cell, antagonist; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Antibodies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(neutralizing; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Skin, disease

(pemphigus vulgaris; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Biliary tract

(primary biliary cirrhosis; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Interleukin 18

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(pro-; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Arthritis

(psoriatic arthritis; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Anemia (disease)

(pure red cell; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Drug delivery systems

(rectal; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Intestine, disease

(rectum, inflammation; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Connective tissue

(scleroderma; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Shock (circulatory collapse)

(septic; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Lupus erythematosus

(systemic; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Multiple sclerosis

(therapeutic agents; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Platelet (blood)

(thrombocytopenia, idiopathic; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Drug delivery systems

(topical; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Intestine, disease

(ulcerative colitis; methods and compns. for modulating responsiveness to **corticosteroids**)

IT Eye, disease

(uveitis, posterior; methods and compns. for modulating responsiveness

- to **corticosteroids**)
- IT Vagina
(vaginitis; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Hepatitis
(viral, chronic active; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Adrenoceptor agonists
(.beta.2-; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT Interferons
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.gamma.; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT 71012-19-6, Asialo-GM1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antibody to; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT 9001-92-7, Protease
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(caspase-family, inhibitors; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT 9036-21-9, Phosphodiesterase IV 128028-50-2, Proteinase PR3
182762-08-9, Caspase 4 186322-81-6, Caspase 192465-11-5, Caspase 5
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; methods and compns. for modulating responsiveness to **corticosteroids**)
- IT 122191-40-6, ICE proteinase
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(methods and compns. for modulating responsiveness to **corticosteroids**)
- IT 169592-56-7, CPP32 proteinase 182372-14-1, ICH-1 proteinase
182372-15-2, Caspase Mch2 189258-14-8, Proteinase Mch3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(methods and compns. for modulating responsiveness to **corticosteroids**)
- IT 230630-17-8P 230630-18-9P 230630-19-0P 230630-20-3P 230630-21-4P
230630-23-6P 230962-66-0P 330798-25-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methods and compns. for modulating responsiveness to **corticosteroids**)
- IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 50-24-8, Prednisolone
53-03-2, Prednisone 53-06-5, Cortisone 83-43-2, Methylprednisolone
86-96-4D, Quinazolinone, derivs. 124-94-7, Triamcinolone 378-44-9,
Betamethasone 3385-03-3, Flunisolide 4419-39-0,
Beclomethasone 7683-59-2, Isoproterenol 13392-18-2, Fenoterol
14484-47-0, Deflazacort 28261-54-3D, Pyrrolidinone, 4-aryl derivs.
56739-21-0, Nitraquazone 57076-71-8, Denbufylline 61413-54-5, Rolipram
89365-50-4, Salmeterol 97852-72-7, Tibenelast 114918-24-0, CP-77059
135637-46-6, CP-80633
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for modulating responsiveness to **corticosteroids**)
- IT 60-92-4, Cyclic AMP
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)
 (methods and compns. for modulating responsiveness to
corticosteroids)

IT 213613-61-7P 230630-46-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (methods and compns. for modulating responsiveness to
corticosteroids)

IT 213613-47-9P 213613-48-0P 213613-60-6P 213613-63-9P 213613-64-0P
 230630-48-5P 230630-49-6P 230630-50-9P 230630-51-0P 230630-52-1P
 230630-55-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. and reaction; methods and compns. for modulating responsiveness
 to **corticosteroids**)


IT 5596-17-8 18108-55-9 22426-86-4 24424-99-5, Di-tert-butyl
 dicarbonate 24731-17-7, Ethyl 2-cyclohexanoneacetate 52928-63-9,
 1-Hydroxy-2-pyrrolidinone 60941-72-2 183133-66-6 188890-84-8
 230630-47-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction; methods and compns. for modulating responsiveness to
corticosteroids)

IT **3385-03-3, Flunisolide**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); **THU (Therapeutic use)**; BIOL (Biological
 study); USES (Uses)
 (methods and compns. for modulating responsiveness to
corticosteroids)

RN 3385-03-3 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-
 methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 18 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:101123 HCAPLUS

DN 134:152630

TI Pharmaceutical compositions containing novel crystalline form of
 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-
 methoxyphenyl)benzo[b]thiophene hydrochloride

IN Bush, Julie Kay; Conrad, Preston Charles; Flom, Merlyn Gerard; Luke, Wayne
 Douglas

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 53 pp.
 CODEN: PIXXD2

DT Patent

LA English
 IC ICM C07D333-64
 ICS A61K031-4535; A61P005-32
 CC 63-5 (Pharmaceuticals)
 Section cross-reference(s): 1
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001009116	A2	20010208	WO 2000-US16333	20000717 <--
	WO 2001009116	A3	20010517		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU	2000063356	A5	20010219	AU 2000-63356	20000717 <--
EP	1204656	A2	20020515	EP 2000-950223	20000717 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
LV	12623	B	20010720	LV 2000-94	20000718 <--
HR	2000000503	A1	20010630	HR 2000-503	20000725 <--
NL	1015821	A1	20010130	NL 2000-1015821	20000727 <--
NL	1015821	C2	20020103		
FI	2000001722	A	20010130	FI 2000-1722	20000728 <--
NO	2000003879	A	20010130	NO 2000-3879	20000728 <--
SE	2000002792	A	20010130	SE 2000-2792	20000728 <--
AU	2000048912	A5	20010201	AU 2000-48912	20000728 <--
FR	2796944	A1	20010202	FR 2000-9969	20000728 <--
FR	2796944	B1	20030131		
GB	2352717	A1	20010207	GB 2000-18641	20000728 <--
DE	10036854	A1	20010301	DE 2000-10036854	20000728 <--
JP	2001064277	A2	20010313	JP 2000-228939	20000728 <--
BR	2000003209	A	20010320	BR 2000-3209	20000728 <--
CN	1288007	A	20010321	CN 2000-122237	20000728 <--
LT	4790	B	20010525	LT 2000-76	20000728 <--
LU	90617	A2	20010615	LU 2000-90617	20000728 <--
SI	20426	C	20010630	SI 2000-172	20000728 <--
BE	1013411	A3	20011204	BE 2000-478	20000728 <--
IT	2000MI1759	A1	20020128	IT 2000-MI1759	20000728 <--
NZ	506046	A	20020328	NZ 2000-506046	20000728 <--
PRAI	US 1999-146286P	P	19990729 <--		
	US 1999-147570P	P	19990806 <--		
	US 1999-149773P	P	19990819 <--		
	WO 2000-US16333	W	20000717 <--		
AB	The present invention is directed to a novel cryst. hydrate of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride (I) and uses for same, including inhibition of disease states assocd. with estrogen deprivation including cardiovascular disease, hyperlipidemia, and osteoporosis; and inhibition of other pathol. conditions such as endometriosis, uterine fibrosis, estrogen-dependent cancer (including breast and uterine cancer), prostate cancer, benign prostatic hyperplasia, CNS disorders including Alzheimer's disease, prevention of breast cancer, and up-regulating ChAT. Form I of I was prepd. by crystn. of arzoxifene from THF. The efficacy of the compd. in the treatment of human benign prostatic hyperplasia was studied. A capsule contained form I 1000, starch 650, starch flowable powder 650, and silicon fluid-350 cSt 15 mg.				
ST	pharmaceutical capsule cryst arzoxifene polymorphism				
IT	Drug delivery systems				

(aerosols; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)

IT Prostate gland
(benign hyperplasia, inhibitors; pharmaceutical compn. contg. novel
cryst. form of arzoxifene)

IT Drug delivery systems
(capsules; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)

IT Nervous system
(central, disease; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)

IT Estrogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugated; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)

IT Bone
(demineralization; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)

IT Cardiovascular system
(disease; pharmaceutical compn. contg. novel cryst. form of arzoxifene)

IT Uterus, disease
(endometriosis, inhibitors; pharmaceutical compn. contg. novel cryst.
form of arzoxifene)

IT Uterus, neoplasm
(endometrium, inhibitors; pharmaceutical compn. contg. novel cryst.
form of arzoxifene)

IT Antitumor agents
(endometrium; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)

IT Uterus
(fibrosis of, inhibitors; pharmaceutical compn. contg. novel cryst.
form of arzoxifene)

IT Ovary, neoplasm
Uterus, neoplasm
(inhibitors; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)

IT Drug delivery systems
(injections, i.v.; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)

IT Antitumor agents
(mammary gland; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)

IT Mammary gland
Prostate gland
(neoplasm, inhibitors; pharmaceutical compn. contg. novel cryst. form
of arzoxifene)

IT Antitumor agents
(ovary; pharmaceutical compn. contg. novel cryst. form of arzoxifene)

IT **Alzheimer's disease**
Hypolipemic agents
Polymorphism (crystal)
(pharmaceutical compn. contg. novel cryst. form of arzoxifene)

IT Antitumor agents
(prostate gland; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)


IT Artery, disease
(restenosis, inhibitors; pharmaceutical compn. contg. novel cryst. form
of arzoxifene)

IT Muscle
(smooth, proliferation inhibitors; pharmaceutical compn. contg. novel
cryst. form of arzoxifene)

IT Drug delivery systems
(suppositories; pharmaceutical compn. contg. novel cryst. form of

- arzoxifene)
 IT Drug delivery systems
 (suspensions; pharmaceutical compn. contg. novel cryst. form of
 arzoxifene)
 IT Osteoporosis
 (therapeutic agents; pharmaceutical compn. contg. novel cryst. form of
 arzoxifene)
 IT Antitumor agents
 (uterus; pharmaceutical compn. contg. novel cryst. form of arzoxifene)
 IT 9000-81-1, Acetyl choline esterase 9039-48-9, Aromatase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (inhibitor; pharmaceutical compn. contg. novel cryst. form of
 arzoxifene)
 IT 182133-27-3, Arzoxifene hydrochloride
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (pharmaceutical compn. contg. novel cryst. form of arzoxifene)
 IT 9012-78-6, Choline acetyltransferase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (pharmaceutical compn. contg. novel cryst. form of arzoxifene)
 IT 67-63-0, Isopropanol, uses 109-99-9, Tetrahydrofuran, uses
 RL: NUU (Other use, unclassified); USES (Uses)
 (pharmaceutical compn. contg. novel cryst. form of arzoxifene)
 IT 57-64-7, Physostigmine salicylate 57-83-0, Progestin, biological studies
 68-22-4, Norethindrone 68-23-5, Norethynodrel
 1684-40-8, Tacrine hydrochloride 9034-40-6D, Lhrh, analogs
 120011-70-3, Donepezil hydrochloride 182133-25-1, Arzoxifene
 324518-17-4
 RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
 (pharmaceutical compn. contg. novel cryst. form of arzoxifene)
 IT **68-22-4, Norethindrone**
 RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
 (pharmaceutical compn. contg. novel cryst. form of arzoxifene)
 RN 68-22-4 HCAPLUS
 CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



- L76 ANSWER 19 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:101122 HCAPLUS
 DN 134:152629
 TI Pharmaceutical composition containing novel crystalline form of
 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-
 methoxyphenyl)benzo[b]thiophene hydrochloride
 IN Bush, Julie Kay; Conrad, Preston Charles; Flom, Merlyn Gerard
 PA Eli Lilly and Company, USA
 SO PCT Int. Appl., 57 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 IC ICM C07D333-64
 ICS A61K031-4535; A61P005-32
 CC 63-5 (Pharmaceuticals)
 Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001009115	A2	20010208	WO 2000-US16332	20000717 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2000063355	A5	20010219	AU 2000-63355	20000717 <--
	EP 1204655	A2	20020515	EP 2000-950222	20000717 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	LV 12733	B	20020220	LV 2000-95	20000718 <--
	HR 2000000502	A1	20010630	HR 2000-502	20000725 <--
	NL 1015822	A1	20010130	NL 2000-1015822	20000727 <--
	FI 2000001721	A	20010130	FI 2000-1721	20000728 <--
	NO 2000003876	A	20010130	NO 2000-3876	20000728 <--
	SE 2000002793	A	20010130	SE 2000-2793	20000728 <--
	AU 2000048911	A5	20010201	AU 2000-48911	20000728 <--
	GB 2352716	A1	20010207	GB 2000-18636	20000728 <--
	CN 1283622	A	20010214	CN 2000-122240	20000728 <--
	JP 2001048880	A2	20010220	JP 2000-228949	20000728 <--
	BR 2000003211	A	20010313	BR 2000-3211	20000728 <--
	FR 2798384	A1	20010316	FR 2000-9972	20000728 <--
	DE 10036855	A1	20010322	DE 2000-10036855	20000728 <--
	LT 4789	B	20010525	LT 2000-75	20000728 <--
	SI 20427	C	20010630	SI 2000-173	20000728 <--
	BE 1013410	A3	20011204	BE 2000-477	20000728 <--
	IT 2000MI1758	A1	20020128	IT 2000-MI1758	20000728 <--
	NZ 506045	A	20020201	NZ 2000-506045	20000728 <--
	SG 90737	A1	20020820	SG 2000-4287	20000728 <--
PRAI	US 1999-146184P	P	19990729 <--		
	US 1999-147642P	P	19990806 <--		
	US 1999-149820P	P	19990819 <--		
	WO 2000-US16332	W	20000717 <--		

AB The present invention is directed to a novel cryst. hydrate of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]-phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride (I) and uses for same, including inhibition of disease states assocd. with estrogen deprivation including cardiovascular disease, hyperlipidemia, and osteoporosis; and inhibition of other pathol. conditions such as endometriosis, uterine fibrosis, estrogen-dependent cancer (including breast and uterine cancer), prostate cancer, benign prostatic hyperplasia, CNS disorders including Alzheimer's disease, prevention of breast cancer, and up-regulating ChAT. I was prepd. by reaction of boron trichloride with 6-isopropoxy-3-(4-[2-(piperidin-1-yl)ethoxy]-phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride. The efficacy of the compd. in the treatment of human benign prostatic hyperplasia was studied. A capsule contained I 1000, starch 650, starch flowable powder 650, and silicon fluid 350-cSt 15 mg.


ST cryst pharmaceutical capsule arzoxifene polymorphism

IT Drug delivery systems
 (aerosols; pharmaceutical compn. contg. novel cryst. form of

arzoxifene)
IT Prostate gland
(benign hyperplasia, inhibitors; pharmaceutical compn. contg. novel
cryst. form of arzoxifene)
IT Drug delivery systems
(capsules; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)
IT Nervous system
(central, disease; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)
IT Estrogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugated; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)
IT Bone
(demineralization; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)
IT Cardiovascular system
(disease; pharmaceutical compn. contg. novel cryst. form of arzoxifene)
IT Uterus, disease
(endometriosis, inhibitors; pharmaceutical compn. contg. novel cryst.
form of arzoxifene)
IT Uterus, neoplasm
(endometrium, inhibitors; pharmaceutical compn. contg. novel cryst.
form of arzoxifene)
IT Antitumor agents
(endometrium; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)
IT Uterus
(fibrosis of, inhibitors; pharmaceutical compn. contg. novel cryst.
form of arzoxifene)
IT Ovary, neoplasm
Uterus, neoplasm
(inhibitors; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)
IT Drug delivery systems
(injections, i.v.; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)
IT Antitumor agents
(mammary gland; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)
IT Mammary gland
Prostate gland
(neoplasm, inhibitors; pharmaceutical compn. contg. novel cryst. form
of arzoxifene)
IT Antitumor agents
(ovary; pharmaceutical compn. contg. novel cryst. form of arzoxifene)
IT **Alzheimer's disease**
Hypolipemic agents
Polymorphism (crystal)
(pharmaceutical compn. contg. novel cryst. form of arzoxifene)
IT Antitumor agents
(prostate gland; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)
IT Artery, disease
(restenosis, inhibitors; pharmaceutical compn. contg. novel cryst. form
of arzoxifene)
IT Muscle
(smooth, proliferation inhibitors; pharmaceutical compn. contg. novel
cryst. form of arzoxifene)
IT Drug delivery systems
(suppositories; pharmaceutical compn. contg. novel cryst. form of
arzoxifene)

- IT Drug delivery systems
(suspensions; pharmaceutical compn. contg. novel cryst. form of arzoxifene)
- IT Osteoporosis
(therapeutic agents; pharmaceutical compn. contg. novel cryst. form of arzoxifene)
- IT Antitumor agents
(uterus; pharmaceutical compn. contg. novel cryst. form of arzoxifene)
- IT 9000-81-1, Acetyl choline esterase 9039-48-9, Aromatase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; pharmaceutical compn. contg. novel cryst. form of arzoxifene)
- IT 182133-27-3, Arzoxifene hydrochloride
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compn. contg. novel cryst. form of arzoxifene)
- IT 9012-78-6, Choline acetyltransferase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pharmaceutical compn. contg. novel cryst. form of arzoxifene)
- IT 67-63-0, Isopropanol, uses
RL: NUU (Other use, unclassified); USES (Uses)
(pharmaceutical compn. contg. novel cryst. form of arzoxifene)
- IT 182133-15-9 182133-31-9 182133-32-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(pharmaceutical compn. contg. novel cryst. form of arzoxifene)
- IT 57-64-7, Physostigmine salicylate 57-83-0, Progestin, biological studies
68-22-4, Norethindrone 68-23-5, Norethynodrel
1684-40-8, Tacrine hydrochloride 9034-40-6D, Lhrh, analogs
120011-70-3, Donepezil hydrochloride 182133-25-1, Arzoxifene
324518-23-2
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(pharmaceutical compn. contg. novel cryst. form of arzoxifene)
- IT **68-22-4, Norethindrone**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(pharmaceutical compn. contg. novel cryst. form of arzoxifene)
- RN 68-22-4 HCAPLUS
- CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




- L76 ANSWER 20 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN
- AN 2000:880945 HCAPLUS
- DN 134:33011
- TI **Solubility** enhancement of drugs in transdermal drug delivery systems and methods of use
- IN Rossi-Montero, Sylvia; Mantelle, Juan; Kanios, David; Houze, David
- PA Noven Pharmaceuticals, Inc., USA
- SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K009-70
 CC 63-6 (Pharmaceuticals)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000074661	A2	20001214	WO 2000-US15538	20000605 <--
	WO 2000074661	A3	20010628		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2000053250	A5	20001228	AU 2000-53250	20000605 <--
	US 6465004	B1	20021015	US 2000-586906	20000605 <--
PRAI	US 1999-137827P	P	19990605 <--		
	WO 2000-US15538	W	20000605 <--		
AB	Disclosed are a compn. and method for the continuous and controlled transdermal delivery of an active agent comprising a pharmaceutically acceptable active agent carrier and cellulose deriv. which provides a solubilizing and stabilizing effect on the active agents incorporated therein. A transdermal prepn. contained polysiloxane adhesive (BIO-PSA Q7-4502) 45.9, polyacrylate adhesive (Duro-Tak 87-2510) 20, cellulose acetate butyrate 15, oleyl alc. 6, dipropylene glycol 8, estradiol 1.1, and methyltestosterone 4 %.				
ST	transdermal cellulose ester crystn prevention; estradiol methyltestosterone cellulose acetate butyrate transdermal				
IT	Analgesics Anti-Alzheimer's agents Anti-inflammatory agents Antiparkinsonian agents Cardiotonics Nervous system agents (transdermal compns. contg. cellulose derivs. to prevent crystn. of drugs in adhesives)				
IT	Hormones, animal, biological studies Polysiloxanes, biological studies Steroids, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (transdermal compns. contg. cellulose derivs. to prevent crystn. of drugs in adhesives)				
IT	50-28-2, Estradiol, biological studies 57-63-6, Ethinylestradiol 57-83-0, Progesterone, biological studies 58-18-4, Methyltestosterone 58-22-0, Testosterone 68-22-4, Norethindrone 9004-36-8, Cellulose acetate butyrate 9004-38-0, Cellulose acetate phthalate 9004-39-1, Cellulose acetate propionate 227762-39-2, Duro-tak 87-2510 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (transdermal compns. contg. cellulose derivs. to prevent crystn. of drugs in adhesives)				
IT	68-22-4, Norethindrone RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (transdermal compns. contg. cellulose derivs. to prevent crystn. of drugs in adhesives)				
RN	68-22-4 HCAPLUS				
CN	19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



L76 ANSWER 21 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:880371 HCAPLUS

DN 135:70752

TI Phase I trial of paclitaxel plus **megestrol acetate** in patients with paclitaxel-refractory ovarian cancer

AU Markman, Maurie; Kennedy, Alexander; Webster, Kenneth; Kulp, Barbara; Peterson, Gertrude; Belinson, Jerome

CS Gynecologic Cancer Program, The Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH, 44195, USA

SO Clinical Cancer Research (2000), 6(11), 4201-4204

CODEN: CCREF4; ISSN: 1078-0432

PB American Association for Cancer Research

DT Journal

LA English

CC 1-6 (Pharmacology)

AB Increased expression of P-glycoprotein has been proposed as one important mechanism for inherent or acquired drug resistance of malignant disease to cytotoxic chemotherapy. In exptl. systems, hormonal agents, including **megestrol acetate** (MA), have been shown to be capable of reversing P-glycoprotein-mediated multidrug resistance to natural products, including paclitaxel. Because paclitaxel is one of the most active cytotoxic agents in ovarian cancer (OC), we sought to det. whether retreating patients with well-defined paclitaxel-resistant OC with a combination of paclitaxel and MA would result in clin. relevant reversal of that resistant state. In this Phase I trial, 44 patients with OC or primary peritoneal carcinoma received paclitaxel (135-175 mg/m² over 3 h) plus an oral loading dose (800-9600 mg over 24 h) and subsequent maintenance dose (800-3200 mg/day .times. 3 days) of micronized MA. Both the loading dose and maintenance therapy were delivered in four equal daily doses. Therapy was repeated every 21 days, assuming recovery from the toxicity of the prior course. There were no inpatient dose escalations. The major toxicity of the regimen was peripheral neuropathy (32% of patients; 11% grade 2-3), although four individuals developed major venous blood clots and one suffered a stroke. Four patients exhibited biol. evidence of antineoplastic effects, although only one patient experienced improvement in clin. relevant symptoms. Although pharmacokinetic studies were not performed as a component of this study, prior evaluation of MA pharmacokinetics and in vitro data examg. the concns. of the agent required to reverse P-glycoprotein-mediated paclitaxel resistance suggest that the majority of our patient population achieved levels of MA theor. capable of producing this desired effect. We conclude that the level of activity and toxicity pattern obsd. in this trial, assocd. with the combination of paclitaxel and MA, does not provide strong support for further exploration of the regimen as a treatment strategy to overcome paclitaxel resistance in OC.

ST ovary cancer paclitaxel **megestrol acetate**

IT Thrombus

(Phase I trial of paclitaxel plus **megestrol acetate** in patients with paclitaxel-refractory ovarian cancer)

IT P-glycoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Phase I trial of paclitaxel plus **megestrol acetate** in patients with paclitaxel-refractory ovarian cancer)

IT Drug resistance
(antitumor; Phase I trial of paclitaxel plus **megestrol acetate** in patients with paclitaxel-refractory ovarian cancer)

IT Peritoneum
(carcinomatosis, inhibitors; Phase I trial of paclitaxel plus **megestrol acetate** in patients with paclitaxel-refractory ovarian cancer)

IT Ovary, neoplasm
(inhibitors; Phase I trial of paclitaxel plus **megestrol acetate** in patients with paclitaxel-refractory ovarian cancer)

IT Toxicity
(neurotoxicity; Phase I trial of paclitaxel plus **megestrol acetate** in patients with paclitaxel-refractory ovarian cancer)

IT Antitumor agents
(ovary; Phase I trial of paclitaxel plus **megestrol acetate** in patients with paclitaxel-refractory ovarian cancer)

IT Antitumor agents
(peritoneum carcinomatosis; Phase I trial of paclitaxel plus **megestrol acetate** in patients with paclitaxel-refractory ovarian cancer)

IT Antitumor agents
(resistance to; Phase I trial of paclitaxel plus **megestrol acetate** in patients with paclitaxel-refractory ovarian cancer)

IT **Brain, disease**
(**stroke**; Phase I trial of paclitaxel plus **megestrol acetate** in patients with paclitaxel-refractory ovarian cancer)

IT **Nerve**
(toxicity; Phase I trial of paclitaxel plus **megestrol acetate** in patients with paclitaxel-refractory ovarian cancer)

IT 33069-62-4, Paclitaxel
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Phase I trial of paclitaxel plus **megestrol acetate** in patients with paclitaxel-refractory ovarian cancer)

IT 33069-62-4, Paclitaxel
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Phase I trial of paclitaxel plus **megestrol acetate** in patients with paclitaxel-refractory ovarian cancer)

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Bissett, D; Br J Cancer 1991, V64, P1168 MEDLINE
- (2) Christen, R; J Clin Oncol 1993, V11, P2417 MEDLINE
- (3) Fleming, G; Cancer Chemother Pharmacol 1992, V29, P445 HCAPLUS
- (4) Johnson, S; Cancer 1993, V71, P644 MEDLINE
- (5) Leyland-Jones, B; Cancer 1993, V72, P3484 MEDLINE
- (6) Lum, B; Cancer 1993, V72, P3502 MEDLINE
- (7) Markman, M; Gynecol Oncol 1998, V70, P272 HCAPLUS
- (8) McGuire, W; N Engl J Med 1996, V334, P1 HCAPLUS
- (9) Miller, A; J Cancer Res Clin Oncol 1988, V114, P186 MEDLINE
- (10) Murren, J; Oncol Res 1992, V4, P1 MEDLINE
- (11) Panasci, L; Biochem Pharmacol 1996, V52, P1097 HCAPLUS
- (12) Patel, N; Investig New Drugs 1994, V12, P1 MEDLINE
- (13) Raderer, M; Cancer 1993, V72, P3553 HCAPLUS
- (14) Sikic, B; Semin Oncol 1986, V13, P26 MEDLINE
- (15) Tansan, S; Cancer Chemother Pharmacol 1997, V39, P333 HCAPLUS
- (16) Wang, L; Cancer Chemother Pharmacol 1994, V34, P96 HCAPLUS

(17) Yang, C; J Biol Chem 1989, V264, P782 HCAPLUS

L76 ANSWER 22 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:741924 HCAPLUS

DN 133:305586

TI Methods of inducing cancer cell death and tumor regression

IN Bishop, Walter R.; Brassard, Diana L.; Nagabhushan, Tattanahalli L.

PA Schering Corporation, USA

SO PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-44

ICS A61K031-55; A61P035-00

CC 1-6 (Pharmacology)

Section cross-reference(s): 8, 15, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061145	A1	20001019	WO 2000-US9124	20000406 <--
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
	US 6316462	B1	20011113	US 1999-289255	19990409 <--
	EP 1165078	A1	20020102	EP 2000-921765	20000406 <--
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO	
	BR 2000009670	A	20020115	BR 2000-9670	20000406 <--
PRAI	US 1999-289255	A	19990409 <--		
	WO 2000-US9124	W	20000406 <--		
AB	Methods are provided for treating cancer, comprising administering (1) a farnesyl protein transferase inhibitor in conjunction with (2) an addnl. Ras signaling pathway inhibitor to induce cancer cell death and tumor regression.				
ST	cancer treatment farnesyl protein transferase inhibitor; Ras signaling pathway inhibitor cancer treatment				
IT	Antitumor agents (bladder carcinoma; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)				
IT	Drug delivery systems (capsules; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)				
IT	Bladder Bladder (carcinoma, inhibitors; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)				
IT	Intestine, neoplasm Intestine, neoplasm (colon, inhibitors; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)				
IT	Antitumor agents				

- (colon; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)
- IT Thyroid gland, neoplasm
(follicular cell carcinoma, metastasis, inhibitors; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)
- IT Neuroglia
Neuroglia
(glioma, inhibitors; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)
- IT Antitumor agents
(glioma; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)
- IT Liver, neoplasm
Liver, neoplasm
(hepatoma, inhibitors; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)
- IT Antitumor agents
(hepatoma; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)
- IT Lung, neoplasm
Lung, neoplasm
Ovary, neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Pancreas, neoplasm
(inhibitors; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)
- IT Epidermal growth factor receptors
Growth factor receptors
Insulin-like growth factor receptors
Platelet-derived growth factor receptors
neu (receptor)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)
- IT Antitumor agents
Antitumor agents
(lung; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)
- IT Antitumor agents
(mammary gland; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)
- IT Antitumor agents
(melanoma; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)
- IT Antitumor agents
Apoptosis
Drug delivery systems

Radiotherapy

Signal transduction, biological

(methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

IT Interferons

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

IT Antibodies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(monoclonal, to epidermal growth factor receptor; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

IT Antibodies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(monoclonal, to erbB2 receptor; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

IT Antitumor agents

(myelogenous leukemia; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

IT Mammary gland

Mammary gland

Prostate gland

Prostate gland

(neoplasm, inhibitors; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

IT Antitumor agents

Antitumor agents

(ovary; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

IT Antitumor agents

Antitumor agents

(pancreas; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

IT Ras proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(pathway, inhibitors; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

IT Antitumor agents

(prostate gland; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

IT Drug interactions

(synergistic; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

IT Antitumor agents

(thyroid gland follicular cell carcinoma, metastasis; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

IT Antibodies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(to growth factor receptor; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

IT Myelodysplastic syndromes

(treatment of; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

IT 9031-44-1, Kinase 79079-06-4, Epidermal growth factor receptor tyrosine kinase 101463-26-7, Platelet-derived growth factor receptor tyrosine kinase 127407-08-3 131384-38-8, Farnesyl protein transferase 137632-09-8, ErbB2 tyrosine kinase 142805-58-1, Protein kinase MEK 301646-57-1, Insulin-like growth factor receptor tyrosine kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors; methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

IT 50-07-7, Mitomycin C 50-18-0, Cyclophosphamide 50-24-8, Prednisolone 50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-18-3, Triethylenemelamine 51-21-8, 5-Fluorouracil 51-75-2, Chlormethine 52-24-4, Triethylenethiophosphoramide 53-03-2, Prednisone 53-19-0, Mitotane 54-91-1, Pipobroman 55-98-1, Busulfan 56-53-1, Diethylstilbestrol 57-22-7, Vincristine 57-63-6, 17.alpha.-Ethinylestradiol 58-18-4, Methyltestosterone 58-22-0, Testosterone 59-05-2, Methotrexate 66-75-1, Uracil mustard 68-96-2, Hydroxyprogesterone 71-58-9, Medroxyprogesterone acetate 76-43-7, Fluoxymesterone 83-43-2, Methylprednisolone 124-94-7, Triamcinolone 125-84-8, Aminogluthetimide 127-07-1, Hydroxyurea 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, 6-Thioguanine 154-93-8, Carmustine 305-03-3, Chlorambucil 521-12-0, Dromostanolone propionate 569-57-3, Chlorotrianisene 595-33-5, Megestrolacetate 645-05-6, Hexamethylmelamine 671-16-9, Procarbazine 865-21-4, Vinblastine 968-93-4, Testolactone 2998-57-4, Estramustine 3778-73-2, Ifosfamide 4342-03-4, Dacarbazine 9015-68-3, L-Asparaginase 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 13010-47-4, Lomustine 13311-84-7, Flutamide 14769-73-4, Levamisole 15663-27-1, Cisplatin 18378-89-7, Mithramycin 18883-66-4, Streptozocin 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 29767-20-2, Teniposide 33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4, Carboplatin 51264-14-3, Amsacrine 53643-48-4, Vindesine 53714-56-0, Leuprolide 53910-25-1, Pentostatin 56420-45-2, Epirubicin 58957-92-9, Idarubicin 65271-80-9, Mitoxantrone 65807-02-5, Goserelin 75607-67-9, Fludarabine phosphate 82413-20-5, Droloxifene 84449-90-1, Raloxifene 85622-93-1, Temozolomide 89778-26-7, Toremifene 95058-81-4, Gemcitabine 100286-90-6, CPT-11 109511-58-2, U0126 112809-51-5, Letrozole 120511-73-1, Anastrozole 125317-39-7, Navelbine 154361-50-9, Capecitabine 167869-21-8, PD 098059 193275-84-2, SCH 66336

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological

study); USES (Uses)

(methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Alessi, D; JOURNAL OF BIOLOGICAL CHEMISTRY 1995, V270(46), P27489 HCAPLUS
- (2) Fry, D; SCIENCE 1994, V265(5175), P1093 HCAPLUS
- (3) Goldstein, N; CLINICAL CANCER RESEARCH 1995, V1, P1311 HCAPLUS
- (4) Graham, S; EXPERT OPINION ON THERAPEUTIC PATENTS 1996, V6(12), P1295 HCAPLUS
- (5) Levitzki, A; SCIENCE 1995, V267, P1782 HCAPLUS
- (6) Liu, M; CANCER RESEARCH 1998, V58(21), P4947 HCAPLUS
- (7) Merck & Co Inc; WO 9745412 A 1997 HCAPLUS
- (8) Merck & Co Inc; WO 9736587 A 1997 HCAPLUS
- (9) Moasser, M; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA 1998, V95(95), P1369
- (10) Schering Corporation; WO 9723478 A 1997 HCAPLUS
- (11) Schering Corporation; WO 9811091 A 1998 HCAPLUS
- (12) The Wellcome Foundation Limited; WO 9211034 A 1992 HCAPLUS

IT 595-33-5, Megestrolacetate


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)

RN 595-33-5 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 23 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:608551 HCAPLUS

DN 133:213151

TI Pharmaceutical compositions and methods for improved delivery of hydrophobic therapeutic agents

IN Patel, Manesh V.; Chen, Feng-Jing

PA Lipocine, Inc., USA

SO PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-127

ICS A61K009-107; A61K038-13

CC 63-6 (Pharmaceuticals)

FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2000050007	A1	20000831	WO 2000-US165	20000105	<--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	US 6294192	B1	20010925	US 1999-258654	19990226	<--
	NZ 513810	A	20010928	NZ 2000-513810	20000105	<--
	EP 1158959	A1	20011205	EP 2000-901394	20000105	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	JP 2002537317	T2	20021105	JP 2000-600619	20000105	<--
PRAI	US 1999-258654	A	19990226			<--
	WO 2000-US165	W	20000105			<--
AB	The present invention relates to triglyceride-free pharmaceutical compns. for delivery of hydrophobic therapeutic agents. Compns. of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon diln. with an aq. solvent, the compn. forms a clear, aq. dispersion of the surfactants contg. the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compns. A pharmaceutical compn. contained cyclosporin 0.14, Cremophor RH-40 0.41, Arlacel186 0.29, sodium taurocholate 0.26, and propylene glycol 0.46 mg.					
ST	pharmaceutical hydrophobic therapeutic agent; cyclosporin Cremophor RH40 Arlacel 186 taurocholate pharmaceutical					
IT	Monoglycerides					
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (acetates; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)					
IT	Drug delivery systems					
	(aerosols; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)					
IT	Quaternary ammonium compounds, biological studies					
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkyl derivs.; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)					
IT	Phenols, biological studies					
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkyl, polyoxyethylene; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)					
IT	Glycosides					
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (alkyl; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)					
IT	Fats and Glyceridic oils, biological studies					
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (almond, ethoxylated; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)					
IT	Opioids					
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (analgesics; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)					
IT	Prostate gland					
	(benign hyperplasia; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)					
IT	Glycerides, biological studies					

- RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(corn, ethoxylated, Crovol M 40; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(essential; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Carbohydrates, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethers; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Castor oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethoxylated, Incrocas 35; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Corn oil
Fatty acids, biological studies
Glycerides, biological studies
Olive oil
Palm kernel oil
Peanut oil
Sterols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethoxylated; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Amino acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fatty acid derivs.; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Drugs
(gastrointestinal; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Drug delivery systems
(gels; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Castor oil
Palm kernel oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogenated, ethoxylated; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Lecithins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogenated; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Sexual behavior
(impotence; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Bladder
(incontinence; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Gout
(inhibitors; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Drug delivery systems
(lotions; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lower, fatty acids esters; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Lysophosphatides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lysophosphatidylglycerols; pharmaceutical compns. and methods for

- improved delivery of hydrophobic therapeutic agents)
- IT Drug delivery systems
(ointments, creams; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Drug delivery systems
(ointments; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligopeptides; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Drug delivery systems
(pastes; pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Analgesics
Anthelmintics
Anti-inflammatory agents
Antianginal agents
Antiarrhythmics
Antibacterial agents
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetic agents
Antihistamines
Antihypertensives
Antimalarials
Antimigraine agents
Antiobesity agents
Antiparkinsonian agents
Antipsychotics
Antitumor agents
Antiviral agents
Anxiolytics
Cognition enhancers
Diuretics
Fungicides
Hypnotics and Sedatives
Immunosuppressants
Inotropics
Muscarinic antagonists
Muscle relaxants
Nervous system stimulants
Nutrition, animal
Protozoacides
Thyroid gland
(pharmaceutical compns. and methods for improved delivery of hydrophobic therapeutic agents)
- IT Alcohols, biological studies
Amides, biological studies
Bile acids
Corticosteroids, biological studies
Diglycerides
Esters, biological studies
Fatty acids, biological studies
Glycerides, biological studies
Lecithins
Lysophosphatidic acids
Lysophosphatidylcholines
Lysophosphatidylethanolamines
Lysophosphatidylserines
Lysophospholipids
Monoglycerides

Peptides, biological studies
Phosphatidic acids
Phosphatidylcholines, biological studies
Phosphatidylethanolamines, biological studies
Phosphatidylglycerols
Phosphatidylserines
Phospholipids, biological studies
Polyoxyalkylenes, biological studies
Salts, biological studies
Sex hormones
Sterols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. and methods for improved delivery of
hydrophobic therapeutic agents)

IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyhydric; pharmaceutical compns. and methods for improved delivery
of hydrophobic therapeutic agents)

IT Ethers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyoxyethylene; pharmaceutical compns. and methods for improved
delivery of hydrophobic therapeutic agents)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(regulating agents; pharmaceutical compns. and methods for improved
delivery of hydrophobic therapeutic agents)

IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(salts; pharmaceutical compns. and methods for improved delivery of
hydrophobic therapeutic agents)

IT Drug delivery systems
(sprays; pharmaceutical compns. and methods for improved delivery of
hydrophobic therapeutic agents)

IT Carbohydrates, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sugar esters; pharmaceutical compns. and methods for improved delivery
of hydrophobic therapeutic agents)

IT Drug delivery systems
(suppositories; pharmaceutical compns. and methods for improved
delivery of hydrophobic therapeutic agents)

IT Osteoporosis
(therapeutic agents; pharmaceutical compns. and methods for improved
delivery of hydrophobic therapeutic agents)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vegetable, ethoxylated, hydrogenated; pharmaceutical compns. and
methods for improved delivery of hydrophobic therapeutic agents)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vegetable, hydrogenated; pharmaceutical compns. and methods for
improved delivery of hydrophobic therapeutic agents)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vegetable; pharmaceutical compns. and methods for improved delivery of
hydrophobic therapeutic agents)

IT Adrenoceptor antagonists
(.beta.-; pharmaceutical compns. and methods for improved delivery of
hydrophobic therapeutic agents)

IT 37220-82-9, Capmul GMO-K
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Arlacel 186; pharmaceutical compns. and methods for improved delivery
of hydrophobic therapeutic agents)

IT 50-14-6, Ergocalciferol 50-21-5D, Lactic acid, glycerides 50-24-8,

Prednisolone 50-28-2, EStradiol, biological studies 50-70-4, Sorbitol, biological studies 51-48-9, L-Thyroxine, biological studies 52-01-7, Spironolactone 55-98-1, Busulphan 56-81-5, 1,2,3-Propanetriol, biological studies 56-81-5D, Glycerol, polyethylene fatty acid esters 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 57-55-6, 1,2-Propanediol, biological studies 57-55-6D, Propylene glycol, ethers 57-83-0, Progesterone, biological studies 57-88-5, Cholesterol, biological studies 57-88-5D, Cholesterol, polyoxyethylene derivs. 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 64-17-5, Ethanol, biological studies 66-76-2, Dicoumarol 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-63-0, Isopropanol, biological studies 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 69-65-8, Mannitol 71-36-3, Butanol, biological studies 76-57-3, Codeine 76-99-3, Methadone 77-89-4, Acetyl triethylcitrate 77-90-7, Acetyl tributyl citrate 77-92-9D, Citric acid, diglycerides 77-93-0, Triethylcitrate 77-94-1, Tributylcitrate 81-24-3 81-25-4 83-44-3 87-33-2, Isosorbide dinitrate 87-69-4D, Tartaric acid, glycerides, biological studies 90-82-4, Pseudoephedrine 100-51-6, Benzenemethanol, biological studies 102-76-1, Triacetin 104-31-4, Benzonatate 105-37-3, Ethyl propionate 105-54-4, Ethyl butyrate 105-60-2, biological studies 105-60-2D, Caprolactam, N-Alkyl derivs. 106-32-1, Ethyl caprylate 107-21-1, 1,2-Ethanediol, biological studies 110-27-0, Isopropyl myristate 111-03-5, Glyceryl monooleate 111-62-6, Crodamol EO 111-90-0, Transcutol 112-80-1, 9-Octadecenoic acid (9Z)-, biological studies 113-15-5, Ergotamine 113-92-8, Chlorpheniramine 115-77-5, biological studies 115-83-3, Pentaerythrityl Tetra stearate 124-07-2, Octanoic acid, biological studies 125-84-8, Aminogluthethimide 126-07-8, Griseofulvin 127-19-5, Dimethylacetamide 128-13-2 141-22-0 142-18-7, Glyceryl monolaurate 142-62-1, Hexanoic acid, biological studies 142-91-6, Isopropyl palmitate 143-07-7, Dodecanoic acid, biological studies 151-41-7, Lauryl sulfate 155-97-5, Pyridostigmine 298-46-4, 5H-Dibenz[b,f]azepine-5-carboxamide 298-57-7, Cinnarizine 298-81-7, Methoxsalen 300-62-9, Amphetamine 302-79-4, Tretinoin 303-49-1, Clomipramine 321-64-2, Tacrine 334-48-5, Decanoic acid 359-83-1, Pentazocine 360-65-6 378-44-9, Betamethasone 404-86-4, Capsaicin 437-38-7, Fentanyl 443-48-1, Metronidazole 463-40-1 474-25-9 475-31-0 511-12-6, Dihydroergotamine 516-35-8 516-50-7 520-85-4, Medroxyprogesterone 542-28-9, .delta.-Valerolactone 544-35-4, Ethyl linoleate 544-63-8, Tetradecanoic acid, biological studies 577-11-7, Sodium docusate 595-33-5 616-45-5, Pyrrolidone 616-45-5D, Pyrrolidone, N-Alkyl derivs. 623-84-7, Propylene glycol diacetate 640-79-9 675-20-7, 2-Piperidone 872-50-4, N-Methylpyrrolidone, biological studies 1134-47-0, Baclofen 1331-12-0, Propylene glycol monoacetate 1335-71-3, Propylene glycol oleate 1338-39-2, Arlacel 20 1338-43-8, Span 80 1397-89-3, Amphotericin B 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1951-25-3, Amiodarone 1972-08-3, Tetrahydrocannabinol 2687-91-4, N-Ethylpyrrolidone 2687-94-7 2687-96-9 3068-88-0, .beta.-Butyrolactone 3445-11-2 4419-39-0, Beclomethasone 4759-48-2, Isotretinoin 5104-49-4, Flurbiprofen 5306-85-4, Dimethyl isosorbide 7261-97-4, Dantrolene 7488-99-5, .alpha. Carotene 7664-93-9D, Sulfuric acid, salts alkyl derivs., biological studies 7689-03-4, Camptothecin 8007-43-0, Sorbitan sesquioleate 9002-89-5, Polyvinylalcohol 9002-92-0, Brij 30 9002-96-4 9003-39-8, Polyvinylpyrrolidone 9004-65-3, Hydroxypropyl methylcellulose 9004-74-4, Methoxy polyethylene glycol 9004-81-3, Polyoxyethylene laurate 9004-95-9, Polyoxyethylene cetyl ether 9004-96-0, PEG-32 oleate 9004-98-2, Polyoxyethylene oleyl ether 9004-99-3, Polyoxyethylene stearate 9005-00-9, Polyoxyethylene stearyl ether 9005-02-1, Polyoxyethylene dilaurate 9005-07-6, Polyoxyethylene dioleate 9005-08-7, Polyoxyethylene distearate 9005-32-7D, Alginic acid, salts 9005-37-2, Propylene glycol alginate 9005-63-4D, Polyoxyethylene sorbitan, derivs. 9005-63-4D, Polyoxyethylene sorbitan,

fatty acid esters 9005-64-5, Tween 20 9005-65-6, Polysorbate 80
 9005-66-7, Tween 40 9005-67-8, Tween 60 9007-48-1, PLUROLLEIQUECC497
 9011-21-6, Polyoxyethylene glyceryl stearate 9016-45-9 9036-19-5
 10238-21-8, Glyburide 10540-29-1, Tamoxifen 11103-57-4, Vitamin A
 11140-04-8, Imwitor 988 12001-79-5, Vitamin K 12619-70-4, Cyclodextrin
 12619-70-4D, Cyclodextrin, derivs. 12619-70-4D, Cyclodextrin,
 hydroxypropyl ethers 13081-97-5, Pentaerythrityl di stearate
 14440-80-3, Stearoyl-2-lactylate 14605-22-2 15307-86-5, Diclofenac
 15574-96-6, Pizotifen 15686-51-8, Clemastine 15687-27-1, Ibuprofen
 18559-94-9, Albuterol 19356-17-3, Calcifediol 20594-83-6, Nalbuphine
 20830-75-5, Digoxin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine
 22882-95-7, Isopropyl linoleate 22916-47-8, Miconazole 23288-49-5,
 Probucol 25168-73-4, Sucrose monostearate 25265-75-2, Butanediol
 25322-68-3 25322-69-4, Polypropylene glycol 25339-99-5, Sucrose
 monolaurate 25523-97-1, Dexchlorpheniramine 25618-55-7D, Polyglycerol,
 fatty acid esters 25637-84-7, Glyceryl dioleate 25637-97-2, Sucrose
 dipalmitate 25812-30-0, Gemfibrozil 26266-57-9, Sorbitan monopalmitate
 26266-58-0, Sorbitan Trioleate 26402-22-2, Glyceryl monocaprate
 26402-26-6, Glyceryl monocaprylate 26446-38-8, Sucrose monopalmitate
 27154-43-4D, Piperidone, N-Alkyl derivs. 27195-16-0, Sucrose distearate
 27203-92-5, TRamadol 27638-00-2, Glyceryl dilaurate 29094-61-9,
 Glipizide 29767-20-2, Teniposide 31692-85-0, Glycofurol 32222-06-3,
 Calcitriol 33069-62-4, Paclitaxel 33419-42-0, Etoposide 34911-55-2,
 Bupropion 36354-80-0, Glyceryl dicaprylate 37321-62-3, Lauroglycol
 38304-91-5, Minoxidil 41340-25-4, Etodolac 42924-53-8, Nabumetone
 43200-80-2, Zopiclone 49562-28-9, Fenofibrate 49697-38-3, Rimexolone
 51333-22-3, Budesonide 51481-61-9, Cimetidine 51938-44-4, Sorbitan
 sesquistearate 52581-71-2, Volpo 3 53123-88-9, Sirolimus 53168-42-6,
 Myvacet 9-45 53179-11-6, Loperamide 53230-10-7, Mefloquine
 53988-07-1, Glyceryl dicaprate 54392-26-6, Sorbitan monoisostearate
 54965-21-8, Albendazole 55079-83-9, Acitretin 55142-85-3, Ticlopidine
 57107-97-8, Polyoxyethylene glyceryl oleate 59467-70-8, Midazolam
 59865-13-3, Cyclosporine 60142-96-3, Gabapentin 61379-65-5,
 Rifapentine 61869-08-7 62013-04-1, Dirithromycin 62356-64-3
 63590-64-7, Terazosin 63612-50-0, Nilutamide 63675-72-9, Nisoldipine
 65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole 68506-86-5,
 Vigabatrin

RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
 (pharmaceutical compns. and methods for improved delivery of
 hydrophobic therapeutic agents)

IT 68958-64-5, Polyoxyethylene glyceryl trioleate 69756-53-2, Halofantrine
 70288-86-7, Ivermectin 72432-03-2, Miglitol 72559-06-9, Rifabutine
 73590-58-6, Omeprazole 73963-72-1, Cilostazol 74103-06-3, Ketorolac
 74504-64-6, Polyglyceryl laurate 75706-12-6, Leflunomide 76547-98-3,
 Lisinopril 76824-35-6, Famotidine 76963-41-2, Nizatidine 79217-60-0,
 Cyclosporin 79617-96-2, Sertraline 79794-75-5, Loratadine
 79902-63-9, Simvastatin 81093-37-0, Pravastatin 81098-60-4, Cisapride
 81103-11-9, Clarithromycin 82626-48-0, Zolpidem 83799-24-0,
 Fexofenadine 83881-51-0, Cetirizine 83905-01-5, Azithromycin
 84057-84-1, Lamotrigine 84371-65-3, Mifepristone 84449-90-1,
 Raloxifene 84625-61-6, Itraconazole 85721-33-1, Ciprofloxacin
 86386-73-4, Fluconazole 86541-75-5, Benazepril 86637-84-5
 88150-42-9, Amlodipine 89778-26-7, Toremifene 90357-06-5, Bicalutamide
 91161-71-6, Terbinafine 93390-81-9, Fosphenytoin 93413-69-5,
 Venlafaxine 93479-97-1, Glimepiride 93790-70-6, Cholylsarcosine
 93790-72-8 93957-54-1, Fluvastatin 95233-18-4, Atovaquone
 97240-79-4, Topiramate 97322-87-7, Troglitazone 97682-44-5, Irinotecan
 98319-26-7, Finasteride 101828-21-1, Butenafine 103577-45-3,
 Lansoprazole 103628-46-2, Sumatriptan 104987-11-3, Tacrolimus
 106133-20-4, Tamsulosin 106392-12-5, Ethylene oxide propylene oxide
 block copolymer 106650-56-0, Sibutramine 107753-78-6, Zafirlukast
 111025-46-8, Pioglitazone 111406-87-2, Zileuton 112965-21-6,
 Calcipotriene 113665-84-2, Clopidogrel 115103-54-3, Tiagabine

117976-89-3, Rabeprazole 118292-40-3, Tazarotene 120014-06-4,
 Donepezil 121679-13-8, Naratriptan 122320-73-4, Rosiglitazone
 123948-87-8, Topotecan 127779-20-8, Saquinavir 129497-78-5,
 Verteporfin 131918-61-1, Paricalcitol 133040-01-4, Eprosartan
 134523-00-5, Atorvastatin 135062-02-1, Repaglinide 137862-53-4,
 Valsartan 138402-11-6 139264-17-8, Zolmitriptan 139481-59-7,
 Candesartan 144034-80-0, Rizatriptan 144494-65-5, Tirofiban
 144701-48-4, Telmisartan 145599-86-6, Cerivastatin 145941-26-0,
 Oprelvekin 147059-72-1, Trovafloxacin 150372-93-3, Polyoxyethylene
 glyceryl laurate 153559-49-0, Targretin 154598-52-4, Efavirenz
 155213-67-5, Ritonavir 156259-68-6, Capmul mcm 158747-02-5,
 Frovatriptan 158966-92-8, Montelukast 159989-64-7, Nelfinavir
 162011-90-7, Rofecoxib 169590-42-5, Celecoxib 171599-83-0, Sildenafil
 citrate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical compns. and methods for improved delivery of
 hydrophobic therapeutic agents)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE

- (1) Crooks; US 4572915 A 1986 HCAPLUS
- (2) Muller; US 4719239 A 1988 HCAPLUS
- (3) Schmidt; US 4727109 A 1988 HCAPLUS
- (4) Story; US 4944949 A 1990 HCAPLUS


IT 595-33-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical compns. and methods for improved delivery of
 hydrophobic therapeutic agents)

RN 595-33-5 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



L76 ANSWER 24 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:553397 HCAPLUS

DN 133:168375

TI Method of manufacture for transdermal **matrixes**

IN Audett, Jay D.; Detroyer, Georges D.

PA Ortho-McNeil Pharmaceutical, Inc., USA

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-70

CC 63-6 (Pharmaceuticals)

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

PI WO 2000045797 A1 20000810 WO 2000-US2491 20000201 <--
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
 DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, IL, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-241662 A 19990202 <--

AB Disclosed is a method of manuf. for the prodn. of transdermal drug delivery **matrixes** and devices, transdermal sampling devices, and dermal conditioning devices. A polymer and an active agent are mixed and heated in a multiple-lobed compounder to produce a polymer mixt. The polymer mixt. is extruded and then at least a portion of the extrudate is formed into, for example, the transdermal drug delivery **matrix**, or incorporated into the transdermal drug delivery device. These alternative methods for prepg. transdermal **matrixes** have several advantages over the current methods of manuf. The **matrix** components, particularly the active agent, are not exposed to extremes in solvent or temp. for extended periods of time during the manuf. process. The transdermal **matrixes** prepd. by these methods perform better in transdermal devices and show greater flux of active agent. As a result of the improved performance, less active agent may be utilized during the manufg. process, and smaller or thinner transdermal **matrixes** may be produced for incorporation into the corresponding transdermal device. An olanzapine transdermal **matrix** was prepd. using a twin screw extruder as follows; HMW polyisobutylene (Vistanex L80) was blended with LMW polyisobutylene, silica gel powder, and PVP. Sep.; olanzapine and lauryl lactate were processed and blended with the polymeric mixts. The resulting mixt. was extruded through a sheet die and coated between a release liner and backing material. A second layer of the same extrudate was coated between a second release liner and a polyester nonwoven porous supporting layer. The release liner from the first coating pass was removed and the exposed extrudate was laminated to the nonwoven side of the second coating pass, sandwiching the porous supporting layer between the two extrudates. The rolls of laminate were converted to transdermal devices of the desired size.

ST transdermal **matrix** pressure sensitive adhesive

IT Alcohols, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (aliph., C12-18; manuf. of transdermal **matrixes** using
 pressure-sensitive adhesives)

IT Deodorants (personal)
 (breath fresheners; manuf. of transdermal **matrixes** using
 pressure-sensitive adhesives)

IT Ion channel blockers
 (calcium; manuf. of transdermal **matrixes** using
 pressure-sensitive adhesives)

IT Pruritus
 (inhibitors; manuf. of transdermal **matrixes** using
 pressure-sensitive adhesives)

IT Adrenoceptor agonists
 Adrenoceptor antagonists
 Allergy inhibitors
 Analgesics
 Anesthetics
 Anthelmintics
 Anti-inflammatory agents
 Antianginal agents
 Antiarrhythmics
 Antiarthritics
 Antiasthmatics

Antibiotics
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetic agents
Antidiarrheals
Antiemetics
Antihistamines
Antihypertensives
Antimalarials
Antimigraine agents
Antioxidants

Antiparkinsonian agents

Antipsychotics
Antipyretics
Antirheumatic agents
Antitumor agents
Antitussives
Antiviral agents
Anxiolytics
Appetite depressants
Cardiotonics
Cholinergic agonists
Cholinergic antagonists
Contraceptives
Decongestants
Diuretics
Fungicides
Hypnotics and Sedatives
Immunostimulants
Immunosuppressants
Muscle relaxants
Psychostimulants
Tranquilizers
Vaccines
Vasodilators
(manuf. of transdermal **matrixes** using pressure-sensitive adhesives)

- IT Estrogens
Growth promoters, animal
Hormones, animal, biological studies
Isobutylene rubber
Progestogens
Steroids, biological studies
Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(manuf. of transdermal **matrixes** using pressure-sensitive adhesives)
- IT Chronotropics
(neg.; manuf. of transdermal **matrixes** using pressure-sensitive adhesives)
- IT Essential oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peppermint; manuf. of transdermal **matrixes** using pressure-sensitive adhesives)
- IT Adhesives
(pressure-sensitive; manuf. of transdermal **matrixes** using pressure-sensitive adhesives)
- IT Muscle relaxants
(spasmolytics; manuf. of transdermal **matrixes** using pressure-sensitive adhesives)
- IT Essential oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(spearmint; manuf. of transdermal **matrixes** using pressure-sensitive adhesives)

IT Drug delivery systems
(transdermal; manuf. of transdermal **matrixes** using pressure-sensitive adhesives)

IT Essential oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(wintergreen; manuf. of transdermal **matrixes** using pressure-sensitive adhesives)

IT 9015-82-1
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; manuf. of transdermal **matrixes** using pressure-sensitive adhesives)

IT 9003-27-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(isobutylene rubber, manuf. of transdermal **matrixes** using pressure-sensitive adhesives)

IT 50-28-2, 17.beta.-Estradiol, biological studies 51-98-9, **Norethindrone** acetate 52-28-8, Codeine phosphate 53-16-7, Estrone, biological studies 57-63-6, Ethinyl estradiol 57-83-0, Progesterone, biological studies 57-91-0, 17.alpha.-Estradiol 58-22-0, Testosterone **68-22-4**, **Norethindrone** 72-33-3, Mestranol 89-78-1, Menthol 94-09-7, Benzocaine 94-14-4, Isobutamben 94-24-6, Tetracaine 111-46-6, Diethylene glycol, biological studies 125-69-9, Dextromethorphan hydrobromide 128-62-1, Noscapine 137-58-6, Lidocaine 152-43-2, Quinestrol 434-22-0, 19-Nortestosterone 474-86-2, Equilin 547-64-8, Methyl lactate 586-60-7, Dyclonine 797-63-7, Levonorgestrel 1155-03-9, Zolamine hydrochloride 1622-61-3, Clonazepam 6283-92-7, Lauryl lactate 6533-00-2, Norgestrel 9003-27-4, Polyisobutylene 9003-39-8, Kollidon 9004-64-2, Hydroxypropyl cellulose 27194-74-7, Propylene glycol monolaurate 35189-28-7, Norgestimate 53016-31-2, 17-Deacetylnorgestimate 54024-22-5, Desogestrel 72509-76-3, Felodipine 106133-20-4, Tamsulosin 132539-06-1, Olanzapine
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(manuf. of transdermal **matrixes** using pressure-sensitive adhesives)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


(1) Cygnus Inc; WO 9837872 A 1998 HCAPLUS
(2) Johnson & Johnson Consumer Products Inc; EP 0598606 A 1994 HCAPLUS
(3) Johnson & Johnson Product's Inc; EP 0250187 A 1987 HCAPLUS
(4) Schwarz Pharma Ag; DE 19728517 A 1999 HCAPLUS

IT **68-22-4, Norethindrone**
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(manuf. of transdermal **matrixes** using pressure-sensitive adhesives)

RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 25 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:240977 HCAPLUS
 DN 132:250028
 TI Methods for the treatment of cancer using cytokines in combination with
 low level doses of chemotherapy and/or radiotherapy
 IN Papermaster, Ben W.
 PA Kinex Medical, Inc., USA
 SO PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K038-19
 ICS A61K041-00
 CC 15-5 (Immunochemistry)
 Section cross-reference(s): 1, 8, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000020022	A1	20000413	WO 1999-US23723	19991007 <--
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9965142	A1	20000426	AU 1999-65142	19991007 <--
PRAI	US 1998-168786	A	19981008 <--		
	WO 1999-US23723	W	19991007 <--		
AB	Apoptosis, the main mechanism of programmed cell death, is a gene directed process responsible for the elimination of excessive cells during development and detrimental cell types in pathophysiol. situations. The invention provides a method for exploiting the mol. mechanisms which regulate the pathways leading to programmed cell death, and tumor regression without significant side-effects to the patient. Both low dose chemotherapy and radiotherapy induce DNA fragmentation, but not necessarily cell death, thereby positioning tumor cells to self-destruct by apoptosis. By infusing low doses of cytokines to patients undergoing chemotherapy and/or radiotherapy, tumor cells contg. damaged DNA are induced into apoptosis resulting in tumor regression without significant side-effects to the patient.				
ST	cytokine chemotherapy radiotherapy cancer apoptosis				
IT	Lung, neoplasm				
	Lung, neoplasm				
	(adenocarcinoma, inhibitors; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)				
IT	Antitumor agents				

(central **nervous system**; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT **Nervous system**

Nervous system

(central, neoplasm, inhibitors; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Intestine, neoplasm

Intestine, neoplasm

(colon, inhibitors; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Antitumor agents

(colon; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Intestine, neoplasm

(colorectal, metastasis, inhibitors; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Antitumor agents

Apoptosis

Atomic nuclei

Chemotherapy

Elementary particles

Gamma ray

Ionizing radiation

Radiotherapy

X-ray

(cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT. Lymphotoxin

Steroids, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Photon

(electromagnetic photon-generating source; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Linear energy transfer

(high linear energy transfer source; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Hormones, animal, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(hormonal drugs; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Drug delivery systems

(implants, radioactive seed implantation; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Kidney, neoplasm

Kidney, neoplasm

Ovary, neoplasm

Ovary, neoplasm

(inhibitors; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Electron beams

(irradn.; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Antitumor agents

Antitumor agents

(kidney; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Antitumor agents
(large intestine, metastasis; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Antitumor agents
(leukemia; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Antitumor agents
(lung adenocarcinoma; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Antitumor agents
(lung non-small-cell carcinoma; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Antitumor agents
(lung squamous cell carcinoma; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Antitumor agents
(lymphoma, large clear cell lymphoma; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Antitumor agents
(mammary gland; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Antitumor agents
(melanoma; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Mammary gland
Mammary gland
Prostate gland
Prostate gland
(neoplasm, inhibitors; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Lung, neoplasm
Lung, neoplasm
(non-small-cell carcinoma, inhibitors; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Antitumor agents
Antitumor agents
(ovary; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Antitumor agents
(prostate gland; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Radionuclides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(radioactive seed implantation; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(radiolabeled; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT Lung, neoplasm
Lung, neoplasm
(squamous cell carcinoma, inhibitors; cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT 50-18-0, Cyclophosphamide 50-44-2, Mercaptopurine 50-76-0, Actinomycin D 51-21-8, 5-Fluorouracil 52-24-4, Thiotepa 55-98-1, Busulphan 57-22-7, Vincristine 71-58-9, Medroxyprogesterone acetate 127-07-1, Hydroxyurea 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine 299-75-2, Treosulfan 427-51-0

566-48-3, Formestane **595-33-5, Megestrol**

acetate 671-16-9, Procarbazine 865-21-4, Vinblastine
1404-00-8, Mitomycin 3778-73-2, Ifosfamide 4342-03-4, Dacarbazine
9015-68-3, Asparaginase 10540-29-1, Tamoxifen 11056-06-7, Bleomycin
13010-47-4, Lomustine 13311-84-7, Flutamide 15663-27-1, Cisplatin
18883-66-4, Streptozocin 21679-14-1, Fludarabine 33069-62-4, Taxol
41575-94-4, Carboplatin 53643-48-4, Vindesine 53714-56-0, Leuporelin
56420-45-2, Epirubicin 57773-63-4, Triptorelin 57982-77-1, Buserelin
58957-92-9, Idarubicin 65271-80-9, Mitozantrone 65807-02-5, Goserelin
71486-22-1, Vinorelbine 89778-26-7, Toremifene 90357-06-5,
Bicalutamide 95058-81-4, Gemcitabine 97682-44-5, Irinotecan
112809-51-5, Letrozole 112887-68-0, Tomudex 120511-73-1, Arimidex
123948-87-8, Topotecan

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

IT 50-18-0, Cyclophosphamide 50-44-2, Mercaptopurine 50-76-0, Actinomycin D 51-21-8, 5-Fluorouracil 52-24-4, Thiotepe 55-98-1, Busulphan 57-22-7, Vincristine 71-58-9, Medroxyprogesterone acetate 127-07-1, Hydroxyurea 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine 299-75-2, Treosulfan 427-51-0
566-48-3, Formestane **595-33-5, Megestrol**

acetate 671-16-9, Procarbazine 865-21-4, Vinblastine
1404-00-8, Mitomycin 3778-73-2, Ifosfamide 4342-03-4, Dacarbazine
9015-68-3, Asparaginase 10540-29-1, Tamoxifen 11056-06-7, Bleomycin
13010-47-4, Lomustine 13311-84-7, Flutamide 15663-27-1, Cisplatin
18883-66-4, Streptozocin 21679-14-1, Fludarabine 33069-62-4, Taxol
41575-94-4, Carboplatin 53643-48-4, Vindesine 53714-56-0, Leuporelin
56420-45-2, Epirubicin 57773-63-4, Triptorelin 57982-77-1, Buserelin
58957-92-9, Idarubicin 65271-80-9, Mitozantrone 65807-02-5, Goserelin
71486-22-1, Vinorelbine 89778-26-7, Toremifene 90357-06-5,
Bicalutamide 95058-81-4, Gemcitabine 97682-44-5, Irinotecan
112809-51-5, Letrozole 112887-68-0, Tomudex 120511-73-1, Arimidex
123948-87-8, Topotecan

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Aggarwal; US 4920196 A 1990 HCAPLUS
- (2) Gray; Nature 1984, V312, P721 MEDLINE
- (3) Seow; Biotechnology 1989, V7, P363 HCAPLUS

IT **595-33-5, Megestrol acetate**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(cytokines in combination with low level doses of chemotherapy and/or radiotherapy for cancer treatment)

RN 595-33-5 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 26 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:736476 HCAPLUS
 DN 131:346535
 TI Use of neomycin for treating angiogenesis-related diseases
 IN Hu, Guo-Fu; Vallee, Bert L.
 PA The Endowment for Research In Human Biology, Inc., USA
 SO PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-37
 CC 1-8 (Pharmacology)
 Section cross-reference(s): 2, 15, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958126	A1	19991118	WO 1999-US10269	19990511 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2331620	AA	19991118	CA 1999-2331620	19990511 <--
AU 9939804	A1	19991129	AU 1999-39804	19990511 <--
EP 1083896	A1	20010321	EP 1999-922915	19990511 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6482802	B1	20021119	US 2000-700436	20001109 <--
PRAI US 1998-84921P	P	19980511 <--		
WO 1999-US10269	W	19990511 <--		
AB The present invention is directed to using neomycin or an analog thereof as a therapeutic agent to treat angiogenesis-related diseases, which are characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells. The present invention is also directed to pharmaceutical compns. comprising: (a) neomycin or an analog and, optionally, (b) another anti-angiogenic agent or an anti-neoplastic agent. The present invention is further directed to a method for screening neomycin analogs having anti-angiogenic activity. A preferred embodiment of the invention relates to using neomycin to treat subjects having such diseases. A dose of 20 ng neomycin/embryo or higher completely inhibited angiogenin-induced angiogenesis in the chorioallantoic membrane (CAM) assay. Neomycin inhibits				

angiogenin-induced angiogenesis mainly through inhibition of nuclear translocation of angiogenin.

ST neomycin analog angiogenesis inhibition antitumor

IT Eye, disease

(Best's disease; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Intestine, disease

(Crohn's; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Eye, disease

(Eales' disease; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents

(Ewing's sarcoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents

(Kaposi's sarcoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Bone, disease

(Paget's; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Lymphoproliferative disorders

(Waldenstrom's macroglobulinemia; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Sarcoidosis

(Wegener's; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents

(Wilms' tumor; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Kidney, neoplasm

(Wilms', inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT **Nerve, neoplasm**

(acoustic neuroma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents

(acoustic neuroma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents

(acute lymphocytic leukemia; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents

(adenocarcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antibiotics

(aminoglycoside; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Artery, disease

(arteritis; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Astrocyte

(astrocytoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents

(astrocytoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Ulcer

(bacterial and fungal; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Skin, neoplasm

(basal cell carcinoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

- IT Antitumor agents
(basal cell carcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Antitumor agents
(bile duct carcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Biliary tract
(bile duct, carcinoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Antitumor agents
(bladder carcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Antitumor agents
(bronchi carcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Bladder
Bladder
Bronchi
Sebaceous gland
Sebaceous gland
(carcinoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Lung, neoplasm
(carcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Artery, disease
(carotid, occlusion; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Uterus, neoplasm
(cervix, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Antitumor agents
(cervix; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Burn
(chem.; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Cartilage
(chondrosarcoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Antitumor agents
(chondrosarcoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Notochord
(chordoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Antitumor agents
(chordoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Chorion
(choriocarcinoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Antitumor agents
(choriocarcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Antitumor agents
(colon carcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Intestine, neoplasm
(colon, carcinoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Drug delivery systems
(compns. of neomycin and analogs for treatment of angiogenesis-related diseases)

diseases)

IT Eye, disease
(contact lens overwear; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Transplant rejection
(corneal; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Pituitary gland, anterior lobe
(craniopharyngioma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(craniopharyngioma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Ovary, neoplasm
(cystadenocarcinoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(cystadenocarcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Eye, disease
(diabetic retinopathy; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(embryonal carcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Blood vessel
(endothelium; neomycin and analogs as inhibitors of angiogenesis in endothelium and chorioallantoic membrane)

IT Brain, neoplasm
(ependymoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(ependymoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(epithelial carcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(fibrosarcoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Neuroglia
(glioma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(glioma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Immunoglobulins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(heavy chain disease inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(hemangioblastoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Blood vessel, neoplasm
(hemangioma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(hemangioma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Blood vessel, neoplasm
(hemangiosarcoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents

(hemangiosarcoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Liver, neoplasm
(hepatoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(hepatoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Capillary vessel
(hereditary hemorrhagic telangiectasia; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Human herpesvirus 3
(herpes zoster from, infections; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Human herpesvirus
Mycobacterium
(infections; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Ovary, neoplasm
Pancreas, neoplasm
Testis, neoplasm
(inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Biological transport
(intracellular; neomycin and analogs are inhibitors of nuclear translocation of angiogenic factors for treatment of angiogenesis-related diseases)

IT Eye, disease
(keratitis; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Eye, disease
(keratoconjunctivitis, epidemic; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(leiomyosarcoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(leukemia, acute myelocytic; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(leukemia, chronic; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lipid degeneration inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Adipose tissue, neoplasm
(liposarcoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(liposarcoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(lymphangioendotheliosarcoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Lymphatic system
(lymphangiosarcoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(lymphangiosarcoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(lymphoma; neomycin, its analogs and other agents for treatment of

- angiogenesis-related diseases)
- IT Eye, disease
(macula, degeneration, Stargardt's disease; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Eye, disease
(macula, degeneration; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Brain, neoplasm
Brain, neoplasm
(medulloblastoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Antitumor agents
(medulloblastoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Antitumor agents
(melanoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Meninges
Meninges
(meningioma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Antitumor agents
(meningioma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Mesothelium
(mesothelioma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Erythema
(multiforme; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Antitumor agents
(multiple myeloma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Antitumor agents
(myxosarcoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Angiogenic factors
Hepatocyte growth factor
Interleukin 8
Platelet-derived growth factors
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(neomycin and analogs are inhibitors of nuclear translocation of angiogenic factors for treatment of angiogenesis-related diseases)
- IT Chorioallantois
(neomycin and analogs as inhibitors of angiogenesis in endothelium and chorioallantoic membrane)
- IT Angiogenesis inhibitors
Anti-AIDS agents
Antibacterial agents
Antirheumatic agents
Antitumor agents
Antiulcer agents
Antiviral agents
Behcet's syndrome
Cytotoxic agents
Fungicides

Lyme disease
 Polycythemia vera
 Protein sequences
 Protozoacides
 Psoriasis
 Sarcoidosis
 Sick cell anemia
 Sjogren's syndrome
 Syphilis
 (neomycin, its analogs and other agents for treatment of
 angiogenesis-related diseases)
 IT Anthracyclines
 Interleukin 12
 Interleukin 2
 Peptides, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (neomycin, its analogs and other agents for treatment of
 angiogenesis-related diseases)
 IT Notochord
 (neoplasm, chordoma, inhibitors; neomycin, its analogs and other agents
 for treatment of angiogenesis-related diseases)
 IT Mammary gland
 Prostate gland
 Sweat gland
 Sweat gland
 (neoplasm, inhibitors; neomycin, its analogs and other agents for
 treatment of angiogenesis-related diseases)
 IT Glaucoma (disease)
 (neovascular; neomycin, its analogs and other agents for treatment of
 angiogenesis-related diseases)
 IT **Nerve, neoplasm**
Nerve, neoplasm
 (neuroblastoma, inhibitors; neomycin, its analogs and other
 agents for treatment of angiogenesis-related diseases)
 IT Antitumor agents
 (neuroblastoma; neomycin, its analogs and other agents for treatment of
 angiogenesis-related diseases)
 IT Schwann cell
 (neurofibroma, inhibitors; neomycin, its analogs and other agents for
 treatment of angiogenesis-related diseases)
 IT Antitumor agents
 (neurofibroma; neomycin, its analogs and other agents for treatment of
 angiogenesis-related diseases)
 IT Artery, disease
 Vein
 (occlusion; neomycin, its analogs and other agents for treatment of
 angiogenesis-related diseases)
 IT Neuroglia
 (oligodendroglioma, inhibitors; neomycin, its analogs and other agents
 for treatment of angiogenesis-related diseases)
 IT Antitumor agents
 (oligodendroglioma; neomycin, its analogs and other agents for
 treatment of angiogenesis-related diseases)
 IT Antitumor agents
 (osteogenic sarcoma; neomycin, its analogs and other agents for
 treatment of angiogenesis-related diseases)
 IT Antitumor agents
 (ovary; neomycin, its analogs and other agents for treatment of
 angiogenesis-related diseases)
 IT Antitumor agents
 (pancreas; neomycin, its analogs and other agents for treatment of

angiogenesis-related diseases)

IT Antitumor agents
(papillary adenocarcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(papillary carcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Eye, disease
(pars planitis; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Eye, disease
(periretinal proliferation; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(pinealoma inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Pineal gland
(pinealoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Placental hormones
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(placenta-derived mitogenic factors; neomycin and analogs are inhibitors of nuclear translocation of angiogenic factors for treatment of angiogenesis-related diseases)

IT Eye, disease
(presumed ocular histoplasmosis; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Proliferation inhibition
(proliferation inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Skin, neoplasm
(pseudoxanthoma elasticum; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(pyogenic granuloma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Kidney, neoplasm
(renal cell carcinoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(renal cell carcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Eye, disease
(retinitis; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Eye, neoplasm
(retinoblastoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(retinoblastoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Eye, disease
(retinopathy, detachment, chronic; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Eye, disease
(retrolental fibroplasia; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(rhabdomyosarcoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Skin, disease
(rosacea; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Eye, disease
(scleritis; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Drug screening
(screening of neomycin and analogs for treatment of angiogenesis-related diseases)

IT Antitumor agents
(sebaceous gland carcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Testis, neoplasm
(seminoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(seminoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Lung, neoplasm
(small-cell carcinoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(squamous cell carcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(sweat gland; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(synovial membrane tumor inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Lupus erythematosus
(systemic; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(testis; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Toxoplasma gondii
(toxoplasmosis from; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(trachoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Injury
(trauma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Synovial membrane
(tumors, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Intestine, disease
(ulcerative colitis; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Eye, disease
(uveitis, chronic; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.-; neomycin and analogs are inhibitors of nuclear translocation of angiogenic factors for treatment of angiogenesis-related diseases)

IT Interferons
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (.beta.-; neomycin and analogs are inhibitors of nuclear translocation of angiogenic factors for treatment of angiogenesis-related diseases)
- IT Interferons
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta.; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT Interferons
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.gamma.; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT 11103-57-4, Vitamin A
RL: BSU (Biological study, unclassified); BIOL (Biological study) (deficiency; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
- IT 9001-86-9, Phospholipase C
RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; neomycin and analogs as inhibitors of phospholipase C for treatment of angiogenesis-related diseases)
- IT 61912-98-9, Insulin-like growth factor 62229-50-9, Epidermal growth factor 65154-06-5, Platelet activating factor 97950-81-7, Angiogenin (human) 106096-92-8, Acidic fibroblast growth factor 106096-93-9, Basic fibroblast growth factor 127464-60-2, Vascular endothelial growth factor 143011-72-7, Granulocyte colony-stimulating factor
RL: BSU (Biological study, unclassified); BIOL (Biological study) (neomycin and analogs are inhibitors of nuclear translocation of angiogenic factors for treatment of angiogenesis-related diseases)
- IT 66-86-4, Neomycin C 119-04-0, Neomycin B 1404-04-2, Neomycin 2037-48-1, 2-Deoxystreptamine 3947-65-7, Neomycin A 7542-37-2, Paromomycin 11111-23-2, Lividomycin 25546-65-0, Ribostamycin 34051-04-2, Nebramine 35025-95-7, Gentamine Cla 50474-67-4, Xylostasin 51053-37-3, Gentamine C1 51053-38-4, Gentamine C2 84420-34-8, Paromomycin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neomycin and analogs for treatment of angiogenesis-related diseases)
- IT 50-18-0, Cyclophosphamide 50-35-1, Thalidomide 50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-18-3, Triethylenemelamine 51-21-8, Fluorouracil 51-75-2, Mechlorethamine 51-79-6, Urethane 52-24-4, Triethylenethiophosphoramidate 52-67-5, D-Penicillamine 53-19-0, Mitotane 53-79-2, Puromycin 54-25-1, 6-Azaauridine 54-91-1, Pipobroman 55-98-1, Busulfan 57-22-7, Vincristine 58-05-9, Folinic acid 58-19-5, Dromostanolone 59-05-2, Methotrexate 66-75-1, Uracil mustard 68-76-8, Triaziquone 69-33-0, Tubercidin 84-16-2, Hexestrol 89-38-3, Pteropterin 115-02-6, Azaserine 125-84-8, Aminogluthethimide 127-07-1, Hydroxyurea 147-94-4, Cytarabine 148-82-3, Melphalan 151-56-4D, Aziridine, derivs., biological studies 154-42-7, Thioguanine 154-93-8, Carmustine 157-03-9, 6-Diazo-5-oxo-L-norleucine 302-22-7, Chlormadinone acetate 302-49-8, Uredopa 302-70-5, Mechlorethamine oxide hydrochloride 305-03-3, Chlorambucil 320-67-2, Azacitidine 362-07-2, 2-Methoxyestradiol 459-86-9, Mitoguanzone 477-30-5, Demecolcine 488-41-5, Mitobronitol 494-03-1, Chlornaphazine 520-85-4, Medroxyprogesterone 522-40-7, Fosfestrol 545-55-1, Triethylenephosphoramidate 555-77-1, 2,2',2''-Trichlorotriethylamine 566-48-3, Formestane 576-68-1, Mannomustine 595-33-5, **Megestrol acetate** 642-83-1, Aceglatone 645-05-6, Altretamine 801-52-5, Porfiromycin 865-21-4, Vinblastine 968-93-4, Testolactone 1402-44-4, Actinomycin F1 1404-00-8, Mitomycin

1404-15-5, Nogalamycin 1508-45-8, Podophyllinic acid 2-ethyl hydrazide
 1661-29-6, Meturedopa 1936-40-9, Novembichin 1954-28-5, Etoglucid
 1980-45-6, Benzodepa 2363-58-8, Epitiostanol 2608-24-4, Puposulfan
 2998-57-4, Estramustine 3094-09-5, Doxifluridine 3546-10-9,
 Phenesterine 3733-81-1, Defosfamide 3778-73-2, Ifosfamide 3819-34-9,
 Phenamet 3930-19-6, Streptonigrin 4291-63-8, Cladribine 4342-03-4,
 Dacarbazine 4533-39-5, Nitracrine 4803-27-4, Anthramycin 5581-52-2,
 Thiamiprine 5633-18-1, Mèlengestrol 8052-16-2, Cactinomycin
 9014-02-2, Zinostatin 9015-68-3, L-Asparaginase 9042-14-2, Dextran
 sulfate 10318-26-0, Mitolactol 10540-29-1, Tamoxifen 11006-70-5,
 Olivomycin 11056-06-7, Bleomycin 13010-47-4, Lomustine 13311-84-7,
 Flutamide 13425-98-4, Improsulfan 13494-90-1, Gallium nitrate
 13647-35-3, Trilostane 13665-88-8, Mopidamol 15663-27-1, Cisplatin
 17021-26-0, Calusterone 17902-23-7, Tegafur 18378-89-7, Plicamycin
 18883-66-4, Streptozocin 20830-81-3, Daunorubicin 21362-69-6,
 Mepitiostane 21416-67-1, Razoxane 21679-14-1, Fludarabine
 22006-84-4, Denopterine 22089-22-1, Trofosfamide 23110-15-8, Fumagillin
 23214-92-8, Doxorubicin 24279-91-2, Carboquone 24280-93-1,
 Mycophenolic acid 28014-46-2, Polyestradiol phosphate 29069-24-7,
 Prednimustine 29767-20-2, Teniposide 31698-14-3, Ancitabine
 33069-62-4, Paclitaxel 33419-42-0, Etoposide 37270-94-3, Platelet
 factor 4 37339-90-5, Lentinan 41575-94-4, Carboplatin 41992-23-8,
 Spirogermanium 42471-28-3, Nimustine 50264-69-2, Lonidamine
 50935-04-1, Carubicin 51264-14-3, Amsacrine 52128-35-5, Trimetrexate
 53123-88-9, Rapamycin 53643-48-4, Vindesine 53714-56-0, Leuprolide
 53910-25-1, Pentostatin 54083-22-6, Zorubicin 54749-90-5,
 Chlorozotocin 55726-47-1, Enocitabine 56420-45-2, Epirubicin
 57773-63-4, Triptorelin 57982-77-1, Buserelin 57998-68-2, Diaziquone
 58066-85-6, Miltefosine 58337-35-2, Elliptinium acetate 58957-92-9,
 Idarubicin 58970-76-6, Ubenimex 58994-96-0, Ranimustine 61163-28-8,
 .beta.-1,3-Glucan sulfate 61422-45-5, Carmofur 61825-94-3, Oxaliplatin
 62435-42-1, Perfosfamide 63612-50-0, Nilutamide 64431-69-2,
 Aclacinomycin S 65271-80-9, Mitoxanthrone 65646-68-6, Fenretinide
 65807-02-5, Goserelin 68247-85-8, Peplomycin 70052-12-9, Eflornithine
 70563-58-5, Herbimycin A 71628-96-1, Menogaril 72496-41-4, Pirarubicin
 72732-56-0, Piritrexim 74913-06-7, Chromomycin 78186-34-2, Bisantrone
 80576-83-6, Edatrexate 82413-20-5, Droloxifene 84088-42-6, Roquinimex
 85622-93-1, Temozolomide 86090-08-6, Angiostatin 87806-31-3, Porfimer
 sodium 89149-10-0, 15-Deoxyspergualin 89778-26-7, Toremifene
 90357-06-5, Bicalutamide 92118-27-9, Fotemustine 95058-81-4,
 Gemcitabine 98631-95-9, Sobuzoxane 99519-84-3, CAI 100286-90-6
 102676-47-1, Fadrozole 103775-75-3, Miboplatin 106486-76-4,
 Carzinophilin 110690-43-2, Emitefur 112809-51-5, Letrozole
 112887-68-0, Tomudex 114977-28-5, Docetaxel 120511-73-1, Anastrozole
 123948-87-8, Topotecan 126509-46-4, Eponemycin 126595-07-1,
 Propagermanium 129298-91-5, AGM 1470 130370-60-4, Batimastat
 142298-75-7, Ribonuclease inhibitor 154039-60-8, Marimastat
 187888-07-9, Endostatin 188417-67-6, CM 101 196858-78-3 197850-48-9
 197850-49-0 250331-65-8 250593-25-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Waksman; US 2799620 A 1957 HCAPLUS


IT **595-33-5, Megestrol acetate**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

RN 595-33-5 HCAPLUS
 CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 27 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:660902 HCAPLUS
 DN 132:164339
 TI Weight loss in cancer and **Alzheimer's** disease is mediated by a similar pathway
 AU Knittweis, J.
 CS Research Solutions, Philadelphia, PA, 19149, USA
 SO Medical Hypotheses (1999), 53(2), 172-174
 CODEN: MEHYDY; ISSN: 0306-9877
 PB Churchill Livingstone
 DT Journal
 LA English
 CC 14-1 (Mammalian Pathological Biochemistry)
 AB Wt. loss, despite adequate caloric intake, occurs in **Alzheimer's** disease and cancer. Similar alterations of biochem. accompany the wt. loss in both diseases, and this suggests a common pathway of wt. loss. If this hypothesis is correct, then drugs that prevent wt. loss in cancer should also prevent wt. loss in **Alzheimer's** disease. **Megestrol acetate** prevents wt. loss in human and animal cancers. Omega 3 fatty acids prevent wt. loss in animal models of cancer. Both compds. might prevent wt. loss in **Alzheimer** patients.
 ST wt loss cancer **Alzheimer** disease megestrol omega3 fatty acid
 IT Brain
 (Alzheimer's; wt. loss in human cancer and **Alzheimer**'s disease is mediated by a similar pathway in relation to omega 3 fatty acids decrease in)
 IT Erythrocyte
 Erythrocyte
 (cell membrane; wt. loss in human cancer and **Alzheimer's** disease is mediated by a similar pathway in relation to omega 3 fatty acids decrease in)
 IT Cell membrane
 Cell membrane
 (erythrocyte; wt. loss in human cancer and **Alzheimer's** disease is mediated by a similar pathway in relation to omega 3 fatty acids decrease in)
 IT Body weight
 (loss; wt. loss in human cancer and **Alzheimer's** disease is mediated by a similar pathway)
 IT Fatty acids, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(polyunsatd., omega-3; wt. loss in human cancer and **Alzheimer**'s disease is mediated by a similar pathway response to)

IT **Alzheimer's disease**

Neoplasm

(wt. loss in human cancer and **Alzheimer**'s disease is mediated by a similar pathway)

IT Interleukin 6

RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)

(wt. loss in human cancer and **Alzheimer**'s disease is mediated by a similar pathway in relation to response of)

IT **595-33-5, Megestrol acetate** 137173-92-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(wt. loss in human cancer and **Alzheimer**'s disease is mediated by a similar pathway response to)


RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Bartlett, D; Surgery 1995, V118, P87 MEDLINE
- (2) Branconnier, R; Am J Psychiatry 1986, V143, P1313 MEDLINE
- (3) Burt, M; Ann Surg 1983, V6, P685
- (4) Chance, W; Life Sci 1988, V43, P67 HCAPLUS
- (5) Chance, W; Physiol Behav 1991, V50, P397 MEDLINE
- (6) Chastain, C; Am J Vet Res 1981, V42, P2029 HCAPLUS
- (7) Craft, S; Behav Neurosci 1993, V6, P926
- (8) Craft, S; Neurobiol Aging 1996, V17, P123 MEDLINE
- (9) Dagnelie, P; Lipids 1994, V29, P195 HCAPLUS
- (10) Du, W; J Geriatr Psychiatry Neurol 1993, V6, P34 MEDLINE
- (11) Espot, N; J Surg Oncol 1995, V57, P77
- (12) Evans, D; Am J Epidemiol 1991, V134, P403 MEDLINE
- (13) Fisman, M; Am J Psychiatry 1985, V142, P71 MEDLINE
- (14) Fujita, J; Int J Cancer 1996, V68, P637 HCAPLUS
- (15) Hoyer, S; J Neural Transm 1989, V75, P227 MEDLINE
- (16) Huell, M; Acta Neuropathol 1995, V89, P544 MEDLINE
- (17) Huell, M; Neurobiol Aging 1996, V17, P795 HCAPLUS
- (18) Inculet, R; J Natl Cancer Inst 1987, V79, P1039 HCAPLUS
- (19) Lawlor, B; Am J Psychiatry 1992, V149, P546 MEDLINE
- (20) Leinung, M; Ann Intern Med 1995, V122, P843 MEDLINE
- (21) Lying-Tunell, U; Acta Neurol Scand 1981, V63, P337 MEDLINE
- (22) Maltoni, M; Cancer 1995, V75, P2613 MEDLINE
- (23) Masugi, F; Methods Find Exp Clin Pharmacol 1989, V11, P707 MEDLINE
- (24) Miyanga, K; Neurobiol Aging 1996, V17, PS73
- (25) Ohaska, A; Jpn J Med Sci Biol 1979, V32, P305
- (26) Plante, M; Cancer 1994, V73, P1882 MEDLINE
- (27) Sauer, L; Cancer Res 1986, V46, P689 HCAPLUS
- (28) Scott, H; Br J Cancer 1996, V73, P1560 MEDLINE
- (29) Singh, S; Age Aging 1988, V17, P21 MEDLINE
- (30) Skinner, E; Biochem Soc Trans 1988, V17, P213
- (31) Strassman, G; J Clin Invest 1992, V39, P1681
- (32) Tavares, A; Weight loss in Alzheimer's disease: a longitudinal study 1987, V42, P165 MEDLINE
- (33) Tisdale, M; Anticancer Drugs 1993, V4, P115 HCAPLUS
- (34) Tisdale, M; Cancer Res 1990, V50, P5022 HCAPLUS
- (35) Tisdale, M; Nutrition 1996, V12(Suppl), PS31
- (36) Uspenskaia, L; Res Int Medical Radiology 1978, V24, P58 MEDLINE
- (37) van der Pompe, G; Psychoneuroendocrinology 1996, V21, P361 MEDLINE
- (38) Wigmore, S; Clin Sci 1997, V92, P215 HCAPLUS
- (39) Wigmore, S; Nutrition 1996, V12(Suppl), PS28
- (40) Zumoff, B; Prostate 1982, V3, P579 MEDLINE

IT **595-33-5, Megestrol acetate**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (wt. loss in human cancer and **Alzheimer's** disease is mediated by a similar pathway response to)
 RN 595-33-5 HCAPLUS
 CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 28 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:402964 HCAPLUS
 DN 131:194408
 TI Alternatives to the use of estrogen in postmenopausal women
 AU Pinkerton, Joann V.; Santen, Richard
 CS Departments of Obstetrics/Gynecology and Endocrinology, The Women's Place and the Cancer Center, University of Virginia Health Sciences Center, Charlottesville, VA, 22903-9301, USA
 SO Endocrine Reviews (1999), 20(3), 308-320
 CODEN: ERVIDP; ISSN: 0163-769X
 PB Endocrine Society
 DT Journal; General Review
 LA English
 CC 2-0 (Mammalian Hormones)
 Section cross-reference(s): 1
 AB A review, with 128 refs., of data regarding the effectiveness of estrogen vs. nonestrogen alternatives such as HMG-CoA reductase inhibitors or statins, bisphosphonates, calcitonins, clonidine and **megestrol acetate**, as well as the partial estrogen agonists/antagonists or SERMs (selective estrogen receptor modulators) in therapy for urogenital atrophy, vasomotor instability, **neurocognitive** dysfunction, and prevention of heart disease and osteoporosis.
 ST estrogen alternative postmenopause review
 IT Cardiovascular agents
 Cognition enhancers
 Urogenital tract
 (alternatives to use of estrogen in postmenopausal women)
 IT Estrogens
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (alternatives to use of estrogen in postmenopausal women)
 IT Menopause
 (postmenopause; alternatives to use of estrogen in postmenopausal women)
 IT Osteoporosis

(therapeutic agents; alternatives to use of estrogen in postmenopausal women)

IT 595-33-5, **Megestrol acetate** 4205-90-7,
Clonidine 9007-12-9, Calcitonin 13598-36-2D, Phosphonic acid,
alkylidenebis- derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); **THU (Therapeutic use)**; BIOL (Biological
study); USES (Uses)

(alternatives to use of estrogen in postmenopausal women)

IT 595-33-5, **Megestrol acetate** 4205-90-7,
Clonidine 9007-12-9, Calcitonin 13598-36-2D, Phosphonic acid,
alkylidenebis- derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); **THU (Therapeutic use)**; BIOL (Biological
study); USES (Uses)

(alternatives to use of estrogen in postmenopausal women)

RE.CNT 128 THERE ARE 128 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Adlercreutz, H; Scand J Clin Lab Invest 1990, V50(Suppl:201), P3
- (2) Agnusdei, D; Bone Miner 1992, V19, PS43
- (3) Anderson, J; N Engl J Med 1995, V333, P276 HCAPLUS
- (4) Anthony, M; Arterioscler Thromb Vasc Biol 1997, V17, P2524 HCAPLUS
- (5) Ayton, R; Br J Obstet Gynaecol 1996, V103, P351 HCAPLUS
- (6) Barakat, R; Oncology 1995, V9, P129 MEDLINE
- (7) Barrett-Connor, E; Ann Intern Med 1991, V115, P455 MEDLINE
- (8) Barton, D; J Clin Oncol 1998, V16, P495 HCAPLUS
- (9) Bass, K; Arch Intern Med 1993, V153, P2209 MEDLINE
- (10) Birge, S; Neurology 1997, V48(5 Suppl 7), PS36 MEDLINE
- (11) Bjarnason, N; Circulation 1997, V96, P1964 HCAPLUS
- (12) Blumsohn, A; J Clin Endocrinol Metab 1994, V79, P730 HCAPLUS
- (13) Boissier, S; Cancer Res 1997, V57, P3890 HCAPLUS
- (14) Bone, H; J Clin Endocrinol Metab 1997, V82, P265 HCAPLUS
- (15) Bush, T; Circulation 1987, V75, P1102 MEDLINE
- (16) Cauley, J; Ann Intern Med 1995, V122, P9 MEDLINE
- (17) Chesnut, C; Am J Med 1995, V99, P144 HCAPLUS
- (18) Chesnut, C; Osteoporos Int 1999, V8(Suppl 13), P13
- (19) Clarkson, T; Br J Obstet Gynaecol 1996, V103(Suppl 13), P53
- (20) Clarkson, T; J Clin Endocrinol Metab 1998, V83, P721 HCAPLUS
- (21) Clarkson, T; Proc Soc Exp Biol Med 1998, V217, P365 HCAPLUS
- (22) Colditz, G; N Engl J Med 1995, V332, P1589 MEDLINE
- (23) Consensus statement; J Clin Endocrinol Metab 1998, V83, P1993
- (24) Cremer, P; Eur J Clin Invest 1994, V24, P444 MEDLINE
- (25) Cummings, S; JAMA 1998, V280, P2077 HCAPLUS
- (26) Cummings, S; Program/Proceedings of The Thirty-fourth Annual Meeting of
The American Society of Clinical Oncology 1998
- (27) Dahlen, G; Circulation 1986, V74, P758 MEDLINE
- (28) Daly, E; Lancet 1996, V348, P977 MEDLINE
- (29) Darling, G; N Engl J Med 1997, V337, P595 HCAPLUS
- (30) Davidson, M; Arch Intern Med 1997, V157, P1186 HCAPLUS
- (31) Dawson-Hughes, B; N Engl J Med 1997, V337, P670 HCAPLUS
- (32) De Groen, P; N Engl J Med 1996, V335, P1016 MEDLINE
- (33) Delmas, P; N Engl J Med 1997, V337, P1641 HCAPLUS
- (34) Downs, J; JAMA 1998, V279, P1615 MEDLINE
- (35) Draper, M; J Bone Miner Res 1996, V11, P835 HCAPLUS
- (36) Eastell, R; N Engl J Med 1998, V338, P736 HCAPLUS
- (37) Ellerington, M; Calcif Tissue Int 1996, V59, P6 HCAPLUS
- (38) Ensrud, K; Arch Intern Med 1997, V157, P2617 HCAPLUS
- (39) Ettinger, B; Am J Man Care 1998, V4, P1377 MEDLINE
- (40) Ettinger, B; Ann Intern Med 1987, V106, P40 MEDLINE
- (41) Ettinger, B; N Engl J Med 1993, V329, P1192 MEDLINE
- (42) Ettinger, B; Osteoporos Int 1998, V8(Suppl 3), P11
- (43) Ettinger, B; Program of the European Congress on Osteoporosis 1998
- (44) Felson, D; Curr Opin Rheumatol 1998, V10, P269 HCAPLUS

- (45) Felson, D; N Engl J Med 1993, V329, P1141 MEDLINE
- (46) Fisher, B; J Natl Cancer Inst 1998, V90, P1371 HCAPLUS
- (47) Friedlander, A; J Bone Miner Res 1995, V10, P574 MEDLINE
- (48) Genant, H; Arch Intern Med 1997, V157, P2609 HCAPLUS
- (49) Gennari, C; Calcif Tissue Int 1991, V49(Suppl 2), PS9
- (50) Goldberg, R; J Clin Oncol 1994, V12, P155 MEDLINE
- (51) Grady, D; Ann Intern Med 1992, V117, P1016 MEDLINE
- (52) Grey, A; J Clin Endocrinol Metab 1995, V80, P3191 HCAPLUS
- (53) Grodstein, F; Ann Intern Med 1998, V128, P705 MEDLINE
- (54) Grodstein, F; N Engl J Med 1996, V335, P453 HCAPLUS
- (55) Grodstein, F; N Engl J Med 1997, V336, P1769 HCAPLUS
- (56) Grodstein, F; Prog Cardiovasc Dis 1995, V38, P199 HCAPLUS
- (57) Grundy, S; Am Fam Physician 1997, V55, P2250 MEDLINE
- (58) Handa, V; Obstet Gynecol 1994, V84, P215 MEDLINE
- (59) Henderson, B; Arch Intern Med 1991, V151, P75 MEDLINE
- (60) Henriksson, L; Am J Obstet Gynecol 1996, V174, P85 HCAPLUS
- (61) Hirata, J; Fertil Steril 1997, V68, P981 MEDLINE
- (62) Hirayama, T; Diet Nutrition Cancer 1986, P41
- (63) Holme, I; Curr Opin Lipidol 1995, V6, P374 HCAPLUS
- (64) Honore, E; Fertil Steril 1997, V67, P148 MEDLINE
- (65) Hosking, D; N Engl J Med 1998, V338, P485 HCAPLUS
- (66) Hulley, S; JAMA 1998, V280, P605 HCAPLUS
- (67) Jacobs, D; Am J Epidemiol 1990, V131, P32
- (68) Jonas, H; Ann Epidemiol 1996, V6, P314 MEDLINE
- (69) Kerr, D; J Bone Miner Res 1996, V11, P218 MEDLINE
- (70) Kiel, D; N Engl J Med 1987, V317, P1169 MEDLINE
- (71) Koff, R; JAMA 1995, V273, P502 MEDLINE
- (72) Laufer, L; Obstet Gynecol 1982, V60, P583 MEDLINE
- (73) Lee, H; Lancet 1991, V337, P1197 MEDLINE
- (74) Liberman, U; N Engl J Med 1995, V333, P1437 HCAPLUS
- (75) Lien, E; J Clin Pharmacol Ther 1996, V2, P101
- (76) Lindsay, R; J Clin Endocrinol Metab 1996, V81, P3829 HCAPLUS
- (77) Lindsey, R; European Congress on Osteoporosis 1998
- (78) Lobo, R; J Clin Endocrinol Metab 1991, V73, P925 HCAPLUS
- (79) Loprinzi, C; J Clin Oncol 1997, V15, P969 HCAPLUS
- (80) Loprinzi, C; J Clin Oncol 1998, V16, P2377 HCAPLUS
- (81) Loprinzi, C; N Engl J Med 1994, V331, P347 HCAPLUS
- (82) Love, R; J Natl Cancer Inst 1994, V86, P1534 MEDLINE
- (83) Lufkin, E; Ann Intern Med 1992, V117, P1 MEDLINE
- (84) Matthews, K; Am J Epidemiol 1996, V143, P971 MEDLINE
- (85) Maxim, P; Osteoporos Int 1995, V5, P23 MEDLINE
- (86) Mosca, L; Circulation 1997, V96, P2468 MEDLINE
- (87) Murkies, A; J Clin Endocrinol Metab 1998, V83, P297 HCAPLUS
- (88) Nachtigall, L; Fertil Steril 1994, V61, P178 MEDLINE
- (89) Nakahara, K; Toxicol Appl Pharmacol 1998, V152, P99 HCAPLUS
- (90) Nestel, P; J Clin Endocrinol Metab 1999, V84, P895 HCAPLUS
- (91) Overgaard, K; Br Med J 1992, V305, P556 MEDLINE
- (92) O'Brien, J; J Am Coll Cardiol 1996, V28, P1111 HCAPLUS
- (93) Paganini-Hill, A; Ann Intern Med 1981, V95, P28 MEDLINE
- (94) Paganini-Hill, A; Arch Intern Med 1995, V155, P2325 MEDLINE
- (95) Pedersen, T; Arch Intern Med 1996, V156, P2085 HCAPLUS
- (96) Pedersen, T; Circulation 1998, V97, P1453 HCAPLUS
- (97) Petitti, D; Ann Epidemiol 1994, V4, P115 MEDLINE
- (98) Petitti, D; Gastroenterology 1988, V94, P91 MEDLINE
- (99) Powles, T; J Clin Oncol 1996, V14, P78 HCAPLUS
- (100) Powles, T; Lancet 1998, V352, P98 HCAPLUS
- (101) Ragaz, J; J Clin Oncol 1998, V16, P2018 MEDLINE
- (102) Reginster, J; Am J Med 1995, V98, P452 MEDLINE
- (103) Register, T; Arterioscler Thromb Vasc Biol 1998, V18, P1164 HCAPLUS
- (104) Santen, R; J Clin Endocrinol Metab 1999, V84, P1875 HCAPLUS
- (105) Santen, R; Obstet Gynecol Surv 1998, V53, PS1 MEDLINE
- (106) Santen, R; Proceedings of the North American Menopause Society 1998
- (107) Scanu, A; Am J Cardiol 1998, V82, P26Q HCAPLUS

- (108) Schneider, D; JAMA 1997, V277, P543 HCAPLUS
- (109) Seeman, E; Am J Med 1997, V103(2A)(Suppl 1S), P74S
- (110) Sheikh, N; Arch Intern Med 1997, V157, P913 MEDLINE
- (111) Shimizu, H; Br J Cancer 1991, V63, P963 MEDLINE
- (112) Sidney, S; Ann Intern Med 1997, V127, P501 HCAPLUS
- (113) Smith, W; Australian N Z J Ophthalmol 1997, V25(Suppl 1), PS13
- (114) Stampfer, M; Prev Med 1991, V20, P47 MEDLINE
- (115) Stein, E; Am J Cardiol 1998, V82, P311 HCAPLUS
- (116) Sturgeon, S; Epidemiology 1995, V6, P227 MEDLINE
- (117) Sullivan, J; Am J Cardiol 1997, V79, P847 HCAPLUS
- (118) Sullivan, J; Arch Intern Med 1990, V150, P2557 MEDLINE
- (119) Sullivan, J; Arch Intern Med 1990, V150, P2557 MEDLINE
- (120) Sullivan, J; Int J Fertil Menopausal Stud 1994, V39(Suppl 1), P28
- (121) The Writing Group for the PEPI; JAMA 1996, V276, P1389
- (122) The Writing Group for the PEPI Trial; JAMA 1995, V273, P199
- (123) Tikkanen, M; Cardiovasc Risk Factors 1993, V3, P138
- (124) Tyler, V; J Am Pharmacol Assoc (Wash) 1996, VNS36, P29 MEDLINE
- (125) Wagner, J; Metabolism 1997, V46, P698 HCAPLUS
- (126) Walsh, B; J Lipid Res 1994, V35, P2083 HCAPLUS
- (127) Wolf, P; Am J Obstet Gynecol 1991, V164, P489 MEDLINE
- (128) Yaffe, K; JAMA 1998, V279, P688 HCAPLUS

IT 595-33-5, **Megestrol acetate**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(alternatives to use of estrogen in postmenopausal women)

RN 595-33-5 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 29 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:231514 HCAPLUS

DN 130:262123

TI Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of NF- κ B via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases

IN Elliot, Peter; Adams, Julian; Plamondon, Louis

PA Proscript Inc., USA

SO PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-69

ICS A61K031-40

CC 1-7 (Pharmacology)

Section cross-reference(s): 28, 63


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9915183	A1	19990401	WO 1998-US20065	19980925 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2304622	AA	19990401	CA 1998-2304622	19980925 <--
	AU 9895800	A1	19990412	AU 1998-95800	19980925 <--
	EP 1017398	A1	20000712	EP 1998-949490	19980925 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001517631	T2	20011009	JP 2000-512552	19980925 <--
	US 2001051654	A1	20011213	US 2001-770889	20010126 <--
PRAI	US 1997-61038P	P	19970925 <--		
	US 1997-69562P	P	19971212 <--		
	US 1998-74887P	P	19980217 <--		
	WO 1998-US20065	W	19980925 <--		
	US 1999-393794	B1	19990910 <--		
AB	The invention is directed to the treatment of inflammatory and autoimmune diseases by administering proteasome inhibitors, ubiquitin pathway inhibitors, agents that interfere with the activation of NF-.kappa.B via the ubiquitin proteasome pathway, or mixts. thereof. The invention is further directed to the treatment of inflammatory and autoimmune diseases by administering an effective combination of a glucocorticoid and a proteasome inhibitor, ubiquitin pathway inhibitor, agent that interferes with the activation of NF-.kappa.B via the ubiquitin proteasome pathway, or mixt. thereof. Pharmaceutical compns. comprising a combination of a glucocorticoid and a proteasome inhibitor, ubiquitin pathway inhibitor, agent that interferes with the activation of NF-.kappa.B via the ubiquitin proteasome pathway, or mixt. thereof are also provided. Prepn. of a series of lactacystin derivs., e.g. 7-n-propyl-clasto-lactacystin .beta.-lactone (I) is described, as is activity of I in e.g. an exptl. autoimmune encephalomyelitis model.				
ST	proteasome inhibitor antiinflammatory autoimmune disease; ubiquitin pathway inhibitor antiinflammatory autoimmune disease; NFkappaB activation inhibition antiinflammatory autoimmune disease; lactacystin deriv prepn antiinflammatory autoimmune disease				
IT	Transcription factors RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (NF-.kappa.B (nuclear factor .kappa.B); proteasome inhibitors, ubiquitin pathway inhibitors, and agents that interfere with NF-.kappa.B activation via ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases)				
IT	Encephalomyelitis (autoimmune; proteasome inhibitors, ubiquitin pathway inhibitors, and agents that interfere with NF-.kappa.B activation via ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases)				
IT	Antiasthmatics Eosinophilia Lymphocyte Macrophage Multiple sclerosis Neutrophil Pharmacokinetics (proteasome inhibitors, ubiquitin pathway inhibitors, and agents that interfere with NF-.kappa.B activation via ubiquitin proteasome pathway				

- to treat inflammatory and autoimmune diseases)
- IT Drug delivery systems
Drug interactions
(proteasome inhibitors, ubiquitin pathway inhibitors, and agents that interfere with NF-.kappa.B activation via ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases, and combinations with glucocorticoids)
- IT Glucocorticoids
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(proteasome inhibitors, ubiquitin pathway inhibitors, and agents that interfere with NF-.kappa.B activation via ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases, and combinations with glucocorticoids)
- IT Leukocyte
(pulmonary; proteasome inhibitors, ubiquitin pathway inhibitors, and agents that interfere with NF-.kappa.B activation via ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases)
- IT Drug interactions
(synergistic; proteasome inhibitors, ubiquitin pathway inhibitors, and agents that interfere with NF-.kappa.B activation via ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases)
- IT Drug delivery systems
(unit doses; proteasome inhibitors, ubiquitin pathway inhibitors, and agents that interfere with NF-.kappa.B activation via ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases, and combinations with glucocorticoids)
- IT 38136-29-7P, 4-Methylvaleryl chloride 96930-27-7P 112459-79-7P
113543-30-9P 123803-51-0P 143868-89-7P 143965-32-6P 163457-34-9P
220805-27-6P 220805-28-7P 220805-29-8P 220805-30-1P 220805-31-2P
220805-32-3P 220805-33-4P 220805-34-5P 220805-35-6P 220805-36-7P
220805-37-8P 220805-38-9P 220805-39-0P 220805-40-3P 220805-41-4P
220805-42-5P 220805-43-6P 220805-44-7P 220805-45-8P 220805-46-9P
220805-47-0P 220805-48-1P 220805-49-2P 220805-50-5P 220805-51-6P
220805-52-7P 220805-53-8P 220805-54-9P 220805-55-0P 220805-56-1P
220805-57-2P 220805-58-3P 220805-70-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction; proteasome inhibitors, ubiquitin pathway inhibitors, and agents that interfere with NF-.kappa.B activation via ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases)
- IT 179324-69-7
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(proteasome inhibitors, ubiquitin pathway inhibitors, and agents that interfere with NF-.kappa.B activation via ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases)
- IT 203935-05-1P 203935-06-2P 203935-08-4P 211866-70-5P 220805-26-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(proteasome inhibitors, ubiquitin pathway inhibitors, and agents that interfere with NF-.kappa.B activation via ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases)
- IT 133343-34-7, Lactacystin 133343-34-7D, Lactacystin, analogs
154226-60-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(proteasome inhibitors, ubiquitin pathway inhibitors, and agents that

- interfere with NF-.kappa.B activation via ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases)
- IT 60267-61-0, Ubiquitin 140879-24-9, Proteasome
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(proteasome inhibitors, ubiquitin pathway inhibitors, and agents that interfere with NF-.kappa.B activation via ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases)
- IT 50-23-7 50-24-8, Prednisolone 53-03-2, Prednisone 76-25-5, Triamcinolone acetone 2392-39-4, Dexamethasone sodium phosphate 3385-03-3, Flunisolide 5534-09-8, Beclomethasone dipropionate 51333-22-3, Budesonide 80474-14-2, Fluticasone propionate 85197-77-9, Tipredane 105102-22-5, Mometasone 120815-74-9, Butixocort
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(proteasome inhibitors, ubiquitin pathway inhibitors, and agents that interfere with NF-.kappa.B activation via ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases, and combinations with glucocorticoids)
- IT 109-89-7, reactions 141-75-3, Butyryl chloride 142-61-0, Hexanoyl chloride 638-29-9, Valeryl chloride 645-45-4, Hydrocinnamoyl chloride 646-07-1, 4-Methylvaleric acid 3587-60-8, Benzyl chloromethyl ether 90719-32-7 123731-35-1 148906-20-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; proteasome inhibitors, ubiquitin pathway inhibitors, and agents that interfere with NF-.kappa.B activation via ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases)
- RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
- RE
- (1) Devillier; REVUE FRANCAISE D'ALLERGOLOGIE ET D'IMMUNOLOGIE CLINIQUE 1996, V36, P937
 - (2) Harvard College; WO 9632105 A 1996 HCAPLUS
 - (3) Levan; AM J OF PHYSIOLOGY 1997, V16, PL838
 - (4) Louis, G; US 5780454 A 1998 HCAPLUS
 - (5) Manning; EXPERT OPINION ON INVESTIGATIONAL DRUGS 1997, V6(5), P555 HCAPLUS
 - (6) Merck Res Lab; the Merck Index 12th edition 1996
 - (7) Royal Pharmaceutical Society; Martindale 13th edition 1993
 - (8) Stacey; BIOCHEM AND BIOPHYS RES COMM 1997, V236(2), P522 HCAPLUS
- IT 3385-03-3, Flunisolide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(proteasome inhibitors, ubiquitin pathway inhibitors, and agents that interfere with NF-.kappa.B activation via ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases, and combinations with glucocorticoids)
- RN 3385-03-3 HCAPLUS
- CN Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 30 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:7831 HCAPLUS
 DN 130:47470
 TI Prevention of ovarian cancer by administration of a vitamin D compound
 IN Rodriguez, Gustavo C.; Whitaker, Regina S.
 PA USA
 SO PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-59
 CC 1-6 (Pharmacology)

Section cross-reference(s): 2

FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9856389	A1	19981217	WO 1998-US11737	19980605 <--
	W: AU, BR, CA, CN, JP, MX, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6034074	A	20000307	US 1997-873010	19970611 <--
	AU 9878222	A1	19981230	AU 1998-78222	19980605 <--
	EP 983070	A1	20000308	EP 1998-926371	19980605 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1997-873010	A	19970611	<--	
	US 1996-713834	A2	19960913	<--	
	WO 1998-US11737	W	19980605	<--	
AB	Methods are provided for preventing the development of epithelial ovarian cancer by administering a Vitamin D compd. in an amt. capable of increasing apoptosis in non-neoplastic ovarian epithelial cells of the female subject.				
ST	vitamin D compd ovarian cancer prevention apoptosis				
IT	Ovary				
	Ovary				
	(epithelium; vitamin D compds. for prevention of ovarian cancer)				
IT	Ovary, neoplasm				
	(inhibitors; vitamin D compds. for prevention of ovarian cancer)				
IT	Antitumor agents				
	(ovary; vitamin D compds. for prevention of ovarian cancer)				
IT	Apoptosis				
	Contraceptives				
	(vitamin D compds. for prevention of ovarian cancer)				
IT	Estrogens				
	Hormones, animal, biological studies				

- RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(vitamin D compds. for prevention of ovarian cancer)
- IT Progesterogens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(vitamin D compds. for prevention of ovarian cancer, and use with other agents)
- IT 11103-57-4, Vitamin A
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(metabolites; vitamin D compds. for prevention of ovarian cancer, and use with other agents)
- IT 1406-16-2, Vitamin D 1406-16-2D, Vitamin D, derivs. 32222-06-3, 1,25-Dihydroxyvitamin D3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitamin D compds. for prevention of ovarian cancer)
- IT 68-22-4, Norethindrone
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(vitamin D compds. for prevention of ovarian cancer)
- IT 50-02-2, Dexamethasone 302-79-4, Retinoic acid
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vitamin D compds. for prevention of ovarian cancer, and use with other agents)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Christopherson, W; Am J Obstet Gynecol 1986, V155(6), P1293 HCAPLUS
- (2) Moore, T; Journal of Pediatric Hematology/Oncology 1995, V17(4), P311 MEDLINE
- (3) Rustin, G; Br J Cancer 1996, V74(9), P1479 HCAPLUS
- (4) Saunders, D; Anti-Cancer Drugs 1993, V4(2), P201 HCAPLUS
- (5) Saunders, D; Anti-Cancer Drugs 1995, V6(4), P562 HCAPLUS
- (6) Saunders, D; Gynecol Oncol 1992, V44(2), P131 HCAPLUS
- (7) Saunders, D; Twenty-Fourth Annual Meeting of the Society of Gynecologic Oncologists, Gynecol Oncol 1993, V49(1), P118
- (8) Saunders, D; Twenty-Third Annual Meeting of the Society of Gynecologic Oncologists, Gynecol Oncol 1992, V45(1), P83

- IT 68-22-4, Norethindrone
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(vitamin D compds. for prevention of ovarian cancer)

RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AN 1998:640257 HCAPLUS
 DN 129:255530
 TI Methods and compositions for modulating responsiveness to
corticosteroids
 IN Sekut, Les; Carter, Adam; Chayur, Tariq; Banerjee, Subhashis; Tracey,
 Daniel E.
 PA Basf A.-G., Germany
 SO PCT Int. Appl., 112 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC A61K039-00
 CC 2-4 (Mammalian Hormones)
 Section cross-reference(s): 1, 15, 25, 27

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9841232	A2	19980924	WO 1998-US4916	19980312 <--
	WO 9841232	A3	20001005		
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 6054487	A	20000425	US 1997-820692	19970318 <--
	AU 9867604	A1	19981012	AU 1998-67604	19980312 <--
	AU 734756	B2	20010621		
	EP 998300	A1	20000510	EP 1998-912929	19980312 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
	BR 9810409	A	20000822	BR 1998-10409	19980312 <--
	JP 2002504091	T2	20020205	JP 1998-540633	19980312 <--
	NZ 337769	A	20020927	NZ 1998-337769	19980312 <--
	NO 9904506	A	19991117	NO 1999-4506	19990917 <--
PRAI	US 1997-820692	A2	19970318 <--		
	US 1998-16346	A2	19980130 <--		
	WO 1998-US4916	W	19980312 <--		

AB Method for modulating responsiveness to **corticosteroids** in a subject are provided. In the method of the invention, an agent which antagonizes a target that regulates prodn. of IFN- γ . in the subject is administered to the subject in combination with a **corticosteroid** such that responsiveness of the subject to the **corticosteroid** is modulated as compared to when the **corticosteroid** is given alone. The method can be used to, for example, reverse steroid resistance of to increase steroid sensitivity, or to ameliorate the steroid rebound effect when subjects are taken off **corticosteroid** treatment. In one embodiment, the agent is an IL-18 antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In yet another embodiment, the agent is an NK cell antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. In yet another preferred embodiment, the agent is an anti-asialo-GM1 antibody or an NK1.1 antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunol. diseases and disorders. Pharmaceutical compns. comprising an agent which antagonizes a target that regulates prodn. of IFN- γ . in a subject, a **corticosteroid** and a pharmaceutically acceptable carrier are also provided. A preferred compn. comprises an ICE inhibitor, a **corticosteroid** and a pharmaceutically acceptable carrier.

ST **corticosteroid** resistance sensitivity modulation; steroid

rebound effect treatment

- IT Intestine, disease
(Crohn's; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)
- IT Eye, disease
(Graves ophthalmopathy; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)
- IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NK1.1 antibody; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Transcription factors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(STAT4, inhibitors; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Erythema
(Stevens-Johnson syndrome; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Granulomatous disease
(Wegener's granulomatosis; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)
- IT Inflammation
(acute; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Respiratory distress syndrome
(adult; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Spider
(allergic responses due to arthropod bite reactions; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Toxins
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(allergic responses due to arthropod bite reactions; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Nose
(allergic rhinitis, inflammation; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)
- IT Dermatitis
(allergic, contact; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)
- IT Interleukin 12
Interleukin 18
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonists; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

- (anti-NK/NK-like cell antibody; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-asialo-GM1 antibody; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Mouth
(aphthous ulcer; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Anemia (disease)
(aplastic; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)
- IT Alopecia
(areata; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Dermatitis
(atopic; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)
- IT Thyroid gland, disease
(autoimmune thyroiditis; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)
- IT Eye, disease
Eye, disease
(autoimmune uveitis; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Arthritis
Encephalomyelitis
Meningitis
(autoimmune; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Musculoskeletal diseases
Musculoskeletal diseases
(cartilage, polychondritis; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Inflammation
(chronic; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Eye, disease
(conjunctivitis; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)
- IT Lupus erythematosus
(cutaneous; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Cartilage
Cartilage
(disease, polychondritis; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Vagina
(disease, vaginitis; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Eye, disease
(dry eye syndrome; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)

- IT Proteins, specific or class
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(engineered protein that binds IL-18, IL-12, IL-18 receptor, or IL-12 receptor; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Interleukin receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(engineered protein that binds IL-18, IL-12, IL-18 receptor, or IL-12 receptor; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Transplant and Transplantation
(graft-vs.-host reaction; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)
- IT Purpura (disease)
(idiopathic thrombocytopenic; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)
- IT Lung, disease
(inflammation, inflammatory pulmonary syndrome; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Intestine, disease
(inflammatory; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)
- IT Lung, disease
(interstitial fibrosis; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Eye, disease
(iritis; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Rheumatoid arthritis
(juvenile; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Eye, disease
(keratoconjunctivitis; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Transplant and Transplantation
(kidney, rejection; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)
- IT Allergy inhibitors
Anemia (disease)
Anti-inflammatory agents
Antiarthritics
Antidiabetic agents
Immunomodulators
Myasthenia gravis
(methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT **Corticosteroids**, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Antiasthmatics

Antirheumatic agents

Autoimmune disease

Dermatitis

Drug allergy

Eczema

Multiple sclerosis

Psoriasis

Sjogren's syndrome

Transplant rejection

(methods and compns. for modulating responsiveness to
corticosteroids in the treatment of a variety of inflammatory
and immunol. diseases and disorders)

IT Antibodies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(monoclonal, anti-IL-12 monoclonal antibody; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)

IT Lymphocyte

(natural killer cell, antagonists; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)

IT Erythema

(nodosum leprosum; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)

IT Skin, disease

(pemphigus vulgaris; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)

IT Biliary tract

(primary biliary cirrhosis; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)

IT Arthritis

(psoriatic arthritis; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)

IT Intestine

(rectum, proctitis; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)

IT Leprosy

(reversal reactions; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)

IT Connective tissue

(scleroderma; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)

IT Shock (circulatory collapse)

(septic; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)

IT Drug resistance

(steroid resistance; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)

IT Lupus erythematosus

(systemic; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)

IT Platelet (blood)

(thrombocytopenia, idiopathic; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)

IT Kidney

(transplant, rejection; methods and compns. for modulating

- responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)
- IT Intestine, disease
(ulcerative colitis; methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)
- IT Eye, disease
(uveitis; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Vagina
(vaginitis; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Hepatitis
(viral, chronic active; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Adrenoceptor agonists
(.beta.2-; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT Interferons
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.gamma., antagonists; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT 143313-51-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ICE inhibitor; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT 60-92-4, CAMP
RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(agent that stimulated cAMP prodn. in cells that produce IL-12; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT 71012-19-6, Asialo-GM1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-asialo-GM1 antibody; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT 9036-21-9, Phosphodiesterase IV 122191-40-6, Interleukin-1.beta. converting enzyme 186322-81-6, Caspase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT 50-23-7, Hydrocortisone 50-24-8, Prednisolone 53-06-5, Cortisone 83-43-2, Methylprednisolone 124-94-7, Triamcinolone 378-44-9, Betamethasone 3385-03-3, Flunisolide 4419-39-0, Beclomethasone 14484-47-0, Deflazacort
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)
- IT 50-02-2, Dexamethasone 53-03-2, Prednisone

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(methods and compns. for modulating responsiveness to **corticosteroids** in the treatment of a variety of inflammatory and immunol. diseases and disorders)

IT 86-96-4D, Quinazolinone, derivs. 28261-54-3D, Pyrrolidinone, 4-aryl derivs. 56739-21-0, Nitraquazone 57076-71-8, Denbufylline 61413-54-5, Rolipram 97852-72-7, Tibenelast 114918-24-0, CP-77059 135637-46-6, CP 80633

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phosphodiesterase IV inhibitor; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)

IT 213613-46-8P 213613-49-1P 213613-51-5P 213613-54-8P 213613-55-9P 213613-59-3P 213613-66-2P 213613-68-4P 213621-81-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of hydroxamate ICE inhibitors)

IT 2687-43-6, O-Benzyl hydroxylamine hydrochloride 5470-11-1, Hydroxylamine hydrochloride 18108-55-9, N-Hydroxyoxindole 22426-86-4 24424-99-5, Di-tert-butyl dicarbonate 24731-17-7, Ethyl 2-cyclohexanoneacetate 57951-36-7, Dimethylaminopyridine 60941-72-2 153088-76-7 213613-50-4 213613-65-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(synthesis of hydroxamate ICE inhibitors)

IT 5596-17-8P 213613-47-9P 213613-48-0P 213613-52-6P 213613-56-0P 213613-57-1P 213613-60-6P 213613-61-7P 213613-63-9P 213613-64-0P 213621-82-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of hydroxamate ICE inhibitors)

IT 7683-59-2, Isoproterenol 13392-18-2, Fenoterol 89365-50-4, Salmeterol

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(.beta.2 agonist; methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)

IT 3385-03-3, Flunisolide


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)

(methods and compns. for modulating responsiveness to **corticosteroids** by co-administration of another agent)

RN 3385-03-3 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 32 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:527193 HCAPLUS

DN 129:166193

TI Therapeutic treatment and prevention of infections with a bioactive material encapsulated within a biodegradable-biocompatible polymeric **matrix**

IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil

PA United States Dept. of the Army, USA; Van Hamont, John E.; et al.

SO PCT Int. Appl., 363 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-52

ICS A61K047-30

CC 63-5 (Pharmaceuticals)

Section cross-reference(s): 1, 2, 15

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9832427	A1	19980730	WO 1998-US1556	19980127 <--
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 6309669	B1	20011030	US 1997-789734	19970127 <--
	AU 9863175	A1	19980818	AU 1998-63175	19980127 <--
PRAI	US 1997-789734	A	19970127 <--		
	US 1984-590308	B1	19840316 <--		
	US 1992-867301	A2	19920410 <--		
	US 1995-446148	A2	19950522 <--		
	US 1995-446149	B2	19950522 <--		
	US 1996-590973	B2	19960124 <--		
	WO 1998-US1556	W	19980127 <--		

AB Novel burst-free, sustained release biocompatible and biodegradable microcapsules are disclosed which can be programmed to release their active core for variable durations ranging from 1-100 days in an aq. physiol. environment. The microcapsules are comprised of a core of polypeptide or other biol. active agent encapsulated in a **matrix** of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically

acceptable adjuvant, as a blend of uncapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.

- ST infection microcapsule sustained release peptide copolymer
- IT Hepatitis
 - (B, chronic; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Hepatitis
 - (C, chronic; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Trypanosoma cruzi
 - (Chagas' disease from; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Immunoglobulins
 - RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 - (G, ampicillin-specific; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Nervous system
 - (Huntington's chorea; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Antitumor agents
 - (Kaposi's sarcoma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Sperm
 - (acrosome, proteinase of; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Diagnosis
 - (agents; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Ragweed (Ambrosia)
 - (allergy; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Ameba
 - (amebiasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Antibiotics
 - (aminoglycoside; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Absidia ramosa
- Actinobacillus equuli
- Actinobacillus seminis
- Arcanobacterium pyogenes
- Aspergillus fumigatus
- Babesia caballi
- Brucella melitensis
- Campylobacter fetus
- Campylobacter fetus intestinalis
- Candida albicans
- Candida tropicalis
- Chlamydia psittaci
- Clostridium tetani
- Equid herpesvirus 1
- Equine arteritis virus

Escherichia coli
 Gardnerella vaginalis
 Human herpesvirus 1
 Human herpesvirus 2
 Leptospira interrogans pomona
 Listeria monocytogenes
 Mycobacterium tuberculosis
 Mycoplasma bovigenitalium
 Mycoplasma hominis
 Neisseria gonorrhoeae
 Pneumocystis carinii
 Pseudomonas aeruginosa
 Rhodococcus equi
 Salmonella abortusovis
 Salmonella abortusovis
 Streptococcus group B
 Toxoplasma gondii
 Treponema pallidum
 Trichomonas vaginalis
 Tritrichomonas foetus
 Trypanosoma equiperdum
 (antigens of; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric
matrix)
 IT Mycobacterium
 (antimycobacterial agents; prevention of infections with bioactive
 material encapsulated within biodegradable-biocompatible polymeric
matrix)
 IT Mouth
 (aphthous ulcer; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric
matrix)
 IT Drugs
 (appetite stimulants; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric
matrix)
 IT Heart, disease
 (arrhythmia; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric
matrix)
 IT Blood vessel
 (artificial, infections surrounding; prevention of infections with
 bioactive material encapsulated within biodegradable-biocompatible
 polymeric **matrix**)
 IT Dermatitis
 (atopic; prevention of infections with bioactive material encapsulated
 within biodegradable-biocompatible polymeric **matrix**)
 IT Babesia
 (babesiasis; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric
matrix)
 IT Skin, neoplasm
 (basal cell carcinoma, inhibitors; prevention of infections with
 bioactive material encapsulated within biodegradable-biocompatible
 polymeric **matrix**)
 IT Antitumor agents
 Skin, neoplasm
 (basal cell carcinoma; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric
matrix)
 IT Natural products, pharmaceutical
 RL: BPR (Biological process); BSU (Biological study, unclassified); DEV
 (Device component use); PRP (Properties); THU (Therapeutic use); BIOL

(Biological study); PROC (Process); USES (Uses)
(belladonna; prevention of infections with bioactive material
encapsulated within biodegradable-biocompatible polymeric
matrix)

IT Prostate gland
(benign hyperplasia; prevention of infections with bioactive material
encapsulated within biodegradable-biocompatible polymeric
matrix)

IT Polymers, biological studies
RL: DEV (Device component use); PRP (Properties); THU (Therapeutic use);
BIOL (Biological study); USES (Uses)
(biodegradable; prevention of infections with bioactive material
encapsulated within biodegradable-biocompatible polymeric
matrix)

IT Nervous system
(central, disease; prevention of infections with bioactive material
encapsulated within biodegradable-biocompatible polymeric
matrix)

IT Polymers, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV
(Device component use); PRP (Properties); THU (Therapeutic use); BIOL
(Biological study); PROC (Process); USES (Uses)
(co-; prevention of infections with bioactive material encapsulated
within biodegradable-biocompatible polymeric **matrix**)

IT Intestine, disease
(colitis; prevention of infections with bioactive material encapsulated
within biodegradable-biocompatible polymeric **matrix**)

IT Antigens
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(colony factor; prevention of infections with bioactive material
encapsulated within biodegradable-biocompatible polymeric
matrix)

IT Intestine, neoplasm
(colorectal, inhibitors; prevention of infections with bioactive
material encapsulated within biodegradable-biocompatible polymeric
matrix)

IT Antitumor agents
Intestine, neoplasm
(colorectal; prevention of infections with bioactive material
encapsulated within biodegradable-biocompatible polymeric
matrix)

IT Thrombosis
(coronary arterial; prevention of infections with bioactive material
encapsulated within biodegradable-biocompatible polymeric
matrix)

IT Artery, disease
(coronary, thrombosis; prevention of infections with bioactive material
encapsulated within biodegradable-biocompatible polymeric
matrix)

IT Vasodilators
(coronary; prevention of infections with bioactive material
encapsulated within biodegradable-biocompatible polymeric
matrix)

IT Tapeworm (Cestoda)
(cysticercosis; prevention of infections with bioactive material
encapsulated within biodegradable-biocompatible polymeric
matrix)

IT Bladder
(cystitis; prevention of infections with bioactive material
encapsulated within biodegradable-biocompatible polymeric
matrix)

IT Mental disorder

- (depression; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Eye, disease
(diabetic retinopathy; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Polyesters, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(dilactone-based; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Digestive tract
(drugs for; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Brain, disease
(edema, peritumoral; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Drug delivery systems
(emulsions; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT B cell (lymphocyte)
T cell (lymphocyte)
(epitopes of; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Alkaloids, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(ergot; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Amino acids, biological studies
Fats and Glyceridic oils, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(essential; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Fasciola
(fascioliasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Filaria
(filariasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Anthelmintics
(filaricides; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Digestive tract
(gastroenteritis, virus causing; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Intestine, disease
(giardiasis; prevention of infections with bioactive material

- encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Transplant and Transplantation
(graft-vs.-host reaction; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Calymmatobacterium granulomatis
(granuloma inguinale from, antigens of; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Antigens
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hepatitis B surface; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Liver, neoplasm
(hepatoma, inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Antitumor agents
Liver, neoplasm
(hepatoma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Human herpesvirus 2
(herpes genitalis from; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Human herpesvirus 3
(herpes zoster from, antigens of; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Parvovirus
Retroviridae
(human; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Globulins, biological studies
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hyperimmune; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Sexual behavior
(impotence; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Eye, disease
Mouth
Skin, disease
(infection; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Prosthetic materials and Prosthetics
(infections surrounding; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Drug delivery systems
(inhalants; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Fertility
Ovary, neoplasm

- Pancreas, neoplasm
(inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Drug delivery systems
(injections; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Diabetes mellitus
(insulin-dependent; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Leishmania
(leishmaniasis from, visceral; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Antitumor agents
(lung small-cell carcinoma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Antibiotics
(macrolide; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Antitumor agents
(mammary gland; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Antitumor agents
(melanoma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Drug delivery systems
(microcapsules; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Drug delivery systems
(microspheres; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Drug delivery systems
(nasal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Mammary gland
Prostate gland
(neoplasm, inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Mammary gland
Prostate gland
(neoplasm; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Meningitis
(neoplastic; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Angiogenesis
(neovascularization, retinal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Diabetes mellitus
(non-insulin-dependent; prevention of infections with bioactive

- material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Anti-inflammatory agents
(nonsteroidal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Emulsions
(oil-in-water; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Drug delivery systems
(oral; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Nitrites
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(org.; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Antitumor agents
(ovary; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Antitumor agents
(pancreas; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Anxiety
(panic disorder; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Paragonimus
(paragonimiasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Hormones, animal, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(peptide; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Periodontium
(periodontitis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Mental disorder
(phobia; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Adhesion, biological
(postsurgical; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT AIDS (disease)
Acinetobacter
Actinomycetales
Adenoviridae
Adrenoceptor agonists
Aerococcus
Aeromonas
Allergy inhibitors
Alzheimer's disease
Analgesics
Anesthetics
Angiogenesis

Angiogenesis inhibitors
Anthelmintics
Anti-infective agents
Anti-inflammatory agents
Antiarrhythmics
Antiarthritics
Antibacterial agents
Antibiotics
Anticholesteremic agents
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetic agents
Antidiarrheals
Antiemetics
Antihistamines
Antihypertensives
Antimalarials
Antimigraine agents
Antiparkinsonian agents
Antipyretics
Antirheumatic agents
Antiserums
Antitumor agents
Antitussives
Antiulcer agents
Antiviral agents
Appetite depressants
Arbovirus
Arcanobacterium haemolyticum
Arenavirus
Asthma
Bacillus (bacterium genus)
Biocompatibility
Blood substitutes
Bordetella
Borrelia
Bronchodilators
Brucella
Cachexia
Calymatobacterium
Campylobacter
Cardiopulmonary bypass
Cardiotonics
Cardiovascular agents
Cholinergic agonists
Clostridium
Contraceptives
Coronavirus
Corynebacterium
Cryptosporidium parvum
Cystic fibrosis
Cytomegalovirus
Cytotoxic agents
Decongestants
Diagnosis
Diarrhea
Dissolution rate
Diuretics
Drug bioavailability
Drug dependence
Ebola virus
Echinococcus

Electrolytes, biological
Emulsifying agents
Enterobacteriaceae
Enterococcus
Enterovirus
Epitopes
Erysipelothrix
Expectorants
Filovirus
Flavobacterium
Freeze drying
Fungicides
Gardnerella
Gram-negative bacteria
Gram-positive bacteria (Firmicutes)
Haemophilus
Haemophilus ducreyi
Helicobacter
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human immunodeficiency virus 1
Human parainfluenza virus
Human poliovirus
Hypercholesterolemia
Hypnotics and Sedatives
Immunization
Immunomodulators
Immunostimulants
Infection
Influenza virus
Kidney, disease
Lactococcus
Legionella
Leptospira
Leuconostoc
Listeria
Measles virus
Melanoma
Micrococcus
Molluscum contagiosum virus
Moraxella
Multiple sclerosis
Mumps virus
Muscle relaxants
Narcotics
Neisseria
Nervous system agents
Nutrients
Opioid antagonists
Osteoarthritis
Osteomyelitis
Osteoporosis
Ovary, neoplasm
Pancreas, neoplasm
Papillomavirus
Parasitocides
Parkinson's disease
Pediococcus
Planococcus (bacterium)

Plesiomonas
 Pneumonia
 Poxviridae
 Pseudomonas
 Psoriasis
 Psychotropics
 Rabies virus
 Reoviridae
 Respiratory syncytial virus
 Rheumatoid arthritis
 Rhinovirus
 Rhodococcus
 Rotavirus
 Rothia (bacterium)
 Rubella virus
 Salmonella typhi
 Sexually transmitted diseases
 Shigella boydii
 Shigella dysenteriae
 Shigella flexneri
 Shigella sonnei
 Spirillum
 Staphylococcus
 Streptobacillus
 Streptococcus
 Thrombosis
 Tranquilizers
 Treponema
 Vaccines
 Vasodilators
 Vibrio
 Vibrio cholerae
 Wolinella succinogenes
 Yersinia

(prevention of infections with bioactive material encapsulated within
 biodegradable-biocompatible polymeric **matrix**)

IT Alkaloids, biological studies
 Antibodies
 Antigens
 Enzymes, biological studies
 Estrogens
 Glycolipids
 Glycopeptides
 Growth factors, animal
 Lipopolysaccharides
 Peptides, biological studies
 Pheromones, animal
 Progestogens
 Prostaglandins
 Proteins, general, biological studies
 Steroids, biological studies
 Sulfonamides
 Tetracyclines
 Vitamins

RL: BPR (Biological process); BSU (Biological study, unclassified); DEV
 (Device component use); PRP (Properties); THU (Therapeutic use); BIOL
 (Biological study); PROC (Process); USES (Uses)
 (prevention of infections with bioactive material encapsulated within
 biodegradable-biocompatible polymeric **matrix**)

IT Drug delivery systems
 (prodrugs; prevention of infections with bioactive material
 encapsulated within biodegradable-biocompatible polymeric
matrix)

- IT Proliferation inhibition
(proliferation inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Antitumor agents
(prostate gland; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Pilus
(proteins; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Scalp
(psoriasis of; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Drug delivery systems
(rectal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Artery, disease
(restenosis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Eye, disease
(retina, neovascularization; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Schistosoma
(schistosomiasis from; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Lung, neoplasm
(small-cell carcinoma, inhibitors; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Lung, neoplasm
(small-cell carcinoma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Muscle relaxants
(spasmolytics; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Contraceptives
(spermicidal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Brain, disease
(spongiform encephalopathy, agent causing; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Appetite
(stimulants; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Brain, disease
(**stroke**; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Strongylus
(strongylodiasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)

- IT Drug delivery systems
(sustained-release, programmable; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Osteoporosis
(therapeutic agents; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Bile
(therapy with; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Drug delivery systems
(topical; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Muscle, disease
(torticollis, spasmodic; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Toxocara
(toxocariasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Toxoplasma gondii
(toxoplasmosis from; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Drug delivery systems
(transdermal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Head
(trauma; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Trichinella
(trichinellosis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Trichomonas
(trichomoniasis; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Drug delivery systems
(vaginal; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Emulsions
(water-in-oil; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT Lactams
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta.-, antibiotics; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT 9002-72-6, Somatotropin
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(deficiency; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric **matrix**)
- IT 9005-49-6, Heparin, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(neutralization of; prevention of infections with bioactive material

- encapsulated within biodegradable-biocompatible polymeric matrix)
- IT 9001-60-9, Lactate dehydrogenase 37326-33-3, Hyaluronidase
 RL: BPR (Biological process); BSU (Biological study, unclassified); DEV (Device component use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (of sperm; prevention of infections with bioactive material encapsulated within biodegradable-biocompatible polymeric matrix)
- IT 50-06-6, Phenobarbital, biological studies 50-12-4, Mephenytoin 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-28-2, 17.beta.-Estradiol, biological studies 50-33-9, Phenylbutazone, biological studies 50-52-2, Thioridazine 50-55-5, Reserpine 50-78-2, Aspirin 51-55-8, Atropine, biological studies 52-24-4, Thiotepe 52-76-6, Lynestrenol 53-03-2, Prednisone 53-16-7, Estrone, biological studies 53-86-1, Indomethacin 54-11-5, Nicotine 55-48-1, Atropine sulfate 55-63-0, Nitroglycerin 55-86-7, Nitrogen mustard 56-53-1, Diethyl stilbestrol 56-75-7, Chloramphenicol 57-27-2, Morphine, biological studies 57-33-0, Sodium pentobarbital 57-42-1, Meperidine 57-53-4, Meproamate 57-63-6, Ethinyl estradiol 57-85-2, Testosterone propionate 57-92-1, Streptomycin a, biological studies 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine 58-22-0 58-25-3, Chlordiazepoxide 58-39-9, Perphenazine 58-73-1, Diphenhydramine 59-01-8, Kanamycin a 59-05-2, Methotrexate 59-92-7, L-Dopa, biological studies 61-33-6, Penicillin g, biological studies 67-20-9, Nitrofurantoin 68-22-4, **Norethisterone** 68-23-5, Norethynodrel 69-09-0, Chlorpromazine hydrochloride 69-53-4, Ampicillin 69-72-7D, Salicylic acid, derivs. 71-58-9, Medroxyprogesterone acetate 72-33-3, Mestranol 76-57-3, Codeine 79-57-2, Oxytetracycline 79-64-1, Dimethisterone 91-81-6, Tripeleminamine 103-90-2, Acetaminophen 113-15-5, Ergotamine 114-07-8, Erythromycin 114-49-8, Hyoscine hydrobromide 121-54-0 122-09-8, Phentermine 125-29-1, Dihydrocodeinone 125-71-3, Dextromethorphan 127-48-0, Trimethadione 128-62-1, Noscipine 145-94-8, Chlorindanol 148-82-3, Melphalan 155-41-9, Methscopolamine bromide 288-32-4D, Imidazole, derivs. 297-76-7, Ethynodiol diacetate 302-22-7, Chlormadinone acetate 305-03-3, Chlorambucil 309-43-3, Sodium secobarbital 315-30-0, Allopurinol 434-03-7, Ethisterone 439-14-5, Diazepam 443-48-1, Metronidazole 469-62-5 471-34-1, Calcium carbonate, biological studies 497-19-8, Sodium carbonate, biological studies 523-87-5, Dimenhydrinate 546-93-0, Magnesium carbonate 578-66-5D, 8-Aminoquinoline, derivs. 578-68-7D, 4-Aminoquinoline, derivs. **595-33-5, Megestrol acetate** 738-70-5, Trimethoprim 846-50-4, Temazepam 1397-89-3, Amphotericin b 1397-94-0, Antimycin a 1403-66-3, Gentamicin 1404-26-8, Polymyxin b 1404-90-6, Vancomycin 1406-05-9D, Penicillin, derivs. 4696-76-8, Kanamycin b 5588-33-0, Mesoridazine 5633-18-1, Melengestrol 5786-21-0, Clozapine 5800-19-1, Metiapine 6533-00-2, Norgestrel 7447-40-7, Potassium chloride (KCl), biological studies 8063-07-8, Kanamycin 9000-83-3, Atpase 9000-92-4, Amylase 9001-62-1, Lipase 9001-63-2, Muramidase 9001-67-6, Neuraminidase 9001-78-9, Alkaline phosphatase 9001-99-4, Ribonuclease 9002-02-2, Succinic acid dehydrogenase 9002-07-7, Trypsin 9004-07-3, Chymotrypsin 9004-10-8, Insulin, biological studies 9025-82-5, Phosphodiesterase 9029-12-3, Glutamic acid dehydrogenase 9035-74-9, Glycogen phosphorylase 9046-27-9, .gamma.-Glutamyltranspeptidase 9079-67-8 10118-90-8, Minocycline 11111-12-9, Cephalosporins 13292-46-1, Rifampin 14271-04-6 21645-51-2, Aluminum hydroxide, biological studies 22232-71-9, Mazindol 24730-10-7, Dihydroergocristine methanesulfonate 25447-66-9 26780-50-7, Poly(lactide co-glycolide) 26787-78-0, Amoxicillin 30516-87-1, Azt 32986-56-4, Tobramycin 35189-28-7, Norgestimate 37205-61-1, Proteinase inhibitor 37517-28-5, Amikacin 53678-77-6D, Muramyl dipeptide, derivs. 53994-73-3, Cefaclor

55268-75-2, Cefuroxime 61036-62-2, Teicoplanin 64221-86-9, Imipenem
80738-43-8, Lincosamide 81103-11-9, Clarithromycin 82419-36-1,
Ofloxacin 85721-33-1, Ciprofloxacin

RL: BPR (Biological process); BSU (Biological study, unclassified); DEV
(Device component use); PRP (Properties); **THU (Therapeutic use)**;
BIOL (Biological study); PROC (Process); USES (Uses)

(prevention of infections with bioactive material encapsulated within
biodegradable-biocompatible polymeric **matrix**)

IT 9002-60-2, Adrenocorticotropin, biological studies 9007-12-9, Calcitonin
9034-40-6, Lhrh 62229-50-9, Epidermal growth factor 115966-68-2,
Histatin 5 (human parotid saliva) 123781-17-9, Histatin 127716-52-3,
Histatin 9 (human parotid saliva) 146553-69-7 174270-18-9,
5-25-Histatin 6 (human parotid saliva) 186138-55-6 186138-60-3
194017-97-5 211118-03-5

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP
(Properties); THU (Therapeutic use); BIOL (Biological study); PROC
(Process); USES (Uses)

(prevention of infections with bioactive material encapsulated within
biodegradable-biocompatible polymeric **matrix**)

IT 9005-64-5, Tween 20 9005-65-6, Tween 80 9005-67-8, Tween 60
106392-12-5, Pluronic

RL: MOA (Modifier or additive use); PRP (Properties); THU (Therapeutic
use); BIOL (Biological study); USES (Uses)

(prevention of infections with bioactive material encapsulated within
biodegradable-biocompatible polymeric **matrix**)

IT 75-09-2, uses

RL: NUU (Other use, unclassified); USES (Uses)

(prevention of infections with bioactive material encapsulated within
biodegradable-biocompatible polymeric **matrix**)

IT 146553-70-0 146553-71-1 146553-72-2 146553-73-3 146553-74-4
146553-75-5 146553-76-6 146553-77-7 146553-78-8 146553-81-3
146553-82-4 146553-83-5 146553-85-7 146553-86-8 146553-87-9
146553-88-0 146553-89-1 146553-90-4 146553-91-5 146553-92-6
164583-46-4 164583-50-0 164583-51-1 211118-14-8 211118-17-1

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(prevention of infections with bioactive material encapsulated within
biodegradable-biocompatible polymeric **matrix**)

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Jeyanthi; Proceedings International Symposium on Controlled Release of
Bioactive Materials 1996, P351 HCAPLUS
- (2) Oppenheim; US 5486503 A 1996 HCAPLUS
- (3) Syntex U S AInc; EP 0052510 B2 1994 HCAPLUS
- (4) Wang; J of Controlled Release 1991, V17, P23 HCAPLUS
- (5) Yan; J of Controlled Release 1994, V32(3), P231 HCAPLUS
- (6) Yeh; A Novel Emulsification-Solvent Extraction Technique for Production of
Protein Loaded Biodegradable Microparticles for Vaccine and Drug Delivery
1995, V33(3), P437 HCAPLUS

IT 68-22-4, Norethisterone 595-33-5,
Megestrol acetate


RL: BPR (Biological process); BSU (Biological study, unclassified); DEV
(Device component use); PRP (Properties); **THU (Therapeutic use)**;
BIOL (Biological study); PROC (Process); USES (Uses)

(prevention of infections with bioactive material encapsulated within
biodegradable-biocompatible polymeric **matrix**)

RN 68-22-4 HCAPLUS


CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



RN 595-33-5 HCAPLUS
 CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 33 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:146574 HCAPLUS
 DN 128:184708
 TI **Topical** pharmaceutical compositions comprising bioadhesive carrier, a solvent and a **clay**
 IN Kanios, David P.; Gentile, Joseph A.; Mantelle, Juan A.; Sablotsky, Steven
 PA Noven Pharmaceuticals, Inc., USA
 SO U.S., 18 pp., Cont.-in-part of U.S. 5,446,070.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM A61K047-32
 ICS A61K009-70
 NCL 514772600
 CC **63-6** (Pharmaceuticals)
 FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5719197	A	19980217	US 1995-477361	19950607 <--
	US 4814168	A	19890321	US 1988-164482	19880304 <--
	US 4994267	A	19910219	US 1989-295847	19890111 <--
	AU 9050349	A1	19900813	AU 1990-50349	19900110 <--
	AU 632534	B2	19930107		
	NL 9020159	A	19910102	NL 1990-20159	19900110 <--
	EP 453505	A1	19911030	EP 1990-902716	19900110 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04502719	T2	19920521	JP 1990-502850	19900110 <--
	JP 07093939	B4	19951011		
	US 5300291	A	19940405	US 1991-671709	19910402 <--

CA 2104474	AA	19920828	CA 1992-2104474	19920227 <--
EP 728477	A2	19960828	EP 1996-106534	19920227 <--
EP 728477	A3	19960911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
US 5686099	A	19971111	US 1993-67001	19930526 <--
AU 9526998	A1	19961230	AU 1995-26998	19950607 <--
AU 9528331	A1	19950928	AU 1995-28331	19950802 <--
AU 694243	B2	19980716		
WO 9640086	A2	19961219	WO 1996-US8294	19960605 <--
WO 9640086	A3	19970213		

W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG

RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA

AU 9660290	A1	19961230	AU 1996-60290	19960605 <--
ZA 9604735	A	19961219	ZA 1996-4735	19960606 <--

PRAI US 1988-164482 A2 19880304 <--
 US 1989-295847 A2 19890111 <--
 US 1991-661827 B2 19910227 <--
 US 1991-671709 A1 19910402 <--
 US 1991-813196 A2 19911223 <--
 US 1993-67001 A2 19930526 <--
 US 1993-112330 A2 19930827 <--
 WO 1990-US242 A 19900110 <--
 EP 1992-907818 A3 19920227 <--
 US 1995-477361 A 19950607 <--
 WO 1995-US7229 W 19950607 <--
 WO 1996-US8294 W 19960605 <--

AB Compns. for topical application comprising a therapeutically effective amt. of a pharmaceutical agent(s), a pharmaceutically acceptable bioadhesive carrier, a solvent for the pharmaceutical agent(s) in the carrier and a **clay**, and methods of administering the pharmaceutical agents to a mammal are disclosed. A topical compn. contained lidocaine base 8.0, dipropylene glycol 5.0, 60% lecithin in propylene glycol 8.0, karaya gum 10.0, and glycerin 6.0%.

ST topical pharmaceutical bioadhesive solvent **clay**; lidocaine dipropylene glycol karaya gum pharmaceutical

IT Androgens

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antiandrogens; topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)

IT Estrogens

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antiestrogens; topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)

IT Muscarinic receptors

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (blocking drugs; topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)

IT Ion channel blockers

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (calcium; topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)

IT Vasodilators

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (coronary; topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)

IT Drug delivery systems

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhalants; topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)

- IT Dizziness
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)
- IT Nervous system agents
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mitotics; topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)
- IT Eye
Eye
Nervous system agents
Nervous system agents
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mydriatics; topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)
- IT Hormones, animal, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-steroidal; topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)
- IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyhydric; topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)
- IT Muscle relaxants
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spasmolytics; topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)
- IT Solvents
(topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)
- IT Adrenoceptor agonists
Allergy inhibitors
Analgesics
Androgens
Anti-inflammatory agents
Antiarrhythmics
Anticonvulsants
Antidepressants
Antidiabetic agents
Antihistamines
Antihypertensives
Antimalarials
Antimicrobial agents
Antimigraine agents
Antiparkinsonian agents
Antipsychotics
Antipyretics
Antitumor agents
Antiulcer agents
Appetite depressants
Bentonite, biological studies
Cardiotonics
Cholinergic agonists
Clays, biological studies
Decongestants
Enzymes, biological studies
Estrogens
Fungicides
Glycols, biological studies
Mucous membrane
Muscarinic antagonists
Muscle relaxants
Nervous system agents

Peptides, biological studies
 Plasticizers
 Polyoxyalkylenes, biological studies
 Resins
 Skin
 Tranquilizers
 Vasoconstrictors
 Vitamins

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)

IT Drug delivery systems

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (topical; topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)

IT Adrenoceptor antagonists

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (.beta.-; topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)

IT 50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-28-2D, Estradiol, esters 50-70-4, Sorbitol., biological studies 51-98-9, **Norethindrone** acetate 52-76-6 53-16-7, Estrone, biological studies 56-53-1, Diethylstilbestrol 56-81-5, 1,2,3-Propanetriol, biological studies 57-55-6, 1,2-Propanediol, biological studies 57-63-6, Ethinyl estradiol; 57-83-0, Progesterone, biological studies 58-18-4, Methyltestosterone 58-22-0, Testosterone; 59-46-1, Procaine **68-22-4, Norethindrone** 68-23-5, Norethynodrel 68-96-2, Hydroxyprogesterone 71-58-9, Medroxyprogesterone acetate; 72-33-3, Mestranol 76-43-7, Fluoxymesterone; 79-64-1, Dimethisterone 85-79-0, Dibucaine 94-09-7, Benzocaine 94-24-6, Tetracaine 96-88-8, Mepivacaine 107-21-1, 1,2-Ethanediol, biological studies 107-41-5, Hexylene glycol, 133-16-4, Chloroprocaine 137-58-6, Lidocaine 152-62-5, Dydrogesterone 297-76-7, Ethynodiol diacetate 472-54-8, 19-Norprogesterone 474-86-2, Equilin 586-60-7, Dyclonine **595-33-5, Megestrol acetate** 630-56-8, Hydroxyprogesterone caproate 721-50-6, Prilocaine 979-32-8, Estradiol valerate 1961-77-9, Chlormadinone; 5633-18-1, Melengestrol 6533-00-2 7280-37-7, Estropipate 9000-30-0, Guar gum 9000-36-6, Karaya gum 9000-65-1, Tragacanth gum 9000-69-5, Pectin 9004-34-6, Cellulose, biological studies 10116-22-0, Demegestone 11138-66-2, Xanthan gum 22916-47-8, Miconazole. 23593-75-1, Clotrimazole. 25265-71-8, Dipropylene glycol 25265-75-2, Butylene glycol 25322-68-3 25322-69-4, Polypropylene glycol 34184-77-5, Promegestone 36637-18-0, Etidocaine 38396-39-3, Bupivacaine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (topical pharmaceutical compns. comprising bioadhesive carrier, solvent and **clay**)

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anon; LU 52460 1966
- (2) Anon; GB 1126849 1968 HCAPLUS
- (3) Anon; GB 2073588 1981 HCAPLUS
- (4) Anon; FR 2479002 1981 HCAPLUS
- (5) Anon; DE 3039540 A1 1981 HCAPLUS
- (6) Anon; EP 0139127 1984 HCAPLUS
- (7) Anon; DE 217989 A1 1985
- (8) Anon; EP 0250187 A2 1987 HCAPLUS
- (9) Anon; JP 62-230716 1987 HCAPLUS
- (10) Anon; JP 62-230717 1987 HCAPLUS
- (11) Anon; WO 8910740 1989 HCAPLUS
- (12) Anon; EP 0363224 A1 1990 HCAPLUS
- (13) Anon; WO 9114463 1991 HCAPLUS
- (14) Anon; WO 9215289 1992 HCAPLUS

- (15) Anon; EP 0598606 A1 1993 HCAPLUS
- (16) Anon; WO 9501766 1995
- (17) Anon; Japanese Abstract 57-181,020
- (18) Campbell; US 4379454 1983
- (19) Folkman; US 4391797 1983 HCAPLUS
- (20) Higuchi; US 4144317 1979 HCAPLUS
- (21) Hymes; US 4675009 1987 HCAPLUS
- (22) Ito; US 4421737 1983 HCAPLUS
- (23) Mantelle; US 5234957 1993
- (24) Mantelle; US 5446070 1995
- (25) Miranda; US 5474783 1995
- (26) Nuwayser; US 4624665 1986 HCAPLUS
- (27) Sablotsky; US 4814168 1989 HCAPLUS
- (28) Sablotsky; US 4994267 1991 HCAPLUS
- (29) Sablotsky; US 5300291 1994 HCAPLUS
- (30) Von Bittera; US 4661099 1987 HCAPLUS
- (31) Wick; US 4751087 1988 HCAPLUS
- (32) Zaffaroni; US 3948262 1976 HCAPLUS

IT 68-22-4, Norethindrone 595-33-5,

Megestrol acetate


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(topical pharmaceutical compns. comprising bioadhesive carrier, solvent and clay)

RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 595-33-5 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AN 1997:107455 HCAPLUS
 DN 126:122452
 TI Compositions and methods for **topical** administration of
 pharmaceutically active agents
 IN Kanios, David P.; Gentile, Joseph A.; Mantelle, Juan A.; Sablotsky, Steven
 PA Noven Pharmaceuticals, Inc., USA; Kanios, David P.; Gentile, Joseph A.;
 Mantelle, Juan A.; Sablotsky, Steven
 SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K009-70
 CC 63-5 (Pharmaceuticals)
 Section cross-reference(s): 1, 2

FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9640086	A2	19961219	WO 1996-US8294	19960605 <--
	WO 9640086	A3	19970213		
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RQ, RU, SD, SE, SG			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA			
	AU 9526998	A1	19961230	AU 1995-26998	19950607 <--
	US 5719197	A	19980217	US 1995-477361	19950607 <--
	AU 9660290	A1	19961230	AU 1996-60290	19960605 <--
PRAI	US 1995-477361	A	19950607	<--	
	US 1988-164482	A2	19880304	<--	
	US 1989-295847	A2	19890111	<--	
	US 1991-661827	B2	19910227	<--	
	US 1991-671709	A1	19910402	<--	
	US 1991-813196	A2	19911223	<--	
	US 1993-67001	A2	19930526	<--	
	US 1993-112330	A2	19930827	<--	
	WO 1995-US7229	W	19950607	<--	
	WO 1996-US8294	W	19960605	<--	
AB	Compns. for topical application comprising a therapeutically effective amt. of a pharmaceutical agent(s), a pharmaceutically acceptable bioadhesive carrier, a solvent for the pharmaceutical agent(s) in the carrier and a clay , and methods of administering the pharmaceutical agents to a mammal are disclosed. Thus, a formulation of the invention can be prepd. which consists (wt. %) of lidocaine base 8.0, dipropylene glycol 5.0, 60% lecithin in propylene glycol 8.0, bentonite (Polargel NF) 2.0, zinc oxide 0.1, and glycerin 6.0.				
ST	topical drug dosage form				
IT	Estrogens				
	RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (antiestrogens; compns. and methods for topical administration of pharmaceutically active agents)				
IT	Hormones, animal, biological studies				
	RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (antimones; compns. and methods for topical administration of pharmaceutically active agents)				
IT	Adhesives				
	(biol.; compns. and methods for topical administration of pharmaceutically active agents)				
IT	Ion channel blockers				
	(calcium; compns. and methods for topical administration of pharmaceutically active agents)				

- IT Adrenoceptor agonists
- Allergy inhibitors
- Analgesics
- Anti-inflammatory agents
- Antiarrhythmics
- Anticonvulsants
- Antidepressants
- Antidiabetic agents
- Antihistamines
- Antihypertensives
- Antimalarials
- Antimicrobial agents
- Antimigraine agents
- Antiparkinsonian agents**
- Antipsychotics
- Antipyretics
- Antitumor agents
- Antiulcer agents
- Appetite depressants
- Cardiotonics
- Cholinergic agonists
- Cognition enhancers**
- Decongestants
- Fungicides
- Gums and Mucilages
- Muscarinic antagonists
- Nervous system agents
- Plasticizers
- Solvents
- Vasoconstrictors
- (comps. and methods for topical administration of pharmaceutically active agents)
- IT Androgens
- Bentonite, biological studies
- Clays**, biological studies
- Enzymes, biological studies
- Estrogens
- Hormones, animal, biological studies
- Peptides, biological studies
- Polyoxyalkylenes, biological studies
- Polyoxyalkylenes, biological studies
- Progestogens
- Vitamins
- RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
- (comps. and methods for topical administration of pharmaceutically active agents)
- IT Vasodilators
- (coronary; comps. and methods for topical administration of pharmaceutically active agents)
- IT Anesthetics
- (local; comps. and methods for topical administration of pharmaceutically active agents)
- IT Plant (Embryophyta)
- (medicinal; comps. and methods for topical administration of pharmaceutically active agents)
- IT Nervous system agents
- (miotics; comps. and methods for topical administration of pharmaceutically active agents)
- IT Eye
- Eye
- Nervous system agents
- Nervous system agents

- (mydriatics; compns. and methods for topical administration of pharmaceutically active agents)
- IT Alcohols, biological studies
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(polyhydric; compns. and methods for topical administration of pharmaceutically active agents)
- IT Clays, biological studies
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(smectitic; compns. and methods for topical administration of pharmaceutically active agents)
- IT Drug delivery systems
(topical; compns. and methods for topical administration of pharmaceutically active agents)
- IT Adrenoceptor antagonists
(.beta.-; compns. and methods for topical administration of pharmaceutically active agents)
- IT 50-27-1, Estriol 50-28-2, 17.beta.-Estradiol, biological studies 50-28-2D, 17.beta.-Estradiol, esters 50-70-4, D-Glucitol, biological studies 51-98-9, **Norethindrone** acetate 52-76-6 53-16-7, Estrone, biological studies 56-53-1, Diethylstilbestrol 56-81-5, 1,2,3-Propanetriol, biological studies 57-55-6, 1,2-Propanediol, biological studies 57-83-0, Progesterone, biological studies 58-18-4, Methyltestosterone 58-22-0, Testosterone 59-46-1, Procaine 68-22-4, **Norethindrone** 68-23-5, Norethynodrel 68-96-2, 17.alpha.-Hydroxyprogesterone 71-58-9, Medroxyprogesterone acetate 72-33-3, Mestranol 76-43-7, Fluoxymesterone 79-64-1, Dimethisterone 85-79-0, Dibucaine 94-09-7, Benzocaine 94-24-6, Tetracaine 96-88-8, Mepivacaine 107-21-1, 1,2-Ethanediol, biological studies 107-41-5, Hexylene glycol 133-16-4, Chlorprocaine 137-58-6, Lidocaine 152-62-5, Dydrogesterone 297-76-7, Ethynodiol diacetate 472-54-8, 19-Norprogesterone 474-86-2, Equilin 586-60-7, Dyclonine 595-33-5, **Megestrol acetate** 630-56-8, Hydroxyprogesterone caproate 721-50-6, Prilocaine 979-32-8, 17.beta.-Estradiol valerate 1961-77-9, Chlormadinone 4717-38-8, 17.beta.-Ethinyl estradiol 5633-18-1, Melengestrol 6533-00-2 7280-37-7, Estropipate 9000-30-0, Guar gum 9000-36-6, Karaya gum 9000-65-1, Tragacanth gum 9004-34-6, Cellulose, biological studies 9004-34-6D, Cellulose, derivs., biological studies 10116-22-0, Demegestone 11138-66-2, Xanthan gum 22916-47-8, Miconazole 23593-75-1, Clotrimazole 25265-71-8, Dipropylene glycol 25265-75-2, Butylene glycol 25322-68-3 25322-69-4, Polypropylene glycol 34184-77-5, Promegestone 36637-18-0, Etidocaine 38396-39-3, Bupivacaine
RL: PEP (Physical, engineering or chemical process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
(compns. and methods for topical administration of pharmaceutically active agents)
- IT 50-27-1, Estriol 50-28-2, 17.beta.-Estradiol, biological studies 50-28-2D, 17.beta.-Estradiol, esters 50-70-4, D-Glucitol, biological studies 51-98-9, **Norethindrone** acetate 52-76-6 53-16-7, Estrone, biological studies 56-53-1, Diethylstilbestrol 56-81-5, 1,2,3-Propanetriol, biological studies 57-55-6, 1,2-Propanediol, biological studies 57-83-0, Progesterone, biological studies 58-18-4, Methyltestosterone 58-22-0, Testosterone 59-46-1, Procaine 68-22-4, **Norethindrone** 68-23-5, Norethynodrel 68-96-2, 17.alpha.-Hydroxyprogesterone 71-58-9, Medroxyprogesterone acetate 72-33-3, Mestranol 76-43-7, Fluoxymesterone 79-64-1, Dimethisterone 85-79-0, Dibucaine 94-09-7, Benzocaine 94-24-6, Tetracaine 96-88-8, Mepivacaine 107-21-1, 1,2-Ethanediol, biological studies 107-41-5, Hexylene glycol 133-16-4, Chlorprocaine 137-58-6, Lidocaine 152-62-5, Dydrogesterone 297-76-7, Ethynodiol diacetate

472-54-8, 19-Norprogesterone 474-86-2, Equilin 586-60-7, Dyclonine
595-33-5, Megestrol acetate 630-56-8;
 Hydroxyprogesterone caproate 721-50-6, Prilocaine 979-32-8,
 17.beta.-Estradiol valerate 1961-77-9, Chlormadinone 4717-38-8,
 17.beta.-Ethinyl estradiol 5633-18-1, Melengestrol 6533-00-2
 7280-37-7, Estropipate 9000-30-0, Guar gum 9000-36-6, Karaya gum
 9000-65-1, Tragacanth gum 9004-34-6, Cellulose, biological studies
 9004-34-6D, Cellulose, derivs., biological studies 10116-22-0,
 Demegestone 11138-66-2, Xanthan gum 22916-47-8, Miconazole
 23593-75-1, Clotrimazole 25265-71-8, Dipropylene glycol 25265-75-2,
 Butylene glycol 25322-68-3 25322-69-4, Polypropylene glycol
 34184-77-5, Promegestone 36637-18-0, Etidocaine 38396-39-3,
 Bupivacaine

RL: PEP (Physical, engineering or chemical process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
 (comps. and methods for topical administration of pharmaceutically active agents)


IT **68-22-4, Norethindrone 595-33-5, Megestrol acetate**

RL: PEP (Physical, engineering or chemical process); **THU (Therapeutic use)**; BIOL (Biological study); PROC (Process); USES (Uses)
 (comps. and methods for topical administration of pharmaceutically active agents)

RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 595-33-5 HCAPLUS

CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



AN 1994:253358 HCAPLUS
 DN 120:253358
 TI **Cyclodextrin** complexes with polymers, drugs, agrochemicals and cosmetics
 IN Loftsson, Thorsteinn
 PA Iceland
 SO Eur. Pat. Appl., 46 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 IC ICM A61K047-48
 CC **63-5** (Pharmaceuticals)
 Section cross-reference(s): 5, 17, 62

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 579435	A1	19940119	EP 1993-305280	19930706 <--
	EP 579435	B1	19990317		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5324718	A	19940628	US 1992-912853	19920714 <--
	AT 177647	E	19990415	AT 1993-305280	19930706 <--
	ES 2132190	T3	19990816	ES 1993-305280	19930706 <--
	US 5472954	A	19951205	US 1994-240510	19940511 <--
PRAI	US 1992-912853		19920714 <--		
	EP 1993-305280		19930706 <--		
AB	A method for enhancing the complexation of a cyclodextrin (I) with a lipophilic and/or water-labile drug, comprising combining .apprx.0.1-70% (wt./vol.) of I and .apprx.0.001-5% (wt./vol.) of a water-sol. polymer in an aq. medium. The polymer and I are dissolved in the aq. medium before the drug is added. To a soln. contg. Na CM-cellulose 0.25 and 2-hydroxypropyl-.beta.-cyclodextrin 10% was added acetazolamide (II) and the soln. was heated at 120.degree. for 20 min and allowed to equilibrate at room temp. for 3 days and amt. of II was detd. The soly. of II was 3.11mg/mL as compared to 0.7 for control contg. only II. Different formulations contg. cyclodextrin complexes with polymers and drugs are disclosed:				
ST	cyclodextrin complex polymer drug soly; acetazolamide CM cellulose cyclodextrin complex				
IT	Cosmetics				
	Food				
	(additives for, complexes with cyclodextrin and polymers, prepn. of)				
IT	Parkinsonism				
	(agents for treatment of, complexes with cyclodextrin and polymers, prepn. of, with enhanced soly.)				
IT	Narcotics				
	(agonists of, complexes with cyclodextrin and polymers, prepn. of, with enhanced soly.)				
IT	Acrylic polymers, biological studies				
	Peptides, biological studies				
	Polysaccharides, biological studies				
	RL: PREP (Preparation)				
	(complexes with cyclodextrin and drugs and agrochems. and cosmetic compns., prepn. of)				
IT	Caseins, biological studies				
	Gelatins, biological studies				
	RL: PREP (Preparation)				
	(complexes with cyclodextrin and drugs and agrochems. and cosmetic compns., prepn. of, with enhanced soly.)				
IT	Agrochemicals				
	(complexes with cyclodextrin and polymers, prepn. of)				
IT	Anabolic agents				
	Anesthetics				
	Anthelmintics				

Anti-infective agents
Antiarrhythmics
Antibiotics
Anticoagulants and Antithrombotics
Anticonvulsants and Antiepileptics
Antidepressants
Antidiabetics and Hypoglycemics
Antiemetics
Antihistaminics
Antihypertensives
Bactericides, Disinfectants, and Antiseptics
Blood platelet aggregation inhibitors
Cardiotonics
Diuretics
Fungicides and Fungistats
Hypnotics and Sedatives
Inflammation inhibitors
Muscle relaxants
Narcotic antagonists
Neoplasm inhibitors
Protozoacides
Tranquilizers and Neuroleptics
Vasoconstrictors
Vasodilators
Virucides and Virustats
Vomiting
Androgens
Estrogens
Steroids, biological studies
Vitamins

RL: PREP (Preparation)

(complexes with cyclodextrin and polymers, prepn. of, with enhanced soly.)

IT Mouthwashes

(cyclodextrin complexes with polymers and drugs and agrochems. and cosmetics in)

IT Analgesics

(non-steroidal, complexes with cyclodextrin and polymers, prepn. of, with enhanced soly.)

IT Mental disorder

(Alzheimer's disease, agents for treatment of, complexes with cyclodextrin and polymers, prepn. of, with enhanced soly.)

IT Antihistaminics

(H2, complexes with cyclodextrin and polymers, prepn. of, with enhanced soly.)

IT Tranquilizers and Neuroleptics

(antipsychotics, complexes with cyclodextrin and polymers, prepn. of, with enhanced soly.)

IT Neurotransmitter agonists

(dopaminergic, complexes with cyclodextrin and polymers, prepn. of, with enhanced soly.)

IT **Corticosteroids**, biological studies

RL: PREP (Preparation)

(gluco-, complexes with cyclodextrin and polymers, prepn. of, with enhanced soly.)

IT Diagnosis

(radio-, agents, complexes with cyclodextrin and polymers, prepn. of, with enhanced soly.)

IT Neurotransmitter antagonists

(serotonergic, complexes with cyclodextrin and polymers, prepn. of, with enhanced soly.)

IT Pharmaceutical dosage forms

(solns., ophthalmic, cyclodextrin complexes with polymers and drugs and

- agrochems. and cosmetics in)
- IT Adrenergic antagonists
(.beta.-, complexes with cyclodextrin and polymers, prepn. of, with enhanced soly.)
- IT 9002-18-0P, Agar
RL: PREP (Preparation)
(complexes with cyclodextrin and drugs and agrochems. and cosmetic compns., prepn. of, with enhanced soly.)
- IT 9001-03-0DP, Carbonic anhydrase, complexes with cyclodextrin and polymers
RL: BSU (Biological study, unclassified); BIOL (Biological study); PREP (Preparation)
(inhibitor, prepn. of, with enhanced soly.)
- IT 50-02-2DP, Dexamethasone, complexes with cyclodextrin and polymers
50-06-6DP, Phenobarbital, complexes with cyclodextrin and polymers
50-23-7DP, Hydrocortisone, complexes with cyclodextrin and polymers
50-24-8DP, Prednisolone, complexes with cyclodextrin and polymers
50-27-1DP, Estriol, complexes with cyclodextrin and polymers 50-28-2DP,
17.beta.-Estradiol, complexes with cyclodextrin and polymers 50-47-5DP,
Desipramine, complexes with cyclodextrin and polymers 50-50-0DP,
Estradiol benzoate, complexes with cyclodextrin and polymers 50-78-2DP,
Aspirin, complexes with cyclodextrin and polymers 51-21-8DP,
5-Fluorouracil, complexes with cyclodextrin and polymers 51-61-6DP,
Dopamine, complexes with cyclodextrin and polymers 51-98-9DP,
Norethindrone acetate, complexes with cyclodextrin and polymers
52-01-7DP, Spironolactone, complexes with cyclodextrin and polymers
53-16-7DP, Estrone, complexes with cyclodextrin and polymers 53-86-1DP,
Indomethacin, complexes with cyclodextrin and polymers 54-31-9DP,
Furosemide, complexes with cyclodextrin and polymers 55-63-0DP,
Nitroglycerin, complexes with cyclodextrin and polymers 56-12-2DP, GABA,
complexes with cyclodextrin and polymers 57-41-0DP, Phenytoin, complexes
with cyclodextrin and polymers 57-63-6DP, 17.alpha.-Ethinylestradiol,
complexes with cyclodextrin and polymers 57-83-0DP, Progestin, complexes
with cyclodextrin and polymers 58-00-4DP, Apomorphine, complexes with
cyclodextrin and polymers 58-18-4DP, 17-Methyltestosterone, complexes
with cyclodextrin and polymers 58-22-0DP, Testosterone, complexes with
cyclodextrin and polymers 58-25-3DP, Chlordiazepoxide, complexes with
cyclodextrin and polymers 59-05-2DP, Methotrexate, complexes with
cyclodextrin and polymers 59-66-5DP, Acetazolamide, complexes with
cyclodextrin and polymers 60-18-4DP, Tyrosine, complexes with
cyclodextrin and polymers 61-32-5DP, Methicillin, complexes with
cyclodextrin and polymers 61-33-6DP, Benzylpenicillin, complexes with
cyclodextrin and polymers 61-54-1DP, Tryptamine, complexes with
cyclodextrin and polymers 61-72-3DP, Cloxacillin, complexes with
cyclodextrin and polymers 66-76-2DP, Dicoumarol, complexes with
cyclodextrin and polymers 66-79-5DP, Oxacillin, complexes with
cyclodextrin and polymers **68-22-4DP, Norethindrone**,
complexes with cyclodextrin and polymers 68-23-5DP, Norethynodrel,
complexes with cyclodextrin and polymers 70-00-8DP, Trifluorothymidine,
complexes with cyclodextrin and polymers 71-63-6DP, Digitoxin, complexes
with cyclodextrin and polymers 72-33-3DP, Ethinylestradiol 3-methyl
ether, complexes with cyclodextrin and polymers 76-25-5DP, Triamcinolone
acetate, complexes with cyclodextrin and polymers 76-73-3DP,
Secobarbital, complexes with cyclodextrin and polymers 76-74-4DP,
Pentobarbital, complexes with cyclodextrin and polymers 99-66-1DP,
Valproic acid, complexes with cyclodextrin and polymers 124-94-7DP,
Triamcinolone, complexes with cyclodextrin and polymers 137-58-6DP,
Lidocaine, complexes with cyclodextrin and polymers 146-22-5DP,
Nitrazepam, complexes with cyclodextrin and polymers 148-82-3DP,
Melfalan, complexes with cyclodextrin and polymers 154-93-8DP,
Carmustine, complexes with cyclodextrin and polymers 298-46-4DP,
Carbamazepine, complexes with cyclodextrin and polymers 305-03-3DP,
Chlorambucil, complexes with cyclodextrin and polymers 434-03-7DP,
Ethinyltestosterone, complexes with cyclodextrin and polymers 439-14-5DP,

Diazepam, complexes with cyclodextrin and polymers 452-35-7DP,
Ethoxzolamide, complexes with cyclodextrin and polymers 554-57-4DP,
Methazolamide, complexes with cyclodextrin and polymers 604-75-1DP,
Oxazepam, complexes with cyclodextrin and polymers 745-65-3DP,
Alprostadiol, complexes with cyclodextrin and polymers 846-49-1DP,
Lorazepam, complexes with cyclodextrin and polymers 846-50-4DP,
Temazepam, complexes with cyclodextrin and polymers 848-75-9DP,
Lormetazepam, complexes with cyclodextrin and polymers 1035-77-4DP,
Estradiol 3-methyl ether, complexes with cyclodextrin and polymers
1622-62-4DP, Flunitrazepam, complexes with cyclodextrin and polymers
3116-76-5DP, Dicloxacillin, complexes with cyclodextrin and polymers
5104-49-4DP, Flurbiprofen, complexes with cyclodextrin and polymers
6533-00-2DP, Norgestrel, complexes with cyclodextrin and polymers
7585-39-9DP, .beta.-Cyclodextrin, derivs., complexes with polymers and
drugs 8064-90-2DP, Cotrimoxazole, complexes with cyclodextrin and
polymers 9000-69-5DP, Pectin, complexes with cyclodextrin and drugs and
agrochems. and cosmetic compns. 9003-39-8DP, Pvp, complexes with
cyclodextrin and drugs and agrochems. and cosmetic compns. 9004-32-4DP,
Sodium carboxymethyl cellulose, complexes with cyclodextrin and drugs and
agrochems. and cosmetic compns. 9004-58-4DP, Hydroxyethyl ethyl
cellulose, complexes with cyclodextrin and drugs and agrochems. and
cosmetic compns. 9004-62-0DP, Hydroxyethyl cellulose, complexes with
cyclodextrin and drugs and agrochems. and cosmetic compns. 9004-64-2DP,
Hydroxypropyl cellulose, complexes with cyclodextrin and drugs and
agrochems. and cosmetic compns. 9004-65-3DP, Hydroxypropyl methyl
cellulose, complexes with cyclodextrin and drugs and agrochems. and
cosmetic compns. 9004-67-5DP, Methyl cellulose, complexes with
cyclodextrin and drugs and agrochems. and cosmetic compns. 9005-38-3DP,
Sodium alginate, complexes with cyclodextrin and drugs and agrochems. and
cosmetic compns. 9005-80-5DP, Inulin, complexes with cyclodextrin and
drugs and agrochems. and cosmetic compns. 9032-42-2DP, Hydroxyethyl
methyl cellulose, complexes with cyclodextrin and drugs and agrochems. and
cosmetic compns. 9062-14-0DP, Hydroxypropyl ethyl cellulose, complexes
with cyclodextrin and drugs and agrochems. and cosmetic compns.
10058-19-2DP, Glucosyl-.alpha.-cyclodextrin, complexes with polymers and
drugs 13010-47-4DP, Lomustine, complexes with cyclodextrin and polymers
13182-89-3DP, Metronidazole benzoate, complexes with cyclodextrin and
polymers 15687-27-1DP, Ibuprofen, complexes with cyclodextrin and
polymers 17465-86-0DP, .gamma.-Cyclodextrin, hydroxypropyl derivs.,
complexes with polymers and agrochems. and cosmetic compns.
17617-23-1DP, Flurazepam, complexes with cyclodextrin and polymers
20830-75-5DP, Digoxin, complexes with cyclodextrin and polymers
22204-53-1DP, Naproxen, complexes with cyclodextrin and polymers
22916-47-8DP, Miconazole, complexes with cyclodextrin and polymers
23214-92-8DP, Doxorubicin, complexes with cyclodextrin and polymers
23930-19-0DP, Alfaxalone, complexes with cyclodextrin and polymers
26839-75-8DP, Timolol, complexes with cyclodextrin and polymers
28911-01-5DP, Triazolam, complexes with cyclodextrin and polymers
29122-68-7DP, Atenolol, complexes with cyclodextrin and polymers
29975-16-4DP, Estazolam, complexes with cyclodextrin and polymers
30516-87-1DP, Zidovudine, complexes with cyclodextrin and polymers
31430-15-6DP, Flubendazole, complexes with cyclodextrin and polymers
35121-78-9DP, Prostacyclin, complexes with cyclodextrin and polymers
36322-90-4DP, Piroxicam, complexes with cyclodextrin and polymers
36735-22-5DP, Quazepam, complexes with cyclodextrin and polymers
38194-50-2DP, Sulindac, complexes with cyclodextrin and polymers
50851-57-5DP, Polystyrene sulfonate, complexes with cyclodextrin and drugs
and agrochems. and cosmetic compns. 52468-60-7DP, Flunarizine, complexes
with cyclodextrin and polymers 59277-89-3DP, Acyclovir, complexes with
cyclodextrin and polymers 61197-73-7DP, Loprazolam, complexes with
cyclodextrin and polymers 65277-42-1DP, Ketoconazole, complexes with
cyclodextrin and polymers 76824-35-6DP, Famotidine, complexes with
cyclodextrin and polymers 84625-61-6DP, Itraconazole, complexes with

cyclodextrin and polymers 92517-02-7DP, Glucosyl-.beta.-cyclodextrin, complexes with polymers and drugs 100817-30-9DP, Maltosyl-.alpha.-cyclodextrin, complexes with polymers and agrochems. and cosmetic compns. 100817-30-9DP, Maltosyl-.alpha.-cyclodextrin, complexes with polymers and drugs 127950-56-5DP, complexes with cyclodextrin and polymers 127950-61-2DP, complexes with cyclodextrin and polymers 127950-62-3DP, complexes with cyclodextrin and polymers

RL: PREP (Preparation)

(prepn. of, with enhanced soly.)

IT 68-22-4DP, Norethindrone, complexes with cyclodextrin and polymers


RL: PREP (Preparation)

(prepn. of, with enhanced soly.)

RN 68-22-4 HCAPLUS

CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 36 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 1994:226984 HCAPLUS

DN 120:226984

TI Compositions of oral nondissolvable **matrixes** for transmucosal administration of medicaments

IN Stanley, Theodore H.; Hague, Brian

PA University of Utah Research Foundation, USA

SO U.S., 20 pp. Cont.-in-part of U.S. 4,863,737.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K009-68

NCL 424440000

CC 63-6 (Pharmaceuticals)

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5288498	A	19940222	US 1989-403752	19890905 <--
	US 4671953	A	19870609	US 1985-729301	19850501 <--
	EP 487520	A1	19920603	EP 1989-909497	19890816 <--
	EP 487520	B1	19950412		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 05501539	T2	19930325	JP 1989-504878	19890816 <--
	JP 2801050	B2	19980921		
	AU 641127	B2	19930916	AU 1989-40704	19890816 <--
	AT 120953	E	19950415	AT 1989-909497	19890816 <--
	CA 1338978	A1	19970311	CA 1989-609378	19890824 <--
	AU 9050352	A1	19910408	AU 1990-50352	19890905 <--
	AU 645966	B2	19940203		
	EP 493380	A1	19920708	EP 1990-902584	19890905 <--
	EP 493380	B1	19971029		

R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE
 US 5132114 A 19920721 US 1989-402881 19890905 <--
 JP 05501854 T2 19930408 JP 1990-502779 19890905 <--
 CA 1339075 A1 19970729 CA 1989-610329 19890905 <--
 AT 159658 E 19971115 AT 1990-902584 19890905 <--
 WO 9103236 A1 19910321 WO 1990-US4369 19900803 <--

W: AU, CA, JP, NO
 RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE
 AU 9063371 A1 19910408 AU 1990-63371 19900803 <--
 AU 642664 B2 19931028
 EP 490944 A1 19920624 EP 1990-913359 19900803 <--
 EP 490944 B1 19960529

R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE
 JP 05500058 T2 19930114 JP 1990-512483 19900803 <--
 JP 2749198 B2 19980513
 AT 138562 E 19960615 AT 1990-913359 19900803 <--
 ES 2089027 T3 19961001 ES 1990-913359 19900803 <--
 CA 2066403 C 19980414 CA 1990-2066403 19900803 <--
 NO 9200565 A 19920213 NO 1992-565 19920213 <--
 DK 9200193 A 19920214 DK 1992-193 19920214 <--
 NO 9200858 A 19920304 NO 1992-858 19920304 <--
 NO 9200855 A 19920410 NO 1992-855 19920304 <--
 NO 9200854 A 19920427 NO 1992-854 19920304 <--
 DK 9200300 A 19920505 DK 1992-300 19920305 <--
 AU 9460697 A1 19940623 AU 1994-60697 19940427 <--
 US 5855908 A 19990105 US 1994-339655 19941115 <--

PRAI US 1985-729301 A2 19850501 <--
 US 1987-60045 A2 19870608 <--
 EP 1989-909497 A 19890816 <--
 WO 1989-US3518 W 19890816 <--
 US 1989-403752 A 19890905 <--
 WO 1989-US3801 A 19890905 <--
 WO 1990-US4369 A 19900803 <--
 US 1993-152414 B1 19931112 <--

AB Compns. and methods of manuf. for producing a medicament compn. capable of absorption through the mucosal tissues of the mouth, pharynx, and esophagus are disclosed. The present invention relates to such compns. and methods which are useful in administering lipophilic and nonlipophilic drugs in a dose-to-effect manner such that sufficient drug is administered to produce precisely a desired effect. The invention also relates to manufg. techniques that enable therapeutic agents to be incorporated into nondissolvable drug containment **matrixes** which are capable of releasing the drug within a patient's mouth. An appliance or holder is preferably attached to the drug containment **matrix**. Employing the present invention the drug may be introduced into the patient's bloodstream almost as fast as through injection, and much faster than using the oral administration route, while avoiding the neg. aspects of both of these methods. The nondissolvable drug containment **matrix** may include permeation enhancers to increase the drug adsorption by the mucosal tissues of the mouth. The **matrix** compn. may also include pH buffering agents to modify the saliva pH thereby increasing the absorption of the drug through the mucosal tissues. Figures show views of some dosage forms.

ST mucosal pharmaceutical nondissolvable containment **matrix**

IT Pruritus

(agent against, transmucosal pharmaceuticals contg.)

IT Kidney

(agents acting on vascular system of, transmucosal pharmaceuticals contg.)

IT Blood vessel

(agents acting on, of kidney, transmucosal pharmaceuticals contg.)

IT Amnesia

(agents for treating, transmucosal pharmaceuticals contg.)

IT Amino acids, biological studies
Antibodies
Antigens
Enzymes
Macromolecular compounds
Nucleosides, biological studies
Peptides, biological studies
Polysaccharides, biological studies
RL: BIOL (Biological study)
(as drugs, transmucosal pharmaceuticals contg.)

IT Buffer substances and systems
Alcohols, biological studies
Salts, biological studies
RL: BIOL (Biological study)
(as permeation enhancer for transmucosal pharmaceuticals)

IT Tobacco smoke and smoking
(drug for cessation of, transmucosal pharmaceuticals contg.)

IT Inflammation inhibitors
(nonsteroidal, transmucosal pharmaceuticals contg.)

IT Nerve center and Ganglion
(stimulator of, transmucosal pharmaceuticals contg.)

IT Analgesics
Anesthetics
Antiarrhythmics
Antibiotics
Anticoagulants and Antithrombotics
Antidiabetics and Hypoglycemics
Antidiuretics
Antiemetics
Antihypertensives
Anxiolytics
Bronchodilators
Cardiovascular agents
Diuretics
Fungicides and Fungistats
Hypnotics and Sedatives
Nervous system agents
Vasodilators
(transmucosal pharmaceuticals contg.)

IT Enkephalins
Gonadotropins
Opioids
Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transmucosal pharmaceuticals contg.)

IT **Parkinsonism**
(transmucosal pharmaceuticals contg. agents for treating)

IT Heart, disease
(angina pectoris, transmucosal pharmaceuticals contg. agents for preventing or treating)

IT Opioids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antagonists, transmucosal pharmaceuticals contg.)

IT Ion channel blockers
(calcium, transmucosal pharmaceuticals contg.)

IT Pharmaceutical dosage forms
(controlled-release, mucosal, nondissolvable containment **matrix** for)

IT Tooth
(disease, plaque, agent against, transmucosal pharmaceuticals contg.)

IT Anesthetics
(local, transmucosal pharmaceuticals contg.)

IT Headache

- (migraine, inhibitors of, transmucosal pharmaceuticals contg.)
- IT Pharmaceutical dosage forms
(mucosal, nondissolvable containment **matrix** for)
- IT Cholinergic antagonists
(muscarinic, transmucosal pharmaceuticals contg.)
- IT Biological transport
(permeation, enhancing agents for, for transmucosal pharmaceuticals)
- IT Biological transport
(secretion, local agent against, transmucosal pharmaceuticals contg.)
- IT Neurotransmitter agonists
(serotonergic, transmucosal pharmaceuticals contg.)
- IT Adrenergic antagonists
(.beta.-, transmucosal pharmaceuticals contg.)
- IT 57-55-6, Propylene glycol, biological studies 58-08-2, Caffeine, biological studies 64-17-5, Ethanol, biological studies 65-85-0, Benzoic acid, biological studies 67-68-5, Dimethyl sulfoxide, biological studies 81-23-2, Dehydrocholate 100-51-6, Benzyl alcohol, biological studies 112-30-1, Decanol 128-13-2, Ursodeoxycholate 145-42-6, Sodium taurocholate 151-21-3, Sodium dodecyl sulfate, biological studies 302-95-4, Sodium deoxycholate 361-09-1, Sodium cholate 474-25-9, Chenodeoxycholate 516-35-8, Taurochenodeoxycholate 516-50-7, Taurodeoxycholate 863-57-0, Sodium glycocholate 872-50-4, N-Methyl pyrrolidone, biological studies 2955-27-3, Ursocholate 2958-05-6 7585-39-9D, .beta.-Cyclodextrin, 2-hydroxypropyl ethers 8059-24-3, Vitamin B6 9002-89-5, Polyvinyl alcohol 9002-92-0, Polyoxyethylene 9 lauryl ether 9003-39-8, Polyvinyl pyrrolidone 16409-34-0, Sodium glycodeoxycholate 25322-68-3, Polyethylene oxide 25322-68-3D, Polyethylene glycol, derivs. 59227-89-3, Laurocapram
RL: BIOL (Biological study)
(as permeation enhancer for transmucosal pharmaceuticals)
- IT 9015-82-1, Angiotensin-converting enzyme
RL: BIOL (Biological study)
(inhibitors of, transmucosal pharmaceuticals contg.)
- IT 56-12-2, GABA, biological studies
RL: BIOL (Biological study)
(stimulator of, transmucosal pharmaceuticals contg.)
- IT 50-56-6, Oxytocin, biological studies 50-57-7, Lypressin 51-30-9, Isoproterenol hydrochloride 51-34-3, Scopolamine 51-43-4, Epinephrine 51-55-8, Atropine, biological studies 51-61-6, Dopamine, biological studies 52-86-8, Haloperidol 53-86-1, Indomethacin 54-11-5, Nicotine 54-31-9, Furosemide 55-63-0, Nitroglycerin 56-29-1, Hexobarbital 58-38-8, Prochlorperazine 58-55-9, Theophylline, biological studies 58-82-2, Bradykinin 59-41-6, Bretylium 59-92-7, Levodopa, biological studies 60-79-7, Ergonovine 63-12-7, Benzquinamide 67-52-7, Barbiturate 76-74-4, Pentobarbital 76-75-5, Thiopental 77-10-1, Phencyclidine 77-27-0, Thiamylal 108-95-2D, Phenol, derivs. 113-15-5, Ergotamine 129-51-1, Oxytocic 137-58-6, Lidocaine 138-56-7, Trimethobenzamide 151-83-7, Methohexital 317-34-0, Aminophylline 361-37-5, Methysergide 364-62-5, Metoclopramide 437-38-7, Fentanyl 439-14-5, Diazepam 465-65-6, Naloxone 479-18-5, Dyphylline 495-40-9, Butyrophenone 511-12-6, Dihydroergotamine 525-66-6, Propranolol 530-08-5, Isoetharine 548-73-2, Droperidol 569-65-3, Meclizine 586-06-1, Metaproterenol 604-75-1, Oxazepam 644-62-2, Meclofenamate 652-67-5, Isosorbide 846-49-1, Lorazepam 848-75-9, Lormetazepam 1400-61-9, Nystatin 1421-14-3, Propanidid 2078-54-8, Propofol **3385-03-3, Flunisolide** 4205-90-7, Clonidine 4419-39-0, Beclomethasone 4499-40-5, Oxtriphylline 5104-49-4, Flurbiprofen 6740-88-1, Ketamine 9002-60-2, Adrenocorticotrophic hormone, biological studies 9002-64-6, Parathyroid hormone 9002-72-6, Growth hormone 9004-10-8, Insulin, biological studies 9005-49-6, Heparin, biological studies 9007-12-9, Calcitonin 9041-90-1, Angiotensin I 11000-17-2, Vasopressin 12794-10-4, Benzodiazepine 15078-28-1, Nitroprusside 15307-86-5, Diclofenac


15687-27-1, Ibuprofen 17560-51-9, Metolazone 18559-94-9, Albuterol
 20594-83-6, Nalbuphine 21829-25-4, Nifedipine 22071-15-4, Ketoprofen
 23031-25-6, Terbutaline 23593-75-1, Clotrimazole 28860-95-9, Carbidopa
 28911-01-5, Triazolam 33125-97-2, Etomidate 36322-90-4, Piroxicam
 36894-69-6, Labetolol 42200-33-9, Nadolol 51384-51-1, Metoprolol
 54182-58-0, Sucralfate 54767-75-8, Suloctidil 56030-54-7, Sufentanil
 59467-70-8, Midazolam 59708-52-0, Carfentanil 60617-12-1,
 .beta.-Endorphin 61380-40-3, Lofentanil 62288-83-9, Desmopressin
 acetate 62571-86-2, Captopril 71195-58-9, Alfentanil 74103-07-4,
 Ketorolac tromethamine 75847-73-3, Enalapril 81147-92-4, Esmolol
 99614-02-5, Ondansetron 103628-46-2, Sumatriptan
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (transmucosal pharmaceuticals contg.)

IT 3385-03-3, Flunisolide
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (transmucosal pharmaceuticals contg.)

RN 3385-03-3 HCAPLUS

CN Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 37 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 1994:226981 HCAPLUS

DN 120:226981

TI Compositions of oral dissolvable medicaments

IN Stanley, Theodore H.; Hague, Brian

PA University of Utah, USA

SO U.S., 22 pp. Cont.-in-part of U.S. 4,863,737.

CODEN: USXXAM

DT Patent

LA English

IC ICM A61K009-68

NCL 424440000

CC 63-6 (Pharmaceuticals)

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5288497	A	19940222	US 1989-403751	19890905 <--
	US 4671953	A	19870609	US 1985-729301	19850501 <--
	EP 487520	A1	19920603	EP 1989-909497	19890816 <--
	EP 487520	B1	19950412		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 05501539	T2	19930325	JP 1989-504878	19890816 <--
	JP 2801050	B2	19980921		

AU 641127	B2	19930916	AU 1989-40704	19890816 <--
AT 120953	E	19950415	AT 1989-909497	19890816 <--
CA 1338978	A1	19970311	CA 1989-609378	19890824 <--
AU 9050352	A1	19910408	AU 1990-50352	19890905 <--
AU 645966	B2	19940203		
EP 493380	A1	19920708	EP 1990-902584	19890905 <--
EP 493380	B1	19971029		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 5132114	A	19920721	US 1989-402881	19890905 <--
JP 05501854	T2	19930408	JP 1990-502779	19890905 <--
CA 1339075	A1	19970729	CA 1989-610329	19890905 <--
AT 159658	E	19971115	AT 1990-902584	19890905 <--
WO 9103237	A1	19910321	WO 1990-US4384	19900803 <--
W: AU, CA, JP, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
AU 9062877	A1	19910408	AU 1990-62877	19900803 <--
AU 645265	B2	19940113		
EP 490916	A1	19920624	EP 1990-912733	19900803 <--
EP 490916	B1	19951018		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 05503917	T2	19930624	JP 1990-512229	19900803 <--
EP 630647	A1	19941228	EP 1994-111352	19900803 <--
EP 630647	B1	19990303		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
AT 129148	E	19951115	AT 1990-912733	19900803 <--
ES 2077686	T3	19951201	ES 1990-912733	19900803 <--
CA 2066423	C	19980414	CA 1990-2066423	19900803 <--
AT 177007	E	19990315	AT 1994-111352	19900803 <--
ES 2133448	T3	19990916	ES 1994-111352	19900803 <--
NO 9200565	A	19920213	NO 1992-565	19920213 <--
DK 9200193	A	19920214	DK 1992-193	19920214 <--
NO 9200857	A	19920406	NO 1992-857	19920304 <--
NO 9200855	A	19920410	NO 1992-855	19920304 <--
NO 9200854	A	19920427	NO 1992-854	19920304 <--
DK 9200300	A	19920505	DK 1992-300	19920305 <--
AU 9455218	A1	19940428	AU 1994-55218	19940218 <--
AU 668004	B2	19960418		
AU 9460697	A1	19940623	AU 1994-60697	19940427 <--
US 5824334	A	19981020	US 1996-636828	19960419 <--
US 5783207	A	19980721	US 1997-795359	19970204 <--
US 5785989	A	19980728	US 1997-822560	19970319 <--
PRAI US 1985-729301	A2	19850501	<--	
US 1987-60045	A2	19870608	<--	
EP 1989-909497	A	19890816	<--	
WO 1989-US3518	W	19890816	<--	
US 1989-403751	A	19890905	<--	
WO 1989-US3801	A	19890905	<--	
EP 1990-912733	A3	19900803	<--	
WO 1990-US4384	A	19900803	<--	
US 1993-152396	B1	19931112	<--	
US 1994-333233	B2	19941102	<--	
US 1995-439127	B1	19950511	<--	

AB Compns. and methods of manuf. for producing a medicament compn. capable of absorption through the mucosal tissues of the mouth, pharynx, and esophagus are disclosed. The present invention relates to such compns. and methods which are useful in administering lipophilic and nonlipophilic drugs in a dose-to-effect manner that sufficient drug is administered to produce precisely a desired effect. The invention also relates to a manufg. technique that enables a therapeutic agent or drug to be incorporated into a flavored dissolvable **matrix**. An appliance or holder is preferably attached to the dissolvable **matrix**. Employing the present invention the drug may be introduced into the patient's bloodstream almost as fast as through injection, and much faster

than using the oral administration route, while avoiding the neg. aspects of both of these methods. The present invention achieves these advantages by incorporating the drug into a carbohydrate, fat, protein, wax, or other dissolvable **matrix** compn. The dissolvable **matrix** may include permeation enhancers to increase the drug absorption by the mucosal tissues of the mouth. The **matrix** compn. may also include pH buffering agents to modify the salival pH thereby increasing the absorption of the drug through the mucosal tissue. Methohexital sodium was incorporated into a dissolvable **matrix** including citric acid; ribotide; Compritol 888; aspartame; vanilla, wild cherry, and peppermint microcapsules; compressible sugar; and maltodextrin.

- ST mucosal pharmaceutical permeation enhancer binding agent
- IT Pruritus
 - (agent against, transmucosal pharmaceuticals contg.)
- IT Flavor
 - (agent enhancing, in transmucosal pharmaceuticals)
- IT Kidney
 - (agents acting on vascular system of, transmucosal pharmaceuticals contg.)
- IT Blood vessel
 - (agents acting on, of kidney, transmucosal pharmaceuticals contg.)
- IT Amnesia
 - (agents for treating, transmucosal pharmaceuticals contg.)
- IT Carbohydrates and Sugars, biological studies
 - Fats and Glyceridic oils
 - Gelatins, biological studies
 - Hydrocarbons, biological studies
 - Proteins, biological studies
 - Waxes and Waxy substances
 - RL: BIOL (Biological study)
 - (as binding agent for transmucosal pharmaceuticals)
- IT Amino acids, biological studies
 - Antibodies
 - Antigens
 - Enzymes
 - Fatty acids, biological studies
 - Macromolecular compounds
 - Nucleosides, biological studies
 - Peptides, biological studies
 - Polysaccharides, biological studies
 - RL: BIOL (Biological study)
 - (as drugs, transmucosal pharmaceuticals contg.)
- IT Buffer substances and systems
 - Alcohols, biological studies
 - Salts, biological studies
 - RL: BIOL (Biological study)
 - (as permeation enhancer for transmucosal pharmaceuticals)
- IT Bile salts
 - RL: BIOL (Biological study)
 - (as permeation enhancers for transmucosal pharmaceuticals)
- IT Tobacco smoke and smoking
 - (drug for cessation of, transmucosal pharmaceuticals contg.)
- IT Binding materials
 - (for transmucosal pharmaceuticals)
- IT Lubricants
 - Surfactants
 - Sweetening agents
 - (in transmucosal pharmaceuticals)
- IT Inflammation inhibitors
 - (nonsteroidal, transmucosal pharmaceuticals contg.)
- IT Nerve center and Ganglion
 - (stimulator of, transmucosal pharmaceuticals contg.)
- IT Analgesics

Anesthetics
 Antiarrhythmics
 Antibiotics
 Anticoagulants and Antithrombotics
 Antidiabetics and Hypoglycemics
 Antidiuretics
 Antiemetics
 Antihypertensives
 Anxiolytics
 Bronchodilators
 Cardiovascular agents
 Diuretics
 Fungicides and Fungistats
 Hypnotics and Sedatives
 Nervous system agents
 Vasodilators
 (transmucosal pharmaceuticals contg.)

IT Enkephalins
 Gonadotropins
 Opioids
 Vitamins
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (transmucosal pharmaceuticals contg.)

IT **Parkinsonism**
 (transmucosal pharmaceuticals contg. agents for treating)

IT Heart, disease
 (angina pectoris, transmucosal pharmaceuticals contg. agents for
 preventing or treating)

IT Opioids
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antagonists, transmucosal pharmaceuticals contg.)

IT Ion channel blockers
 (calcium, transmucosal pharmaceuticals contg.)

IT Pharmaceutical dosage forms
 (controlled-release, mucosal, binding agent and permeation enhancer
 for)

IT Tooth
 (disease, plaque, agent against, transmucosal pharmaceuticals contg.)

IT Pharmaceutical dosage forms
 (hydrogels, transmucosal, binding agent and permeation enhancer for)

IT Anesthetics
 (local, transmucosal pharmaceuticals contg.)

IT Headache
 (migraine, inhibitors of, transmucosal pharmaceuticals contg.)

IT Pharmaceutical dosage forms
 (mucosal, binding agent and permeation enhancer for)

IT Cholinergic antagonists
 (muscarinic, transmucosal pharmaceuticals contg.)

IT Biological transport
 (permeation, enhancing agents for, for transmucosal pharmaceuticals)

IT Biological transport
 (secretion, local agent against, transmucosal pharmaceuticals contg.)

IT Neurotransmitter agonists
 (serotonergic, transmucosal pharmaceuticals contg.)

IT Adrenergic antagonists
 (.beta.-, transmucosal pharmaceuticals contg.)

IT 57-55-6, Propylene glycol, biological studies 58-08-2, Caffeine,
 biological studies 64-17-5; Ethanol, biological studies 65-85-0,
 Benzoic acid, biological studies 67-68-5, Dimethyl sulfoxide, biological
 studies 81-23-2, Dehydrocholate 100-51-6, Benzyl alcohol, biological
 studies 112-30-1, Decanol 128-13-2, Ursodeoxycholate 145-42-6,
 Sodium taurocholate 151-21-3, Sodium dodecyl sulfate, biological studies
 302-95-4, Sodium deoxycholate 361-09-1, Sodium cholate 474-25-9,

Chenodeoxycholate 516-35-8, Taurochenodeoxycholate 516-50-7,
 Taurodeoxycholate 863-57-0, Sodium glycocholate 872-50-4, N-Methyl
 pyrrolidone, biological studies 2955-27-3, Ursocholate 2958-05-6
 7585-39-9D, .beta.-Cyclodextrin, 2-hydroxypropyl ethers 8059-24-3,
 Vitamin B6 9002-89-5, Polyvinyl alcohol 9002-92-0, Polyoxyethylene 9
 lauryl ether 9003-39-8, Polyvinyl pyrrolidone 16409-34-0, Sodium
 glycodeoxycholate 25322-68-3, Polyethylene oxide 25322-68-3D,
 Polyethylene glycol, derivs. 59227-89-3, Laurocapram

RL: BIOL (Biological study)

(as permeation enhancer for transmucosal pharmaceuticals)

IT 77-92-9, Citric acid, biological studies 9050-36-6, Maltodextrin
 18641-57-1, Compritol 888 80702-47-2, Ribotide

RL: BIOL (Biological study)

(in transmucosal pharmaceuticals)

IT 9015-82-1, Angiotensin-converting enzyme

RL: BIOL (Biological study)

(inhibitors of, transmucosal pharmaceuticals contg.)

IT 56-12-2, GABA, biological studies

RL: BIOL (Biological study)

(stimulator of, transmucosal pharmaceuticals contg.)

IT 50-56-6, Oxytocin, biological studies 50-57-7, Lypressin 51-30-9,
 Isoproterenol hydrochloride 51-34-3, Scopolamine 51-43-4, Epinephrine
 51-55-8, Atropine, biological studies 51-61-6, Dopamine, biological
 studies 52-86-8, Haloperidol 53-86-1, Indomethacin 54-11-5, Nicotine
 54-31-9, Furosemide 55-63-0, Nitroglycerin 56-29-1, Hexobarbital
 58-38-8, Prochlorperazine 58-55-9, Theophylline, biological studies
 58-82-2, Bradykinin 59-41-6, Bretylium 59-92-7, Levodopa, biological
 studies 60-79-7, Ergonovine 63-12-7, Benzquinamide 67-52-7,
 Barbiturate 76-74-4, Pentobarbital 76-75-5, Thiopental 77-10-1,
 Phencyclidine 77-27-0, Thiamylal 108-95-2D, Phenol, derivs.
 113-15-5, Ergotamine 129-51-1, Oxytocic 137-58-6, Lidocaine
 138-56-7, Trimethobenzamide 151-83-7, Methohexital 309-36-4,
 Methohexital sodium 317-34-0, Aminophylline 361-37-5, Methysergide
 364-62-5, Metoclopramide 437-38-7, Fentanyl 439-14-5, Diazepam
 465-65-6, Naloxone 479-18-5, Dyphylline 495-40-9, Butyrophenone
 511-12-6, Dihydroergotamine 525-66-6, Propranolol 530-08-5,
 Isoetharine 548-73-2, Droperidol 569-65-3, Meclizine 586-06-1,
 Metaproterenol 604-75-1, Oxazepam 644-62-2, Meclofenamate 652-67-5,
 Isosorbide 846-49-1, Lorazepam 848-75-9, Lormetazepam 1400-61-9,
 Nystatin 1421-14-3, Propanidid 2078-54-8, Propofol 3385-03-3
 , Flunisolid 4205-90-7, Clonidine 4419-39-0, Beclomethasone
 4499-40-5, Oxtriphylline 5104-49-4, Flurbiprofen 6740-88-1, Ketamine
 9002-60-2, Adrenocorticotrophic hormone, biological studies 9002-64-6,
 Parathyroid hormone 9002-72-6, Growth hormone 9004-10-8, Insulin,
 biological studies 9005-49-6, Heparin, biological studies 9007-12-9,
 Calcitonin 9041-90-1, Angiotensin I 11000-17-2, Vasopressin
 12794-10-4, Benzodiazepine 15078-28-1, Nitroprusside 15307-86-5,
 Diclofenac 15687-27-1, Ibuprofen 17560-51-9, Metolazone 18559-94-9,
 Albuterol 20594-83-6, Nalbuphine 21829-25-4, Nifedipine 22071-15-4,
 Ketoprofen 23031-25-6, Terbutaline 23593-75-1, Clotrimazole
 28860-95-9, Carbidopa 28911-01-5, Triazolam 33125-97-2, Etomidate
 36322-90-4, Piroxicam 36894-69-6, Labetolol 42200-33-9, Nadolol
 51384-51-1, Metoprolol 54182-58-0, Sucralfate 54767-75-8, Suloctidil
 56030-54-7, Sufentanil 59467-70-8, Midazolam 59708-52-0, Carfentanil
 60617-12-1, .beta.-Endorphin 61380-40-3, Lofentanil 62288-83-9,
 Desmopressin acetate 62571-86-2, Captopril 71195-58-9, Alfentanil
 74103-07-4, Ketorolac tromethamine 75847-73-3, Enalapril 81147-92-4,
 Esmolol 99614-02-5, Ondansetron 103628-46-2, Sumatriptan

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(transmucosal pharmaceuticals contg.)


IT 3385-03-3, Flunisolid

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(transmucosal pharmaceuticals contg.)

RN 3385-03-3 HCAPLUS
 CN Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L76 ANSWER 38 OF 39 HCAPLUS COPYRIGHT 2003 ACS on STN
 AN 1994:116847 HCAPLUS
 DN 120:116847
 TI Biodegradable controlled release melt-spun delivery system
 IN Fuisz, Richard C.
 PA Fuisz Technologies, Ltd., USA
 SO PCT Int. Appl., 45 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 IC ICM A61L015-62
 ICS A61K009-70; A61K047-30
 CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9324154	A1	19931209	WO 1993-US5307	19930602 <--
	W: AU, CA, HU, JP, KR, PL, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5518730	A	19960521	US 1992-893238	19920603 <--
	AU 9344058	A1	19931230	AU 1993-44058	19930602 <--
	AU 665844	B2	19960118		
	JP 07507548	T2	19950824	JP 1994-500877	19930602 <--
	EP 746342	A1	19961211	EP 1993-914373	19930602 <--
	EP 746342	B1	20020814		
	R: BE, CH, DE, DK, FR, GB, IE, IT, LI, LU, NL, SE				
PRAI	US 1992-893238	A2	19920603 <--		
	WO 1993-US5307	A	19930602 <--		
AB	Biodegradable controlled-release delivery systems using melt-spun biodegradable polymers as carriers for bio-effecting agents such as pharmaceutical actives are disclosed. Oral dose forms as well as implants are described. For example, polyglycolide was melt-spun in combination with various drugs such as vancomycin, gentamicin, tolmetin, diphenhydramine, ibuprofen, and insulin and controlled drug release was demonstrated.				
ST	controlled drug release melt spun polymer				
IT	Erythropoiesis Fertility (agents for, controlled-release pharmaceuticals formed by flash-flow				

- melt-spinning contg., biodegradable polymers as carriers in)
- IT Phosphazene polymers
 Polyanhydrides
 Polycarbonates, biological studies
 Polyesters, biological studies
 Polyoxymethylenes, biological studies
 Proteins, biological studies
 RL: BIOL (Biological study)
 (controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., as carriers)
- IT Anabolic agents
 Anti-infective agents
 Anticholesteremics and Hypolipemics
 Anticonvulsants and Antiepileptics
 Antidepressants
 Antidiabetics and Hypoglycemics
 Antiemetics
 Antiobesity agents
 Antipyretics
 Antitussives
 Appetite stimulants
 Cathartics
 Chelating agents
 Contraceptives
 Deodorants
 Diuretics
 Inflammation inhibitors
 Muscle relaxants
 Neoplasm inhibitors
 Parasitocides
 Tranquilizers and Neuroleptics
 Vasoconstrictors
 Witch hazel
 (controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)
- IT Alkaloids, biological studies
 Amino acids, biological studies
 Castor oil
 Cocoa butter
 Cod-liver oil
 Kaolin, biological studies
 Lanolin
 Lecithins
 Minerals
 Paraffin oils
 Prostaglandins
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)
- IT Ruminant
 (diseases in, treatment of, with controlled-release pharmaceuticals formed by flash-flow melt-spinning)
- IT Diarrhea
 Thyroid gland, disease
 (inhibitors, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)
- IT Acne
 Neuromuscular disease
 Vertigo (disease)
 (therapeutics for, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)
- IT Wound
 (treatment of, controlled-release pharmaceuticals formed by flash-flow

melt-spinning for)

IT Balsams
(Peru, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)

IT Pharmaceutical natural products
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aloe, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)

IT Bronchodilators
(antiasthmatics, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)

IT Caseins, compounds
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calcium complexes, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)

IT Pharmaceutical natural products
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cascara sagrada, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)

IT Vasodilators
(cerebral, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)

IT **Mental activity**
(cognition, activators, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)

IT Pharmaceutical dosage forms
(implants, flash-flow melt-spinning drugs with biodegradable polymers in)

IT Pharmaceutical natural products
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ipecac, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)

IT Pharmaceutical dosage forms
(oral, controlled-release, flash-flow melt-spinning drugs with biodegradable polymers in)

IT Polyethers, biological studies
RL: BIOL (Biological study)
(ortho ester group-contg., controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., as carriers)

IT Essential oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peppermint, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)

IT Vasodilators
(peripheral, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)

IT Esters, polymers
RL: BIOL (Biological study)
(polymers, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., as carriers)

IT Fats and Glyceridic oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sesame, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)

IT Fats and Glyceridic oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(shark-liver, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)

IT **Brain, disease**
(stroke, inhibitors, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)

IT 9011-97-6, Cholecystokinin

RL: BIOL (Biological study)

(antagonists, controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)

IT 123-91-1D, 1,4-Dioxane, polymers 144-62-7D, Oxalic acid, polymers
3753-81-9D, polymers 15802-18-3D, Cyanoacrylic acid, alkyl esters,
polymers 24980-41-4, Polycaprolactone 25248-42-4, Polycaprolactone
25322-68-3, Polyethylene glycol 26009-03-0, Glycolic acid homopolymer,
sru 26023-30-3, Polylactic acid 26124-68-5, Glycolic acid homopolymer
26776-29-4, Sebacic acid polymer 47168-52-5D, polymers

RL: BIOL (Biological study)

(controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., as carrier)

IT 50-03-3, Hydrocortisone acetate 50-06-6, biological studies 50-13-5,
Meperidine hydrochloride 50-21-5, Lactic acid, biological studies
50-23-7, Hydrocortisone 50-78-2, Acetylsalicylic acid 50-81-7, Vitamin
C, biological studies 51-42-3, Epinephrine bitartrate 51-98-9,
Norethindrone acetate 52-28-8, Codeine phosphate 53-86-1,
Indomethacin 54-11-5, Nicotine 54-31-9, Furosemide 55-63-0
56-75-7, Chloramphenicol 56-81-5, 1,2,3-Propanetriol, biological studies
57-27-2, Morphine, biological studies 57-33-0, Pentobarbital sodium
57-41-0, Phenytoin 57-63-6, Ethinyl estradiol 58-08-2, biological
studies 58-55-9, Theophylline, biological studies 58-85-5, Biotin
58-93-5, Hydrochlorothiazide 59-30-3, Folic acid, biological studies
59-67-6, Niacin, biological studies 61-68-7, Mefenamic acid 61-76-7,
Phenylephrine hydrochloride 64-17-5, Ethanol, biological studies
64-19-7, Acetic acid, biological studies 64-75-5, Tetracycline
hydrochloride 65-23-6, Pyridoxine 65-85-0, Benzoic acid, biological
studies 67-63-0, Isopropanol, biological studies 68-04-2, Sodium
citrate 68-19-9, Cyanocobalamin 68-22-4, **Norethindrone**
69-53-4, Ampicillin 69-72-7, biological studies 71-58-9,
Medroxyprogesterone acetate 73-78-9, Lidocaine hydrochloride 76-22-2,
Camphor 76-49-3, Bornyl acetate 76-57-3, Codeine 77-09-8,
Phenolphthalein 77-41-8, Methsuximide 77-92-9, biological studies
78-11-5, Pentaerythritol tetranitrate 83-88-5, Riboflavin, biological
studies 85-79-0, Dibucaine 87-67-2, Choline bitartrate 87-89-8,
Inositol 93-14-1, Guaifenesin 93-60-7, Methyl nicotinate 94-09-7,
Benzocaine 94-36-0, Benzoyl peroxide, biological studies 97-59-6,
Allantoin 98-92-0, Niacinamide 103-90-2, Acetaminophen 104-46-1,
Anethole 108-46-3, 1,3-Benzenediol, biological studies 108-95-2,
Phenol, biological studies 112-38-9, Undecylenic acid 113-92-8,
Chlorpheniramine maleate 114-07-8, Erythromycin 115-67-3,
Paramethadione 117-10-2, Danthron 119-36-8, Methyl salicylate
119-61-9, Benzophenone, biological studies 123-03-5, Cetylpyridinium
chloride 125-69-9, Dextromethorphan hydrobromide 126-07-8,
Griseofulvin 128-49-4, Docusate calcium 131-53-3, Dioxybenzone
131-57-7, Oxybenzone 132-20-7, Pheniramine maleate 136-77-6,
Hexylresorcinol 137-58-6, Lidocaine 139-12-8, Aluminum acetate
140-65-8, Pramoxine 141-01-5, Ferrous fumarate 143-71-5, Hydrocodone
bitartrate 144-55-8, Sodium bicarbonate, biological studies 147-24-0,
Diphenhydramine hydrochloride 150-13-0, PABA 152-11-4, Verapamil
hydrochloride 152-43-2, Quinestrol 154-41-6, Phenylpropanolamine
hydrochloride 156-51-4, Phenelzine sulfate 299-29-6, Ferrous gluconate
299-42-3, Ephedrine 302-79-4, Tretinoin 303-25-3, Cyclizine
hydrochloride 318-98-9, Propranolol hydrochloride 321-64-2, Tacrine
345-78-8, Pseudoephedrine hydrochloride 439-14-5, Diazepam 443-48-1,
Metronidazole 469-62-5, Propoxyphene 470-82-6, Eucalyptol 471-34-1,
Calcium carbonate, biological studies 546-93-0, Magnesium carbonate
550-70-9, Triprolidine hydrochloride 557-08-4, Zinc undecylenate
562-10-7, Doxylamine succinate 577-11-7, Docusate sodium 587-23-5,
Methenamine mandelate 603-50-9, Bisacodyl 614-39-1, Procainamide
hydrochloride 637-58-1, Pramoxine hydrochloride 644-62-2, Meclofenamic
acid 723-46-6, Sulfamethoxazole 882-09-7 980-71-2, Brompheniramine
maleate 1218-35-5, Xylometazoline hydrochloride 1305-62-0, Calcium

hydroxide, biological studies 1309-42-8, Magnesium hydroxide 1321-11-5, Aminobenzoic acid 1321-23-9, Chloroxylenol 1327-41-9, Aluminum chlorohydrate 1400-61-9, Nystatin 1403-66-3, Gentamicin 1404-90-6, Vancomycin 1405-10-3, Neomycin sulfate 1405-20-5, Polymyxin B sulfate 1405-87-4, Bacitracin 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1490-04-6, Menthol 1639-60-7, Propoxyphen hydrochloride 1684-40-8, Tacrine hydrochloride 2391-03-9, Dexbrompheniramine maleate 2398-96-1, Tolnaftate 2955-38-6, Prazepam 3380-34-5, Triclosan 3819-18-9, 8-Hydroxyquinoline sulfate 4205-90-7, Clonidine 4205-91-8, Clonidine hydrochloride 4499-40-5, Oxtriphylline 5534-09-8, Beclomethasone dipropionate 5874-97-5, Metaproterenol sulfate 6385-02-0, Sodium meclofenamate 6740-88-1, Ketamine 7054-25-3, Quinidine gluconate 7280-37-7, Estropipate 7439-89-6, Iron, biological studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium, biological studies 7447-40-7, Potassium chloride (KCl), biological studies 7460-12-0, Pseudoephedrine sulfate 7491-09-0, Docusate potassium 7553-56-2, Iodine, biological studies 7681-49-4, Sodium fluoride, biological studies 7704-34-9, Sulfur, biological studies 7720-78-7, Ferrous sulfate 7733-02-0, Zinc sulfate 7757-79-1, Potassium nitrate, biological studies 8011-96-9, Calamine 8050-81-5, Simethicone 8065-29-0, Liotrix 9004-10-8, Insulin, biological studies 9004-67-5, Methyl cellulose 9006-65-9, Dimethicone 9036-19-5, Octoxynol 10163-15-2, Sodium monofluorophosphate 11041-12-6, Cholestyramine resin 11096-26-7, Erythropoietin 11099-07-3, Glyceryl stearate 11103-57-4, Vitamin A 12001-76-2, Vitamin B 12001-79-5, Vitamin K 14362-31-3, Chlorcyclizine hydrochloride 14455-29-9, Aluminum carbonate 14698-29-4, Oxolinic acid 14838-15-4, Phenylpropanolamine 14987-04-3, Magnesium trisilicate 15307-79-6, Diclofenac sodium 15686-71-2, Cephalexin 15687-27-1, Ibuprofen 17140-78-2, Propoxyphene napsylate 18472-51-0, Chlorhexidine gluconate 18559-94-9, Albuterol 18917-89-0, Magnesium salicylate 20830-75-5, Digoxin 21245-02-3, Padimate o 21645-51-2, Aluminum hydroxide, biological studies 21829-25-4 22204-53-1 22832-87-7, Miconazole nitrate 22839-47-0, Aspartame 24390-14-5, Doxycycline hyclate 25441-16-1 25812-30-0, Gemfibrozil 26027-38-3, Nonoxynol-9 26100-51-6, Polylactic acid 26159-34-2, Naproxen sodium 26171-23-3, Tolmetin 26787-78-0, Amoxicillin 26921-17-5, Timolol maleate 28911-01-5, Triazolam 28981-97-7, Alprazolam 29094-61-9, Glipizide 29122-68-7, Atenolol 29984-33-6, Vidarabine phosphate 30837-62-8, Thioperimidone 34552-84-6, Isoxicam 36322-90-4, Piroxicam 36505-84-7, Buspirone 36653-82-4, Cetyl alcohol 38304-91-5, Minoxidil 42399-41-7 50370-12-2, Cefadroxil 50679-08-8, Terfenadine 51022-70-9, Albuterol sulfate 51264-14-3, Amsacrine 53910-25-1, Pentostatin 53994-73-3, Cefaclor 56296-78-7, Fluoxetine hydrochloride 56392-17-7, Metoprolol tartrate 58817-05-3, Octyl dimethyl PABA 59729-33-8, Citalopram 60142-96-3, Gabapentin 62571-86-2, Captopril 66357-35-5, Ranitidine 68252-19-7, Pirmenol 68497-62-1, Pramiracetam 69198-10-3 70059-30-2, Cimetidine hydrochloride 72332-33-3, Procaterol 73590-58-6, Omeprazole 74011-58-8, Enoxacin 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 85441-61-8, Quinapril 88637-37-0, Diphenhydramine citrate 89197-32-0, Efaroxan 93107-08-5, Ciprofloxacin hydrochloride

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)

IT 93390-81-9, Fosphenytoin 93738-40-0, Ralitoline 96436-87-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)


IT 93390-81-9, Fosphenytoin 93738-40-0, Ralitoline 96436-87-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(controlled-release pharmaceuticals formed by flash-flow melt-spinning contg., biodegradable polymers as carriers in)

IT 68-22-4, Norethindrone
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (controlled-release pharmaceuticals formed by flash-flow melt-spinning
 contg., biodegradable polymers as carriers in)
 RN 68-22-4 HCAPLUS
 CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



L76 ANSWER 39 OF 39 HCAPLUS. COPYRIGHT 2003 ACS on STN
 AN 1992:658241 HCAPLUS
 DN 117:258241
 TI Compositions for **topical** administration of pharmaceuticals
 IN Mantelle, Juan A.
 PA Noven Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC A61K009-70; A61L015-44
 CC 63-6 (Pharmaceuticals)
 FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9215289	A1	19920917	WO 1992-US1730	19920222 <--
	W: AT, AU, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LU, NL, NO, PL, RO, RU, SE, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	CA 2104474	AA	19920828	CA 1992-2104474	19920227 <--
	AU 9214610	A1	19921006	AU 1992-14610	19920227 <--
	AU 658870	B2	19950504		
	EP 573576	A1	19931215	EP 1992-907818	19920227 <--
	EP 573576	B1	19961030		
	EP 573576	B2	20030709		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	JP 06508820	T2	19941006	JP 1992-507433	19920227 <--
	EP 728477	A2	19960828	EP 1996-106534	19920227 <--
	EP 728477	A3	19960911		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	AT 144704	E	19961115	AT 1992-907818	19920227 <--
	ES 2094906	T3	19970201	ES 1992-907818	19920227 <--
	SG 77626	A1	20010116	SG 1998-355	19920227 <--
	US 5332576	A	19940726	US 1993-64587	19930521 <--
	NO 9303296	A	19931101	NO 1993-3296	19930916 <--
	AU 9526998	A1	19961230	AU 1995-26998	19950607 <--
	AU 9528331	A1	19950928	AU 1995-28331	19950802 <--
	AU 694243	B2	19980716		
PRAI	US 1991-661827	A2	19910227	<--	
	US 1991-813196	A	19911223	<--	

EP 1992-907818 A3 19920227 <--
WO 1992-US1730 A 19920227 <--
WO 1995-US7229 W 19950607 <--

AB A compn. for topical delivery of pharmaceuticals comprises a soln. of the drug, preferably a local anesthetic, incorporated into a flexible, finite carrier. The use of 2 different anesthetics, one in base form and the other in salt form, allows the attainment of .ltoreq.50% concns., without crystn. A compn. contg. lidocaine 28, prilocaine-HCl 14, propylene glycol 7, lecithin 11, glycerol 19, and karaya gum 21% wt./wt. was applied to a polyester backer and heated to 100.degree., to give a finite, flexible gel.

ST topical formulation drug

IT Hormones

RL: BIOL (Biological study)
(nonsteroidal, topical formulation of)

IT Adrenergic agonists

Allergy inhibitors

Analgesics

Antiarrhythmics

Antidepressants

Antidiabetics and Hypoglycemics

Antihistaminics

Antihypertensives

Antimalarials

Antipyretics

Appetite depressants

Bactericides, Disinfectants, and Antiseptics

Cardiotonics

Cholinergic agonists

Decongestants

Fungicides and Fungistats

Inflammation inhibitors

Miotics

Muscle relaxants

Mydriatics

Neoplasm inhibitors

Nervous system agents

Psychotropics

Tranquilizers and Neuroleptics

Ulcer inhibitors

Vasoconstrictors

Peptides, biological studies

Vitamins

Androgens

Enzymes

Estrogens

RL: BIOL (Biological study)

(topical formulation of)

IT **Parkinsonism**

(treatment of, drugs for, formulation for topical delivery of)

IT Estrogens

RL: PROC (Process)

(antiestrogens, topical formulation of)

IT Tranquilizers and Neuroleptics

(antipsychotics, topical formulation of)

IT Ion channel blockers

(calcium, topical formulation of)

IT Vasodilators

(coronary, topical formulation of)


IT Headache

(migraine, treatment of, drugs for, formulation for topical delivery of)

IT Cholinergic antagonists


- (muscarinic, topical formulation of)
- IT Pharmaceutical dosage forms
(topical, with high drug concn., in flexible and finite carrier)
- IT Adrenergic antagonists
(.beta.-, topical formulation of)
- IT 50-27-1, Estriol 50-28-2, 17.beta.-Estradiol, biological studies
51-98-9, **Norethindrone** acetate 52-76-6 53-16-7, Estrone,
biological studies 56-53-1, Diethylstilbestrol 57-63-6 57-83-0,
Progesterone, biological studies 58-18-4, Methyltestosterone 58-22-0,
Testosterone 59-46-1, Procaine **68-22-4, Norethindrone**
68-23-5, Norethynodrel 68-96-2, 17.alpha.-Hydroxyprogesterone 71-58-9,
Medroxyprogesterone acetate 72-33-3, Mestranol 76-43-7,
Fluoxymesterone 79-64-1, Dimethisterone 85-79-0, Dibucaine 94-09-7,
Benzocaine 94-24-6, Tetracaine 96-88-8, Mepivacaine 133-16-4,
Chlorprocaine 136-47-0, Tetracaine hydrochloride 137-58-6, Lidocaine
152-62-5, Dydrogesterone 297-76-7, Ethynodiol diacetate 472-54-8,
19-Norpregn-4-ene-3,20-dione 474-86-2, Equilin 536-43-6, Dyclonine
hydrochloride 586-60-7, Dyclonine **595-33-5, Megestrol**
acetate 630-56-8 721-50-6, Prilocaine 979-32-8,
17.beta.-Estradiol valerate 1722-62-9, Mepivacaine hydrochloride
1786-81-8, Prilocaine hydrochloride 1961-77-9, Chlormadinone
5633-18-1, Melengestrol 6533-00-2, Norgestrel 7280-37-7, Estropipate
10116-22-0, Demegestone 18010-40-7, Bupivacaine hydrochloride
34184-77-5, Promegestone 36637-18-0, Etidocaine 38396-39-3,
Bupivacaine
RL: PROC (Process)
(topical formulation of)
- IT **68-22-4, Norethindrone 595-33-5,**
Megestrol acetate
RL: PROC (Process)
(topical formulation of)
- RN 68-22-4 HCAPLUS
- CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17.alpha.)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



- RN 595-33-5 HCAPLUS
- CN Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



=> fil medline

FILE 'MEDLINE' ENTERED AT 13:33:20 ON 27 AUG 2003

FILE LAST UPDATED: 26 AUG 2003 (20030826/UP). FILE COVERS 1958 TO DATE.

On April 13, 2003, MEDLINE was reloaded. See HELP_LOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See <http://www.nlm.nih.gov/mesh/changes2003.html> for a description on changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all tot

L112 ANSWER 1 OF 8 MEDLINE on STN

AN 2001034662 MEDLINE

DN 20519492 PubMed ID: 11063639

TI Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.

AU Amezcua C A; Lu J J; Felix J C; Stanczyk F Z; Zheng W

CS Department of Pathology, Women's and Children's Hospital, Los Angeles, California, 90033, USA.

SO GYNECOLOGIC ONCOLOGY, (2000 Nov) 79 (2) 169-76.

Journal code: 0365304. ISSN: 0090-8258.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200011

ED Entered STN: 20010322

Last Updated on STN: 20010322

Entered Medline: 20001130

AB OBJECTIVE: The aim of this study was to investigate the role of apoptosis during progestin therapy for the treatment of endometrial hyperplasia.

METHODS: Pre- and posttreatment paraffin-embedded endometrial tissue samples from 19 women with endometrial hyperplasia were examined for changes in glandular cellularity and apoptotic activity related to the administration of progestins. Twelve patients were successfully treated with progestin therapy and 7 patients failed treatment. Glandular cellularity was assessed based on calculating the average number of cells per gland obtained on histologic examination of hematoxylin and eosin stained tissue sections. Apoptotic activity was assessed on the same tissue sections by counting the average number of apoptotic cells per 10 high power fields (hpf) using the terminal deoxynucleotidyl

transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) assay. The effects of progesterone on apoptotic activity in a low-grade endometrial adenocarcinoma cell line (Ishikawa cells) was also examined using an ELISA cell death detection kit. RESULTS: Glandular cellularity significantly decreased with progestin therapy in both treatment outcome groups. The reduction in cells per gland was significantly greater in the group of successfully treated cases compared to the treatment failures ($P = 0.005$). However, within the successfully treated group, in situ detection of apoptotic cells using the TUNEL assay showed no statistical difference between pre- and posttreatment endometrial samples. Interestingly, a significant decrease in apoptosis was found in posttreatment samples of the group with persistent hyperplasia. The average number of apoptotic cells detected in 10 hpf was reduced from 7.9 prior to treatment to 3.1 after progestin therapy ($P = 0.03$). In the progesterone-treated Ishikawa cell line, an increase in apoptotic activity started at 24 h, reached a peak at 48 h, and continued up to 72 h of hormone treatment. At 48 h, apoptotic activity was 42.6% greater than in the untreated control ($P = 0.04$). By 72 h of progesterone treatment, apoptosis was 37.2% greater in the treated cells compared to the noninoculated cells ($P = 0.04$). CONCLUSIONS: Progestin-induced apoptosis may occur during the early period of treatment for endometrial hyperplasia. Compared to the fully responsive group, persistent endometrial hyperplasia may have intrinsically different molecular mechanisms in response to progestin therapy.

Copyright 2000 Academic Press.

CT Check Tags: Female; Human; Support, Non-U.S. Gov't
Adult

***Apoptosis: DE, drug effects**

Cell Count

*Endometrial Hyperplasia: DT, drug therapy

*Endometrial Hyperplasia: PA, pathology

Endometrium: PA, pathology

In Situ Nick-End Labeling

Medroxyprogesterone 17-Acetate: PD, pharmacology

Medroxyprogesterone 17-Acetate: TU, therapeutic use

Megestrol Acetate: PD, pharmacology

Megestrol Acetate: TU, therapeutic use

Middle Age

Paraffin Embedding

Progestational Hormones: PD, pharmacology

*Progestational Hormones: TU, therapeutic use

Progestational Hormones, Synthetic: PD, pharmacology

*Progestational Hormones, Synthetic: TU, therapeutic use

Tumor Cells, Cultured

RN **51154-23-5 (Megestrol Acetate); 71-58-9 (Medroxyprogesterone 17-Acetate)**

CN 0 (Progestational Hormones); 0 (Progestational Hormones, Synthetic)

L112 ANSWER 2 OF 8 MEDLINE on STN

AN **88265233** MEDLINE

DN **88265233** PubMed ID: **3388464**

TI Oral contraceptive use and risk of stroke.

AU Xuereb M; Pullicino P

SO **STROKE, (1988 Jul) 19 (7) 922-3.**

Journal code: 0235266. ISSN: 0039-2499.

CY United States

DT Letter

LA English

FS Priority Journals

EM 198808

ED Entered STN: 19900308

Last Updated on STN: 19900308

Entered Medline: 19880811

CT Check Tags: Case Report; Female; Human
Adult
*Cerebrovascular Disorders: CI, chemically induced
Cerebrovascular Disorders: CO, complications
Contraceptives, Oral, Combined: AE, adverse effects
*Ethinyl Estradiol: AE, adverse effects
Migraine: CO, complications
*Norethindrone: AE, adverse effects
Risk Factors

RN 37270-71-6 (Modicon); 57-63-6 (Ethinyl Estradiol); 68-22-4
(Norethindrone)

CN 0 (Contraceptives, Oral, Combined)

L112 ANSWER 3 OF 8 MEDLINE on STN
AN 82014828 MEDLINE
DN 82014828 PubMed ID: 7279642
TI [Cerebral vascular accident during progestational therapy].
Accident vasculaire cerebral au cours d'un traitement progestatif.
AU Julien J; Lagueny A; Larrieu J M
SO NOUVELLE PRESSE MEDICALE, (1981 Aug 29-Sep 5) 10 (31) 2589.
Journal code: 0312552. ISSN: 0301-1518.
CY France
DT Letter
LA French
FS Priority Journals
EM 198111
ED Entered STN: 19900316
Last Updated on STN: 20000303
Entered Medline: 19811118

CT Check Tags: Case Report; Female; Human
*Brain Ischemia: CI, chemically induced
Middle Age
*Norethindrone: AE, adverse effects

RN 68-22-4 (Norethindrone)

L112 ANSWER 4 OF 8 MEDLINE on STN
AN 81052781 MEDLINE
DN 81052781 PubMed ID: 7432644
TI [Transitory ischemic attacks, migraine and progestogen drugs.
Etiopathogenetic correlations].
Attacchi ischemici transitori, emicrania e progestinici. Correlazioni
etiopatogenetiche.
AU Moretti G; Manzoni G C; Carpeggiani P; Parma M
SO MINERVA MEDICA, (1980 Aug 25) 71 (30) 2125-9.
Journal code: 0400732. ISSN: 0026-4806.
CY Italy
DT Journal; Article; (JOURNAL ARTICLE)
LA Italian
FS Priority Journals
EM 198101
ED Entered STN: 19900316
Last Updated on STN: 20000303
Entered Medline: 19810129

AB Two cases of transitory ischaemic attacks, which occurred during
progestogen therapy, are reported. Clinical history and symptoms of both
patients suggested migraine disorder. Therefore, the hypothesis is made
that also progestogen-only preparations, likewise oestrogen-progestogen
oral contraceptives, may cause neurological troubles by vasomotor
mechanisms.

CT Check Tags: Case Report; Female; Human
Adult
*Cerebrovascular Disorders: CI, chemically induced
Confusion: CI, chemically induced

*Contraceptives, Oral: AE, adverse effects
*Contraceptives, Oral, Synthetic: AE, adverse effects
English Abstract
Hemiplegia: CI, chemically induced
Ischemia: CI, chemically induced
*Ischemic Attack, Transient: CI, chemically induced
Leg: BS, blood supply
*Menstruation Disturbances: DT, drug therapy
Middle Age
*Migraine: CI, chemically induced
Norethindrone: AE, adverse effects
*Progestational Hormones, Synthetic: AE, adverse effects
*Vascular Diseases: CI, chemically induced

RN 68-22-4 (Norethindrone)

CN 0 (Contraceptives, Oral); 0 (Contraceptives, Oral, Synthetic); 0
(Progestational Hormones, Synthetic)

L112 ANSWER 5 OF 8 MEDLINE on STN

AN 80239606 MEDLINE

DN 80239606 PubMed ID: 7395941

TI Chorea associated with oral contraceptive therapy.

AU Dove D J

SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, (1980 Jul 15) 137
(6) 740-2.

Journal code: 0370476. ISSN: 0002-9378.

Report No.: PIP-801175; POP-00078277.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals; Population

EM 198009

ED Entered STN: 19900315

Last Updated on STN: 20021101

Entered Medline: 19800928

AB Fernando and Chir 1st reported an association between chorea and oral contraceptives (OCs) in 1966. Differential diagnosis of chorea, in addition to Sydenham chorea, include Wilson disease; encephalitis; Huntington chorea; drug intoxication; benign familial chorea; pregnancy; systemic lupus erythematosus; Henoch-Schonlein purpura; polycythemia vera; hypocalcemia; hyperthyroidism; carbon monoxide poisoning; cerebral infarction, and; intracranial tumor. Chorea can also occur as an untoward side-effect of OC therapy, as shown by the case report of a 20-year old white woman. Chorea associated with OC therapy occur unilaterally but has also been bilateral in 37% of reported cases. 8 of 24 reported cases (33%) had a prior history of rheumatic fever - mean age of patient was 22 years (range, 16 to 40 years). The time between initiation of OC therapy and appearance of choreiform movements can vary from 6 days to 9 months, with a mean of 3 months. Time between discontinuation of OC therapy and cessation of symptoms vary from 3 days to 3 months, with a mean of 5 weeks. Speculations by various authors on the pathogenesis of chorea are described.

ST Chorea; Contraception; Contraceptive Methods--therapeutic use; Diseases; Family Planning; Oral Contraceptives--therapeutic use; Signs And Symptoms

CT Check Tags: Case Report; Female; Human
Adult

*Chorea: CI, chemically induced

*Contraceptives, Oral: AE, adverse effects

Mestranol: AE, adverse effects

Norethindrone: AE, adverse effects

RN 68-22-4 (Norethindrone); 72-33-3 (Mestranol)

CN 0 (Contraceptives, Oral)

L112 ANSWER 6 OF 8 MEDLINE on STN

AN 72088731 MEDLINE
DN 72088731 PubMed ID: 5136191
TI Cerebral ischaemic lesions and oral contraception.
AU Kjaer M; De Fine Olivarius B; Waarst A
SO DANISH MEDICAL BULLETIN, (1971 Dec) 18 (6) 129-37.
Journal code: 0066040. ISSN: 0907-8916.
CY Denmark
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 197203
ED Entered STN: 19900310
Last Updated on STN: 20000303
Entered Medline: 19720328
CT Check Tags: Female; Human
Adolescent
Adult
*Cerebrovascular Disorders: CI, chemically induced
*Contraceptives, Oral: AE, adverse effects
Ethinyl Estradiol: AE, adverse effects
Ethinodiol Diacetate: AE, adverse effects
Intracranial Embolism and Thrombosis: CI, chemically induced
Ischemic Attack, Transient: CI, chemically induced
Lynestrenol: AE, adverse effects
Megestrol: AE, adverse effects
Mestranol: AE, adverse effects
Middle Age
Norethindrone: AE, adverse effects
Norethynodrel: AE, adverse effects
Norgestrel: AE, adverse effects
Pregnancy
RN 297-76-7 (Ethinodiol Diacetate); 3562-63-8 (Megestrol); 52-76-6
(Lynestrenol); 57-63-6 (Ethinyl Estradiol); 6533-00-2 (Norgestrel);
68-22-4 (Norethindrone); 68-23-5 (Norethynodrel); 72-33-3
(Mestranol)
CN 0 (Contraceptives, Oral)

L112 ANSWER 7 OF 8 MEDLINE on STN
AN 71290068 MEDLINE
DN 71290068 PubMed ID: 5571013
TI Chorea associated with oral contraceptive therapy.
AU Gamboa E T; Isaacs G; Harter D H
SO ARCHIVES OF NEUROLOGY, (1971 Aug) 25 (2) 112-4.
Journal code: 0372436. ISSN: 0003-9942.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 197111
ED Entered STN: 19900101
Last Updated on STN: 19900101
Entered Medline: 19711116
CT Check Tags: Female; Human
Adult
Chlorpromazine: TU, therapeutic use
*Chorea: CI, chemically induced
Chorea: DT, drug therapy
*Contraceptives, Oral: AE, adverse effects
*Mestranol: AE, adverse effects
*Norethindrone: AE, adverse effects
Penicillins: TU, therapeutic use
Pregnancy
Pregnancy Complications

Rheumatic Fever: CO, complications
 Streptococcal Infections: CO, complications
 Trifluoperazine: TU, therapeutic use
 RN 117-89-5 (Trifluoperazine); 50-53-3 (Chlorpromazine); **68-22-4**
(Norethindrone); 72-33-3 (Mestranol)
 CN 0 (Contraceptives, Oral); 0 (Penicillins)

L112 ANSWER 8 OF 8 MEDLINE on STN
 AN **68014584** MEDLINE
 DN **68014584** PubMed ID: **6054589**
 TI Strokes in young women using oral contraceptives.
 AU Cole M
 SO ARCHIVES OF INTERNAL MEDICINE, (1967 Nov) 120 (5) 551-5.
 Journal code: 0372440. ISSN: 0003-9926.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 196712
 ED Entered STN: 19900101
 Last Updated on STN: 20000303
 Entered Medline: 19671221
 CT Check Tags: Female; Human
 Adult
 *Carotid Artery Thrombosis: ET, etiology
 *Cerebrovascular Disorders: ET, etiology
 *Contraceptives, Oral: AE, adverse effects
 Hemiplegia: ET, etiology
 Infarction: ET, etiology
 Intracranial Embolism and Thrombosis: ET, etiology
 Menstruation Disturbances: DT, drug therapy
 *Mestranol: AE, adverse effects
 *Norethindrone: AE, adverse effects
 *Norethynodrel: AE, adverse effects
 RN **68-22-4 (Norethindrone)**; 68-23-5 (Norethynodrel); 72-33-3
 (Mestranol)
 CN 0 (Contraceptives, Oral)

=> d his

(FILE 'HOME' ENTERED AT 12:27:28 ON 27 AUG 2003)
 SET COST OFF

FILE 'REGISTRY' ENTERED AT 12:27:40 ON 27 AUG 2003

FILE 'HCAPLUS' ENTERED AT 12:27:52 ON 27 AUG 2003

L1 7 S US20030013692/PN OR (WO2002-US1700# OR US2001-262720#)/AP, PRN
 L2 1 S L1 AND (GULLANS S? OR SARANG S?)/AU
 L3 23 S 17() (OH OR HYDROXY#) ()19 NORPREGN?
 L4 3 S 17() (OH OR HYDROXY#) ()19 NORPREGN?(S)4 EN 20 YN 3 ONE
 L5 0 S 17 ALPHA ACETYLOXY 6 METHYLPREGN? (L) 4 6 DIENE 3 20 DIONE
 L6 0 S 17(L) ACETYLOXY 6 METHYLPREGN? (L) 4 6 DIENE 3 20 DIONE
 L7 67 S 6 METHYLPREGN? (L) 4 6 DIENE 3 20 DIONE
 L8 3 S L7 (L) 17 ALPHA (L) ACYLOXY

FILE 'REGISTRY' ENTERED AT 12:34:01 ON 27 AUG 2003

L9 1 S 3385-03-3
 L10 1 S 68-22-4
 L11 1 S 595-33-5
 L12 3 S L9-L11
 SEL RN
 L13 40 S E1-E3/CRN

L14 5 S L13 NOT MXS/CI

FILE 'HCAPLUS' ENTERED AT 12:35:39 ON 27 AUG 2003

L15 3194 S L12
L16 348 S FLUNISOLID# OR AEROBID OR BRONALIDE OR NASALIDE OR NASAREL OR
L17 773 S MAGESTIN# OR MAYGACE OR MEGACE OR MEGERON OR MEGESTAT OR MEGE
L18 1454 S DMAP
L19 1288 S ANOVULE OR CONLUDAF OR CONLUDAG OR ETH!NYLNORTESTOSTERONE OR
L20 1539 S NORETHISTERONE
L21 5918 S L4,L8,L15-L20
E GULLANS S/AU
L22 98 S E3-E9
E SARANG S/AU
L23 11 S E3-E6
L24 1 S L21 AND L22,L23
L25 1 S L2,L24
E CELL DEATH/CT
L26 3881 S E4
E E3+ALL
L27 59825 S E4,E3+NT
E OXIDATIVE STRESS/CT
E E5+ALL
L28 21459 S E1
E APOPTOSIS/CT
E E3+ALL
L29 52921 S E5,E4
E PARKINSON/CT
E E6+ALL
L30 10331 S E4,E3+NT
E E10+ALL
L31 961 S E3+NT
E E6+ALL
E E9+ALL
L32 2690 S E4
E HUNTINGTON/CT
E E6+ALL
L33 0 S E2
E ALZHEIMER/CT
L34 12282 S E9-E20
E E9+ALL
L35 12296 S E6,E5+NT
L36 7454 S E23+NT OR E24+NT OR E27+NT OR E28+NT OR E29+NT
E E25+ALL
L37 3442 S E4
E E9+ALL
L38 11090 S E4,E3
E E9+ALL
L39 2196 S E6,E5+NT
E E15+ALL
L40 29693 S E2+NT
E E15+ALL
L41 2171 S E3
E E8+ALL
L42 20364 S E15,E14+NT
E E28+ALL
L43 151105 S E5,E4+NT
L44 6659 S E25+NT
E E27+ALL
L45 30136 S E4,E5,E3+NT
E AMYOTROPHIC/CT
E E4+ALL
L46 2784 S E2
E DIABETIC NEUROPATH/CT


```

      E E4+ALL
L47      1337 S E2
      E HYPOXIA/CT
L48      16248 S E3,E5-E8
      E E3+ALL
      E E2+ALL
      E BRAIN, DISEASE/CT
L49      915 S E3 (L) HYPOX?
L50      6166 S E3 (L) STROKE
      E MENINGIT/CT
      E MENINGIT/CT
L51      2730 S E5-E10
      E E5+ALL
L52      2730 S E3
      E ENCEPHALIT/CT
L53      2313 S E4-E10
      E E4+ALL
L54      6505 S E7,E6+NT
      E HUNTINGTON/CT
      E E7+ALL
      E NERVOUS SYSTEM, DISEASE/CT
L55      5974 S E3-E6
      E NERVOUS SYSTEM DISEASE/CT
      E E4+ALL
L56      3239 S NERVOUS SYSTEM?/CT (L) (HUNTINGTON? OR CHOREA?)
L57      125 S L21 AND L26-L56
L58      89 S L57 AND (PD<=20010117 OR PRD<=20010117 OR AD<=20010117)
L59      44 S L58 AND L15
L60      2 S L59 AND RELEASE PROFILE
L61      9 S L59 AND CORTICOSTEROID
L62      1 S L59 AND SOLUBILITY NOT L61
L63      2 S L59 AND CLAY
L64      3 S L59 AND TOPICAL?/TI
L65      1 S L59 AND ALZHEIM?/TI
L66      1 S L59 AND CYCLODEXTRIN?/TI
L67      8 S L59 AND MATRIX
L68      38 S L12(L)THU/RL AND L59
L69      30 S L59 AND (1 OR 63)/SC
L70      14 S L68,L59 NOT L69
L71      7 S L70 AND (?ALZHEIM? OR NERVOUS SYSTEM OR STROKE OR NERV? DISEA
L72      7 S L70 NOT L71
L73      1 S L72 AND NEUROCOGN?
L74      38 S L69,L71,L73
L75      45 S L58 NOT L59
L76      39 S L25,L74 AND L1-L8,L15-L75

```

FILE 'REGISTRY' ENTERED AT 13:14:41 ON 27 AUG 2003

FILE 'HCAPLUS' ENTERED AT 13:14:54 ON 27 AUG 2003

FILE 'MEDLINE' ENTERED AT 13:15:25 ON 27 AUG 2003

```

L77      3754 S L12
L78      6281 S L16-L20
L79      6281 S L77,L78
L80      5801 S L79 AND PY<=2000
L81      191 S A8./CT AND L80
L82      168 S C10./CT AND L80
      E CELL DEATH/CT
      E E3+ALL
L83      112007 S E4+NT
      E E18+ALL
L84      54368 S E5+NT
      E OXIDATIVE STRESS/CT

```

```

L85      14170 S E3+ALL
           S E4+NT
           E PARKINSON/CT
           E E7+ALL
L86      26784 S E13+NT OR E30+NT
           E HYPOXIA/CT
           E E6+ALL
L87      35878 S E9+NT
           E HUNTINGTON/CT
           E E7+ALL
L88      5142 S E18+NT
           E AMYOTROPHIC/CT
           E E5+ALL
L89      5695 S E12+NT
           E MENINGITIS/CT
           E E3+ALL
L90      29877 S E10+NT
           E ENCEPHALITIS/CT
           E E3+ALL
L91      25219 S E20+NT
L92      5281 S E64+NT
L93      38909 S E19+NT
           E MENINGITIS/CT
           E E3+ALL
L94      76266 S E9+NT
           E E8+ALL
           E DIABETIC NEUROPATHY/CT
           E E3+ALL
           E E2+ALL
L95      9362 S E11+NT
           E STROKE/CT
           E E3+ALL
           E E2+ALL
L96      9171 S E9
           E ALZHEIMER/CT
           E E8+ALL
L97      124703 S E11+NT
L98      12968 S E46+NT OR E47+NT OR E48+NT OR E49+NT OR E50+NT OR E51+NT OR E
L99      23 S L80 AND L83-L98
L100     11 S L99 AND L81,L82
           SEL DN AN 6-8 11
L101     4 S L100 AND E1-E12
L102     12 S L99 NOT L100
           SEL DN AN 3
L103     1 S L102 AND E13-E15
L104     5 S L101,L103
L105     327 S L81,L82 NOT L99
L106     1137075 S C10./CT
L107     86 S L106/MAJ AND L105
L108     947446 S A8./CT
L109     112 S L108/MAJ AND L105
L110     194 S L107,L109
           E CHOREA/CT
           E E3+ALL
           SEL DN AN 56 96 151
L111     3 S L110 AND E1-E9
L112     8 S L104,L111 AND L77-L111

```